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The cytochrome P450 enzymes CYP101B1 and CYP101C1, which are from the aromatic 
hydrocarbon degrading bacterium Novosphingobium aromaticivorans DSM12444, can 
hydroxylate norisoprenoids with high activity and selectivity. With the aim of further 
understanding their substrate range, a selection of cyclic alkanes, ketones and alcohols were 
studied. Cycloalkanes were oxidised, but both enzymes displayed low binding affinity and 
productive activity. The presence of a ketone moiety in the cycloalkane skeleton significantly 
improved the substrate binding affinity and the oxidation activity. CYP101C1 catalysed the 
oxidation of the cycloalkanones at the C-2 position with high regioselectivity. The 
regioselectivity of CYP101B1 was different. It oxidised cycloalkanones at positions remote 
from the carbonyl group. This indicated that the binding orientation of the cyclic ketones in the 
active site of each enzyme must be different. Cyclic alcohols and cyclohexylacetic acid showed 
little to no activity with either enzyme. The introduction of an ester protecting group to these 
substrates significantly enhanced the monooxygenase activity. These substrates were oxidised 
regioselectively on the opposite side of the ring system to the ester directing group. For 
example, both enzymes preferentially oxidised the C-H bond at the C4, C5 and C7 position of 
the cyclohexyl, cyclooctyl and cyclododecyl ester compounds, respectively. In addition, certain 
linear ketones and esters were also found to be suitable substrates for these biocatalysts.  
CYP101B1 mediated metabolism of the tricyclic compounds adamantane, 1‐ and 2‐
adamantanol and 2‐adamantanone proceeds with low oxidation activity and multiple 
metabolites were identified. Insertion of a directing group (acetate/isobutyrate) at the alcohol 
of these adamantanols significantly increased the affinity, activity and coupling efficiency 
(productive use of reducing equivalents) of CYP101B1 compared to the parent compounds. 
This substrate engineering approach with these adamantyl derivatives led to a 65 to 122-fold 
higher product formation activity. The turnovers were also regioselective and in some instances 
stereoselective. Additionally, the amide N‐(1‐adamantyl)acetamide was oxidised efficiently by 
CYP101B1, whereas 1‐adamantylamine was not. Whole-cell biotransformation systems were 
used to generate the metabolites in good yield (g/L scale). Overall, the use of ester directing 
groups and the modification of the amine to an amide enabled CYP101B1 to oxidise the 
adamantane skeleton more efficiently and selectively. 
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Wild-type (WT) CYP101B1 can catalyse the oxidation of aromatic substrates such as 
alkylbenzenes, alkylnaphthalenes and acenaphthene, but the binding affinities and the 
oxidation activities were low. Both the binding affinity and product formation activity of this 
enzyme for these hydrophobic substrates were enhanced using site-directed mutagenesis. The 
Histidine 85 (H85) of CYP101B1 aligns with tyrosine 96 of CYP101A1 (P450cam), which, in 
the latter enzyme forms the only hydrophilic interaction with its natural substrate, camphor. 
The H85 residue of CYP101B1 was therefore replaced with phenylalanine (F), and this H85F 
variant exhibited greater affinity and activity towards hydrophobic substrates. For instance, the 
product formation activity of the H85F variant for acenaphthene oxidation was increased six-
fold to 245 nmol.nmol-CYP–1.min–1. This indicated that this residue is in the substrate binding 
pocket or the access channel of the enzyme.  
Methylcubanes have been used as mechanistic probes to differentiate between radical and 
cationic pathways in cytochrome P450 oxidation. A series of methylcubanes were designed 
which would place the methyl group close to reactive heme iron centre of CYP101B1. 
CYP101B1 efficiently oxidised the substituted methylcubane derivatives yielding the 
equivalent cubylmethanol in 93 ± 7 % yield. The cube was found to be intact in all the turnover 
products, and no methylcubanols or any other rearranged metabolites containing homocubyl 
were detected. These results were consistent  with a rapid radical rebound step in these 
oxidations and argued against the involvement of any carbocation-based intermediates during 
the oxidation. 
The CYP101B1 system, which also combines a FAD-containing ferredoxin reductase and a 
[2Fe-2S] ferredoxin, was investigated with oxygenated aromatics including naphthols, 
naphthoquinones, dihydroxynaphthalene and phenols. In vitro NADH oxidation rates in both 
the presence and absence of CYP101B1 were fast with these substrates (≥800 min-1). Minimal 
metabolite formation was detected, and the majority of reducing equivalents were transformed 
into hydrogen peroxide. Large amount of H2O2 in these reactions in the absence of P450 indicated 
that the ferredoxin (Arx) and ferredoxin reductase (ArR) catalysed futile redox cycling with 
naphthoquinones giving rise to the uncoupling of the reducing equivalents. Further examination of 
naphthols and naphthoquinones together with 2-adamantyl acetate in the fully reconstituted 
CYP101B1 turnovers demonstrated that the presence of naphthoquinones led to diminished product 
formation as they interfere with the electron transfer process. This type of uncoupling in the bacterial 
P450 electron transfer partners containing ferredoxin system would be considered an additional 
form of uncoupling over those which arise in the P450 active site. 
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1.1. General Overview of Cytochrome P450s 
 
Cytochrome P450 enzymes (P450s or CYPs) are a superfamily of monooxygenase 
metalloproteins which are found in all kingdoms of life, including animals, plants, bacteria and 
fungi 1. The name "P450" is derived due to its red pigmentation (P) and the enzyme has a 
characteristic absorption peak at 450 nm when it is reduced and bound with carbon monoxide 
(Figure 1. 1) 2. P450 systems were first recognised in 1958. Klingenberg and Garfinkel 
independently identified and reported a unique CO-bound red pigment, which exhibits a Soret 
absorption peak at 450 nm, in rat and pig liver microsomes 3, 4. Omura and Sato first described 
the hemoprotein nature of this pigment in 1964 5. The protoporphyrin (heme) centre is attached 
to the enzyme via coordination of the ferric ion with a proximal cysteine thiolate ligand (I; 
Figure 1. 1 and Figure 1. 3) 1, 6. This thiolate ligand is significant for enzymatic activity and 
contributes to the unique Soret absorption peak of the carbon monoxide reduced enzyme (450 
nm) 6, 7.  
 
          
  
                                                                           
                      




Figure 1. 1 UV-Vis absorbance spectrum of the ferric resting state of a P450 enzyme (black). 
The Soret absorbance peak at ∼450 nm is observed upon binding the ferrous form with a CO 
ligand (dashed red) 2. 
 




The P450 superfamily is currently comprised of more than 300,000 (as of January 2018) 
cytochrome P450 sequences and among these nomenclature has been assigned to 41,000 8. For 
instance, the human genome has 57 unique P450 systems, while the Mycobacterium 
tuberculosis bacterium contains 20 P450 genes 9, 10. Other examples include 458 different 
P450s are found in rice, and the carnivorous mushroom (Laccaria bicolor) has 91 P450 
sequences 11, 12. However, the bacterium Escherichia. coli contains no P450 system 13. 
 
The systematic naming of each member of this superfamily is based on their sequence 
similarity and function 14, 15. Each member of this superfamily is grouped according to amino 
acid sequence similarity into a specific family (≥40% similarity) and subfamily (≥55% 
similarity) 8, 16-18. The name of a P450 enzyme is designated by its family number and subfamily 
letter following the prefix CYP. Families are denoted with a numerical identifier such as 
CYP1–CYP49, CYP301–CYP499, CYP3001–CYP4999 for mammalian, CYP51–CYP69 for 
fungal, CYP501–CYP699, CYP5001–CYP6999 for lower eukaryotes, CYP71–CYP99, 
CYP701–CYP999 for plant and CYP101–CYP299, CYP1001–CYP1050 for bacterial P450 
enzymes families 1, 8, 19, 20. The subfamily is expressed by a letter, for instance, A and a number 
such as 1, which catalogues the P450 enzyme within the subfamily. For example, CYP102A1 
from the bacterium Bacillus megaterium is the first identified P450 enzyme in the subfamily 
“A” of the family “102” 21-23.  
 
These P450 enzymes are capable of introducing one oxygen atom into chemically inert C-H 
bonds with high chemo-, regio- and stereo-selectivity (Equation 1. 1) 1, 13. The primary activity 
which they perform is hydroxylation, but P450 enzymes can also catalyse a wide range of 
reactions including alkene epoxidation, heteroatom oxidation, desaturation, oxidative ester 
cleavage, isomerisation, rearrangement, ring expansion and ring formation. These make P450s 
one of the most versatile biological catalyst superfamilies (Figure 1. 2) 13, 24-31. 
 
   R-H  +  NAD(P)H+  +  H+  +  O2                         NAD(P)
+  +  H2O  +  R-OH                 (1. 1) 
where R-H is the substrate and R-OH is the metabolite generated by the P450 enzyme. 
 






      Figure 1. 2 A selection of reactions catalysed by cytochrome P450 enzymes 13, 24-31. 
 
1.2. The Catalytic Cycle of Cytochrome P450s 
 
The catalytic cycle for the majority of the members of the P450 superfamily is believed to be 
predominantly the same (Figure 1. 3) 9, 13. However, substrate selectivity and activity of 
individual P450 enzymes depend on the sequential and structural differences in the active site 
1. P450cam (CYP101A1), isolated from the bacterium Pseudomonas putida, was one of the first 
and hence most well-known P450 to be purified in soluble and crystalline form, and its three-
dimensional structure has been determined 32-34. CYP101A1 has been therefore used as a model 
system to gain a detailed understanding of the P450 catalytic cycle 32-34. 




In the resting state, the 6th distal coordination site of the heme centre is usually occupied by a 
water molecule (I) and this ligand can be observed in the substrate-free crystal structure of 
P450 enzymes (Figure 1. 3) 9. The water ligand is displaced by the substrate which initiates the 
catalytic cycle (II), and this step can be monitored by UV-Vis spectrophotometry as the enzyme 
gives a characteristic shift from the low spin resting state (I; ~418-419 nm) to a high spin-state 
(II) which absorbs at ~390 nm (Figure 1. 3 and Figure 1. 4). The high spin form (II) of the 
ferric centre then accepts an electron from NADPH (or NADH), delivered by electron transfer 
partners to generate the ferrous form (III). The ferrous ion can bind molecular dioxygen to form 
a ferrous-dioxygen complex (IV) 9. This complex (IV) receives another electron to yield the 
ferric-peroxy anion complex (V) 35. The ferric-peroxy anion complex undergoes protonation 
(VI) at the distal oxygen of the complex (V) to give compound 0 (VI) followed by cleavage of 
the O-O bond to generate a highly reactive species called compound I (Cpd I) 36, 37. Cpd I is 
considered as the primary oxidant in the majority of P450 reactions and is capable of 
abstracting a hydrogen atom from a substrate C-H bond 38. This is followed by the introduction 
of the oxygen atom to the substrate via a radical rebound mechanism (Figure 1. 3) 36.  
 
The characterisation of compound I is difficult due to its extremely short lifetime. However, 
recently it was characterised under cryogenic conditions which confirmed its nature and 
identification as a key intermediate 36, 39. The iron centre of Cpd I has two unpaired electrons 
in the 3d π* orbital of the iron and one in the porphyrin a2u π* orbital (Figure 1. 3) 
40-42. It can 
exist in a high spin quartet state, 4A2u, in which all electrons have parallel spin or in the low-
spin doublet state with the electron in porphyrin orbital inverted (2A2u) 
40-42. A pair of sextet 
and quartet excited states has also been described which are higher in energy than the doublet 
and quartet ground states of Cpd I 41.  
 
Cpd I breaks the substrate C-H bond homolytically, resulting in a substrate radical (.R) and 
forms an intermediate iron-hydroxy species [FeIV–OH] (Figure 1. 3). The substrate radical 
recombines with the iron bound hydroxy group to generate the product (R-OH; Figure 1. 3). 
Once the product (R-OH) formation is complete, it dissociates from the active site of the 
enzyme. A water ligand then binds to the iron centre of the enzyme to reform the resting state 
(I).  






 Figure 1. 3 (a) The catalytic cycle of cytochrome P450 enzymes. (b) The electronic structure   
 of Cpd I 38, 40-42. 





Figure 1. 4 UV-Vis absorbance spectrum of the resting state of the P450 enzyme (I; black). 
The Soret absorbance peak is at ~419 nm, and this absorbance peak shifted to ∼390 nm upon 
binding of a substrate (II; dashed red). 
         
The catalytic cycle of P450 enzymes requires two electron transfer steps II to III and IV to V 
(Figure 1. 3). These reducing equivalents are usually derived from NADH or NADPH and are 
shuttled to the P450 via electron transfer proteins 43. The P450 enzyme must form a complex 
with one of its redox partners. During the early stage of P450 discovery, two prime classes of 
redox partners were described, class I and class II 44, 45. Many bacterial P450s such as 
CYP101A1 from P. putida receives electrons from NADH via a class I redox partner system, 
which consists of an iron-sulfur protein (ferredoxin) and a flavin-containing reductase 
(ferredoxin reductase) 46-50. Most of the mitochondrial P450s such as CYP11B1 accept 
reducing equivalents from NADPH through NADPH-adrenodoxin reductase and adrenodoxin 
which are similar to these bacterial systems (Figure 1. 5) 44, 45, 51, 52. In both 
ferredoxin/adrenodoxin reductase first gains two electrons from NAD(P)H. These electrons are 
then transported one at a time to the second component of the system, a ferredoxin/ adrenodoxin 
and which then delivered individually to the target P450 enzyme (Figure 1. 5) 53. The most 
studied ferredoxins in this class of redox partners contain iron-sulfur [2Fe-2S] clusters 44, 54. 
However, there are few other cluster types which have also been reported 44, 55-57. For example, 
CYP105D1 from Streptomyces griseus receives the reducing equivalents from ferredoxins 
which contains a [3Fe–4S] and a [4Fe–4S] cluster 55-57. 
 
The membrane-bound and eukaryote microsomal monooxygenases, e.g. CYP2C5 and 
CYP3A4 typically belong to the class II system, which is associated with a single membrane-
bound NADPH reductase containing FAD and flavin mononucleotide (FMN) domains (Figure 




1. 5) 46, 50, 58-60. Several other redox partner systems have been identified for P450s. These have 
been divided into a total of ten different classes including the class I and class II system 







Figure 1. 5 (a) Example of the different types of electron transfer proteins used by P450s 
including class I, class II, class III, class VIII and class IX 44. CPR: Cytochrome P450 reductase. 
(b) Class I and class II electron transfer process from NAD(P)H to the P450 enzymes 44, 53. 




Other examples of electron transfer partners for P450 enzymes include class III P450 systems, 
e.g. CYP176A1 (P450cin). This has two separate redox partners like the class I system, but 
instead of an iron-sulfur protein, it uses a second mediator protein, a flavodoxin (FMN), which 
is similar to the class II systems (Figure 1. 5) 44, 46, 61. CYP102A1 (P450BM3) from Bacillus 
megaterium belongs to the class VIII catalytically self-sufficient P450 system. In this system, 
the P450 domain is fused to a reductase, which contains both FAD and FMN domains (Figure 
1. 5) 21, 44, 62. The class VI P450 system stands somewhere between the self-sufficient P450BM3 
(Class VIII) and P450cin (Class III) systems. It consists of a putative NAD(P)H-dependent 
flavoprotein reductase and a flavodoxin-P450-fusion protein 44, 63-65. The class IX system, such 
as the soluble eukaryotic P450nor or CYP55 from the fungus Fusarium oxysporum, has been 
shown not to require a flavoprotein to supply the reducing equivalents and it can use NADH 
directly for the reduction process (Figure 1. 5) 66-68. 
 
The product formation activity and efficiency of substrate oxidation by P450 enzymes depend 
on several factors including the rates of electron and proton transfer within the catalytic cycle 
of the enzyme. In theory, each molecule of NADH/NAD(P)H and oxygen consumed during a 
turnover of the catalytic cycle, should produce one molecule of product. However, this 
complete utilisation of redox equivalents for product formation is rarely observed due to 
uncoupling reactions. These processes can arise if a particular step of the catalytic cycle occurs 
too slowly (Figure 1. 3) 69. If the second electron transfer step is inefficient, superoxide may be 
released from the ferrous-dioxygen complex (IV) which reverts to the ferric state 70.  A second 
possible uncoupling event originates if the second protonation of the distal oxygen of ferric-
hydroperoxide (VI) occurs too slowly and instead a proton is transferred to the proximal 
oxygen. Hydrogen peroxide is then released as a by-product (Figure 1. 3). Excess H2O in the 
P450 active site can accelerate this peroxide forming uncoupling process 70. The third 
uncoupling pathway is due to the unproductive two-electron reduction of compound I (VII) to 
water. This can occur when the substrate does not bind in the active site of the P450 in an 
orientation where Cpd I can attack a C-H bond. In general, if the substrate does not have 
favourable active site interactions, the uncoupling processes are increased 71, 32, 72, 73.  
 
In some cases, the product may act as an inhibitor by reversibly binding to the active site of the 
P450 enzyme and preventing productive substrate binding and oxygenation. Uncoupling in the 
electron-transport chain has also been reported for the P450s that accept reducing equivalents 




from electron-transport chains 71, 74-78. Therefore, the electron transfer between the redox 
proteins and the P450 enzyme has to be fine-tuned to minimise the uncoupling, which is vital 
for efficient P450 activity 79. Certain aromatic compounds, such as polycyclic aromatic 
hydrocarbons, arylamines and quinones can inhibit the activity of mammalian 
cytochrome P450s by interfering with electron transfer to the heme through futile redox cycling 
and this can be considered another type of uncoupling process 80, 81-83.  
 
1.3. Mechanistic Probes of Cytochrome P450s 
 
The majority of the steps in P450 catalytic oxidation cycle are well characterised, including the 
steps involving the binding of the substrate, reduction of ferric ion, ferrous-dioxygen complex 
formation and the second reduction step (Figure 1. 3) 84. However, an understanding of the 
final oxidation mechanism is still not complete. This step dictates the resulting metabolite 
distribution in P450 catalysed oxidation reactions 84, 85. There are numerous proposed 
mechanisms for the final product determining step.  
The C-H hydroxylation step was hypothesised to be carried out by a high-valent iron-oxo 
species which transferred oxygen in the C-H bonds via a direct insertion mechanism (Figure 1. 
6 (a)) 25, 86-89. This was later replaced by a “radical rebound” mechanism based on studies with 
mechanistic probes of Groves and co-workers (Figure 1. 6 (b)) 84, 86, 90-92.  
 
Figure 1. 6 The (a) insertion and (b) radical rebound mechanisms of P450-mediated 
hydroxylation reactions 38.  




Mechanistic probes have the potential to differentiate between radical and cationic 
intermediates formed during the oxidation which make them useful in the mechanistic 
investigation of hydroxylation reaction of P450s 84 85, 86, 93. Groves and co-workers described 
the oxidation of norbornane, 3,3,6,6-tetradeuteriocyclohexene, methylenecyclohexane and β-
pinene with P450 systems and suggested hydroxylation occurs through the radical rebound 
mechanism 74-76. For example, different mechanisms can be validated using the intermediates 
formed during the P450 mediated oxidation of cyclohexene. The concerted insertion of oxygen 
(A) could explain why the hydroxylation occurs at the allylic site of cyclohexene, but this 
mechanism could not justify the allylic rearrangement products that were observed with 
hydroxylation (Figure 1. 7) 92. The mechanism ‘D’predicts that the hydroxylation at allylic C-
H bond should occur with the rearrangement of the π bond, but this path is unable to explain 
hydroxylation metabolites formed without rearrangement (Figure 1. 7) 92. The mechanism “C” 
is a preferential path for epoxidation of cyclohexene, but allylic hydroxylation of cyclohexene 
without rearrangement is unlikely to arise by this mechanism either as the oxidant should 
interact initially with the π bond (Figure 1. 7). The hydroxylation of cyclohexene both with or 
without rearrangement can be validated with a two-step radical rebound mechanism (B; Figure 
1. 6 and Figure 1. 7) 92, 84, 90.  
 
Figure 1. 7 (i) P450 mediated oxidation of cyclohexene 92. (ii) Several pathways for 
cyclohexene oxidation by an oxoiron (IV) species. (A) Concerted oxygen insertion, (B) radical 
recombination, (C) electron transfer from alkene to generate π-cation radical which later loses 
an allylic hydrogen atom, (D) addition of iron-bound oxygen to π bond followed by elimination 
of proton 92.  
 
Cpd I is widely recognised as the main oxidising species. However, observations during several 
studies have been interpreted as evidence of multiple oxidants, also including the  




ferric peroxy anion (V) and ferric-hydroperoxy species Cpd 0 (VI; Figure 1. 3) 94-96. For 
illustration, Newcomb and co-workers studied the two hypersensitive mechanistic probes 
trans,trans-2-methoxy-3-phenylmethylcyclopropane and methylcubane which were capable of 
distinguishing between potential radical and cation intermediates by rearranging to give distinct 
products based on the intermediate formed during the P450 product formation steps 84. 
Oxidation of these probes by P450s generated different rearrangement products resulting from 
cationic and radical intermediates (Figure 1. 8) 84. These results have been rationalised via a 
concerted “non-synchronous” mechanism, and the cationic intermediate rearrangement 
products were hypothesised to arise from the reaction with the hydroperoxo-iron intermediate 
(Fe-O-OH; Figure 1. 8) 84.   
 
Figure 1. 8 (a) Products generated by P450s which can be used for differentiating between 
cationic and radical intermediates formed during hydroxylation 84. (b) Newcomb et al. 
proposed the hydroxylation via the P450 hydroperoxo-iron species 84.    




However, DFT investigations disagree with the involvement of the hydroperoxo-iron 
intermediate (Cpd 0) as the redox potential of this is inadequate for C-H bond abstraction 97-99. 
Other experimental studies were also in agreement with this theoretical observation 100. 
Recently a "two-state" reactivity model has been proposed based on theoretical studies which 
hypothesised the radical or cationic intermediates formed are controlled by the spin-state of 
compound I 98.  
 
In the two-state model, reactive intermediates can be present in doublet and quartet states 
(Figure 1. 3) 101, 102. Calculations predict that the oxygenation pathways undertaken via doublet 
state proceed in a barrierless fashion, whereas the quartet state has a significant rebound barrier 
extending the lifetime of the intermediate 101, 103. Many experimental observations have been 
interpreted using this theory and by assuming that the longer lived intermediate of the quartet 
state undertakes alternative pathways involving radical rearrangements or electron transfer 
reactions to give the cation. 
 
Further investigation is required to fully characterise of the product formation step and to 
understand the product distribution of P450 catalysed metabolism of a wide range of natural 
and non-natural substrates 104.  
 
1.4. Applications of Cytochrome P450s 
 
Cytochrome P450 enzymes play various roles in the synthesis of natural products and are 
involved in the breakdown of xenobiotic compounds. They are engaged in a range of oxidative 
processes as part of the biosynthesis of hormones, vitamins and secondary metabolites as well 
as the metabolism and degradation of cholesterol, environmental chemicals, pollutants and a 
wide variety of organic compounds 105-108. For example, CYP17A1, CYP21B1, CYP3A4, 
CYP3A5 and CYP105A1 catalyse the synthesis of cholesterol, vitamins, steroids and other 
lipids, and are also capable of the oxidation of drug molecules (Figure 1. 9) 105-108. 
 









In the last few decades, notable progress has been made in the development of chemical 
strategies to functionalise inert C-H bonds 109. Transition metal-containing catalysts and 
directing groups have been collectively applied to favour oxidation of an sp3 or sp2 C-H bond 
110-112. Other approaches such as the use of non-heme iron hydroxylation catalysts, peptide-
embedded trifluoromethyl ketone catalysts and iron (Fe)-based small molecule catalysts have 
been used to oxidise electronically activated (typically tertiary or heteroatom-bearing) C-H 
bonds with high selectivity over less reactive secondary and primary C-H bonds 105, 113-115. For 
example, the selective oxidation of cis-1,2-dimethylcyclohexane and 2,6-dimethyloctane using 
different non-heme iron complexes were reported (Figure 1. 10) 113. Regioselectivity in C-H 
bond oxidation has also been improved through “biomimetic” supramolecular approaches, for 
instance, regio- and stereoselective functionalisation of 4-methylcyclohexyl acetic acid by a 
catalytic Mn-oxo complex (Figure 1. 10) 116-118. Manganese-porphyrin catalysts containing 
2′,4′,6′-triphenyl phenyl groups showed better activity on primary C-H bonds over secondary, 




and the selectivity of oxidation was improved for N-alkylpyrrolidines C(sp3)-H bonds without 
the requirement for directing groups by utilising Pt-catalyst (Figure 1. 10) 116, 119, 120. The 
supramolecular (manganese and iron) porphyrins combined with structural elements to bind 
and hold the substrate in a specific orientation/position above a metal centre to oxidise the C-
H bond selectively, has also been reported 105, 116-118. 
 
         Figure 1. 10 Different chemical approaches to activate inert C-H bonds 116, 117, 119, 121, 122. 
 
Despite this progress, conventional chemical strategies for inert C-H bond oxidation are not 
devoid of drawbacks. The regioselectivity of chemical reagents/catalysts to the most reactive 
C-H bond over the other bonds due to electronic or stereoelectronic effects is still the most 
limiting aspect 105. Moreover, harsh or toxic chemical reactants are required to functionalise 
the inert C-H bonds, and these often result in low product yields or unwanted side-products. In 
this context, cytochrome P450 enzymes have emerged as an attractive strategy, which can 
catalyse the reactions under mild ambient conditions 105. It is also a valuable methodology for 
green chemistry because these catalysts utilise natural molecular oxygen, which is abundant, 
inexpensive and non-toxic to the environment 123, 124. P450s are capable of oxidising inactive 
C-H bond with high chemo-, regio- and stereo-selectivity in the presence of multiple other C-




H bonds of similar or higher reactivity. For examples, the regioselective oxidation of quinoline-
6-carboxylic acid and α-irone by CYP199A2 and CYP267B1, respectively and the 
enantioselective hydroxylation of 2-arylacetic acid in the ‘α’ C-H bond using CYP102A1 
highlighted the advantages of using biocatalytic systems in selective oxidation (Figure 1. 11) 
125, 126. Another example, the P450 enzyme CYP154E1 from bacterium Thermobifida fusca YX, 
catalysed the double hydroxylation of (E)‐stilbene efficiently and selectively 127.  Therefore, 
the biocatalytic production of fine chemicals in larger scale using P450 enzyme would be 
attractive 128-131. For instance, pravastatin, a cholesterol-lowering drug was synthesised on an 
industrial scale by a bioconversion process using a water-soluble P450 named CYP105A3 from 
Streptomyces carbophilus (Figure 1. 11) 132, 133.  
   
      Figure 1. 11 P450 mediated selective oxidation of different substrates 125, 127, 133, 134. 
 
Whole-cell biotransformation using P450s is also a valuable approach to produce drugs, 
vitamins, flavours, fragrances and pesticides 133. Application of P450s in the field of 
bioremediation has generated significant interest as P450s can catalyse the degradation of 
chlorinated dibenzo-p-dioxin, polychlorinated biphenyl (PCB) and other pollutants which are 




formed by different industrial processes 133, 135-137. However, practical applications of P450 
enzymes are still limited because of their low affinity and activity towards non-natural 
substrates 76, 138, 139. Some P450s suffer from low stability and activity, and the desired 
substrates and products can be toxic to cells 76, 138, 139.  
 
To address these issues, different approaches have been taken to improve P450 enzymes for 
use on a larger scale. Protein engineering of P450 enzymes including site-directed mutagenesis, 
random mutagenesis, construction of chimeric P450s and DNA shuffling methods have been 
used to improve their activity towards a broad range of non-physiological substrates 133, 140, 141. 
For example, P450BM3 from Bacillus megaterium is capable of oxidising β-ionone but exhibits 
weak binding and low product formation activity 142. By using site-directed mutagenesis, the 
performance of P450BM3 (F87V mutant) was increased towards β-ionone, resulting in a 115-
fold increased product formation rate when compared to the wild-type (Figure 1. 12) 142. The 
catalytic activity of CYP101A1 and CYP101D1 have also been enhanced via protein 
engineering approaches to enable the oxidation of hydrophobic substrates which were not 
generally accepted by the WT enzymes (Figure 1. 12) 143, 144.  
 
Figure 1. 12 The activities of wild-type CYP101D1 and CYP101A1 (P450cam) which have 
been improved by protein engineering 143, 144. No or little product was reported in the turnover 
of wild-type CYP101A1 enzyme with diphenylmethane and diphenylamine. However, Y96A 
and Y96G CYP101A1 variants catalysed the oxidation of these substrates efficiently. 
 




The activity of different P450s such as CYP2A6 and CYP102A1 were expanded via random 
mutagenesis 145, 146. For example, the F209T mutant of CYP2A6 displayed 13-fold higher 
activity over the wild-type in the oxidation of coumarin, and different variants of CYP102A1 
such as F81I, E267V and L86I increased the catalytic activity of this enzyme with 
dextromethorphan and 3,4-methylenedioxy-methylamphetamine 145, 146. Effective shuffling of 
P450 enzyme sequences could be another way to improve catalytic activities 147. For example, 
a shuffled library of mammalian CYP2C9, CYP2C11 and CYP2C19 genes, was constructed 
using a modified DNA family shuffling approach and these enzymes displayed higher indole 
oxidation activity than the parental P450s 147. 
 
Instead of protein modification, substrate engineering represents another useful strategy to 
enhance the efficacy of these enzymes for synthetic applications 138, 148-150. This can be done 
via the installation of a functional group in a specific position of the substrate or the 
introduction of a chemical moiety to the substrate which then anchors the substrate in the active 
site of the enzyme in a place so that P450-mediated oxidation occurs efficiently 105. This 
approach using a chemical auxiliary was successfully implemented to afford predictable 
oxidation of small hydrocarbon substrates and improve the activity of various P450s such as 
CYP102A1, CYP3A4 and CYP2E1 toward these non-natural substrates (Figure 1. 13) 105, 150-
155. Structural analysis by X-ray crystallography enables a better understanding of the substrate 
selectivity of the enzyme, and this information can be used to expand P450 activity 156. 
 
Figure 1. 13 P450 activity and selectivity has been improved through using type II P450 
ligands 105, 151, 153. These chemical auxiliaries allow P450s to oxidise inert C-H bonds with high 
regio-, chemo- and stereo-selectively. 




As the performance of the P450 enzymes usually depend on the electron transfer, the 
requirement for appropriate redox partners and the expensive co-factor (NAD(P)H) for 
catalysis are still major limiting factors to utilise them in larger scale synthesis 157-159. To 
overcome the ‘cofactor challenge’ different approaches have been developed including whole-
cell biotransformation, biomimetic systems containing enzymatic cofactor regeneration 
systems and alternative nonenzymatic regeneration methods 160, 161.  
 
Whole-cell biotransformation systems containing the desired P450 and electron transfer partner 
genes, can be used to regenerate the expensive reducing equivalents. These systems can be 
scaled up to larger-scale production 76, 139. For example, different drug metabolites were 
generated in large-scale to support toxicity and biological activity assays using human P450s, 
e.g. CYP3A4, CYP2C9 and CYP1A2 which are expressed in Escherichia coli (Figure 1. 14) 
162.  
 
Figure 1. 14 Drug metabolites which have been synthesised in larger yield using different 
P450s to assess toxicity and biological activity 162. 
 
Theoretically, the oxidised coenzyme NAD(P)+ requires two electrons and a hydrogen ion to 
be reduced to NAD(P)H 163. Different enzymatic systems for cofactor regeneration have been 
reported such as glucose dehydrogenase, phosphite dehydrogenase, alcohol dehydrogenase, 
amino acid dehydrogenase, formate dehydrogenase and NAD(P) oxidase 160, 161, 164, 165. Many 
of these have been successfully applied in larger-scale syntheses 165. There are some advantages 
to using glucose dehydrogenase such as it is commercially available, inexpensive and stable 
under aerobic conditions 166. However, isolation of the generated P450 metabolites becomes 




challenging due to the presence of glucose and gluconolactone 167. To overcome this, formate 
dehydrogenase (FDH) can be used which uses formate as a substrate and catalyses NAD+-
mediated oxidation to form CO2 and NADH (Figure 1. 15) 
159. Kragl and co-workers have 
reported a mutated FDH suitable for NADPH dependent P450s 159. 
 
 
                    Figure 1. 15 Enzymatic regeneration of expensive redox cofactor 160, 168. 
 
Electrochemical regeneration of either NADH or NADPH has the advantage which does not 
require a second enzyme and co-substrate, thereby avoiding the production of unwanted by-
product(s) 160, 164. Chemical catalysts such as organometallic complex [Cp*Rh(bpy)(H2O)]
2+ 
have also been reported to regenerate NADH and NADPH in monooxygenase turnovers 163, 169. 
In this NAD(P)H regeneration approach the organometallic complex act as a hydride transfer 
reagent, and a cathode is used as a source of reducing equivalents 169. 
 
1.5.  P450 Enzymes from Novosphingobium aromaticivorans 
 
Novosphingobium aromaticivorans DSM12444 is an oligotrophic bacterium first isolated from 
coastal plain subsurface sediments (at a depth of 410 m below land surface) in the USA 170, 171. 
It is believed that the bacterium is capable of utilising different aromatic hydrocarbons 
including toluene, p-cresol, naphthalene, salicylate and xylenes as the sole carbon and energy 
source 170. The genome of this bacteria contains sixteen P450 enzyme-encoding genes 48. A 
large number of  P450 and other monooxygenase and dioxygenase genes within the bacterium 
allow it to metabolise a wide variety of compounds and enable it to survive in an environment 
that offers very little support for life 171. The sixteen P450s from this bacterium belong to ten 
different families, and among those, four enzymes (B1, C1, D1 and D2) are from the CYP101 
family. These and one other from the CYP111 family (A2) use a common class I electron 




transfer system consisting of a flavin-dependent ferredoxin reductase, ArR, and a [2Fe-2S] 
ferredoxin, Arx (Figure 1. 5) 30, 48-50, 172. These five enzymes have been cloned with these 
physiological electron transfer partners in Escherichia coli cells to generate whole-cell 
biotransformation systems 48, 49, 172.  
 
CYP101D1 and CYP101D2 have both been shown to selectively oxidise camphor to 5-exo-
hydroxycamphor (Figure 1. 16) 48, 49. This is the same metabolite formed with CYP101A1 
(P450cam) 
25, 33, 48, 49, 173, 174. CYP101B1 was found to oxidise camphor 48. Unlike CYP101A1, 
CYP101D1 and CYP101D2, it was unselective, generating four different products (Figure 1. 
16) 48, 49. However, it displayed high activity and selectivity, when oxidising norisoprenoids 
such as α- and β-ionone. Furthermore, CYP101B1 exhibited high binding affinity with both α- 
and β-ionone (≥95% spin-state shift, Kd = 0.23 µM and 0.26 µM, respectively) and a fast 
product formation rate was observed in each substrate turnover. CYP101B1 catalysed the 
oxidation of these substrates efficiently and generated a 3-hydroxy α/β- ionone as a significant 
metabolite alongside a minor 4-hydroxy product (Figure 1. 17) 175. This indicated that these 
norisoprenoids could closely resemble the natural substrates of this enzyme 175.  
 
Figure 1. 16 The products reported from camphor oxidation by CYP101D1, CYP101D2, 
CYP101A1 and CYP101B1 48, 49. 
 
Further investigation of CYP101B1 has been carried out with a variety of other norisoprenoids 
such as β-damascone, which also bound to the enzyme with high affinity (≥80% HS, Kd = 8.3 




µM). This was oxidised to two metabolites 3-hydroxy-β-damascone and 4-hydroxy-β-
damascone (Figure 1. 17). When screened with monoterpenoids, CYP101B1 was found to be 
capable of oxidation, but levels of product formation activity and selectivity were lower when 
compared to norisoprenoids 176. For instance, CYP101B1 catalysed the oxidation of (+)-
fenchone to generate three hydroxylated metabolites with poor product formation activity 
compared to α- and β-ionone (Figure 1. 17) 176. The efficiency and selectivity of oxidation of 
monoterpenoid substrates have been improved using their ester derivatives 176. For example, 
CYP101B1 catalysed the oxidation of monoterpenoid esters such as myrtenyl acetate, bornyl 
acetate and fenchyl acetate with high product formation activities and selectivity. The turnovers 
of borneol, myrtenol and isoborneol generated multiple products at low yields 176.  
 
 
        
         Figure 1. 17 CYP101B1 catalysed the oxidation of different classes of substrates 175, 176. 




CYP101B1 was also able to bind and oxidise aromatic substrates including p-cymene and 
phenylcyclohexane (Figure 1. 18) 175. These aromatic substrates induced a minimal spin-state 
shift in CYP101B1. The enzyme also exhibited weaker binding affinities for these substrates 
than norisoprenoids. The reactions were selective, but the product formation activities were 
lower suggesting that they are less effective substrates for CYP101B1 than those outlined 
above (Figure 1. 18) 175. 
    
 
                           Figure 1. 18 Oxidation of aromatic substrates by CYP101B1 175. 
 
CYP101C1 from Novosphingobium aromaticivorans is a homologue of the CYP101B1 
enzyme, also accepts electrons from the ArR/Arx class I electron transfer system 47. CYP101C1 
displays no activity for camphor oxidation 47. CYP101C1 can oxidise norisoprenoid substrates, 
e.g. β-ionone with high activity. Interestingly only marginal changes in the heme spin-state 
shifts have been observed on substrate binding to CYP101C1 with any of these compounds 47, 
48. While CYP101C1 oxidised β-ionone to the same metabolites as CYP101B1, but the 
selectivity was different (Figure 1. 19). The major metabolite for CYP101C1 arises from C4 
(75%) oxidation while CYP101B1 oxidised the substrate predominantly at the C3 (90%) 
position (Figure 1. 19) 47. 
 
 
                                     
                                  Figure 1. 19 Oxidation of β-ionone by CYP101C1 47. 
 




Whole-cell oxidation systems of both CYP101B1 and CYP101C1 have been generated, and 
these systems enabled the production of oxidised metabolites on a gram-per-litre scale which 
indicated they were viable for use in the production of metabolite for further characterisation 
47, 176.  
 
1.6. Thesis Aims 
 
CYP101B1 and CYP101C1 exhibit activity for norisoprenoid oxidation resulting in different 
metabolite selectivity in β-ionone oxidation. CYP101B1 also shows interesting activity with 
monoterpenoid esters. To further explore the potential of both enzymes as biocatalysts for 
valuable chemical or drug metabolite synthesis, they will be tested with a series of compounds 
(C6–C15) which contain an alcohol, ester, or ketone functional group. These investigations will 
allow us to explore the substrate range of these enzymes in more detail and will generate 
valuable information about the activity with different sized substrates. Substrate engineering 
techniques will be implemented to improve the acceptance of alcohol substrates which show 
little or no affinity with the enzymes. It was hypothesised that introduction of a directing group, 
mimic to the butenone side chain of β-ionone, to cyclic alcohols, could enable more efficient 
and selective catalytic oxidation by both enzymes. A similar approach will be applied for 
tricyclic adamantane substrates to allow efficient oxidation of the inert tricyclic hydrocarbon 
skeleton of these substrates, and the regio and stereoselectivity will be assayed. Turnovers will 
be scaled up using whole-cell biotransformation systems and the products will be isolated for 
characterisation. 
 
CYP101B1 has been shown to oxidise aromatic compounds like p-cymene and 
phenylcyclohexane, but the efficiency is low. To expand the substrate range, site-directed 
mutagenesis of CYP101B1 will be carried out with the intention of improving the activity 
towards these hydrophobic aromatic substrates. A variety of hydrophobic alkylbenzenes and 
naphthalenes will be screened with both wild-type and mutant CYP101B1 to determine if any 
hydroxy compounds can be generated. The whole-cell system will also be used to synthesise 
the metabolites on a larger-scale. 
 




Cubane can act as bioisostere for benzene due to its similar size and shape, and it can be used 
to develop new drugs and agrochemicals with improved characteristics over existing 
candidates.  Cubane derivatives can be synthesised using different chemical techniques, but 
new methodologies for functionalising these substrates are required. Methylcubane has also 
been used as a probe to elucidate the mechanism of the methane monooxygenase (MMO) from 
Methylosinus trichosporium OB3b and various P450 enzymes 177. A series of 4-methylcubane 
derivatives will be designed and screened with CYP101B1 to assess how efficiently and 
selectively these cubane derivatives are oxidised. These reactions may be useful as mechanistic 
probes for CYP101B1 mediated hydroxylation of inert C-H bonds. This could determine if any 
rearrangement reactions arise from a radical or cationic intermediate which are formed during 
the hydroxylation process. 
 
Finally, an additional form of uncoupling of the reducing equivalents by P450 systems in the 
presence of oxygenated aromatics will be investigated. Different electron transfer partners (ET) 
including those of the CYP101B1 system (ArR and Arx) will be used to provide a better 
understanding of this form of uncoupling in these systems. 
 







2.1.  General 
 
General reagents, substrates, laboratory solvents, HPLC solvents were purchased from Sigma-
Aldrich, Tokyo Chemical Industry (TCI), Alfa Aesar and Acros Organics. Antibiotics 
(ampicillin and kanamycin), isopropyl β-D-1-thiogalactopyranoside (IPTG), detergent (Tween 
80) and dithiothreitol (DTT) were supplied by Astral Scientific (Australia). 
 
2.2.  Media Solution  
 
The different media used for bacterial growth and whole-cell turnovers were as follows (all per 
litre of media) 233:  
Lysogeny Broth (LB) 
• Yeast extract (5 g) 
• Tryptone (10 g) 
• NaCl (10 g) 
2 x YT broth 
• Yeast extract (10 g) 
• Tryptone (16 g) 
• NaCl (5 g) 
Trace elements solution 
• FeCl3 (6H2O) (16.7 g) 
• Na2EDTA (20.1 g) 
• CoCl2 (6H2O) (0.25 g) 
• CaCl2 (H2O) (0.74 g) 




• ZnSO4 (7H2O) (0.18 g) 
• CuSO4 (5H2O) (0.10 g) 
• MnSO4 (4H2O) (0.132 g) 
Super Optimal broth with Catabolite repression (SOC) 
• Yeast extract (5 g) 
• Tryptone (20 g) 
• NaCl (0.5 g) 
• MgCl2 (1 g) 
• KCl (0.2 g) 
• Glucose (0.2% w/v) 
E. coli minimal media (EMM) 
• K2HPO4 (7 g) 
• KH2PO4 (3 g) 
• (NH4)2SO4 (1 g) 
• Na3C6H5O7 (Trisodium citrate) (0.5 g) 
• MgSO4 (0.1 g) 
• 20% D-glucose (40 ml) 
The required antibiotics such as ampicillin (100 µg ml-1) and kanamycin (30 µg ml-1) were 
added to LB and 2 x YT media as required.  
 
UV/Vis spectroscopy was performed on a Varian Cary 60 or 5000 spectrophotometer, and 
these assays were recorded at 30 ± 0.5 ºC. The details of Gas Chromatography-Mass 
Spectrometry (GC-MS) and Gas Chromatography (GC) analyses, methods, columns and 
instrument conditions are provided in Table 2. 1. HPLC analyses were performed using an 
Agilent 1260 Infinity pump equipped with an Agilent Eclipse Plus C18 column (250 mm x 4.6 
mm x 5 µm) and coupled with a UV detector (monitored at 280 nm for naphthalene, 
acenaphthene turnovers and 254 nm for biphenyls assays). A gradient of 20-95% acetonitrile 
(with trifluoroacetic acid, 0.1%) in water (TFA, 0.1%) was used. 
 




                                                Table 2. 1 Instrument Operating Conditions 
 
GC-MS Shimadzu GC-17A instrument attached to a QP5050A 
MS detector 
Column ZebronDB-5 MS fused silica column 
 (30 m x 0.25 mm x 0.25 µm) 
Column carrier gas Helium; flow rate 1.3 ml min–1 
Injector and interface  
temperature 
250 °C and 280 °C 
Methods for cyclic alkanes, cyclic 
ketones, cyclic esters, cubane, 
aromatic and adamantane 
compounds 
140 °C (hold 3 min), 10 °C/ min to 220 °C (hold 7 min.) 
Methods for cyclic alkanes (C6-C8) 
and small aromatic compounds 
120 °C (hold 3 min), 10 °C/ min to 220 °C (hold 7 min.) 
GC-MS Shimadzu GC-2010 coupled to a GC-MS-QP2010S 
detector 
Column DB-5 MS fused silica column  
(30 m x 0.25 mm x 0.25 µm) 
Column carrier gas Helium; flow rate 1.3 ml min–1 
Injector and interface  
temperature 
250 °C and 280 °C 
Methods for cyclic alkanes, ketones, 
esters, cubane, aromatic compounds 
140 °C (hold 3 min), 10 °C min–1 to 220 °C (hold 7 min) 
Methods for cyclic alkanes (C6-C8) 
and small aromatic compounds 
120 °C (hold 3 min), 10 °C min–1 to 220 °C (hold 7 min) 
GC Shimadzu Tracera GC coupled to Barrier Discharge 
Ionization Detector (BID)  
Column Supelcowax column 
(Shimadzu Supelco, 30 m x 0.32 mm x 0.25 µm) 
Column carrier gas Helium and flow rate 1.3 ml min–1 
Injector and BID temperatures 250 °C 
Methods for cyclic alkanes, ketones, 
esters, cubane, aromatic compounds 
120 °C (hold 3 min), 5 °C min–1 to 220 °C (hold 3 min) 
Methods for cyclic alkanes (C6-C8) 
and small aromatic compounds 
80 °C (hold 3 min), 5 °C min–1 to 220 °C (hold 3 min) 
GC Shimadzu Tracera GC coupled to Barrier Discharge 
Ionization Detector (BID)  
Chiral Column RT®- BDEXse chiral silica column  
(Restek; 30 m x 0.32 mm x 0.25 µm) 
Column carrier gas Helium and flow rate 3 ml min–1 
Injector and BID temperatures 230 °C 
Methods for cyclic alkanes, ketones, 
esters, cubane, aromatic compounds 
100 °C (hold 3 min), 5 °C min–1 to 200 °C (hold 3 min) 
Methods for cyclic alkanes (C6-C8) 
and small aromatic compounds 
80 °C (hold 3 min), 5 °C min–1 to 200 °C (hold 3 min) 
 
 




2.3. Enzyme Purification  
 
2.3.1. Purification of CYP101B1 and CYP101C1 
 
BL21 (DE3) E. coli competent cells were transformed with a plasmid vector (pET26; Merck 
Millipore) harbouring the appropriate CYP101B1 or CYP101C1 gene and grown on LBkan 
plate. A single colony was added to each flask of 2xYTkan or LBkan (500 mL in each 2 L flask 
and a total of 3-4 L of media). These were grown at 37 ºC with shaking at 110 RPM for 10 
hours. The temperature was decreased to 18 ºC, and 30 min later, ethanol (2% v/v) and benzyl 
alcohol (0.02% v/v) were added. Protein production was facilitated by adding 0.1 mM of IPTG 
from a 0.5 M stock solution. The culture was grown for a further 48 to 72 hours at 18 ºC and 
90 rpm. The cell pellets were harvested by centrifugation (5000 g, 20 min at 4 ºC) and stored 
at -20 ºC before extraction. The pellets were resuspended in 200 mL Tris buffer (50 mM, pH 
7.4) containing 1 mM DTT (Buffer T). The resuspended cells were lysed by sonication using 
an Autotune CV334 Ultrasonic Processor equipped with a standard probe (136 mm x 13 mm; 
Sonics and Materials, US). Pulses (40 x 20s on with 40 s intervals) were used to lyse the cells. 
The cell debris was discarded by centrifugation (37 000 g, 20 min, 4 ºC). The suspended protein 
was loaded onto a DEAE Sepharose column (XK50, 200 mm x 40 mm; GE Healthcare), and 
purified using a gradient from 100 to 250 mM KCl in buffer T at a flow rate of 6 mL min–1. 
The red coloured protein containing fractions were combined and concentrated by 
ultrafiltration (10 kDa exclusion membrane). The concentrated protein was desalted by 
Sephadex G-25 coarse grain column (200 mm x 40 mm) using Buffer T.  
 
The desalted protein was concentrated and loaded onto a Source-Q ion-exchange column 
(XK26, 80 mm x 30 mm; GE Healthcare) linked to an AKTA Pure (GE Healthcare), and eluted 
using a linear gradient from 50 to 400 mM KCl in Buffer T. The fractions containing pure 
protein, which had an absorbance ratio A419/A280 >1, were combined and concentrated via 
ultrafiltration (10 kDa exclusion membrane). The concentrated protein was then centrifuged 
(7000 g, 10 min at 4 ºC) to remove solid debris. The protein was filtered using a 0.22 µm 
syringe filter after mixing with an equal volume of 80% glycerol and stored at -20 ºC. The 
extinction coefficients of CYP101B1 and CYP101C1 were reported as ε417 = 113 mM
–1 cm–1 




and ε417 = 121 mM
–1 cm–1 respectively, which were henceforth used to determine the 
concentration of the enzymes 5, 49. 
 
2.3.2. Carbon Monoxide Binding Assays of Purified P450s 
 
The ferrous- carbon monoxide (CO) spectrum was recorded to check the purified P450s and 
their mutant forms were functional. The P450 enzyme was diluted to ≈ 1 µM, and its spectrum 
was recorded from 700 nm to 250 nm using a UV-visible spectrophotometer. Sodium dithionite 
(~1 mg) was then added to the enzyme and the spectrum recorded. Carbon monoxide was 
gently bubbled through the enzyme solution, and the spectrum was re-recorded to generate 





             Figure 2. 1 An example of ferrous-carbon monoxide assay of purified P450. 
 
2.3.3. Purification of Ferredoxin Reductase (ArR) 
 
BL21 (DE3) E. coli competent cells (25 µL) were transformed with pET26 vector containing 
the ArR gene and grown on a LBkan plate overnight 
49, 175. Colonies were added to LBkan (6 x 
500 mL) solutions and grown at 37 ºC at 120 rpm for 10 hours. The temperature was reduced 
to 18 ºC, and half an hour later, 10 mL ethanol and 200 µL benzyl alcohol were added to each 
flask. IPTG (0.1 mM) was added to induce the protein production, and the culture was grown 
for a further 72 h at 18 ºC and 90 rpm. The cell pellets were harvested by centrifugation (5000 




g, 20 min at 4 ºC) and resuspended in 200 mL 50 mM buffer T, pH 7.4. The cells were lysed 
via sonication using 40 x 20 s with 40 s intervals. The resulting suspension was centrifuged to 
discard cell debris (37 000 g, 20 min, 4 ºC). The protein containing supernatant was loaded 
onto a DEAE Sepharose column (XK50, 200 mm x 40 mm; GE Healthcare) and purified using 
a salt gradient of 100 to 300 mM KCl in buffer T at a flow rate of 6 mL min–1. The yellow 
coloured fractions combined and concentrated by ultrafiltration (10 kDa exclusion membrane). 
The concentrated protein was then desalted via a Sephadex G-25 medium grain column (250 
mm x 40 mm; GE Healthcare). The desalted protein was further purified using Source-Q ion-
exchange column (XK26, 80 mm x 30 mm; GE Healthcare) as described previously with 
elution using a linear gradient from 50 to 400 mM KCl in Buffer T. The ferredoxin reductase 
containing fractions with A280/A458 <8, were combined and concentrated using ultrafiltration. 
The concentrated protein was centrifuged (7000 g, 10 min at 4 ºC) to remove particulate matter 
and protein was diluted with an equal volume of 80% glycerol. The diluted protein was further 
purified via a 0.22 µm syringe filter and stored at -20 ºC. The ArR concentration was estimated 
using extinction coefficient, ε458 = 10 mM
–1 cm–1 49. 
 
2.3.4.  Purification of Ferredoxin (Arx) 
 
A pRSFDuet plasmid harbouring the gene encoding the ferredoxin (Arx) was transformed into 
BL21 (DE3) E. coli competent cells, and cells were grown on a LBkan plate overnight 
49. The 
colonies from LBkan plate were added to LBkan (5 x 500 mL) media and grown at 37 ºC with 
continuous shaking at 120 rpm for 10 hours. The temperature was decreased to 18 ºC, and after 
half an hour 10 mL ethanol and 200 µL benzyl alcohol were added in each flask (500 mL 
growth media). Protein production was facilitated by adding 0.1 mM IPTG (from a 0.5 M stock 
solution), and the culture was grown for a further 72 hours at 90 rpm. The cell pellets were 
harvested by centrifugation (5000 g, 20 min at 4 ºC) and resuspended in 300 mL 10 mM, pH 
7.4 Tris buffer solution (containing 1 mM DTT, 20% v/v glycerol, 1% v/v 2-mercaptoethanol, 
300 mg lysozyme, 2 mL Triton X-100 and 2 mL Tween 20). The resuspended cells were stirred 
for 30 minutes on ice before sonication (see above).  
 
The resulting solution was centrifuged to separate the cell debris from the soluble protein (37 
000 g, 20 min, 4 ºC). The brown supernatant was loaded onto a DEAE Sepharose column 




(XK50, 200 mm x 40 mm; GE Healthcare) and protein was eluted using a salt gradient of 100 
to 600 mM KCl in Buffer T at a rate 6 mL min-1. The brown fractions containing the ferredoxin 
were combined and concentrated using by ultrafiltration (3 kDa exclusion membrane). The 
concentrated protein was desalted using Sephadex G-25 medium grain column (200 mm x 40 
mm) pre-equilibrated with Buffer T. The desalted protein was further purified using a Source-
Q ion-exchange column (XK26, 80 mm x 30 mm; GE Healthcare) with elution using a linear 
gradient from 100 mM to 600 mM KCl in buffer T at a rate 6 mL min–1. The fractions which 
had an absorbance A415/A280 >0.6, were combined and concentrated using ultrafiltration (3 kDa 
exclusion membrane). The concentrated protein was centrifuged (7000 g, 10 min at 4 ºC) to 
remove any particulate matter before adding an equal amount of 80% glycerol. The protein was 
sterilised via a 0.22 µm syringe filter and stored at -20 ºC. The Arx concentration was calculated 
using the extinction coefficient, ε415 = 9.2 mM
–1 cm–1 49. 
 
2.4.  Whole-cell Biotransformation  
 
The DNA vectors pETDuet harbouring the genes of the ferredoxin (Arx) and ferredoxin 
reductase (ArR), and the pRSFDuet containing the relevant P450 and Arx genes, were 
transformed together into BL21 (DE3) E. coli competent cells 49. The transformed cells were 
grown on a LBkan/amp plate overnight at 37 ºC. A single colony from the plate was added to 
LBkan/amp (500 mL) media and allowed to grow for another 10 hours at 37 ºC with shaking (120 
rpm). Protein production was induced as described in the previous sections and the culture was 
grown at 18 ºC and 90 rpm overnight (Figure 2. 2). The cell pellets were harvested from the 
growth media by centrifugation (5000 g, 20 min at 4 ºC), and cells were resuspended in 1 L E. 
coli minimal media (EMM).  
 
The resuspended cells (200-250 mL) were transferred to 2 L baffled flasks and 0.5 to 1 mM 
substrate was added (the amount depended on substrate solubility). The flasks were shaken at 
30 ºC and 150 rpm for 4 h. Further aliquots of the substrate (0.5 to 2 mM) were added along 
with additional glucose (2 mL from 20% solution) and phosphate-buffered saline (PBS, 2.5% 
v/v). The reactions were continued overnight before the cells were removed from the 
supernatant by centrifugation (5000 g, 20 min, 4 ºC). Products were extracted from the 
supernatant by liquid-liquid extraction using ethyl acetate or dichloromethane (3 x 100 mL), 




washed with brine and dried with anhydrous magnesium sulphate. The extracted products were 
isolated by silica column chromatography with a gradient from 90:10 to 50:50 hexane to ethyl 
acetate, using a 5% increase in every 50 to 100 mL. The purified metabolites were characterised 
by NMR in deuterated chloroform or DMSO. NMR spectra were acquired on an Agilent DD2 
or a Varian Inova spectrometer, operating at 500 or 600 MHz for 1H and 126 or 151 MHz for 
13C. A combination of 1H, 13C, COSY, HSQC, HMBC and ROESY experiments were used to 
determine the structure of the metabolites. 
 
2.5. Spin-State Shift 
 
The relevant P450 enzyme was diluted to ~ 3 µM with 50 mM Tris buffer (pH 7.4). The UV-
Vis spectrum was recorded from 700 nm to 250 nm. Aliquot of the substrate (1 µL from 100 
mM stock solution in ethanol or DMSO) was added to 500 µL of the enzyme solution, and the 
spectrum was recorded. Further aliquots of the substrate were added until the shift from low-
spin (420 nm) to high-spin (390 nm) did not change. The percentage of high-spin (HS) state 
shift induced by the substrate was estimated by comparing with the spectra of camphor-free 




Figure 2. 2 The spin-state shifts of CYP101A1 (P450cam) induced by camphor. This set of 
spectra was used to determine the heme spin-state change of substrate-bound P450 enzyme. 




2.6. Substrate Binding Assays 
 
Dissociation constants (Kd) were determined to measure how tightly the substrates bind to the 
enzymes. The P450 enzymes were diluted to ~1 M with 50 mM Tris buffer pH 7.4. The UV-
Vis spectrum of 2.5 mL of the enzyme was recorded between 600 nm to 300 nm, and the 
spectrophotometer was baselined. Successive aliquots of the substrate (cumulative volumes 
from 0.5 to 10 µL from 1 mM stock solution in ethanol/DMSO) were added, and the different 
spectra were recorded. Further aliquots (1 to 10 µL) of the substrate from 10 mM stock solution 
were then added. Finally, aliquots from 100 mM stock solution were added until the peak to 
trough absorbance difference remained constant. The peak to trough absorbance differences 
were plotted against the substrate concentration to determine the dissociation constant of the 












                             Eqn 2. 1 
 
Where ∆A represents the peak to trough absorbance difference, ∆Amax is the maximum 
absorbance difference, [S] represents substrate concentration, and Kd is the dissociation 
constant.  
 
If substrates exhibited tight binding, defined as having a dissociation constant less than five 
times that of the enzyme concentration (Kd  5[E]), the data was instead fitted to the tight 
binding quadratic equation (Morrison) (Eqn 2. 2) 180. 
 
 Eqn 2. 2 
 
where ΔA is the peak-to-trough absorbance difference, ΔAmax represents the maximum 
absorbance difference, [S] is the substrate concentration and [E] represents the enzyme 














2.7. In Vitro NADH Turnover Assays 
 
NADH turnover/consumption rates were measured by preparing a 1.2 mL mixture containing 
0.5 µM of P450 enzyme, 5 µM ferredoxin (Arx), 1 µM ferredoxin reductase (ArR), 12 µL 
bovine liver catalase and oxygenated 50 mM Tris buffer, pH 7.4, in a cuvette. This was allowed 
to reach 30 ºC, and NADH was added to a concentration ~ 320 µM (A340~ 2). The absorbance 
was monitored at 340 nm by a UV-Vis spectrophotometer (Figure 2.3). After one minute, 0.2 
-1 mM of the substrate from a 100 mM stock solution in ethanol or DMSO was then added and 
mixed by inversion (the amount of substrate added was dependent on the substrate solubility). 
The NADH oxidation rate was calculated by recording the gradient of the absorbance at 340 
nm versus time and using the extinction coefficient of NADH, ε340 = 6.22 mM
–1 cm–1 (Figure 
2. 3). 
The in vitro turnovers were analysed via GC, GC-MS and HPLC to assess product formation 
(Table 2. 1). Co-elution experiments were used to identify the products generated in turnovers 
with authentic standards in GC, GC-MS, and HPLC. If standards were not available, the 
metabolites were synthesised in larger yield using a whole-cell oxidation system for 
characterisation. For GC and GC-MS analysis, 990 µL of the reaction mixture was taken and 
mixed with 10 µL of internal standard (20 mM p-cresol in ethanol). The mixture was then 
extracted with 400 µL of ethyl acetate. The organic extracts were analysed directly by GC/GC-
MS. For HPLC, 150 µL of the reaction mixture was mixed with 2 µL internal standard (9-
hydroxyfluorene in ethanol) and 100 µL of acetonitrile (AcCN). This sample was then analysed 
in HPLC. 
 
 (a)                                                         (b) 
Figure 2. 3 (a) The in vitro turnover of CYP101B1 with cyclooctyl acetate monitored at 340 
nm. (b) Calibration curve of 2-methyl-1-phenyl-2-propanol. 




The ratio of total area of product(s) and internal standard was used to calculate the product 
concentration. Metabolites were calibrated using the authentic product standard or isomers of 
the product or substrates where authentic products not available. These standards, at different 
concentrations (10 µM to 200 µM), were combined with an internal standard (500 µM) as 
described above for sample preparation. These were then analysed via HPLC/GC/GC-MS 
using the same method as for the turnovers. Product and internal standard area ratios were 
plotted against the concentrations to create the calibration curve which was used to measure 
the amount of metabolite generated in the turnovers (Figure 2. 3). To calculate the productive 
use of reducing equivalents (coupling efficiency), the concentration of the product formed in 
the turnover was divided by the concentration of NADH that was added (calculated from the 
absorbance at 340 nm). The proportion of product formed per NADH molecule oxidised (the 
coupling efficiency) was used with the NADH oxidation rate to give the product formation 
rate. 
 
The total turnover number (TTN) was determined with the best substrates to monitor the 
efficiency and activity of the enzyme over an extended period. These were determined using a 
ArR:Arx:CYP101B1 concentration ratio of 1:10:1. The CYP enzyme (0.1 Μ) was combined 
with ArR (0.1 mΜ), Arx (1 Μ), 2 mM substrate and 4 mM NADH. Oxygenated 50 mM Tris 
buffer, pH 7.4, was added to the mixture to a final volume of 1.2 mL. The turnover mixture 
was kept at room temperature for 2 hours before extraction with 400 µL of ethyl acetate. The 
organic extracts were analysed directly by GC/GC-MS.   
 
2.8. Hydrogen Peroxide Assays 
 
The concentration of hydrogen peroxide (H2O2), generated from the uncoupling of NADH 
during in vitro turnovers, was determined using horseradish peroxidase (HRP), phenol and 
aminoantipyrine (4-AP) 181. The turnover incubation mixture (400 L) was combined with 200 
µL of a solution of 50 mM phenol (in Tris buffer, pH 7.4) and 200 µL aminoantipyrine (5 mM 
stock solution in 50 mM Tris buffer, pH 7.4). The absorbance of the resulting mixture at 510 
nm (λmax of the quinoneimine coupling product, ε510 = 6580 M
−1cm−1) was set to zero, and 1 
µL of horseradish peroxidase (20 mg mL−1 HRP in water) was then added. The absorbance at 
510 nm was recorded. The concentration of resulting quinoneimine, which arises from the 




reaction between peroxidase-mediated oxidation of phenol by hydrogen peroxide and 4-AP, 
was calculated in µM, using equation Eqn 2. 3: 
[𝒒𝒖𝒊𝒏𝒐𝒏𝒆𝒊𝒎𝒊𝒏𝒆] =
𝑨𝟓𝟏𝟎 𝐗  𝟏𝟎
𝟔
𝟔𝟓𝟖𝟎
                       Eqn 2. 3 
 
As the incubation mixture was diluted 2-fold (400 µL to 800 µL) and two molecules of 
hydrogen peroxide (H2O2) are required to form the quinone, the concentration of hydrogen 
peroxide formed was then calculated using equation Eqn 2. 4: 
[𝑯𝟐𝑶𝟐] = 𝟒 𝐱 
𝑨𝟓𝟏𝟎 𝐗  𝟏𝟎
𝟔
𝟔𝟓𝟖𝟎
                       Eqn 2. 4 
 
2.9. Synthesis of Ester Substrates 
 
The cyclic alcohols (cyclohexanol, cyclooctanol, cyclododecanol and adamantanol) substrates 
(~0.5 g, 1.0 eq) were dissolved in dichloromethane (~20 mL), and trimethylamine (~2.0 eq) 
was added at 0 C and stirred for 5.0 minutes. Isobutyryl chloride (~1.2 eq) or acetyl chloride 
(~1.2 eq) was then added dropwise at 0 C, and the reaction was subsequently stirred at room 
temperature for 3.0 hours (Figure 2. 4). 
 
Adamantyl derivatives were synthesised by Samrat Dasgupta using the following method 182. 
For 1-adamantyl acetate synthesis, pyridine (~0.65 mL, 3.0 eq) was added to a solution of 1-
adamantanol (500 mg, 1.0 eq) in dichloromethane (~20 mL) at 0 C and stirred for 5 minutes. 
Acetyl chloride (~0.3 mL, 1.5 eq) was added dropwise at 0 C, and the reaction was stirred at 
room temperature (RT) for two to four hours. The progress of the synthesis was monitored by 
TLC or GC/GC-MS.  
 
On completion, the reaction mixtures were washed with a saturated sodium bicarbonate 
solution. The organic layer was isolated and washed with brine solution, dried over anhydrous 
Na2SO4 or MgSO4, filtered and concentrated under vacuum to obtain the crude product. The 
products were separated by silica chromatography using a 5% ethyl acetate/petroleum benzine 
mixture, and the acetate/isobutyrate products were obtained as colourless oils. Similar methods 
were used to synthesise cyclohexyl isobutyrate, cyclooctyl acetate, cyclooctyl isobutyrate and 




cyclododecyl acetate but in all cases, trimethylamine was used instead of pyridine. The 
synthesised substrates were characterised using NMR spectroscopy and mass spectrometry 




Figure 2. 4 The synthesis of 1-adamantyl acetate, 2-adamantyl acetate, 1-adamantyl 
isobutyrate, 2-adamantyl isobutyrate, cyclohexyl isobutyrate, cycooctyl acetate, cyclooctyl 
isobutyrate and cyclododecyl acetate. 
 
 




Table 2. 2 NMR analysis of synthesised ester derivatives (Full data in Appendix A;  




1-adamantyl acetate # 
Conversion and Yield  
 (44% and 230 mg) 
 
1H NMR (500 MHz, CDCl3) 
182 δ 2.18-2.13 (m, 3H, H3, H5 & 
H7), 2.11-2.08 (m, 6H, 2xH2, 2xH9 & 2xH10), 1.96 (s, 3H, 
3xH12), 1.70-1.61 (m, 6H, 2xH4, 2xH6 & 2xH8). 
13C NMR (126 MHz, CDCl3) δ 172.92 (C11), 82.65 (C1), 43.68 
(C2, C9 & C10), 38.65 (C4, C6 & C8), 33.31 (C3, C5 & C7), 
25.47 (C12). 
2-adamantyl acetate # 
Conversion and Yield  
 (43% and 215 mg) 
 
1H NMR (500 MHz, CDCl3) 
182 δ 4.96-4.83 (m, 1H, H2), 2.07 
(s, 3H, 3xH12), 2.05-1.97 (m, 4H, H1, H3, H8 & H10), 1.88-
1.82 (m, 4H, H4, H5, H7 & H9), 1.80-1.73 (m, 4H, H4, 2xH6 & 
H9), 1.56 (d, J = 10.6 Hz, 2H, H8 & H10). 
13C NMR (126 MHz, CDCl3) δ 173.50 (C11), 79.54 (C2), 40.04 
(C6), 39.01 (C4 & C9), 34.65 (C1 & C3), 34.37 (C8 & C10), 
29.88/29.69 (C5/C7), 24.23 (C12). 
1-adamantyl isobutyrate # 
Conversion and Yield  
 (36% and 185 mg) 
1H NMR (500 MHz, CDCl3) 
182 δ 2.43 (septet, J = 7.0 Hz, 1H, 
H12), 2.19-2.14 (m, 3H, H3, H5 & H7), 2.13-2.05 (m, 6H, 2xH2, 
2xH9 & 2xH10), 1.72-1.63 (m, 6H, 2xH4, 2xH6 & 2xH8), 1.11 
(d, J = 7.0 Hz, 6H, 3xH13 & 3xH14). 
2-adamantyl isobutyrate  
Conversion and Yield  
 (66% and 330 mg) 
 
1H NMR (500 MHz, CDCl3) 
182 δ 4.93-4.87 (m, 1H, H2), 2.57 
(septet, J = 7.0 Hz, 1H, H12), 2.05-1.96 (m, 4H, H1, H3, H8 & 
H10), 1.87-1.81 (m, 4H, H4, H5, H7 & H9), 1.79-1.41 (m, 4H, 
H4, 2xH6 & H9), 1.56 (d, J = 11.9 Hz, 2H, H8 & H10), 1.19 (d, 
J = 7.0 Hz, 6H, 3xH13 & 3xH14). 
13C NMR (126 MHz, CDCl3) δ 179 (C11), 79.04 (C2), 40.04 
(C6), 38.98 (C4 & C9), 37.06 (C12), 34.49 (C1 & C3), 34.44 
(C8 & C10), 29.91/29.66 (C5/C7), 21.70 (C13 & C14). 
cyclohexyl isobutyrate # 
Conversion and Yield  
 (55% and 273 mg) 
1H NMR (500 MHz, CDCl3) δ 4.82-4.66 (m, 1H, H1), 2.52 
(septet, J = 7.0 Hz, 1H, H8), 1.88-1.66 (m, 10H), 1.16 (d, J = 7.0 
Hz, 6H, 3xH9 & 3xH10). 
cyclooctyl acetate 
Conversion and Yield  
(48% and 240 mg) 
1H NMR (500 MHz, CDCl3) δ 4.95-4.85 (m, 1H, H1), 1.99 (s, 
3H, 3xH10), 1.83-1.42 (m, 14H). 
 
cyclooctyl isobutyrate 
Conversion and Yield  
 (62% and 310 mg) 
1H NMR (500 MHz, CDCl3) δ 4.99-4.84 (m, 1H, H1), 2.49 
(septet, J = 7.0 Hz, 1H, H10), 1.85-1.43 (m, 14H), 1.15 (d, J = 
7.0 Hz, 6H, 3xH11 & 3xH12). 
 
cyclododecyl acetate 
Conversion and Yield  
 (50% and 270 mg) 
1H NMR (500 MHz, CDCl3) δ 5.05-4.95 (m, 1H, H1), 2.03 (s, 
3H, 3xH14), 1.76-1.63 & 1.53-1.26 (m, 22H). 




3. Biocatalytic Oxidation of Saturated Hydrocarbons by   
    CYP101B1 and CYP101C1 
 
3.1.  Introduction 
 
Alicyclic compounds, which constitute a large class of organic compounds including 
monocyclic cycloalkanes, cycloalkanones and cycloalkyl esters, are used in manufacturing 
perfumes, flavours, essential oils, tobacco products, herbicides, insecticides and serve as 
intermediates in the pharmaceutical industry 183, 184. They are the main constituents of 
petroleum; for example, n-alkanes, branched alkanes, monocyclic substrates like cyclopentane 
and cyclohexane compounds are the most predominant. They are also commonly used as 
solvents and found as secondary metabolites in microbes and plants such as terpenoids 183-188. 
Functionalisation of the C-H bonds of alicyclic compounds would have an enormous impact 
on the field of chemical synthesis 189-193. Indeed, selective C-H bond activations could pave the 
way for preparing more complex molecular skeletons 194, 195. Unfortunately, selective C-H bond 
functionalisation is one of the most challenging chemical processes due to the low reactivity 
of the bond and overoxidation issues 193, 196. The selective hydroxylation of alicyclic 
hydrocarbons using mild conditions is a primary goal for synthetic chemistry 196-198. Different 
metal catalysts and oxidising reagents have been reported to oxidise the inert C-H bonds of 
alicyclic compounds 199-203. For instance, cyclohexanone and cyclohexanol, which are essential 
chemical intermediates for the synthesis of polyamide and plastics, are synthesised using 
various cyclohexane oxidation processes including H2O2-based hydroxylation, Au-Pd 
bimetallic catalysts and homogeneous transition-metal salt catalysts which are designed to 
reduce the occurrence of overoxidation products 193, 204-206. However, despite an enormous 
effort over the last few decades, several challenges remain 196. The main concern is that harsh 
chemicals, heavy metals and toxic solvents are used in most of these chemical oxidation 
approaches 207.  
The use of an enzyme biocatalyst instead of the toxic chemical catalyst could be an alternative 
and efficient approach to avoid the issues discussed above. Many bacterial and fungal species 
have been shown to oxidise cyclic compounds C-H bonds 187. For examples, Fonken et al. 
Chapter 3                                                                        Cyclic Alkanes, Alcohols and Ketones 
40 
 
reported oxidation of C12-, C13- and C14- macrocyclic compounds using Sporotrichum 
sulfurescens (Beauveria sulfurescens ATCC7159) and Ashton et al. described the oxidation of 
cyclododecanone and cyclopentadecanone by different fungi such as Calonectria decora, 
Daedalea rufescens, Ophiobolus herpotrichus and Rhizopus nigricans 208, 209. CYP153A6 from 
a Mycobacterium sp. hydroxylates medium-chain-length alkanes and cyclic alkanes (C6 to 
C11) 210. CYP153A13a from Alcanivorax borkumensis SK2 was fused to RhFred to improve 
the activity towards alkane hydroxylation. The oxidation of different length alkanes and cyclic 
alkanes were also catalysed with high regioselectively at the terminal carbon by membrane-
bound P450s such as rabbit CYP4B1 and CYP52A3 from Candida maltosa  211, 212. Self-
sufficient P450 BM3 and some of its mutants have been reported to oxidise C8-C12 
cycloalkanes 213. However, in most of the above cases, product formation activity or selectivity 
was low. For example, the turnover rate for CYP4B1 was 11-33 min-1 with C7 to C10 n-alkyl 
hydrocarbons and in other instance, the oxidation of cyclic and linear alkanes by wild type 
CYP102A1 proceeded with low activity and selectivity 211-213.  
CYP101B1 and CYP101C1 can oxidise β-ionone and other norisoprenoids, and CYP101B1 
has been shown to be a highly efficient biocatalyst for other related substrates including 
monoterpenoids acetates 47, 175, 176. CYP101B1 oxidises β-ionone preferentially hydroxylating 
at the C-3 (90%) position while CYP101C1 can efficiently hydroxylate at the C-4 (75%) 47, 175. 
The butenone side chain of β-ionone is an important structural feature enabling the substrate to 
bind effectively to CYP101B1 175. It is hypothesised that this butenone side chain holds the 
substrate in a place for efficient and selective oxidation. This is one of the key features which 
allows these oxidation reactions to proceed with high catalytic activity, turnover number and 
coupling efficiency 175. Previous studies have shown that when an acetate ester directing group 
was added to monoterpenoid structures the binding affinity and oxidation activity with 
CYP101B1 increased dramatically 176. With these bicyclic terpenoids the regioselectivity of 
oxidation also improved with the site of C-H bond abstraction being on the opposite side of the 
ring system to the ester group. This is in agreement with the regioselectivity of norisoprenoid 
oxidation by CYP101B1. The substrates chosen here would test the directing capability of the 
ester group on more flexible cycloalkyl rings. With this in mind, it was decided to investigate 
a series of cyclic substrates, ranging in ring size from 6 to 15 carbons including their alcohols 
and ketones, with CYP101B1 and CYP101C1 (Figure 3. 1). Both enzymes were tested with a 
range of compounds containing an ester directing group, such as acetate and isobutyrate which 
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would mimic the butenone side chain of β-ionone, to assess this effect on the catalytic activity 
of these two enzymes (Figure 3. 24).  
 
        Figure 3. 1 The cyclic compounds screened with CYP101B1 and CYP101C1. 
 
3.2.  Results 
 
3.2.1 The oxidation of cyclic alkanes, alcohols and ketones by CYP101B1 and CYP101C1 
 
The spin-state shift induced by substrate binding gives a general indication of the ability of the 
substrates to replace the water ligand bound to the heme iron and hence if it fits into the active 
site. The spin-state shift of CYP101B1 was analysed with each substrate (Figure 3. 1). None 
of the previous substrates investigated with CYP101C1 induced a substantial change of the 
spin-state from the low spin form. None of the substrates studied here significantly altered the 
spin-state of CYP101C1 either. This could be due to this enzyme having a very specific active 
site or other reasons as described previously 47.  
Cyclohexane induced a shift to 15% high spin in CYP101B1 (henceforth % will be assigned to 
the proportion of high spin (HS) heme-induced by substrate binding).  Cyclooctane shifted the 
spin-state by a greater degree than cyclohexane (35%; Table 3. 1 and Figure 3. 2). The larger 
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cycloalkanes cyclodecane and cyclododecane displayed similar heme spin-state shifts to that 
of cyclooctane (30-40%; Table 3. 1 and Figure 3. 2). These results indicated that these 
hydrocarbon substrates were not well accommodated in the active site of CYP101B1. The 
substrate binding affinity of cyclooctane, cyclodecane and cyclododecane was analysed. With 
cyclodecane and cyclododecane, the binding affinity was tighter with a low dissociation 
constant Kd = 0.88 ± 0.04 µM and Kd = 0.16 ± 0.03 µM, respectively, while cyclooctane bound 
with the enzyme more weakly (Kd = 31 ± 4 µM; Figure 3. 3).  
 
The cyclic alcohols cyclohexanol and cyclooctanol shifted the spin-state to less than 5%, 
suggesting these are poor substrates for the CYP101B1 enzyme (Table 3. 1 and Figure 3. 2). 
4-tert-Butylcyclohexanol induced the heme spin-state shift to 15% high spin upon addition to 
CYP101B1 (Figure 3. 2). However, cyclododecanol altered 90% of the heme iron spin to high 
spin-state and exhibited a tight binding with a dissociation constant Kd of 1.5 µM (Figure 3. 3).  
 
The NADH oxidation and product formation rates give a general indication of P450 activity; 
these were observed to be low for CYP101B1 with cyclohexane, 61 nmol.(nmol-P450)-1 .min-
1 and 2 nmol.(nmol-P450)-1.min-1, respectively (henceforth abbreviated to min-1; Table 3. 1). 
The coupling efficiency which is the productive use of reducing equivalent was also minimal 
(3%; Table 3. 1). These results were in agreement with the small spin-state shift induced by 
cyclohexane. CYP101C1 showed even lower product formation activity with cyclohexane 
(Table 3. 1). The conversion of cyclohexane by both enzymes yielded to a single metabolite, 
which was identified as cyclohexanol by a GC coelution experiment with an authentic standard 
(Figure 3. 4). The turnover of cyclohexanol with CYP101B1 also displayed a slow NADH 
oxidation rate (53 min-1), and no product was detected in GC/GC-MS analysis (Table 3. 1). 
Although CYP101B1 exhibited high NADH oxidation activity for 4-tert-butylcyclohexanol, 
no product was observed in the turnovers (Table 3. 1). These results indicated that cyclohexanol 
and 4-tert-butylcyclohexanol were not accepted by CYP101B1 and CYP101C1 at all.
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     (a)                                                    (b) 
      
     (c)                                                     (d) 
 
  (e)                                                   (f) 
  
                                              (g)                                                   (h) 
 
Figure 3. 2 The spin-state shifts (red) of CYP101B1 after addition of (a) cyclohexane, (b) 
cyclooctane, (c) cyclodecane, (d) cyclododecane, (e) cyclohexanol, (f) 4-tert-
butylcyclohexanol, (g) cyclooctanol and (h) cyclododecanol.  
 




(a)                                                            (b) 
              
                                         (c)                                                              (d) 
 
Figure 3. 3 Dissociation constant analysis with (a) cyclooctane (2.19 µM CYP101B1/ Kd 31 ± 
4 µM), (b) cyclodecane (1.23 µM CYP101B1/Kd 0.88 ± 0.04 µM), (c) cyclododecane (2.37 
µM CYP101B1/ Kd 0.16 ± 0.03 µM), and (d) cyclododecanol (2.37 µM CYP101B1/ Kd 1.5 ± 
0.3 µM). The concentration of enzyme used in the analyses and the dissociation constants (Kd) 
are provided in brackets. The dissociation constant for cyclohexane was not measured due to 
the low response of the spin-state to substrate addition. 
 
Addition of cyclooctane to CYP101B1 induced a six-fold faster NADH oxidation rate (391 
min-1) than that observed with cyclohexane (Table 3. 1). Higher levels of product formation 
activity compared to the cyclohexane turnovers were detected, and this was reflected in the 
coupling efficiency of the turnover (49% versus 3%; Table 3. 1). Cyclooctane displayed lower 
NADH oxidation activity (90 min-1) and product formation rate (18 min-1) in the CYP101C1 
system than the CYP101B1 (Table 3. 1). A significant metabolite (99% selectivity) was 
detected in the GC-MS analyses of the in vitro turnovers of both CYP101B1 and CYP101C1 
with cyclooctane. This metabolite was identified as cyclooctanol by GC-MS coelution 
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experiment with an authentic cyclooctanol standard (m+/z = 128.05; Figure 3. 4 and Figure B. 
1). A minor peak was also detected in the GC-MS analysis that had a different mass spectrum 
(1%; m+/z = 126.05; Figure B. 1). This product was confirmed as cyclooctanone by GC-MS 
coelution experiment with an authentic standard (Figure 3. 4). The oxidation of cyclooctanol 
by CYP101B1 resulted in little or no detectable product formation activity despite having a 
NADH oxidation rate of 158 min-1 (Table 3. 1). Overall, both enzymes oxidised cyclooctane 
more efficiently when compared with cyclohexane, but CYP101B1 was a better system than 
CYP101C1. 
 
CYP101B1 displayed a higher NADH oxidation rate (397 min-1) upon addition of cyclodecane 
than the CYP101C1 system (164 min-1, Table 3. 1). However, the product formation rates with 
both enzymes were lower than the cyclooctane. In the case of CYP101B1, this was 
predominantly due to a reduced coupling efficiency (11% versus 49%; Table 3. 1). CYP101B1 
also exhibited a lower total turnover number with cyclodecane than the cyclooctane (420 versus 
3400; Table 3. 1). This could be due to the lower water solubility of cyclodecane. The in vitro 
turnovers of cyclodecane by both enzymes generated two monooxygenase metabolites. The 
minor product (5% for CYP101B1 and 25% for CYP101C1) was identified as cyclodecanone 
(m+/z = 154.20) by GC-MS coelution experiments with a commercial standard (Figure 3. 5 and 
Figure B. 1). The other metabolite was confirmed as cyclodecanol (m+/z = 156.20) by coeluting 
the product generated from the reduction of cyclodecanone with sodium borohydride (NaBH4) 
using a standard method (Figure 3. 4 and Figure B. 1) 214. 
 
Cyclododecane induced a faster NADH oxidation activity (174 min-1) in CYP101B1 than 
CYP101C1 (84 min-1; Table 3. 1). The product formation rates of CYP101B1 and CYP101C1 
with cyclododecane were slower compared to cyclooctane (Table 3. 1). Despite the low product 
formation activity and coupling efficiency, both enzymes catalysed the oxidation of 
cyclododecane and formed a single major metabolite (92% for CYP101B1 and 60% for 
CYP101C1; based on GC peaks area) alongside two minor products. The metabolites detected 
in the GC-MS analyses of the in vitro turnovers of both enzymes did not coelute with a 
cyclododecanol standard (Figure 3. 6). In order to identify these products, cyclododecanol was 
investigated as a substrate with both enzymes. Cyclododecanol changed the heme spin-state to 
90% high spin upon addition to CYP101B1. The product formation rate (41 min-1) and the 
coupling efficiency (21%) were superior to those of the parent cycloalkane (Table 3. 1). 
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CYP101C1 had a slightly higher NADH oxidation activity (280 min-1) than the CYP101B1 
system, but the product formation rate was lower due to a coupling efficiency of only 11% 
(Table 3. 1).  
 
Table 3. 1 Substrate binding, turnover and coupling efficiency data for CYP101B1 and 
CYP101C with cyclic alkanes and alcohols. The in vitro turnover activities were measured 
using a ArR: Arx: P450 concentration ratio of 1:10:1 (0.5 μM CYP enzyme, 50 mM Tris, pH 
7.4). TTN, the total turnover numbers, were determined using assays set up with the same ratio 
of enzymes as used in vitro turnovers but with 0.1 μM CYP enzyme, 1 to 2 mM substrate and 
4 mM NADH (theoretical maximum value 20,000 for 2 mM substrate). N is the NADH 
oxidation rate, PFR the product formation rate and C is the coupling efficiency, which is the 
percentage of NADH utilised for the formation of products. The data are reported as mean ± 















CYP101B1 15 61 ± 9 2 ± 1 3 - 
CYP101C1 - 42 ± 4 <1 <1 - 
cyclohexanol CYP101B1 5 53 ± 2 - - - 
4-tert-
butylcyclohexanol 
CYP101B1 15 363 ± 9 - - - 
cyclooctane 
CYP101B1 35 391 ± 11 209 ± 17 49 3400 ± 150 
CYP101C1 - 90 ± 13 18 ± 7 20 - 
cyclooctanol CYP101B1 10 158 ± 2 - - - 
cyclodecane 
CYP101B1 40 397 ± 15 42 ± 34 11 420 ± 75 
CYP101C1 -  164 ± 5 17 ± 7 13 - 
cyclododecane 
CYP101B1 30 174 ± 5 15 ± 3 9 - 
CYP101C1 - 84 ± 10 2 ± 1 2 - 
cyclododecanol 
CYP101B1 90 198 ± 7 41 ± 1 21 1360 ± 90 
CYP101C1 - 280 ± 5   31 ± 20 11 650 ± 40 
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                                     (a)                                                                    (b) 
  
         (c)                                                                       (d) 
Figure 3. 4 (a) GC analysis of the turnover of cyclohexane by CYP101B1 (black) and 
CYP101C1 (red). Cyclohexane (RT 2.05 min, not shown) and the product; cyclohexanol (8.9 
min). (b) GC-MS analysis of the turnovers of cyclooctane by CYP101B1 (black) and 
CYP101C1 (red). Cyclooctane (RT 3.2 min) and the products; cyclooctanone (6.6 min) and 
cyclooctanol (6.9 min). (c) GC-MS analysis of the turnovers of cyclodecane by CYP101B1 
(black) and CYP101C1 (red). Cyclodecane (RT 5.1 min) and the products; cyclodecanone (9.7 
min) and cyclodecanol (10.45 min). (d) The control of cyclodecanone, and cyclodecanol 
generated from the reduction of cyclodecanone by NaBH4. Impurities are labelled (*). The 
chromatograms (a, b, c) were offset along the x and y-axes for clarity (CYP101C1; red). 
 
The GC-MS/GC analysis of CYP101B1 in-vitro turnover with cyclododecanol showed a 
primary product (90% based on GC peaks area; m+/z = 200.10) alongside two minor 
metabolites. The metabolites were generated by whole-cell biotransformation resulting in a 
total conversion of substrate into the products (Figure 3. 6). The metabolites (total ~25 mg) 
were difficult to separate from each other. However, the products were identified via 13C NMR 
carbon signals and their relative intensities (Figure 3. 5). The major product (at RT 19.6 min; 
90%) was characterised as 1,7-cyclododecanediol which showed four carbon signals 71.48 
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(C1, C7), 35.21 (C2, C6, C8, C12), 26.86 (C4, C10) and 23.72 (C3, C5, C9, C11) in the 13C 
NMR with an intensity ratio 2:4:2:4 (Figure 3. 5, Table 3. 2 and Figure B. 2-B. 6) 215. One of 
the minor (6%; RT 19.65 min) metabolites was characterised as 1,6-cyclododecanediol due to 
six equal intensity carbon signals 71.25 (C2, C6), 35.40 (C2, C5), 35.31 (C7, C12), 26.26 (C3, 
C4), 24.79 (C8, C11), 23.5 (C9, C10) in the 13C NMR (Table 3. 2 and Figure B. 2-B. 6). The 
other minor product (RT 9.7 min) was presumed to be either the other diastereomer of 1,6-
cyclododecanediol or 1,4-cyclododecanediol as the 13C NMR also had additional six carbon 
signals of equal intensity. 
The metabolites of the cyclododecane in vitro turnovers by CYP101B1 and CYP101C1 were 
then confirmed by GC-MS coelution experiments with the cyclododecanol turnover (Figure 3. 
6). The main (~92%) and minor metabolites of cyclododecane turnovers by CYP101B1 were 
1,7-cyclododecanediol and 1,6-cyclododecanediol, respectively as the retention time matched 
with the major and minor products of the cyclododecanol turnover (Figure 3. 6). The selectivity 
of cyclododecane and cyclododecanol oxidation was reduced for CYP101C1. This generated 
the same major metabolite (60%) which was observed in the GC-MS analysis of CYP101B1 
turnover, alongside two minor products accounted for the remaining 40% of the total turnover 
products formed. It is assumed that both enzymes converted the cyclododecane into 
cyclododecanol, which is then further oxidised to 1,7-cyclododecanediol and 1,6-
cyclododecanediol (Figure 3. 6). 
 
Figure 3. 5 13C NMR of a mixture of 1,7-cyclododecanediol, 1,6-cyclododecanediol and an 
unknown metabolite. The details of assignment of the carbon peaks see Table 3. 2. Full data 
are given in Appendix B (Figure B. 2-B. 6).  
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                  Table 3. 2 The assignments of cyclododecanol metabolites using 13C NMR. 
 











 (6 signals) 
equal intensity 
Remaining 
 (6 signals) 
Equal intensity 
Carbons  Intensity 
    
Either 
diastereomer 
of C6 or C4 as 
six signals 
72.12 1    
71.48 2 C1, C7   
71.25 2  C1, C6   
35.63 1    
35.40 2  C2, C5  
35.31 2  C7, C12  
35.21 4 C2, C6, C8, C12   
33.90 1    
27.24 1    
26.86 2 C4, C10   
26.26 2  C3, C4  
25.07 1    
24.79 2  C8, C11  
23.72 4 C3, C5, C9, C11   
23.5 2  C9, C10  
22.02 1    
 
 
   





  (a)                                                              `        (b) 
    
         (c) 
 
Figure 3. 6 (a) GC-MS analysis of cyclododecane in vitro turnovers by CYP101B1 (black) 
and CYP101C1 (red). Cyclododecane (RT 6.8 min) and the products; 1,7-cyclododecanediol 
(RT 12.9 min), 1,6-cyclododecanediol and unknown metabolite (RT 12.95 min and RT 13.0 
min) labelled as # and $. The chromatogram (CYP101C1) was offset along the x and y-axis for 
clarity. (b) GC-MS analysis of cyclododecanol turnover with CYP101B1. Cyclododecanol (RT 
7.9 min) and the products; 1,7-cyclododecanediol (RT 12.9 min) and 1,6-cyclododecanediol 
(RT 12.95 min) labelled as #. (c) The GC analysis of the whole-cell turnover of cyclododecanol. 
Cyclododecanol (RT 10.2 min) and the product; 1,7-cyclododecanediol (RT 19.6 min) and the 
minor metabolites; 1,6-cyclododecanediol and an unknown (RT 19.65 min# and RT 19.7 min$). 
Impurities are marked (*).  
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Overall, the spin-state shifts of CYP101B1 with smaller C6 cycloalkane and cyclic alcohols 
were lower compared to C8 to C12 cycloalkane substrates. Cyclooctane, cyclodecane and 
cyclododecane induced almost similar spin-state changes upon addition to the CYP101B1 
enzyme. CYP101C1 and CYP101B1 are capable of metabolising cycloalkanes, and the later 
enzyme showed higher product formation activity (Figure 3. 7). Neither enzyme showed little 




Figure 3. 7 The overall product formation rates of CYP101B1 and CYP101C1 with cyclic 
alkanes and alcohols. Product formation rates are given in nmol.nmol-CYP–1.min–1. 
 
 
Different cycloalkanones were screened with both enzymes to explore the binding affinity and 
catalytic activity with substrates containing a ketone moiety. Cyclooctanone induced a 10% 
heme spin-state shift in CYP101B1, which was even lower than cyclooctane (Figure 3. 8 and 
Table 3. 3). Both enzymes displayed low activity, and there was no evidence of any product 
formation with cyclooctanone. 
 
Addition of cyclononanone shifted the heme spin-state of CYP101B1 to 30% high spin form 
(Figure 3. 8). The dissociation constant (Kd) of CYP101B1 with cyclononanone was 
determined 46 ± 21 µM (Figure 3. 8 and Table 3. 3). The NADH oxidation rate for CYP101B1 
and CYP101C1 was 308 min-1 and 289 min-1, respectively (Table 3. 3). In the case of 
CYP101B1, the product formation activity measured 131 min-1 which was higher than that 
observed for CYP101C1 (75 min-1; Table 3. 3). This was due to the greater coupling efficiency 
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of 43% for CYP101B1. The improved product formation rates and coupling efficiencies of 
CYP101B1 and CYP101C1 with cyclononanone compared to the C10 and C12 cycloalkanes 
illustrated that the ketone group might play an important role in enhancing substrate binding 
and oxidation activity.  
 
 




Figure 3. 8 The spin-state shifts (red) of CYP101B1 after addition of (a) cyclooctanone and 
(b) cyclononanone. (c) The dissociation constant analysis with cyclononanone (2.11 µM 
CYP101B1/ Kd 46 µM). The concentration of the enzyme used in the binding assay and the 
dissociation constant (Kd) are provided in brackets.  
 
The GC-MS analyses of the in vitro turnovers of CYP101B1 and CYP101C1 with 
cyclononanone showed different regioselectivity (Figure 3. 9). Both transformed the 
cyclononanone to monooxygenase metabolites, and whole-cell turnovers were carried out to 
generate each metabolite in a sufficient amount for identification (Figure B. 1). Each product 
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was purified via silica column chromatography and identified by NMR and their mass spectra 
(Figure 3. 9, Figure B. 1 and Figure B. 7-B. 16). 
The primary metabolite (98%; at RT 12.2 min) generated by CYP101C1 was assigned as 2-
hydroxycyclononanone by NMR analysis 216, 221. It contained a multiplet peak at 4.28-4.21 (H2) 
and a distinct peak of -COH proton (C2) at 3.7-3.72 ppm in 1H NMR, which is observed due 
to the interaction with C=O (Figure 3. 9 and Figure B. 7-B. 10) 216, 221. The mass spectrum also 
matched with that reported in the literature (m+/z = 156.15; Figure B. 1) 216, 221. This product 
was the minor metabolite in the CYP101B1 turnover (4%; Figure 3. 9). The chiral GC analysis 
of the in vitro turnover of CYP101C1 displayed a mixture of 2-hydroxycyclononanone 
enantiomers in a distribution of 30 to 70 % (Figure 3. 9). Further investigation is required to 
find out which enantiomer is in excess. 
 
The main product (87%; at RT 11.2 min) from the CYP101B1 in vivo turnover was purified 
(~22 mg) by silica column chromatography. The 1H NMR spectrum had a multiplet signal at δ 
4.04-4.17 ppm (Figure 3. 10). However, in the 13C spectrum C1 (C=O) peak was not detectable 
and a distinct signal at 100.36 ppm was present (Figure B. 12). The HMBC NMR spectrum 
showed a strong correlation of C1 (100.36 ppm) to H5 δ (4.04-4.17 ppm), which indicated a 
cyclisation connecting C1 to C5 (Figure B. 11-B. 16 and Table 3. 4). This metabolite was 
assigned as 1-hydroxy-10-oxabicyclo[4.3.1]decane (Figure 3. 10, Table 3. 4, and Figure B. 11-
B. 16) 217, 218. The NMR and mass spectrum were also in agreement with those reported in the 
literature (m+/z = 156.15; Figure B. 11-B. 16 and Figure B. 1) 217. Initially, hydroxylation 
occurred at C5, which converts to the corresponding cyclic hemiacetal through intramolecular 
nucleophilic attack of the C5 hydroxyl group to the electrophilic carbonyl group. The 
mechanism leading to the formation of this cyclic metabolite is given in Figure 3. 10. 
 
The NMR displayed that a minor metabolite was also present (~9% from the NMR integration 
of HC5(OH) and HC5O) with 1-hydroxy-10-oxabicyclo[4.3.1]decane 218. It was predicted to 
be the corresponding 5-hydroxycycloalkanone precursor to the 1-hydroxy-10-
oxabicyclo[4.3.1]decane hemiacetal which could be present in equilibrium. This was 
confirmed by comparing the 1H NMR spectrum peak of H5 at 3.79-3.73 ppm with that reported 
in the literature (Table 3. 4 and Figure 3. 10 (b)) 218. The minor product from the CYP101C1 
turnover coeluted with the primary product (1-hydroxy-10-oxabicyclo[4.3.1]decane) of 
CYP101B1 in GC-MS (~2%; at RT 11.2 min, Figure 3. 9). 






Table 3. 3 Substrate binding, turnover and coupling efficiency data for CYP101B1 and 
CYP101C with cycloalkanones. The in vitro turnover activities were measured using a 
ArR:Arx: CYP101B1/CYP101C1 concentration ratio of 1:10:1 (0.5 mM CYP enzyme, 50 mM,  
pH 7.4). N is the NADH oxidation rate, PFR the product formation rate, C is the coupling 
efficiency and TTN, total turnover number. The data are reported as mean ± S.D. (n = 3), and 
rates are given in nmol.nmol-CYP–1.min–1. - Not measured or not able to be determined 












CYP101B1 - 93.4 ± 9 n.p n.p - 
CYP101C1 - 88 ± 2 n.p n.p - 
cyclononanone 
CYP101B1 46 ± 21 308 ± 10 131 ± 11 43 886 ± 77 
CYP101C1 - 289 ± 16 75 ± 4 26   226 ± 36 
cyclodecanone 
CYP101B1 46 ± 2 323 ± 38 149 ± 54 45 1728 ± 48 
CYP101C1 - 531 ± 75 113 ± 13 22 1185 ± 91 
cycloundecanone 
CYP101B1 8.4 ± 0.3 409 ± 11 222 ± 14 54 3481 ± 293 
CYP101C1 - 660 ± 53 141 ± 18 22 3301 ± 332 
cyclododecanone 
CYP101B1 2.4 ± 0.4 391 ± 11 283 ± 38 72 5750 ± 276 
CYP101C1 - 853 ± 24 239 ± 31 28 543 ± 62 
cyclopentadecanone 
CYP101B1 0.5 ± 0.1 
0.1 
0.000.1 
126 ± 4 47 ± 3 38 - 










    (a) 
                     
   (b) 
 
Figure 3. 9 (a) GC-MS analyses of the in vitro turnovers of cyclononanone by CYP101B1 and 
CYP101C1. Cyclononanone (RT 9.1 min) and the products; 1-hydroxy-10-
oxabicyclo[4.3.1]decane in equilibrium with 5-hydroxycyclononanone (RT 11.2 min) and 2-
hydroxycyclononanone (RT 12.2 min). (b) The chiral GC analysis of the in vitro turnover of 
cyclononanone by CYP101C1. Cyclononanone (RT 12.0 min) and the product 2-
hydroxycyclononanone (two enantiomers: RT 16.4 min and RT 16.5 min). Impurities are 
labelled (*).  
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Figure 3. 10 (a) 1H NMR of 2-hydroxycyclononanone (CYP101C1). (b) 1H NMR of 1-
hydroxy-10-oxabicyclo[4.3.1]decane and 5-hydroxycyclononanone (9%). Full data are given 
in appendix B (Figure B. 7-B. 16). (c) The proposed mechanism of 1-hydroxy-10-
oxabicyclo[4.3.1]decane formation 218. 
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Addition of cyclodecanone generated a 50% shift to the high spin form in CYP101B1 (Figure 
3. 11). The binding affinity for cyclodecanone (Kd = 46 µM) was similar to that of 
cyclononanone (Table 3. 3 and Figure 3. 11). When cyclodecanone was added to both the 
CYP101B1 and CYP101C1 turnover system, a higher oxidation activity was observed in each 
case compared to cyclononanone (Table 3. 3). Although the CYP101C1 system displayed a 
greater NADH oxidation rate (531 min-1) than CYP101B1 (323 min-1), the product formation 
rate was reduced due to a low coupling efficiency (22% versus 45%, Table 3. 3). 
 
 
                                          (a)                                                         (b) 
 
Figure 3. 11 (a) The spin-state shift (red) of CYP101B1 after addition of cyclodecanone. (b) 
The dissociation constant analysis with cyclodecanone (2.35 µM CYP101B1/ Kd 46 µM). The 
concentration of the enzyme used in the study and the dissociation constant (Kd) are provided 
in brackets. 
 
Turnovers of each enzyme with cyclodecanone showed the formation of monooxygenase 
products in the GC-MS analyses (m+/z = 170.2 and m+/z = 170.1; Figure 3. 12 and Figure B. 
1). The GC-FID analysis of both in vitro and in vivo turnover of CYP101B1 indicated that 
CYP101B1 generated two major metabolites in a 3:2 ratio (RT 10.0 min and RT 10.9 min; 
Figure 3. 12). A minor metabolite, which eluted earlier, was also formed (RT 7.2 min; m+/z 
=170.20; Figure 3. 12 and Figure B. 1). But in the case of CYP101C1, the GC/GC-MS analyses 
of the turnovers displayed one major metabolite (90%; at RT 7.2 min) which coeluted with the 
minor product from CYP101B1 oxidation. The minor metabolites of CYP101C1 turnovers 
coeluted with the main metabolites of the CYP101B1 turnover and made up the remainder 
(10%; RT 10.0 min and RT 10.9 min; Figure 3. 12).  
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Figure 3. 12 (a) GC-FID analyses of the in vitro turnovers of cyclodecanone by CYP101B1 
and CYP101C1. Cyclodecanone (RT 2.9 min) and the products; 2-hydroxycyclodecanone (RT 
7.2 min); 1-oxabicyclo[5.3.1]undecan-1-ol and 5-hydroxycyclodecanone (RT 10.0 min); a 
mixture of 1-oxabicyclo[6.3.1]undecan-1-ol and 6-hydroxycyclodecanone (RT 10.9 min). 
Impurities are labelled (*). (b) The metabolites generated in the turnovers of CYP101B1 and 
CYP101C1 with cyclodecanone. The product distributions are given as percentages. 
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Both major metabolites from CYP101B1 in vivo turnovers of cyclodecanone were purified by 
silica column chromatography. The main product (60%; at RT 10.0 min) was characterised 
using NMR. It was isolated as an equilibrium mixture but was confirmed as 1-
oxabicyclo[5.3.1]undecan-1-ol 218. The expected C1 (C=O) signal in the 13C NMR spectrum 
was not present, but a peak was observed at 98.80 ppm (Figure 3. 13 and Figure B. 21-B. 26). 
The 1H-13C HMBC NMR spectrum showed a correlation of C1 with H5 which demonstrated a 
cyclisation product (Figure 3. 13, Table 3. 4 and Figure B. 21-B. 26) 218. The minor peaks in 
the NMR spectrum of 1-oxabicyclo[5.3.1]undecan-1-ol were consistent with 5-
hydroxycyclodecanone and the 1H NMR peak of H5 (3.83-3.78 ppm) was in agreement with 
the NMR reported in the literature (Table 3. 4 and Figure B. 21-B. 26) 218. 1-
Oxabicyclo[5.3.1]undecan-1-ol has been demonstrated to co-exist in a transannular tautomeric 
equilibrium with 5-hydroxycyclodecanone (Figure 3. 13 (b)) 218. The 1H NMR signals of the 
methine protons HC5(OH) (3.81-3.72 ppm) and HC5O (3.97-4.07 ppm) were used to 
determine the concentration/percentage of 1-oxabicyclo[5.3.1]undecan-1-ol (~72%) and 5-
hydroxy cyclodecanone (~28%) metabolites in CDCl3 
218.  
 
The other metabolite (37%; at RT 10.9 min) was purified (~12 mg). The NMR analysis 
confirmed that it was a mixture of 1-oxabicyclo[6.3.1]undecan-1-ol (~42%) and 6-
hydroxycyclodecanone. Both displayed symmetry and a reduced number of carbon peaks in 
the 13C NMR and the characteristic proton peaks at 4.13-4.01 (HC6O) and 3.90-3.79 
(HC6(OH)) in the 1H NMR spectrum, enabling their identification (Figure 3. 13, Table 3. 4 
and Figure B. 27-B. 31) 218. These assignments were also in agreement with the NMR reported 
in literature 218. The percentage of each product isomer was determined using these 1H NMR 
methine proton integrations 218. The mechanism of 1-oxabicyclo[5.3.1]undecan-1-ol and 1-
oxabicyclo[6.3.1]undecan-1-ol formation was assumed to be similar to 1-hydroxy-10-
oxabicyclo[4.3.1]decane formation (Figure 3. 10).  
 
The other minor product (1%; at RT 7.2 min) of CYP101B1 coeluted with the main metabolite 
(2-hydroxycyclodecanone) of CYP101C1 (Figure 3. 12 and Figure 3. 13). Additional carbon 
peaks were also noticed in the 13C NMR spectrum of 1-oxabicyclo[6.3.1]undecan-1-ol and 6-
hydroxycyclodecanone which indicated another minor product (~2%) was also present. This 
was presumed to be a 4-hydroxy metabolite due to the correlation of 72.83 ppm (C4) with the 
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protons of 2.41-2.33 (H2) and 2.01-1.87 (H3) in the HMBC NMR spectrum, but the product 
was not able to be fully characterised due to noise (Figure  B. 32). 
 
 
The regioselectivity of CYP101C1 was different. This system generated a single major 
hydroxylated metabolite (m+/z = 170.2, Figure 3. 12 and Figure B. 1). This product was 
synthesised in large-scale by a CYP101C1 whole-cell biotransformation system. The 
metabolite from the in vivo turnover was extracted and purified (~15 mg) using silica column 
chromatography. The 1H NMR spectrum of the isolated product had two distinct peaks of H2 
at 4.29-4.17 ppm and C2OH at 3.88-3.76 ppm. In the 13C NMR spectrum, the signal of C2 
carbon (79.11 ppm) which would be adjacent to the carbonyl group displayed significant 
deshielding. The data was in agreement with that in the literature for 2-hydroxycyclodecanone 
219. Therefore, the hydroxylation was assigned at C-2 (Figure 3. 13 and Figure B. 17-B. 20). 
The mass spectrum analysis also confirmed this assignment (Figure B. 1) 219. Coelution of the 
minor metabolites (~10%) of CYP101C1 turnover with the major products of CYP101B1 in 
GC showed an identical retention time (Figure 3. 12). 
 




Hydroxy ketone HC-OH (C) 
(δ) 
Hemiacetal HC-O (C) 
(δ) 
5-hydroxycyclononanone 3.70 (71.3) 1-hydroxy-10-oxabicyclo 
[4.3.1]decane 
4.08 (73.7) 
5-hydroxycyclodecanone 3.75 (69.9) 1-oxabicyclo[6.3.1] 
undecan-1-ol 
4.0 (73.6) 
6-hydroxycyclodecanone 3.83 (69.9) 1-oxabicyclo[6.3.1] 
undecan-1-ol 










                                                                       (a) 
 
                                                                       (b) 
 
                                                                       (c) 
 
Figure 3. 13 (a) 1H NMR spectrum of 2-hydroxycyclodecanone (CYP101C1). (b) 1H NMR 
spectrum of 1-oxabicyclo[5.3.1]undecan-1-ol and 5-hydroxycyclodecanone (CYP101B1). (c) 
1H NMR spectrum of a mixture of 1-oxabicyclo[6.3.1]undecan-1-ol (~42%) and 6-
hydroxycyclodecanone (CYP101B1). A small amount of potential 4-hydroxy metabolite was 
also present. Full data are provided in Appendix B (Figure B. 17-B. 32). 
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The spin-state shift of CYP101B1 after addition of cycloundecanone was higher than that 
observed with cyclodecanone and cyclononanone (80%; Figure 3. 14 and Table 3. 3). This 
substrate also bound several times more tightly than the smaller cycloalkanones (Table 3. 3). 
The dissociation constant was 8.4 µM which signified that cycloundecanone was well 
accommodated in the active site of the CYP101B1 enzyme (Figure 3. 14). In the presence of 
cycloundecanone, NADH was oxidised by CYP101B1 at a rate of 409 min-1, and the product 
formation rate was 222 min-1 (Table 3. 3). CYP101C1 exhibited a faster NADH oxidation rate 
of 660 min-1 than CYP101B1 (Table 3. 3). However, the product formation rate was slower 
compared to CYP101B1 due to the recurring lower coupling efficiency observed with this 
system (22%; Table 3. 3). CYP101B1 displayed an improved coupling efficiency (54%) with 
cycloundecanone compared to cyclononanone and cyclodecanone. The rates and coupling 
efficiency followed the trend in the improvement of the binding affinity and magnitude of the 
heme spin-state induced in CYP101B1 with cycloundecanone.  
 
(a)                                                         (b) 
 
Figure 3. 14 (a) The spin-state shift (red) of CYP101B1 after addition of cycloundecanone. 
(b) The dissociation constant analysis with cycloundecanone (2.0 µM CYP101B1/Kd 8.4 µM). 
The concentration of enzyme used in the binding assay and the dissociation constant (Kd) are 
provided in brackets.  
 
The GC-MS analysis of the extract obtained following in vitro turnover of CYP101C1 with 
cycloundecanone revealed a single major hydroxylated product (~92%; RT 8.4 min; m+/z = 
184.40) with three minor metabolites making up the remainder (Figure 3. 15 and Figure B. 1). 
The primary metabolite of this substrate was generated in a higher yield using a CYP101C1 
whole-cell oxidation system and was isolated (~20 mg) via silica column chromatography. The 
1H NMR spectrum of this metabolite had two distinct multiplet peaks for H2 at (4.30-4.24 ppm) 
and C2-OH at (3.6-3.44 ppm). In the HMBC NMR, the carbonyl C1 showed strong correlations 
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with C2-OH (3.6-3.44 ppm), H3, H10 and H11, indicating hydroxylation occurred at the C2 
position (Figure B. 33-B. 38). The product was thus assigned as 2-hydroxycycloundecanone 
and confirmed by comparing the 1H and 13C NMR signals with the NMR reported previously 
(Figure 3. 16 and B. 33-B. 38) 220. The mass spectrum analysis was also in agreement of this 
assignment (Figure B. 1) 220. Chiral-GC analysis showed that this turnover generated two 
enantiomers of 2-hydroxycycloundecanone an almost equal amount (46:54; Figure 3. 15). Two 
of the minor products were identified by GC-MS coelution experiment with the metabolites of 
CYP101B1 (Figure 3. 15).   
 
       (a) 
 
        (b) 
Figure 3. 15 (a) GC-MS analyses of the in vitro turnovers of cycloundecanone by CYP101B1 
and CYP101C1. Cycloundecanone (RT 6.4 min) and product 1; 2-hydroxycycloundecanone 
(RT 8.4 min), product 2; 5-hydroxycycloundecanone (RT 9.3 min) and product 3; 6-
hydroxycycloundecanone (RT 9.45 min). There is minor (≤4%) unidentified product# in both 
enzymes turnover at RT 8.8 min. (b) The chiral GC analysis of in vitro turnover of 
cycloundecanone by CYP101C1. Cycloundecanone (RT 9.4 min; not shown) and the product; 
2-hydroxycycloundecanone (two enantiomers RT 13.5 min and RT 13.6 min). Impurities are 
labelled (*).  
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GC-MS analyses of the in vitro turnovers of CYP101B1 indicated two metabolites were 
generated in significant yield (~42%; m+/z = 184.30 and ~52%; m+/z = 184.20) alongside two 
minor hydroxylated metabolites (Figure 3. 15 and Figure B. 1). In vivo turnovers were used to 
generate the products in larger-scale for characterisation and the metabolites were isolated by 
silica column chromatography (~10 mg and ~15 mg). The 1H NMR of the metabolite at RT 9.3 
min in GC-MS, had a multiplet peak at 3.76-3.70 ppm suggesting a hydroxylated product 
(Figure 3. 16 and Figure B. 40-B. 44). The correlations of C1 (216.69 ppm) with H2, H11 
(2.55-2.42 ppm), H3 (1.89-1.82 ppm) and H10 (1.81-1.74 ppm) in 1H-13C HMBC NMR 
spectrum, were used to assign these proton peaks. The C4 (44.97 ppm) signal was confirmed 
using its interaction with H2 (2.55-2.42 ppm) in the HMBC NMR (Figure B. 40-B. 44). The 
product was identified as the 5-hydroxy metabolite due to the CHOH carbon signal (72.36 
ppm) displaying strong correlations with H3 (1.89-1.82 ppm), H4 (1.73-1.63 ppm) and H6 
(1.54-1.50 ppm) in the HMBC NMR (Figure B. 40-B. 44). Some additional minor peaks in the 
1H and 13C NMR of this product indicated that another metabolite (~1) was also present as an 
impurity, but this was not able to be characterised (Figure 3. 16 and Figure B. 40-B. 44). 
 
The 1H NMR spectrum of the other major metabolite (RT 9.45 min in GC-MS) had a multiplet 
peak at 3.72-3.66 ppm demonstrating a monohydroxylated product (Figure 3. 16). The 13C-1H 
HMBC NMR spectrum analysis revealed the correlations of C1 (216.91 ppm) with the H2, 
H11 (2.60-2.36 ppm) and H3, H10 (1.84-1.72 ppm) proton signals. C4 (24.42 ppm) and C5 
(34.79 ppm) were assigned using the interactions with H2 (2.60-2.36 ppm) and H3 (1.84-1.72 
ppm), respectively in the HMBC NMR (Figure B. 45-B. 49). The CHOH carbon signal (72.73 
ppm) displayed strong correlations with H4 (1.47-1.42 ppm), H5 (1.63-1.56 ppm), H7 (1.47-
1.42 ppm) and H8 (1.41-1.33 ppm) in the HMBC NMR spectrum (Figure B. 45-B. 49). The 
metabolite was therefore identified as 6-hydroxycycloundecanone. Some additional minor 
signals in the proton and carbon NMR of this product indicated that an unidentified metabolite 
(~1) was also present as an impurity (Figure 3. 16, Figure B. 45-B. 49). 
 
One of the minor (~3%; RT 8.4 min) metabolites coeluted with 2-hydroxycycloundecanone in 
GC-MS (Figure 3. 15). The other product (RT 8.8 min in GC-MS, ≤4%) for both CYP101B1 
and CYP101C1 turnovers was unidentified as it was not generated in large enough quantity for 
NMR characterisation (Figure 3. 15). However, the mass spectrum suggested it may be a 
further oxidation product with a mass, m+/z = 182.30 (Figure B. 1). 
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                                                                       (a) 
 
                                                                        (b) 
  
                                                                         (c) 
Figure 3. 16 (a) 1H NMR spectrum of 2-hydroxycycloundecanone (CYP101C1) 220, 221. (b) 1H 
NMR of 5-hydroxycycloundecanone (CYP101B1). (c) 1H NMR spectrum of 6-
hydroxycycloundecanone (CYP101B1). In NMR of both 5-hydroxycycloundecanone and 6-
hydroxycycloundecanone, a small unidentified metabolite or impurity was present. Complete 
NMR spectra are provided in Appendix B (Figure B. 33-B. 49). 
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Cyclododecanone altered the heme spin-state of CYP101B1 almost entirely to the high spin 
form (90%), and the enzyme bound tightly with a higher affinity than cycloundecanone (Kd = 
2.4 µM; Table 3. 3 and Figure 3. 17). The rate of NADH oxidation of CYP101B1 with 
cyclododecanone was 391 min-1, which was in-between those observed for cyclodecanone and 
cycloundecanone (Table 3. 3). The majority of the NADH reducing equivalents were used for 
product formation, leading to a higher product formation activity, 283 min-1, compared to 
cycloundecanone (coupling efficiency; 72% versus 54%; Table 3. 3). The total turnover 
number was significantly greater compared to other cycloalkanones investigated here (TTN 
5750; Table 3. 3). Interestingly CYP101C1 showed an even higher NADH oxidation activity 
(853 min-1) in the presence of cyclododecanone (Table 3. 3). However, the product formation 
rate and efficiency of productive NADH utilisation for the oxidation of this substrate were 
lower; 239 min-1 and 28%, respectively (Table 3. 3).  
 
 
(a)                                                               (b) 
                                                 
Figure 3. 17 (a) The spin-state shift (red) of CYP101B1 after addition of cyclododecanone. 
(b) Dissociation constant analysis with cyclododecanone (1.58 µM CYP101B1/Kd 2.4 µM). 
The concentration of enzyme used in the binding assay and the dissociation constant (Kd) are 
provided in brackets.  
 
GC-MS analysis of the turnovers of cyclododecanone by CYP101C1 displayed a single major 
metabolite (98%; RT 15.5 min) with one other minor (RT 17.7 min) product (Figure 3. 18). 
The mass spectra of both these products were consistent with monooxygenase metabolites 
(m+/z = 198.25 and m+/z = 198.05; Figure 3. 18 and Figure B. 1).  




        (a)                                                                    (b) 
 
 
       (c) 
 
Figure 3. 18 (a) GC-MS analyses of the in vitro turnovers of cyclododecanone by CYP101B1 
(black) and CYP101C1 (red). Cyclododecanone (RT 12.1 min) and the product 1; 2-
hydroxycyclododecanone (RT 15.5 min), product 2; 7-hydroxycyclododecanone (RT 17.7 
min). There is a minor product# in CYP101B1 enzyme turnover at RT 16.9 min. (b) The 
authentic commercial standard (red) coeluted with CYP101C1 turnover (black) in GC-MS. (c) 
Chiral GC analysis of the in vitro turnover of cyclododecanone by CYP101C1. 
Cyclododecanone (RT 10.2 min; not shown) and the product; 2-hydroxycyclododecanone (two 
enantiomers; RT 15.6 min and 15.8 min). Impurities are labelled (*). 
 
 
The primary metabolite of cyclododecanone turnover was generated using the CYP101C1 in 
vivo turnover system for characterisation. The metabolite was purified (~29 mg) by column 
chromatography and assigned as 2-hydroxycyclododecanone by NMR analysis (Figure 3. 18, 
Figure B. 50-B. 55) 219, 220. The 1H NMR spectrum of this product had two characteristic peaks 
for H2 (4.44-4.34 ppm) and C2OH (3.58-3.50 ppm). The latter peak is observed due to the 
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correlation with the carbonyl oxygen (Figure 3. 19). 1H-1H gCOSY NMR also showed strong 
interaction between the H2 and C2OH (Figure B. 53). The HMBC NMR spectrum analysis 
displayed the correlation of C1 (215.55 ppm) with C2OH proton indicating hydroxylation 
occurred at C2 (Figure 3. 19 and Figure B. 50-B. 55). The product was further confirmed by 
GC-MS coelution experiment with a commercial standard. The 1H NMR spectrum of the 
standard matched with the isolated product proton NMR (Figure 3. 18 and Figure B. 50). The 
chiral GC analysis revealed that the turnover of CYP101C1 generated a mixture of enantiomers 
(45%:55%) of 2-hydroxycyclododecanone (Figure 3. 18).  
 
One major product (96%; RT 17.7 min) and a minor metabolite (RT 16.9 min) were detected 
in the GC-MS analyses of the in vitro and in vivo turnovers of CYP101B1 with 
cyclododecanone (Figure 3. 18). The mass spectra suggested that both were monohydroxylated 
products (m+/z = 198.35 and m+/z = 198.50; Figure 3. 18 and Figure B. 1). The primary 
metabolite from a CYP101B1 in vivo turnover was isolated (~27 mg) using silica column 
chromatography and identified as 7-hydroxycyclododecanone by NMR analysis (Figure 3. 19 
and Figure B. 56-B. 60) 208. The 13C NMR spectrum of this metabolite exhibited seven carbon 
signals demonstrating the hydroxylation took place at the C7 position generating a symmetrical 
metabolite (Figure 3. 19 and Figure B. 57). Five out of seven signals displayed double the 
intensity of the others, representing pairs of equivalent carbons, which is in agreement with 
this metabolite assignment. 
 
The primary product of the CYP101B1 turnovers coeluted in GC-MS with the minor metabolite 
of the CYP101C1 turnover, confirming the identity of this minor product as 7-
hydroxycyclododecanone (m+/z = 198.05). The minor metabolite (~4%) of CYP101B1 with 
the retention time 16.9 min, was unable to be generated in a large enough quantity for 
characterisation by NMR. However, the mass spectrum suggested that this was consistent with 
a monooxygenase product with a mass, m+/z 198.35 (Figure B. 1). 









Figure 3. 19 (a) 1H NMR of 2-hydroxycyclododecanone (CYP101C1). (b) 1H NMR of 7-
hydroxycyclododecanone (CYP101B1). (c) 13C NMR of 7-hydroxycyclododecanone 
(CYP101B1). Full data are presented in Appendix B (Figure B. 50-B. 60). 
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The fifteen-carbon containing alicyclic ketone cyclopentadecanone induced a 75% spin-state 
shift in CYP101B1 (Figure 3. 20). It displayed very tight binding to CYP101B1 (Kd = 0.45 µM; 
Figure 3. 20 and Table 3. 3). This suggested the active site of the enzyme can accommodate 
these larger substrates. CYP101B1 exhibited increased product formation activity toward 
cyclopentadecanone with a rate of 47 min-1 compared to CYP101C1 (14 min-1; Table 3. 3). 
However, these rates were slower than those with cyclododecanone and cycloundecanone 
(Table 3. 3). The productive utilisation of NADH was reduced for CYP101C1 (7% versus 38%; 
Table 3. 3). 
  
  
  (a)                                                                  (b) 
 
Figure 3. 20 (a) The spin-state shift (red) of CYP101B1 after addition of cyclopentadecanone. 
(b) The dissociation constant analysis with cyclopentadecanone (2.3 µM CYP101B1/Kd 0.45 
µM). The concentration of enzyme used in the binding study and the dissociation constant (Kd) 
are provided in brackets.  
 
CYP101C1 oxidised this substrate into two metabolites, and GC-MS analysis revealed that 
both of these were monohydroxylated products (m+/z = 240.25, m+/z = 240.25; Figure 3. 21 
and Figure B. 1). Whole-cell turnover containing CYP101C1 enzyme was used to generate the 
metabolites of cyclopentadecanone in larger yield for NMR characterisation. However, neither 
was generated in sufficient quantity for NMR analysis. The primary metabolite (64%; RT 14.6 
min) was confirmed by comparing its mass spectrum with the reported mass spectrum of 2-
hydroxycyclopentadecanone in the literature (Figure B. 1) 219, 222. Hence the product was 
consistent with a 2-hydroxy metabolite as found for other cycloalkanones tested above with 
CYP101C1.  
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   (a) 
                   
      (b) 
Figure 3. 21 (a) GC-MS analysis of the in vitro turnover of cyclopentadecanone by CYP101B1 
and CYP101C1. Cyclopentadecanone (RT 13.1 min) and the product 1; 2-
hydroxycyclopentadecanone (RT 14.6 min), product 2; 8-hydroxycyclopentadecanone (RT 
15.6 min) 208. There is a minor product# in CYP101B1 enzyme turnover at RT 15.1 min was 
assigned as cyclopentadecane-1,8-dione (≤5%) 208. (b) The chiral GC analysis of in vitro 
turnover of cyclopentadecanone by CYP101C1 and CYP101B1. Impurities are labelled (*). 
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CYP101B1 mediated oxidation of cyclopentadecanone generated a single major hydroxylated 
product, which was detected in the GC-MS analysis (90%; RT 15.6 min; m+/z = 240.25; Figure 
3. 21). To confirm the identity of the metabolite, it was synthesised in higher yield using a 
CYP101B1 whole-cell turnover system, purified (~24 mg) via silica column chromatography. 
The metabolite was assigned as 8-hydroxycyclopentadecanone by NMR analysis (Figure 3. 22 
and Figure B. 61-B. 68) 208. In the 1H NMR, a multiplet peak at 3.71-3.64 ppm confirmed a 
monohydroxylated product. HMBC correlations were used to assign the metabolite (Figure 3. 
22 and Figure B. 61-B. 68). The interactions of C1 (215.30) with H2, H15 (2.47-2.33 ppm) and 
H3, H14 (1.74-1.60 ppm) were used to determine these proton peaks. C4 (29.64 ppm) and C5 
(30.18 ppm) were identified using the HMBC correlations with H2 (2.47-2.33 ppm) and H3 
(1.74-1.60 ppm), respectively. C5 (30.18) did not show any interaction with the CH(OH) peak 
(3.71-3.64 ppm), indicating hydroxylation did not occur in C6 or C7. C6 (25.90) was assigned 
via the correlation of H5 (1.40-1.25), and C6 displayed a weak interaction with the peak at 
3.71-3.64 ppm, demonstrating the insertion of oxygen likely occurred at C8 (72.70 ppm; Figure 
3. 22 and Figure B. 61-B. 68). The mass spectrum was also in agreement with this assignment 
(Figure B. 1) 208. The 13C NMR of 8-hydroxycyclopentadecanone also had some small peaks 
suggesting minor unidentified metabolites were also present (≤5%; Figure B. 62). 
 
The 8-hydroxycyclopentadecanone coeluted with the minor product (36%) of CYP101C1 in 
GC-MS (Figure 3. 21). There was also a small amount of further oxidation product (5%) 
observed in the GC-MS analysis of the CYP101B1 turnovers (m+/z = 238.20; Figure 3. 21 and 
Figure B. 1). This minor product was presumed to be cyclopentadecane-1,8-dione by 
comparing its mass spectrum with that reported in the literature, m+/z 238.20, 220.20, 181.20, 
125.15, 112.10, 111.15, 98.15, 84.15, 83.10, 69.10, 55.10 and 43.10. (Figure B. 1) 208. The 
chiral GC analyses of both CYP101B1 and CYP101C1 in vitro turnovers did not display any 












Figure 3. 22 (a) 1H NMR spectrum of 8-hydroxycyclopentadecanone (CYP101B1). (b) 
Zoomed in (20 to 30 ppm region) version of HMBC NMR spectrum of 8-
hydroxycyclopentadecanone, which highlighted the correlations of carbons with the protons. 
Full data are provided in Appendix B (Figure B. 61-B. 68).  
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In summary, the oxidative activities of both enzymes were better with the cycloalkanones 
compared to the cyclic alkanes and alcohols. Substrate profiling indicated that CYP101B1 and 
CYP101C1 were able to accommodate and oxidise different size of cyclic compounds with 




Figure 3. 23 An overview of product formation rates of CYP101B1 and CYP101C1 with 
cycloalkanones. Product formation rates are given in nmol.nmol-CYP–1.min–1. 
 
The CYP101C1 predominantly hydroxylated at C2 while CYP101B1 was more selective for 
C-H bond abstraction at carbons on the remote sites of the ring to the ketone. 
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3.2.2 Use of Directing Groups to Improve the Activity of CYP101B1 and CYP101C1 for 
Cyclic Alcohols 
 
Both CYP101B1 and CYP101C1 were able to oxidise certain cyclic alkanes and 
cycloalkanones, in some instances with high selectivity. CYP101B1 and CYP101C1 oxidised 
β-ionone and other norisoprenoid class of compounds efficiently (Figure 1. 17 and Figure 1. 
19) 47, 175. It has also been shown that ester directing groups can help to hold certain substrates 
in a suitable position of CYP101B1 in the active site for efficient and selective oxidation 175, 
176. Cyclohexanol and cyclooctanol did not show any activity with CYP101B1 and CYP101C1 
(Table 3. 1). However, cyclododecanol exhibited higher activity compared to cyclohexanol and 
cyclooctanol. Both enzymes oxidised cyclododecanol unselectively and with a low coupling 
efficiency. In order to assess if a directing group could improve the catalytic activity and 
selectivity of both enzymes, different ester derivatives of cyclic alcohols were synthesised and 
investigated (Figure 3. 24). First, a range of cyclohexanol derived esters (acetate, isobutyrate 
and butyrate), as well as the ethyl and methyl esters of cyclohexylacetic acid were tested to 
assess if the oxidation of cyclohexane rings could be improved (Figure 3. 24). Cyclooctanol 
and cyclododecanol derived esters were also evaluated. The synthesis of these ester substrates 
was described in Chapter 2.  
 
       Figure 3. 24 Substrates with ester directing groups were screened with both enzymes. 
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Addition of cyclohexyl acetate induced a spin-state shift of 25% in CYP101B1, which was 
only a minor improvement over cyclohexane and the parent alcohol cyclohexanol (Figure 3. 
25, Table 3. 5 and Table 3. 1). The binding affinity was low, Kd = 544 µM (Figure 3. 25). The 
NADH oxidation rate for turnovers of this substrate with CYP101B1 and CYP101C1 were 415 
min-1 and 173 min-1, respectively. Little or no product formation activity was detected for 
CYP101C1. The CYP101B1 turnover generated a single metabolite with a low product 
formation rate (56 min-1) and a coupling efficiency of 14% (Table 3. 5 and Figure 3. 26).  
 
A larger scale in vivo turnover was carried out to generate the metabolite in adequate yield, 
which was then purified (~29 mg) via silica column chromatography, and characterised by 
NMR and mass spectrum analysis (m+/z 158.0; Figure 3. 26, Figure B. 1, Figure B. 69-B. 74). 
A characteristic multiplet peak at 3.76-3.72 ppm in the 1H NMR spectrum indicates a hydroxy 
metabolite (Figure 3. 27). The identity of this metabolite was determined to be 4-
hydroxycyclohexyl acetate 223. The main reason for this assignment was that the 13C NMR 
spectrum has six signals, two of which 34.94 (C3 and C5) and 31.27 (C2 and C6) can be 
attributed from their intensity to pairs of identical carbons indicating hydroxylation took place 
at C4 (Figure B. 69-B. 74). The product was further confirmed from the correlations of C1 
(74.38 ppm) and C4 (73.25 ppm) with the protons at δ 2.02-1.93 (H2, H3, H5 and H6) and δ 
1.54-1.36 (H2, H3, H5 and H6) in HMBC NMR spectrum (Figure B. 69-B. 74).  
 
1H-1H ROESY NMR was carried out to determine the stereoselectivity (Figure B. 69-B. 74). 
However, this assignment was hindered due to overlapping signals of the axial and equatorial 
protons of C2, C3, C5 and C6. The stereoselectivity was assigned using the 1H NMR signals 
of the H1 and H4 protons. The splitting patterns of H1 and H4 peaks are similar (triplet of 
triplets) suggesting they have the same environment in relation to the ring system. The coupling 
constants, JH4 = 3.4, 9.2 Hz and JH1 = 3.4, 9.5 Hz demonstrated that they are in the same 
orientation (both axial based on the higher coupling constants; Figure B. 69 and Figure 3. 27). 









                                        (a)                                                              (b) 
 
Figure 3. 25 (a) The spin-state shift (red) of CYP101B1 after addition of cyclohexyl acetate. 
(b) The dissociation constant analysis with cyclohexyl acetate (1.74 µM CYP101B1/Kd 544 
µM). The concentration of enzyme used in the binding assay and the dissociation constant (Kd) 





Figure 3. 26 GC-MS analysis of the in vitro turnover of cyclohexyl acetate by CYP101B1. 
















Figure 3. 27 (a) 1H NMR spectrum of trans-4-hydroxycyclohexyl acetate (CYP101B1). (b) 
Zoomed in H1 and H4 peaks to highlight their splitting pattern. Full data are provided in 
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Table 3. 5 Substrate binding, turnover and coupling efficiency data for CYP101B1 and 
CYP101C with a series of substrates containing the ester directing group. The turnover 
activities were measured as described in Table 3. 3. The data are reported as mean ± S.D. (n = 
3). Rates are given in nmol.nmol-CYP–1.min–1. - not measured or not able to be determined 










CYP101B1 544 ± 40 415 ± 56 56 ± 6 14 910 ± 385 
CYP101C1 - 173 ± 13 n.p - - 
cyclohexyl butyrate 
CYP101B1 114 ± 4 603 ± 32 310 ± 62 51 9580 ± 530 
CYP101C1 - 188 ± 16 25 ± 10 13 741 ± 48 
cyclohexyl 
isobutyrate 
CYP101B1 61 ± 5 383 ± 26 220 ± 62 57 3230 ± 65 
CYP101C1 - 106 ± 11 20 ± 2 19 144 ± 10 
4-tert-butyl-
cyclohexyl acetate 
CYP101B1 1.1 ± 0.04 766 ± 70 208 ± 50 27 5640 ± 740 
methylcyclohexyl 
acetate 
CYP101B1 31 ± 1.5 736 ± 26 261 ± 20 34 9460 ± 535 
CYP101C1 - 257 ± 8 36 ± 11 14 288 ± 21 
ethylcyclohexyl 
acetate 
CYP101B1 40 ± 1 667 ± 29 274 ± 15 42 7250 ± 1720 
CYP101C1 - 284 ± 35 56 ± 12 21 421 ± 60 
cyclooctyl acetate 
CYP101B1 1.6 ± 0.2 722 ± 16 223 ± 20 31 8180 ± 1100 
CYP101C1 - 961 ± 23 268 ± 24 28 3334 ± 686 
cyclooctyl 
isobutyrate 
CYP101B1 1.3 ± 0.2 732 ± 11 626 ± 30 75 4660 ± 1700 
CYP101C1 - 301 ± 2 25 ± 5 9 186 ± 75 
cyclododecyl 
acetate 
CYP101B1 0.05 ± 0.01 394 ± 8 94 ± 7 23 2990 ± 773 
CYP101C1 - 587 ± 7 50 ± 8 9 797 ± 100 
α-terpinyl acetate 
CYP101B1 - 178 ± 20 - -  




Increasing the size of the ester directing group, for example, butyrate and isobutyrate instead 
of acetate, improved the binding affinity of the cyclohexyl substrates for CYP101B1. 
Cyclohexyl butyrate shifted the spin-state of CYP101B1 to 60% and showed a dissociation 
constant of Kd = 114 µM (Figure 3. 28 and Table 3. 5). CYP101B1 catalysed the oxidation of 
this substrate with a high NADH consumption rate of 603 min-1 and a coupling efficiency of 
51% which resulted in a product formation rate of 310 min-1 (Table 3. 5). The total turnover 
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number (9580) was also significantly increased compared to cyclohexyl acetate (910). In 
comparison with CYP101B1, CYP101C1 had substantially lower product formation rates and 
coupling efficiencies (Table 3. 5). Both enzymes oxidised cyclohexyl butyrate to the same 
single metabolite (Figure 3. 29). Using an in vivo turnover system of CYP101B1, the metabolite 
was generated in sufficient yield for NMR characterisation. The metabolite was isolated (~26 
mg) using silica column chromatography and characterised by NMR analysis (Figure 3. 29 and 
Figure B. 75-B. 79). 1H NMR spectrum had a distinct multiplet peak of hydroxylation at 3.71-
3.60 ppm. The product has eight 13C NMR signals, and HSQC NMR spectrum displays the 
connections of 34.80 (C3 and C5), 31.25 (C2 and C6) with the protons of 1.99-1.88 ppm and 
1.47-1.33 ppm regions indicating hydroxylation occurred at the C-4 position resulting in a 
symmetrical metabolite (Figure 3. 29 and Figure B. 75-B. 79). gCOSY NMR spectrum analysis 
was also in agreement with this assignment. The splitting patterns and coupling constants of 
the H1 and H4 protons, JH1 = 3.1, 9.4 Hz and JH4 = 3.1, 9.2 Hz were similar, indicating their 




                                      (a)                                                              (b) 
 
Figure 3. 28 (a) The spin-state shift (red) of CYP101B1 after addition of cyclohexyl butyrate. 
(b) The dissociation constant analysis with cyclohexyl butyrate (1.33 µM CYP101B1/Kd 114 
µM). The concentration of enzyme used in the binding assay and the dissociation constant (Kd) 
are provided in brackets.  
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                                                                           (a) 
 
(b) 
      
(c) 
Figure 3. 29 (a) GC-MS analysis of in vitro turnover of cyclohexyl butyrate by CYP101B1 
and CYP101C1. Cyclohexyl butyrate (RT 5.7 min) and the product; trans-4-
hydroxycyclohexyl butyrate (RT 8.5 min). The chromatogram (CYP101C1) was offset along 
the x and y-axes for clarity. (b) 1H NMR spectrum of trans-4-hydroxycyclohexyl butyrate 
(CYP101B1). (c) Zoomed in version of 1H NMR spectrum to highlight the peaks of H1 and 
H4. Full data are provided in Appendix B (Figure B. 75-B. 79).  
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Addition of cyclohexyl isobutyrate also changed the spin-state of CYP101B1 to 60% and 
bound with a dissociation constant of 61 µM (Figure 3. 30 and Table 3. 5). Cyclohexyl 
isobutyrate caused the CYP101B1 turnover system to oxidise NADH at a rate of 383 min-1 
which was less than the other substrates tested above, but a faster product formation rate was 
observed compared to cyclohexyl acetate due to improved coupling efficiency (57%; Table 3. 
5). The total turnover number of CYP101B1 with cyclohexyl isobutyrate was in between the 
cyclohexyl acetate and cyclohexyl butyrate (3226; Table 3. 5). CYP101C1 oxidation of 
cyclohexyl isobutyrate proceeded with a low NADH oxidation activity of 106 min-1, product 
formation rate of 20 min-1 and coupling efficiency of 19% (Table 3. 5). Both in vitro and in 
vivo turnovers of this substrate with these enzymes generated the same product with high 
selectivity (≥99%), which was detected in GC-MS analysis (Figure 3. 31). The CYP101B1 
whole-cell system was used to generate the metabolite in the required yield for characterisation. 
The product was isolated by silica column chromatography and characterised by NMR analysis 
(~10 mg; Figure 3. 31 and Figure B. 80-B. 83). The 1H NMR had a characteristic signal at 3.78-
3.70 ppm, which is an indication of a hydroxylation metabolite (Figure 3. 31). The 1H-13C 
HSQC NMR analysis displayed the correlations of carbons at 34.75 ppm (C3 and C5) and 
31.04 ppm (C2 and C6) with the protons at δ 2.04-1.89 (H2, H4, H5 and H6) and δ 1.51-1.43 
(H2, H4, H5 and H6), confirming the hydroxylation occurred at the C4 position, which is the 
only position equidistant to the C2, C6 and C3, C5 carbons (Figure B. 82). The 1H, 13C, 1H-1H 
gCOSY NMR spectra were also in agreement with this assignment. The stereoisomer of this 
metabolite was confirmed as trans due to the high coupling constants of JH4 = 3.3, 8.8 Hz and 
JH1 = 4.7, 9.1 Hz, demonstrating their axial orientations (Figure 3. 31 and Figure B. 80-B. 83). 
 
    (a)                                                    (b) 
Figure 3. 30 (a) The spin-state shift (red) of CYP101B1 after addition of cyclohexyl 
isobutyrate. (b) Dissociation constant analysis with cyclohexyl isobutyrate (1.65 µM 
CYP101B1/Kd 61 µM). The concentration of enzyme used in the study and the dissociation 
constant (Kd) are provided in brackets.  
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 (a) 
 
                                                                      (b) 
  
                                                                       (c) 
Figure 3. 31 (a) GC-MS analysis of in vitro turnover of cyclohexyl isobutyrate by CYP101B1 
and CYP101C1. Cyclohexyl isobutyrate (RT 5.1 min) and the product; trans-4-
hydroxycyclohexyl isobutyrate (RT 7.9 min). The chromatogram (CYP101C1) was offset 
along the x and y-axes for clarity. (b) 1H NMR spectrum of trans-4-hydroxycyclohexyl 
isobutyrate (CYP101B1). (c) Zoomed in version of 1H NMR spectrum to highlight the H1 and 
H4 peaks splitting patterns. Full data are presented in Appendix B (Figure B. 80-B. 83).  
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The cyclohexyl ester derivative containing a tert-butyl group in the para position was also 
examined with CYP101B1. The spin-state shift induced by a mixture of the cis/trans isomers 
of 4-tert-butylcyclohexyl acetate was significantly higher than the 4-tert-butylcyclohexanol 
(~85% versus 15%, Figure 3. 32 and Figure 3. 2). The binding affinity was tighter compared 
to other cyclohexanol derived esters tested above, indicating this substrate was better 
accommodated in the active site of the enzyme (Figure 3. 32 and Table 3. 5). 
  
(a)                                                            (b) 
Figure 3. 32 (a) The spin-state shift (red) of CYP101B1 after addition of 4-tert-
butylcyclohexyl acetate. (b) Dissociation constant analysis with 4-tert-butylcyclohexyl acetate 
(1.75 µM CYP101B1/Kd 1.1 µM). The concentration of enzyme used in the binding assay and 
the dissociation constant (Kd) are provided in brackets. 
  
4-tert-Butylcyclohexyl acetate induced a faster NADH oxidation activity in the CYP101B1 
system (766 min-1; Table 3. 5). It catalysed the turnover of this substrate with a product 
formation rate of 208 min-1 and a coupling efficiency of 27% (Table 3. 5). The in vitro 
CYP101B1 turnovers of cis and trans isomers of 4-tert-butylcyclohexyl acetate were analysed 
by GC/GC-MS, which indicated that each diastereomer was transformed to a 
monohydroxylated metabolite (GC-MS RT 13.2 min; m+/z = 214.10 and RT 14.1 min; m+/z = 
214.20; Figure 3. 33 and Figure B. 1). The products were generated in a sufficient amount using 
the CYP101B1 whole-cell biotransformation system for characterisation. One of the 
metabolites (RT 14.1 min in GC) was isolated (~15 mg) using silica column chromatography, 
and this was characterised by NMR analysis. The metabolite was identified as 4-(1-hydroxy-
2-methylpropan-2-yl)cyclohexyl acetate (trans; JH1 = 4.5, 11.2 Hz and JH4 = 2.9, 12.1 Hz) using 
the distinct methyl hydroxylation peak which was observed at 3.39 (2H, 2xH8) in the 1H NMR 
spectrum (Figure 3. 33 and Figure B. 85). The 13C, gCOSY, HSQC NMR spectra were also in 
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agreement with this assignment (Figure B. 84-B. 88). The other product was not isolated, but 
it was presumed to be the hydroxylated metabolite of the cis diastereomer (m+/z = 214.10, 
Figure B. 1 and Figure B. 85). Further confirmation is required, which could be done using 
NMR. The substrate tert-butyl side chain must, therefore, be held in close proximity to the 
heme centre which inserted the hydroxyl group in one of the methyl groups instead of 
cyclohexane skeleton. 
 




Figure 3. 33 (a) GC analysis of the in vitro turnover of 4-tert-butylcyclohexyl acetate (cis and 
trans mixture) by CYP101B1. Cis and trans-4-tert-butylcyclohexyl acetate (RT 10.45 min and 
10.90 min) and the product 4-(1-hydroxy-2-methylpropan-2-yl)cyclohexyl acetate (RT 13.2 
min (cis) and 14.1 min (trans)). (b) 1H NMR spectrum trans-4-(1-hydroxy-2-methylpropan-2-
yl)cyclohexyl acetate. Full data are provided in Appendix B (Figure B. 84-B. 88). 
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The above results demonstrate that the catalytic activity of both enzymes was improved for 
cyclohexyl derived esters. Cyclohexylacetic acid was also investigated as a substrate. It did not 
induce the heme spin of the CYP101B1 enzyme to high spin-state, and no product was 
detectable when this substrate was added to either the CYP101B1 or CYP101C1 system 
(Figure not shown). However, the methyl and ethyl esters of cyclohexylacetic acid showed 
better binding characteristics. 
 
A substantial heme spin-state alteration was noticed when methylcyclohexyl acetate was added 
to CYP101B1. This substrate gave a 95% shift to the high spin form, and the binding affinity 
was improved with a Kd of 31 µM (Figure 3. 34 and Table 3. 5). This was tighter than the 
binding affinities of cyclohexanol derived esters investigated above (Figure 3. 34). The NADH 
oxidation and product formation activity were also enhanced for both enzymes (Table 3. 5). 
Compared to CYP101C1, CYP101B1 showed a better NADH oxidation activity of 736 min-1 
and product formation rate of 261 min-1 with a two-fold greater coupling efficiency (Table 3. 
5). 
 
The same monooxygenase metabolite was detected in the GC/GC-MS analyses of the in vitro 
turnovers of this substrate with CYP101B1 and CYP101C1 (m+/z = 172.0; Figure 3. 35 and 
Figure B. 1). A larger-scale whole-cell oxidation of methylcyclohexyl acetate with the 
CYP101B1 system was carried out to generate the metabolite in sufficient amount (Figure 3. 
35). The product was isolated (~32 mg) by silica column chromatography and identified via 
NMR analysis. In 1H NMR spectrum, a characteristic multiplet peak at 3.59-3.52 ppm is 
present, demonstrating a hydroxylation metabolite was formed (Figure 3. 35 and Figure B. 89-
B. 95). The product was identified as the 4-hydroxy metabolite based on 1H-13C HMBC NMR 
correlations of C4 (73.25 ppm) with the protons of H3, H5 (1.36-1.28 ppm) and H2, H6 (1.84-
1.74 ppm). This assignment was further confirmed by 1H-13C HSQC NMR spectrum analysis 
where two equal intensity of carbon peaks at 37.86 ppm (C3 & C5) and 33.61 ppm (C2 & C6) 
showed connections with the protons in the region of 2.02-1.94 ppm, 1.84-1.74 ppm, 1.36-1.28 
ppm and 1.12-1.00 ppm, which are only possible if hydroxylation took place at C4 position to 
form a symmetrical product (Figure B. 89-B. 95).  
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Figure 3. 34 (a) The spin-state shift (red) of CYP101B1 after addition of methylcyclohexyl 
acetate. (b) The dissociation constant analysis with methylcyclohexyl acetate (1.70 µM 
CYP101B1/Kd 31 µM). The concentration of enzyme used in the binding assay and the 
dissociation constant (Kd) are provided in brackets.  
 
 
The stereoselectivity of this metabolite was confirmed using 1H-1H ROESY NMR spectrum 
analysis (Figure 3. 36 and Figure B. 94-B. 95). H4 showed a characteristic interaction with 
H2/6ax (1.12-1.00 ppm) indicating the axial orientation of this proton. The axial orientation of 
H4 and H1 were confirmed by their axial-axial and axial-equatorial coupling constants of JH4 
= 10.8, 4.1 Hz and JH1 = 3.8, 7.4 Hz (Figure 3. 35). The H7 displayed a strong correlation with 
H6eq and a weak interaction with H6ax in ROESY NMR spectrum that also indicates the axial 
orientation of H1. Therefore, the product was assigned as methyl-2-(trans-4-
hydroxycyclohexyl)acetate (Figure 3. 36 and Figure B. 94-B. 95). 
  




                                         (a)                                                                   (b) 
 
                                                                      (c) 
Figure 3. 35 (a) GC analyses of in vitro turnovers of methylcyclohexyl acetate by CYP101B1 
and CYP101C1. Methylcyclohexyl acetate (RT 9.8 min) and the product; methyl-2-(trans-4-
hydroxycyclohexyl)acetate (RT 18.5 min), and a peak for esterification of the substrate to 
ethylcyclohexyl aceate$ (RT 11.5 min) and product of ethylcyclohexyl acetate oxidation@ (RT 
19.9 min). (b) GC-MS analysis of the in vivo turnover of methylcyclohexyl acetate by 
CYP101B1. Methylcyclohexyl acetate (RT 6.7 min) and the product; methyl-2-(trans-4-
hydroxycyclohexyl)acetate (RT 9.9 min). (c) 1H NMR spectrum of methyl-2-(trans-4-
hydroxycyclohexyl)acetate (CYP101B1). Full data are provided in Appendix B (Figure B. 89-
B. 95).  
 




                     (a) 
        
                       (b) 
Figure 3. 36 1H-1H ROESY NMR spectrum of methyl-2-(trans-4-hydroxycyclohexyl)acetate 
showed the interactions of (a) H4 (axial) with the H2/6ax  protons, and (b) H7 (equatorial side 
chain) displayed correlations with the protons of H6ax/eq. 
 
 
Ethylcyclohexyl acetate shifted the spin-state of CYP101B1 to ~85% high spin form (Figure 
3. 37), and it displayed slightly lower binding affinity than methylcyclohexyl acetate (Kd = 40 
µM versus Kd = 31 µM; Figure 3. 37 and Table 3. 5). Addition of this substrate in the in vitro 
turnover assay of CYP101B1 induced a fast NADH oxidation rate (667 min-1), indicative of 
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efficient product formation rate (274 min-1; Table 3. 5). The oxidation of this substrate by 
CYP101C1 progressed at a slower NADH oxidation activity and a product formation rate of 
284 and 56 min-1, respectively. The coupling efficiency was also lower for the CYP101C1 
system (42% versus 21%; Table 3. 5). CYP101B1 exhibited a significantly higher total 
turnover number compared to CYP101C1 (7250 versus 421; Table 3. 5).     
 
                                       (a)                                                              (b) 
Figure 3. 37 (a) The spin-state shift (red) of CYP101B1 after addition of ethylcyclohexyl 
acetate. (b) The dissociation constant analysis with ethylcyclohexyl acetate (1.65 µM 
CYP101B1/Kd 40 µM). The concentration of enzyme used in the binding study and the 
dissociation constant (Kd) are provided in brackets.  
 
The GC-MS analyses of the in vitro turnovers of both CYP101B1 and CYP101C1 indicated 
that same major monohydroxylated metabolite was formed, which accounted for 99% of the 
total turnover products (m+/z = 186.15; Figure 3. 38 and Figure B. 1). This metabolite was 
generated using the CYP101B1 in vivo turnover system, and then extracted and isolated for 
NMR analysis (~24 mg; Figure 3. 38 and Figure B. 96-B. 102). The H2 and H6 proton peaks 
(1.84-1.71 and 1.11-1.01 ppm) were determined via 1H-1H coupling with H1 in gCOSY NMR 
(Figure B. 98). These proton peaks were further confirmed via the 1H-13C HMBC NMR 
correlations of C2 and C6 (33.59 ppm) with H7 (2.19 ppm) (Figure 3. 37 and Figure B. 96-B. 
102). The HMBC NMR interactions of C2 and C6 with the H3 and H5 (1.3-1.23 ppm) protons 
were used to assign the C3 and C5 (37.87 ppm) carbon signals (Figure 3. 39). Two carbon 
signals 37.87 (C3 & C5) and 33.59 (C2 & C6) in the 13C NMR spectrum showed double the 
intensity compared to the other peaks, suggesting each signal represented two equivalent 
carbons. Hence, the hydroxylation occurred at the C4 position, resulting in a symmetrical 
metabolite (Figure 3. 39 and Figure B. 96-B. 102). 




      (a) 
 
        (b) 
 
Figure 3. 38 (a) GC analyses of the in vitro turnovers of ethylcyclohexyl acetate by CYP101B1 
and CYP101C1. Ethylcyclohexyl acetate (RT 11.5 min) and the product; ethyl-trans-2-(4-
hydroxycyclohexyl)acetate (RT 20.1 min). (b) GC-MS analysis of the in vivo turnover of 
ethylcyclohexyl acetate by CYP101B1. Ethylcyclohexyl acetate (RT 3.9 min) and the product; 
ethyl-trans-2-(4-hydroxycyclohexyl)acetate (RT 7.0 min) and a further oxidation metabolite at 
RT 6.9 min# (1%; m+/z =184.25, Figure B. 1). 
 
The stereoselectivity was confirmed by 1H-1H ROESY NMR analysis (Figure 3. 40 and Figure 
B. 101-B.102). The interaction of H4 with H2/6ax in ROESY NMR spectrum indicated its axial 
orientation. The correlations of H7 with H6ax/eq in the ROESY NMR suggested the axial 
orientation of H1. The axial-axial and axial-equatorial coupling constants of H4, JH4 = 10.9, 
4.1 Hz and H1, JH1 = 7.7, 3.7 Hz, were also confirmed their axial orientation (Figure 3. 40 and 
Figure B. 101-B. 102). Therefore, the diastereomer was assigned as a trans isomer of ethyl-2-
(4-hydroxycyclohexyl)acetate (Figure 3. 40 and Figure B. 101-B. 102).  
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                                                                        (a) 
   
                                                                        (b) 
 
                                                                        (c) 
Figure 3. 39 (a and b) 1H and 13C NMR spectrum of ethyl-trans-2-(4-
hydroxycyclohexyl)acetate (CYP101B1). (c) HMBC NMR spectrum of ethyl-trans-2-(4-
hydroxycyclohexyl)acetate. Full data are in Appendix B (Figure B. 96-B. 102).  







Figure 3. 40 Zoomed in version of ROESY NMR (600 MHz) spectrum of ethyl-trans-2-(4-
hydroxycyclohexyl)acetate, which highlighted the interactions of (a) H4 (axial) with the H2/6ax  
protons, and (b) H7 (equatorial side chain) showed correlations with the H6ax/eq protons. 
 
Cyclooctyl acetate and cyclooctyl isobutyrate both generated a significantly higher spin-state 
shift (~85 to 95%) upon addition to CYP101B1 when compared to cyclooctane (35%) and their 
parent alcohol cyclooctanol (5%; Figure 3. 41 and Figure 3. 2). The dissociation constants of 
CYP101B1 with both substrates were investigated to determine how tightly each substrate 
bound in the active site. CYP101B1 had tighter binding affinities with both of these substrates 
than the cyclic (C6) ester derivatives (Kd 1.3 µM and 1.6 µM; Figure 3. 41 and Table 3. 5). 
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Compared to cyclooctane and cyclooctanol, cyclooctyl acetate and isobutyrate induced faster 
NADH oxidation rates in CYP101B1 system. Among these two ester substrates, higher product 
formation activity and coupling efficiency were observed with cyclooctyl isobutyrate (Table 3. 
5). CYP101C1 catalysed the oxidation of cyclooctyl acetate with greater NADH oxidation 
activity (961 min-1) and marginally faster product formation rate than the CYP101B1 (268 min-
1 versus 223 min-1; Table 3. 5). However, for cyclooctyl isobutyrate, CYP101C1 had a slower 
product formation rate compared to CYP101B1, due to a significant reduction in the coupling 
efficiency (9% versus 75%). Total turnover number of CYP101B1 with cyclooctyl acetate was 
3-fold higher than the CYP101C1 system (Table 3. 5). TTNs with cyclooctyl isobutyrate were 
reduced in both systems, and this may be due to the lower water solubility of this substrate 
(Table 3. 5). 
 
(a)                                                                (b) 
 
(c)                                                               (d) 
Figure 3. 41 The spin-state shifts (red) of CYP101B1 with (a) cyclooctyl acetate and (b) 
cyclooctyl isobutyrate. Dissociation constants with (c) cyclooctyl acetate (1.59 µM 
CYP101B1/ Kd 1.6 µM) and (d) cyclooctyl isobutyrate (1.50 µM CYP101B1/Kd 1.3 µM). The 
concentration of enzyme used in the binding assays and the dissociation constants (Kd) are 
provided in brackets.  
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Cyclooctyl acetate, when turned over by CYP101B1, formed a single metabolite, and the mass 
spectrum analysis indicated that it was a hydroxylated metabolite with a mass, m+/z = 186.20 
(98%; Figure 3. 42 and Figure B. 1). CYP101C1 generated the same metabolite (80%) observed 
in the GC-MS analysis of CYP101B1 turnover, alongside a minor product which accounted for 




Figure 3. 42 GC-MS analyses of in vitro turnovers of cyclooctyl acetate by CYP101B1 and 
CYP101C1. Cyclooctyl acetate (RT 6.5 min) and the product; 5-hydroxycyclooctyl acetate (RT 
8.95 min), and a minor peak at RT 8.8 min# with CYP101C1 turnover which was not formed 
in large enough yield to be identified using NMR but that was assigned as a further oxidation 
product based on its spectrum (m+/z = 184.10; Figure B. 1). The chromatogram (CYP101C1) 
was offset along the x and y-axes for clarity. 
 
The primary metabolite of the CYP101B1 turnover was generated using a whole-cell oxidation 
system, extracted and purified by silica column chromatography. Sufficient amount (~31 mg) 
of the metabolite was obtained for NMR characterisation (Figure 3. 43 and Figure B. 103-B. 
108). The 13C NMR spectrum had six carbon signals between the region 20-80 ppm, three of 
which 37.87 ppm (C4 & C6), 34.93 ppm (C2 & C8) and 21.55 ppm (C3 & C7) displayed almost 
double the intensity of the other three carbons peaks at 76.61 ppm (C1), 73.88 ppm and 24.13 
(C10) (Figure B. 103-B. 108). This could only be possible if hydroxylation occurs at C5 to 
generate a symmetrical product. The HSQC and HMBC NMR spectra were also in agreement 
with the assignment (Figure B. 103-B. 108). The stereoselectivity was not able to be confirmed 
using 1H-1H ROESY NMR spectrum due to overlapping proton peaks in the 1H NMR (Figure 
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3. 43 and Figure B. 108). However, the coupling constants of H1 (3.6 and 8.6 Hz), H5 (3.7 and 
8.3 Hz) and their splitting patterns (tt) indicated their similar orientation (both axial; Figure B. 
103). Hence, the product was presumed to be a trans isomer (Figure 3. 43 and Figure B. 103).  
 
  
                                                                      (a) 
 
                                                                       (b) 
                    
Figure 3. 43 (a) 1H NMR spectrum of 5-hydroxycyclooctyl acetate (trans). (b) 13C NMR 
spectrum of 5-hydroxycyclooctyl acetate (trans). Full data are presented in appendix B (B. 
103-B. 108). The detail of minor signals of the 13C NMR is given in Figure B. 104. 
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In the turnovers of cyclooctyl isobutyrate by CYP101B1 and CYP101C1, a single major 
metabolite was detected in the GC-MS analyses (m+/z = 214.9; Figure 3. 44 and Figure B. 1). 
A whole-cell oxidation system containing CYP101B1 enzyme was used to generate this 
metabolite in larger yield for NMR characterisation. The metabolite was extracted and purified 
(~25 mg) using silica column chromatography. The presence of a characteristic multiplet peak 
at 3.88-3.74 ppm in 1H NMR spectrum indicated a hydroxylated metabolite (Figure 3. 45 and 
Figure B. 109-B. 114). The 13C NMR spectrum had eight carbon signals among these four 
signals 37.85 ppm, 34.92 ppm, 21.59 ppm and 21.53 ppm showed approximately two-
fold higher intensity compared to 76.10 ppm (C1), 73.92 ppm, 36.81 ppm (C10) as observed 
in cyclooctyl acetate, which demonstrated each signal represents the pair of equivalent carbons, 
and that indicated hydroxylation at C5 to form a symmetrical metabolite (Figure B. 109-B. 
114). The 1H-13C interactions in HSQC and HMBC NMR spectra were also in agreement with 
this assignment (Figure B. 109-B. 114). 1H-1H ROESY NMR spectrum was carried out to 
determine the stereoselectivity, however, overlapping of the proton peaks hampered 
identification. The coupling constants of H5 (JH5 = 3.8, 8.0 Hz) and H1 (JH1 = 3.5, 8.1 Hz) 
demonstrating their similar orientation (both axial). Therefore, the metabolite was proposed as 
a trans isomer. Some additional minor peaks in the 13C NMR spectrum of this product indicated 
that two other metabolites were also present as impurities, but these were not able to be fully 
characterised (B. 110).  
 
Figure 3. 44 GC-MS analyses of the in vitro turnovers of cyclooctyl isobutyrate by CYP101B1 
and CYP101C1. Cyclooctyl isobutyrate (RT 8.0 min) and the product; 5-hydroxycyclooctyl 
isobutyrate (RT 10.2 min; trans). The chromatogram (CYP101C1) was offset along the x and 
y-axes for clarity. 







Figure 3. 45 (a) 1H NMR spectrum of 5-hydroxycyclooctyl isobutyrate (trans). (b) Zoomed in 
version of 1H NMR spectrum to highlight the H1 and H5 peaks splitting patterns. Full data are 
provided in Appendix B (Figure B. 109-B. 114).  
 
Cyclododecyl acetate induced a complete shift of heme spin-state to the high spin form (~ 95%) 
in CYP101B1 (Figure 3. 46). The enzyme also bound tightly to the substrate (Kd = 0.05 µM; 
Figure 3. 46). The rates of NADH oxidation of CYP101B1 and CYP101C1 with this substrate 
were 394 and 587 min-1, respectively and these were significantly faster compared to 
cyclododecane and cyclododecanol (Table 3. 5). However, both enzymes displayed low 
coupling efficiencies (≤23%), that resulted in reduced product formation rates (≤94 min-1; 
Table 3. 5). These were lower than those of cyclododecanone and cyclooctyl acetate (Table 3. 
5). 




                                            (a)                                                      (b) 
Figure 3. 46 (a) The spin-state shift (red) of CYP101B1 after addition of cyclododecyl acetate. 
(b) The dissociation constant analysis with cyclododecyl acetate (2.1 µM CYP101B1/Kd 0.05 
µM). The concentration of enzyme used in the binding assay and the dissociation constant (Kd) 
are provided in brackets. 
  
CYP101B1 catalysed the oxidation of cyclododecyl acetate and generated one significant 
(74%) product alongside three minor metabolites (Figure 3. 47). These products were generated 
in larger quantity for characterisation using the CYP101B1 whole-cell system. The major 
metabolite (at RT 17.3 min in GC) was purified (~21 mg) and identified as a 7-
hydroxycyclododecyl acetate by NMR analysis (Figure 3. 48 and Figure B. 115-B. 118) 150. 
The HCOH signal was observed at 3.89-3.80 ppm in the 1H NMR (Figure 3. 48). The 13C NMR 
displayed nine carbon signals, five of which were double the height of the other peaks, 
representing pairs of equivalent carbons (Figure B. 116 and Table B. 1). The carbons and 
hydrogens were assigned via 1H-13C HSQC analysis and the metabolite was identified as a 7-
hydroxycyclododecyl acetate (Figure B. 118 and Figure 3. 48) 150. This metabolite was 
confirmed as a single diastereomer by comparing the 13C NMR signals and 1H NMR spectrum 
protons peaks of HC1(OAC) (δ 4.91, J = 5.5, 8.1 Hz, H1) and HC7OH (δ 3.89-.380 ppm; J = 
5.0, 8.0 Hz, H7) with the NMR reported previously (Table B. 1, Figure 3. 48 and Figure B. 
115-B. 118) 150. The splitting patterns of H1 and H7, and similar coupling constants suggested 
their orientation must be in the same direction (both axial; Figure 3. 48). Therefore, the product 
was assigned as the trans isomer 150. This metabolite was also detected in CYP101C1 turnover 
as a minor metabolite (~5%; Figure 3. 47). The other products of CYP101B1 turnover were 
not generated in sufficient quantity for characterisation by NMR. However, the 1H and 13C 
NMR spectra of the primary metabolite had some additional signals, which indicated these 
minor products were also present in the NMR sample (Table B. 1, Figure B. 115-B. 123). The 
detail of the 13C NMR signals is provided in Table B. 1. 
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One of the minor metabolites (at RT 16.5 min; 2%) was assigned as the other diastereomer of 
7-hydroxycyclododecyl acetate (cis) via the carbon signals (Figure B. 116 and Figure B. 123). 
These 13C NMR signals (71.73, 68.75, 32.43, 29.14, 24.07, 21.36, 20.97, 20.94, 18.97 ppm; 
carbonyl signal not detected) were in good agreement with the reported NMR carbon signals 
(71.6, 68.7, 32.4, 29.1, 24.0, 21.3, 21.0, 20.9, 18.6; Table B. 1, Figure B. 116) 150. This 
metabolite coeluted in GC with the major product (80%; RT 16.5 min) of CYP101C1 (Figure 
B. 123) 150. 
Another minor metabolite (at RT 16.2 min) was not able to be purified in  sufficient yield. 
However, the NMR of the mixture of metabolites suggested that this was a 5-hydroxy 
metabolite (Figure B. 119-B. 122, Table B. 1). The correlations of H1 (5.05-4.95 ppm) with 
carbons in the 1H-13C HMBC NMR were used to assign the signals C2 (29.69), C3 (20.32), 
C11 (20.70) and C12 (29.56). The product was confirmed as 5-hydroxycyclododecyl acetate 
as C3 (20.70) displayed a strong correlation with the multiplet H5 (3.72-3.88 ppm) in the 
HMBC NMR (Figure B. 119-B. 122). The high coupling constants of H1 (JH1 = 6.4, 11.9 Hz) 
and H5 (JH5 = 6.4, 12.4 Hz) indicated their axial orientation, hence the product was proposed a 
trans isomer of 5-hydroxycyclododecyl acetate (Figure B. 119). The minor product peak at RT 
16.4 min (GC) was thought to be another alcohol or the other diastereomer of 5-
hydroxycyclododecyl acetate as additional twelve minor carbon signals were present in 13C 
NMR of 5-hydroxycyclododecyl acetate (Table B. 1, Figure B. 120 and Figure 3. 47). 
However, full characterisation of this metabolite was not possible due to inadequate yield. 
These two minor metabolites were also observed in the CYP101C1 turnovers (Figure 3. 47).  
 
Figure 3. 47 GC analyses of in vitro turnovers of cyclododecyl acetate by CYP101B1 and 
CYP101C1. Cyclododecyl acetate (RT 5.6 min; not shown) and the products; proposed 5-
hydroxycyclododecyl acetate$ (RT 16.2 min) and unidentified metabolite# (RT 16.4 min); 
product 1; 7-hydroxycyclododecyl acetate (RT 16.5 min; cis isomer) 150; product 2; 7-
hydroxycyclododecyl acetate (RT 17.3 min; trans isomer) 150.  








Figure 3. 48 (a) 1H NMR spectrum of 7-hydroxycyclododecyl acetate (RT 13.6 min; trans) 
150. (b) Zoomed in version of 1H NMR spectrum of 7-hydroxycyclododecyl acetate which 
highlighted the splitting patterns of H1 and H7 peaks, and this product was presumed to be a 
trans isomer of 7-hydroxycyclododecyl acetate. Full data are presented in Appendix B (Table 
B. 1, Figure B. 115-B. 123).  
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α-Terpinyl acetate containing p-menthane backbone was also screened to find out the effect of 
the presence of a double bond in the ring on the activity of both enzymes. Oxidation of α-
terpinyl acetate by CYP101C1 proceeded with a significantly higher NADH oxidation rate than 
that measured for CYP101B1 (898 min-1 versus 178 min-1; Table 3. 5). CYP101B1 did not 
oxidise this substrate with no product detected in the GC-MS analysis of the in vitro turnover 
233. CYP101C1 oxidised the α-terpinyl acetate efficiently with a product formation rate of 497 
min-1 and a coupling efficiency of 55% (Table 3. 5). The GC analysis of the CYP101C1 in 
vitro turnover revealed a primary (82%) alongside a minor metabolite (Figure 3. 49). The 
epoxide of α-terpinyl acetate was synthesised by mCPBA using a standard method (Figure not 
shown) 230. m-Chloroperbenzoic acid (1.2 equivalent) was mixed with the α-terpinyl acetate in 
dichloromethane (DCM) at 0 ºC, and the mixture was stirred for two hours to generate the 
epoxide 230. The progress of the reaction was monitored in GC-MS. However, this did not 
coelute with the metabolite generated by CYP101C1 (at RT 15.25 min in GC-MS).  
 
The CYP101C1 whole-cell system was used to generate the metabolite in the required yield 
for characterisation. The major metabolite was extracted and isolated using silica column 
chromatography and characterised by NMR analysis (~10 mg; Figure 3. 49 and Figure B. 124-
B. 131). The presence of a broad peak at 4.20 ppm in 1H NMR confirmed a hydroxylated 
metabolite (Figure 3. 49). The H6 signal was assigned via the correlations of C1 (44.56 ppm) 
with the protons of 1.48-1.41 (H9 and H10), 2.19-2.13 (H6) and 1.35-1.20 (H6) in the 1H-13C 
HMBC NMR (Figure B. 124-B. 131). The H2 peaks (2.02-1.97 and 1.92-1.85 ppm) also 
showed interaction with the π-bond proton H3 (5.48 ppm) in the gCOSY NMR. The product 
was identified as 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-trimethyl-,α-acetate due to the 
correlations of H5 (4.20 ppm) with both hydrogens on C6 (H6 (2.19-2.13 ppm) and H6 (1.35-
1.20)) in 1H-1H gCOSY NMR (Figure B. 126). 
 
The minor metabolite (at RT 12.5 min) was not generated and purified in high enough yield 
for NMR characterisation. However, by using the small peaks in the 1H and 13C NMR spectra 
of the major metabolite, this minor product was assigned to be the other diastereomer of 3-
cyclohexene-1-methanol, 5-hydroxy-α,α,4-trimethyl-,α-acetate. The minor signal at 71.25 ppm 
(C5) in the 13C NMR spectrum of the primary product displayed a correlation with (H7) in the 
HMBC NMR, as well as the presence of the two alkene carbons peaks at 120 to 140 ppm 
region, were in agreement with this assignment (Figure B. 131).  




                                          (a)                                                                 (b) 
 
Figure 3. 49 (a) GC analysis of the in vitro turnover of α-terpinyl acetate by CYP101B1 and 
CYP101C1. α-Terpinyl acetate (RT 10.4 min) and the products; 3-cyclohexene-1-methanol, 5-
hydroxy-α,α,4-trimethyl-,α-acetate (RT 12.8 min; CYP101C1) and its other diastereomer# (RT 
12.5 min). (b) GC-MS analysis of the in vitro turnover of α-terpinyl acetate by CYP101C1. α-
Terpinyl acetate (RT 12.6 min) and the products; 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-
trimethyl-,α-acetate (RT 17.4 min; CYP101C1) and its other diastereomer# (RT 17.0 min). The 
impurities are marked (*). 
 
 
Figure 3. 50 1H NMR spectrum of the 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-trimethyl-
,α-acetate. Full data are presented in Appendix B (Figure B. 124-B. 131).




In summary, introduction of an ester directing group to the cycloalkanols or cyclohexylacetic 
acid significantly improved the activity of CYP101B1 toward these cyclic substrates. The 
cyclohexyl derivatives possess a similar ring system to the ionones, and the ester moieties could 
mimic the butenone chain of the norisoprenoids. These two factors are likely to contribute to 
improving the activity and better binding of these substrates, especially with CYP101B1. The 
oxidation of cyclic esters by CYP101B1 and CYP101C1 occurred predominantly at the C-H 
bonds on the opposite side of the ring to the ester group, for example, C4 for cyclohexyl 
derivatives, and C5, and C7 for the cyclooctyl and cyclododecyl derivatives, respectively. 
CYP101B1 displayed superior product formation rates and total turnover number than the 
CYP101C1 system for most substrates. Both enzymes preferentially formed the trans 
diastereomer, however, for 7-hydroxycyclododecyl acetate CYP101C1 generated the cis 
isomer.
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3.2.3 The Oxidation of Linear Ketones and Terpene Esters by CYP101B1 and CYP101C1 
 
To further explore the substrate range of CYP101B1 and CYP101C1, they were studied with 
linear substrates containing a ketone moiety such as 2-nonanone, 2-undecanone, and 
monoterpenoid esters (Figure 3. 51). These are commonly used as fragrance, flavouring and 
insect repellent agents 224-227. Functionalisation of the C-H bonds of these compounds are 




Figure 3. 51 The linear alkyl ketones and esters which were screened with CYP101B1 and 
CYP101C1. 
 
2-Nonanone and 2-undecanone induced 20% and 30% heme spin-state shift in CYP101B1, 
respectively (Figure 3. 52). 2-Nonanone bound with a lower affinity to CYP101B1 than 2-
undecanone (140 µM versus 44 µM; Figure 3. 52). 2-Nonanone and 2-undecanone mediated 
spin-state shifts and binding affinities of CYP101B1 were weaker when compared with their 
cyclic counterparts cyclononanone and cycloundecanone (Figure 3. 52 and Table 3. 3).  
 
CYP101B1 oxidised 2-nonanone with a faster NADH oxidation activity (552 min-1 versus 270 
min-1), product formation (219 min-1 versus 92 min-1) rate and higher coupling efficiency than 
the CYP101C1 system (40% versus 34%; Table 3. 6). GC-MS analyses of the in vitro turnovers 
of 2-nonanone by CYP101B1 revealed one single major metabolite peak at RT 11.25 min, 
accounted 98% of total turnover products arising from the enzymatic oxidation (Figure 3. 53). 
The mass spectrum indicated that is a monooxygenase metabolite (m+/z = 158.20; Figure B. 
1). With an aim to identify this metabolite, a whole-cell turnover containing CYP101B1 
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enzyme was used to generate the product in sufficient yield for NMR characterisation. The 1H 
NMR spectrum had a multiplet peak at 3.86-3.73 ppm, confirming a hydroxylation metabolite 
(Figure 3. 53). The product was assigned as 8-hydroxy due to the correlation of C8 (70.71 ppm) 
with the doublet peak of the H9 methyl protons at 1.19 ppm in the 1H-13C HMBC NMR 
spectrum (Figure B. 132-B. 136) 228. The metabolite was confirmed as hydroxylation at H8 by 
the strong interaction with the protons of C9 in gCOSY NMR spectrum (Figure B. 134).  
 
 
(a)                                                               (b) 
   
 (c)                                                                (d) 
 
Figure 3. 52 The spin-state shifts (red) of CYP101B1 after addition of (a) 2-nonanone and (b) 
2-undecanone. The dissociation constants analysis with (c) 2-nonanone (2.63 µM 
CYP101B1/Kd 140 µM) and (d) 2-undecanone (2.11 µM CYP101B1/Kd 44 µM). The 
concentration of enzyme used in the binding studies and the dissociation constants (Kd) are 
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The selectivity of oxidation completely changed in the case of CYP101C1 system as it oxidised 
the 2-nonanone to one different major product (~93%; at RT 8.5 min) alongside with a minor 
metabolite. The mass spectra suggested that both these were monohydroxylated metabolites 
(m+/z = 158.65, m+/z = 158.20; Figure B. 1). The minor product (at RT 11.25 min) was 
confirmed as 8-hydroxy-2-nonanone by coeluting with the turnover metabolite of CYP101B1 
using GC-MS (Figure 3. 53). The CYP101C1 whole-cell turnover was carried out to generate 
the primary metabolite for NMR characterisation, however, it was not generated in enough 
yield. The product was identified as 3-hydroxy-2-nonanone based on its mass spectrum 
fragmentation patterns (158.65, 115.15, 97.15, 85.10, 71.15, 69.15, 55.10, 43.10; Figure B. 1). 
Fragments detected at m+/z 115.15, 97.15 and 85.10, corresponding to the elimination of -
COCH3 (43), -OH, -H3 (18) and -C3 (12), respectively, enabling the identification of this 
metabolite. 
Table 3. 6 Substrate binding, turnover and coupling efficiency data for CYP101B1 and 
CYP101C1 with linear ketones and terpene esters. The in vitro turnover activities were 
measured as described in Table 3. 1 and Table 3. 3. The data are reported as mean ± S.D. (n = 











CYP101B1 552 ± 11 219 ± 34 40 5700 ± 85 
CYP101C1 270 ± 12 92 ± 15 34 - 
2-undecanone 
CYP101B1 568 ± 3 340 ± 50 60 1660 ± 95 
CYP101C1  311 ± 12 59 ± 25 19 - 
citronellyl acetate 
CYP101B1 418 ± 4 115 ± 1 28 - 
CYP101C1 654 ± 8   304 ± 11 47 1540 ± 216 
linalyl acetate 
CYP101B1 205 ± 8 8 ± 1 4 - 












Figure 3. 53 (a) GC-MS analyses of the in vitro turnovers of 2-nonanone by CYP101B1. 2-
Nonanone (RT 5.8 min); the major products 8-hydroxy-2-nonanone (RT 11.25 min; m+/z 
=158.20) and 3-hydroxy-2-nonanone (RT 8.5 min; m+/z =158.65). The chromatogram 
(CYP101C1) was offset along the x and y-axes for clarity. (b) 1H NMR spectrum of 8-hydroxy-
2-nonanone (RT 11.25 min). Full data are given in Appendix B (Figure B. 132-B. 136).  
   
CYP101B1 exhibited a lower binding affinity with 2-undecanone than cycloundecanone, 
despite this the in vitro turnovers of 2-undecanone by CYP101B1 induced at a faster oxidation 
activity (568 min-1) and a higher product formation rate (340 min-1) as well as a high coupling 
efficiency of 60% (Table 3. 3 and Table 3. 6). CYP101C1 catalysed the oxidation of this 
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substrate with slower NADH oxidation rate, and that resulted in a reduced product formation 
activity of 59 min-1 (Table 3. 6). These lower rates could be rationalised due to the lower 
coupling efficiency of CYP101C1 (19%; Table 3. 6).   
 
CYP101B1 catalysed the oxidation of 2-undecanone to form one major product (80%) 
alongside three minor metabolites (Figure 3. 54). A larger scale in vivo turnover of CYP101B1 
was carried out to generate the metabolites sufficient quantity for characterisation. The major 
product (RT 14.95 min) was isolated (~18 mg) using silica column chromatography and 
characterised by NMR (Figure 3. 54, Figure B. 1 and Figure B. 137-B. 142). The characteristic 
multiplet peak at 3.63-3.53 ppm in 1H NMR spectrum indicated a hydroxylated metabolite 
(Figure 3. 54). The 2xH10 protons were assigned using the interaction with H11 (0.96-0.88 
ppm) in 1H-1H gCOSY NMR spectrum (Figure B. 138). The C6 (28.06), C7 (39.90) and C9 
(42.38) were assigned using correlations with protons in the 1H-13C HMBC and HSQC NMR. 
The interactions of carbon (74.26 ppm) with the protons of 1.52-1.37 ppm (H6, H7, H9, and 
H10) in the HMBC NMR spectrum suggested that the hydroxylation took place at the C8 
position (Figure B. 137-B. 142).  
 
The two minor metabolites (at RT 15.2 min and 15.9 min) were not generated in large enough 
yield for NMR identification. However, the 13C NMR of the major metabolite displayed minor 
carbon signals CH(OH) at 75.92 ppm and 74.34 ppm. In the HMBC NMR spectrum, the carbon 
signal (75.92 ppm) correlated strongly with H11 (0.96-0.88 ppm) and this metabolite was 
identified as 9-hydroxy-2-undecanone, not the 10-hydroxy product (Figure B. 137-B. 142). If 
hydroxylation took place at C10, the chemical shift (doublet peak) of the protons on carbon 
C11 would move further downfield (Figure B. 142). The other carbon signal at 74.34 ppm 
showed the correlation with the protons at 1.52-1.1.28 ppm, and the detail of this product 
assignment is presented in Appendix B (Figure B. 142) 229. The third minor metabolite at RT 
6.2 min was identified by coelution experiment in GC-MS with the main product of CYP101C1 
(Figure 3. 54). 
CYP101C1 metabolised 2-undecanone into three metabolites with a ratio of 70:20:10 (Figure 
3. 54 and Figure B. 1). The major (70%; RT 6.2 min) metabolite was assigned as 3-hydroxy-
2-undecanone by matching its mass spectrum with the published data (Figure B. 1) 219. The 
experimental mass spectrum (m+/z = 186.25, 143.20, 125.25, 111.50, 97.15, 83.10, 69.15, 
55.10, 43.05) closely matched with the reported mass spectrum m+/z = 186, 143, 125, 111, 97, 
Chapter 3.2.3                                                                        Linear Ketones and Terpene Esters 
110 
 
83, 69, 55 and 43 (Figure B. 1) 219. The minor metabolites of CYP101C1 turnovers were 
confirmed by coeluting the products of CYP101B1 in GC-MS (Figure 3. 54 and Figure B. 1).  
 
  (a) 
 
(b) 
Figure 3. 54 (a) GC analyses of in vitro turnovers of 2-undecanone by CYP101B1 (black) and 
CYP101C1 (red). 2-Undecanone (RT 6.2 min) and the product 1: 3-hydroxy-2-undecanone 
(RT 11.5 min), product 2: 8-hydroxy-2-undecanone (RT 14.95 min), and proposed 7-hydroxy-
2-undecanone# (RT 15.2 min; based on carbon signal (74.92 ppm) intensity in 13C NMR) and 
9-hydroxy-2-undecanone# (RT 15.9 min, based on C9 (75.92 ppm) carbon signal intensity in 
the 13C NMR). The chromatogram (CYP101C1) was offset along the x and y-axes for clarity. 
(b) 1H NMR of 8-hydroxy-2- undecanone (RT 14.95 min). Full data are given in Appendix B 
(Figure B. 137-B. 142).  
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CYP101C1 catalysed the oxidation of linear esters such as citronellyl acetate and linalyl acetate 
with significantly faster NADH oxidation activity than the CYP101B1 system (Table 3. 6). 
The turnover of citronellyl acetate with CYP101C1 resulted in higher levels of product 
formation activity. This was also due to the greater coupling efficiency of the turnover (47% 
versus 28%; Table 3. 6) 
 
GC analysis revealed that a single product was generated in both the CYP101B1 and 
CYP101C1 in vitro turnovers of citronellyl acetate (Figure 3. 55). The product was confirmed 
as citronellyl acetate epoxide by coeluting with a standard, which was synthesised via the 
oxidation of citronellyl acetate with m-chloroperbenzoic acid (Figure 3. 55) 230, 231. m-
Chloroperbenzoic acid (1.2 equivalent) was mixed with the citronellyl acetate in 
dichloromethane (DCM) at 0 ºC, and the mixture was stirred for one hour to generate the 
epoxide (Figure 3. 55). The progress of the reaction was monitored in GC-MS.  
 
   
(a)                                                                     (b) 
 
Figure 3. 55 (a) In vitro turnover of citronellyl acetate by CYP101B1 and CYP101C1, coeluted 
with a synthesised epoxide in GC. Citronellyl acetate (RT 14.4 min) and the product; citronellyl 
acetate epoxide (RT 18.3 min). The chromatogram (CYP101C1) was offset along the x and y-
axes for clarity. (b) GC-MS analysis of epoxide synthesis reaction of citronellyl acetate. 
Citronellyl acetate (RT 12.7 min) and the product; citronellyl acetate epoxide (RT 15.5 min). 
Mass spectrum is provided in Appendix B (Figure B. 1). The impurities are marked (*). 
 
 
CYP101B1 and CYP101C1 oxidised linalyl acetate with lower NADH oxidation and product 
formation rates compared to citronellyl acetate (Table 3. 6). The NADH oxidation rates of 
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CYP101C1 (200 min-1) and CYP101B1 (205 min-1) were similar (Table 3. 6). The product 
formation rate was six-fold faster for CYP101C1 (50 min-1 versus 8 min-1) due to the better 
coupling efficiency of this system (25% and 4%; Table 3. 6). The in vitro turnovers of 
CYP101C1 and CYP101B1 with this substrate generated a single major metabolite 90% and 
60%, respectively with a second product making up the remainder (Figure 3. 56). The products 
were proposed as 6,7-epoxy-3,7-dimethyl-1-octen-3-yl acetate 231 (RT 12.5 min)   and 1,2-
epoxy-3,7-dimethyl-6-octen-3-yl acetate by coeluting with standards synthesised via the 
oxidation of linalyl acetate using m-CPBA (Table 3. 6 and Figure 3. 56) 230, 231. However, NMR 




(a)                                                                  (b) 
 
Figure 3. 56 (a) GC-MS analysis of the in vitro turnover of linalyl acetate by CYP101C1 (red), 
which coeluted with the epoxidation reaction of linalyl acetate with mCPBA (blue). Linalyl 
acetate (RT 9.9 min) and the products; 6,7-epoxy-3,7-dimethyl-1-octen-3-yl acetate (RT 12.5 
min) and 1,2-epoxy-3,7-dimethyl-6-octen-3-yl acetate (RT 12.6 min). (b) The GC-MS analysis 
of epoxide synthesise reactions of linalyl acetate. Linalyl acetate (RT 9.9 min) and products; 
6,7-epoxy-3,7-dimethyl-1-octen-3-yl acetate, 48% (RT 12.5 min) 232; 1,2-epoxy-3,7-dimethyl-
6-octen-3-yl acetate, 52% (RT 12.6 min). Mass spectra are provided in Appendix B (Figure B. 
1).  
 




CYP101B1 and CYP101C1 exhibited low oxidation and product formation activities with 
cyclic alkanes (C6 to C12). Despite this, both enzymes were able to oxidise these substrates. 
The smallest substrate tested, cyclohexane induced a low spin-state shift in CYP101B1, and a 
hydroxylated product was detected. The larger cyclic alkanes cyclooctane, cyclodecane and 
cyclododecane bound better to CYP101B1. The product formation rates for both enzymes with 
these larger substrates were improved compared to that of cyclohexane. One major 
hydroxylated product alongside a small amount of ketone further oxidation metabolite was 
detected in the turnovers of these enzymes with most of the cyclic alkanes. The majority of the 
cyclic alcohols did not show any significant binding affinity with CYP101B1 and CYP101C1, 
and little or no product formation was observed in GC/GC-MS analyses. The exception was 
cyclododecanol, which was oxidised by both enzymes and generated the 1,7-
cyclododecanediol metabolite alongside two other minor products.  
Cycloalkanones (C9 to C15) induced higher spin-state shifts in the CYP101B1 compared to their 
cyclic alkanes and alcohol equivalents. With these substrates, CYP101B1 displayed faster 
product formation rates than the CYP101C1. In particular, CYP101B1 oxidation activity was 
highest with cycloundecanone and cyclododecanone. CYP101B1 oxidised cyclononanone and 
cyclodecanone yielding 1-hydroxy-10-oxabicyclo[4.3.1]decane, 1-oxabicyclo[5.3.1]undecan-
1-ol and 1-oxabicyclo[6.3.1]undecan-1-ol. These exist in a transannular tautomeric equilibrium 
with their corresponding hydroxy cycloalkanones. The regioselectivity of CYP101C1 
oxidation with these cyclic ketones was different, and it predominantly generated 2-hydroxy 
metabolites irrespective of the size of the ring. The improved activity of CYP101B1 and 
CYP101C1 with these cycloalkanone structures is likely due to the presence of the ketone 
moiety. This enables more favourable binding in the active site of the enzyme and therefore 
more efficient turnover. Note that the binding orientation of these substrates in CYP101B1 and 
CYP101C1 must be significantly different to account for these observed regioselectivity 
differences. 
Cyclic compounds containing ester directing groups displayed greater binding affinities with 
CYP101B1 than their cyclic alcohol and acid counterparts. Cyclohexanol derivatised with 
acetate, butyrate and isobutyrate directing groups were oxidised by CYP101B1 efficiently 
whereas no product formation was observed with cyclohexanol. The enzyme metabolised these 
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substrates regioselectively at C4 with the trans diastereomer being favoured. Introducing an 
ester directing group to cyclohexylacetic acid, significantly increased the binding affinity with 
CYP101B1 and resulted in high product formation activities. CYP101C1 was able to oxidise 
the majority of these substrates, but the catalytic performance was lower due to the poor 
productive utilisation of the reducing equivalents compared to the CYP101B1 system. The total 
turnover number was higher for these ester derivatives with CYP101B1 than the CYP101C1. 
The use of ester directing groups significantly increased the activity of CYP101B1 with 
cyclooctanol ester derivatives. Cyclooctyl acetate and cyclooctyl isobutyrate displayed tight 
binding with CYP101B1 as well as high product formation rates. Both substrates were oxidised 
regioselectively at the C5 (trans-isomer) position by CYP101B1. CYP101C1 also preferred to 
insert the hydroxyl group into the C5 position of both substrates but the activity was 
significantly reduced for cyclooctyl isobutyrate when compared to its acetate counterpart, and 
in both cases, further oxidation metabolite was also detected as minor products. CYP101B1 
bound tightly with cyclododecyl acetate. The product formation rate and coupling efficiency 
were lower than the smaller cyclic acetate esters. CYP101B1 favoured hydroxylation at the C7 
position of cyclododecyl acetate and generated mainly trans isomer of 7-hydroxycyclododecyl 
acetate, while CYP101C1 preferred to form the other C7 hydroxy diastereomer. Both enzymes 
also formed 5-hydroxycyclododecyl acetate as a minor metabolite in these turnovers. In the 
case of α-terpinyl acetate, CYP101B1 did not show any catalytic activity while CYP101C1 







Figure 3. 57: An overview of Product formation rates (PFR) of CYP101B1 and CYP101C1 
with best substrates investigated in this chapter. PFRs are given in nmol.nmol-CYP–1.min–1. 
Linear ketones were oxidised with low to moderate activity by CYP101B1. In contrast to the 
cyclic compounds, several linear substrates exhibited higher activity with CYP101C1. 
CYP101B1 oxidised 2-nonanone and 2-undecanone predominantly at the C8 position. A 
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significant amount of 3-hydroxy metabolite in addition to the 8-hydroxy product was also 
observed in the turnovers of CYP101C1 with 2-nonanone and 2-undecanone. CYP101C1 
oxidised citronellyl acetate and linalyl acetate to their epoxides with higher activities than the 
CYP101B1 system.  
In summary, the screening of different cyclic ketones and esters as well as linear ketones and 
esters with the enzymes demonstrated that CYP101B1 and CYP101C1 are capable of 
generating metabolites in good yield and often with high selectivity. The regioselectivity 
achieved for cyclic alkanes, ketones and specially for esters are impressive given the lack of 
other distinguishing features on these cyclic molecules. CYP101B1 catalysed the oxidation of 
compounds containing ester directing group with high regio- and stereoselectively. The high 
product formation rates and TTNs for the optimal substrates combined with the levels of 
selectivity are favourable compared to other systems such as the monooxygenase system PikC 
from Streptomyces venezuelae 369, 370. Previously this monooxygenase system was shown to be 
capable of oxidising cyclic substrates including cycloalkyls, macrolides and macrolactones 
substituted with desosamine and related dimethylamine containing synthetic anchoring groups 
(TTN approx. 500) 369, 370, 371. However the selectivity of these oxidation reactions was reduced 
for cycloalkyl substrates compared to more functionalised macrolides and macrolactones; e.g., 
7 products were generated with the protected cyclododecanol 369, 371. Generally, the addition of 
double bonds or other functional groups to larger ring structures has been shown to improve 
the selectivity of P450 catalysed oxidations. For instance, the activity and selectivity of the 
CYP102A1 catalysed oxidation of cembrenoid derivatives has been optimised with multiple 
rounds of mutagenesis and substrate engineering resulting in the formation multiple products 
at allylic and non-activated C-H bonds but more saturated analogues displayed lower 
selectivity 369, 372, 373. The cytochrome P450 monooxygenase enzyme CYP101B1 and 
CYP101C1 when combined with its physiological electron transfer partner Arx and ArR can 
efficiently oxidise cyclic hydrocarbon derivatives 369. The C-H bond abstraction and selectivity 
of oxidation for a given methylene group was high and this could be made almost totally 
selective by modifying the ester protecting group or functional group on the ring system and 
these P450 enzymes are therefore ideal candidates for study to generate biocatalysts for the 
selective functionalisation of more complex substrates 369. Further studies of these P450 
enzymes would be needed to expand the substrate range and enhance the monooxygenase 
activity and selectivity towards these alicyclic substrates. 





4. The Selective and Efficient Biocatalytic Oxidation of   




CYP101B1 has been shown to be a highly efficient biocatalyst for the oxidation of β-ionone, 
other norisoprenoids and monoterpenoid acetates 175, 176. The butenone side chain of β-ionone 
is an important structural feature, enabling the substrate to bind with the enzyme. It is 
hypothesised that the chain holds the substrate in a place for efficient and selective oxidation. 
This is one of the main features which allows these oxidation reactions to proceed with high 
catalytic activity, turnover number and coupling efficiency 175. Adamantane and adamantanols 
have been demonstrated to be poor substrates for CYP101B1 233. CYP101B1 catalysed the 
oxidation of different cyclic alcohol compounds more efficiently when an ester directing group 
was inserted in these substrates (Chapter 3). With an aim of improving the activity of 
CYP101B1 towards inert tricyclic adamantyl substrates, ester protecting groups were 
introduced to the adamantanols via esterification reactions, and these substrates were 
investigated (Chapter 2 and Figure A. 1-A. 14). This modification, by inserting an ester 
directing group which is simple to add to and remove from alcohols, could allow CYP101B1 
to oxidise these substrates more efficiently. The amide equivalent of an adamantyl amine was 





Biocatalytic Oxidation of Unactivated Adamantyl C-H Bonds 
 
Tricyclic adamantane compounds are considered vital for the production of functional 
materials, polymers and pharmaceuticals 234-237. Current chemical methods to activate or 
functionalise the inert C-H bonds of adamantane substrates require harsh oxidants, are poorly 




selective and prone to over-oxidation 234-236. Different microbial strains have been reported, 
which can oxidise adamantane and its derivatives, and several cytochrome enzymes including 
CYP101A1 are capable of hydroxylating adamantane and 2-adamantanone 143, 234-236, 238-240. 
However, in most instances the activity is low. In this study, a range of substrates with an 




                Figure 4. 1 The adamantane substrates screened with CYP101B1 182. 
  




Previous studies have demonstrated that the heme spin-state shifts of CYP101B1 upon addition 
of adamantane and adamantanone were 30-35%, and these were lower than the spin-state shifts 
induced by 1- and 2-adamantanol (55-60%) 182, 233. The dissociation constants of CYP101B1 
with 1-adamantanol (Kd = 711 µM) and 2-adamantanone (548 µM) indicated a weak binding 
affinity 182, 233. The NADH oxidation rate of CYP101B1 in the presence of adamantane was 
only 140 min-1, while this rate was reported to be faster for 1-adamantanol (415 min-1) and 2-
adamantanol (563 min-1) 233. In the case of 2-adamantanone, the rate of NADH oxidation was 
higher compared to the adamantanols. Despite these high NADH oxidation activities, the 
productive use of reducing equivalents by CYP101B1 with all these substrates were minimal 
which resulted in low product formation activities (Table 4. 1) 233. The product formation 
activity of CYP101B1 with 2-adamantanone was the highest (104 min-1) which was 
hypothesised to be due to the presence of a ketone moiety 233. Repeating these turnovers showed 
similar results to those reported previously 233. 
 
Table 4. 1 Substrate binding, turnover and coupling efficiency data for the CYP101B1 with 
adamantane, 2-adamantanone, 1- and 2-adamantanol 233. The in vitro turnover activities were 
measured using a ArR:Arx:CYP101B1 concentration ratio of 1:10:1 (0.5 μM CYP enzyme, 50 
mM Tris, pH 7.4). N is the NADH oxidation rate, PFR is the product formation rate and C is 
the coupling efficiency. - Not calculated due to low detector response to the addition of 
substrate or low substrate solubility interfered with the titration. Data are reported as mean  













adamantane 30% - 140 ± 10 0.2 ± 0.1 0.11 
1-adamantanol 60% 711 ± 26 415 ± 55 11 ± 4 3 
2-adamantanol 55% - 563 ± 10 11 ± 3 2 
2-adamantanone 35% 548 ± 15 669 ± 7 104 ± 9 16 
 
 




Adamantane and 1-adamantanol were oxidised by CYP101B1 to generate a major and minor 
monooxygenase product while 2-adamantanone was hydroxylated to give two metabolites in 
almost equal amounts (Figure 4. 2). The oxidation of 2-adamantanol was unselective 
generating up to six products (Figure 4. 2).  
 
Overall, CYP101B1 showed low product formation activity and coupling efficiency with 




Figure 4. 2 The products formed from CYP101B1 turnovers of adamantane, adamantanols and 
2-adamantanone 182, 233. The product distributions are given as percentages. 
 




Addition of 1-adamantylmethyl ketone in CYP101B1 shifted the spin-state to the ~70% high-
spin form (Figure 4. 3). This was a relatively small increase compared to the shift induced by 
1-adamantanol (60%), but the binding affinity was an order of magnitude higher (Kd = 32 µM 
versus 711 µM; Figure 4. 3). The NADH oxidation (923 min-1) and product formation (473 
min-1) rates of CYP101B1 with this substrate were also faster compared to the adamantanols 
and 2-adamantanone (Table 4. 2). 
 
 
    (a)                                                             (b) 
 
 (c)                                                              (d) 
 
Figure 4. 3 Spin-state shifts (left) and dissociation constants (right) of CYP101B1 with 1-
adamantylmethyl ketone and methyl-2-(1-adamantyl acetate). Spin-state shifts (red) of 
CYP101B1 after addition of (a) 1-adamantylmethyl ketone and (c) methyl-2-(1-adamantyl 
acetate). Dissociation constants analysis with (b) 1-adamantylmethyl ketone (2.1 µM 
CYP101B1/Kd 32 µM) and (d) methyl-2-(1-adamantylacetate) (2.0 µM CYP101B1/Kd 0.2 
µM). The concentration of enzyme used in binding assays and the dissociation constant are 
provided in brackets. 




A significant increase in the coupling efficiency (51%) was also observed with 1-
adamantylmethyl ketone and therefore the levels of metabolite formation (473 min-1; Table 4. 
2). Two products, in an approximate 3:1 ratio, were detected in the GC-MS analyses of both 
the in vitro and whole-cell turnovers (MS of both m+/z = 194.05; Figure 4. 4 and Figure C. 1, 
Figure C. 2-C. 13). These metabolites were generated by the whole-cell oxidation system for 
characterisation. The in vivo turnover products were extracted and purified by silica column 
chromatography, and the yield of main and minor metabolite after purification was ~31 mg and 
~20 mg, respectively.  
 
NMR spectroscopy was used to identify the metabolites (Figure 4. 5, Figure 4. 7 and Figure C. 
2-C. 13) 182. The H2, H9 and H10 proton peaks of major metabolite (RT 10.2 min) were 
assigned using the correlations with C11 (216.17 ppm) in 13C-1H HMBC NMR spectrum 
(Figure C. 6). H5 was determined from the interaction with H10 in gCOSY NMR spectrum 
(Figure C. 4). The primary product was identified as a 4-hydroxy-1-adamantylmethyl ketone 
due to the carbon signal at 76.15 ppm (C4) showed correlations with H3, H5 (2.02-1.95); H2, 
H10 (1.90-1.83); H2, H10 (1.82-1.75) and H6, H8 (1.45) in the HMBC NMR spectrum (Figure 
C. 6) 182. The enzyme selectively generated the trans isomer of 4-hydroxy-1-adamantylmethyl 
ketone, which was confirmed by characteristic interactions of H4 (δ 3.88-3.84) with H5 (δ 2.02-
1.95) and H10 (δ 1.82-1.75) in the 1H-1H ROESY NMR spectrum (Figure 4. 5 and Figure C. 
7-C. 8). 
 
The minor product was assigned 3-hydroxy-1-adamantylmethyl ketone as the absence of 
characteristic multiplet peak for hydroxylation at a methylene group (CH-OH) in the 1H NMR 
spectrum. The carbon signal 71.21 ppm (C3) displayed strong correlations with H2 (1.78-1.74), 
H4, H8 (1.73-1.67) and weak interactions with H5, H7 (2.34-2.27) in the 1H-13C HMBC NMR 
spectrum, which suggested hydroxylation at a more reactive bridgehead position (COH; Figure 
C. 13) 182. The 13C NMR spectrum showed three distinct carbon signals at 47.03 ppm (C4 & 
C8), 39.76 ppm (C9 & C10), 32.92 ppm (C5 & C7), their intensities were almost double than 








Table 4. 2 Substrate binding, turnover and coupling efficiency data for the CYP101B1 with 1-
adamantylmethyl ketone, methyl-2-(1-adamantyl acetate), 1- and 2-adamantyl acetate and 1- 
and 2-adamantyl isobutyrate. The in vitro turnover activities were measured as described in 
Table 4. 1. TTN (total turnover number) was determined using assays set up with the same 
ratio of enzymes as used in Table 4. 1 but with 0.1 μM CYP enzyme, 2 mM substrate and 4 
mM NADH (theoretical maximum value 20,000). The other data and rates are given as 




Given the improvement observed in the binding affinity and activity of CYP101B1 with 1-
adamantylmethyl ketone over the adamantanols, other adamantyl substrates which contain 
carbonyl ester groups were investigated. Methyl-2-(1-adamantyl acetate) induced an almost 
complete heme spin-state shift of CYP101B1 to the high-spin form (95%), and the enzyme 
bound this substrate very tightly (Kd = 0.2 µM; Table 4. 2). CYP101B1 oxidised methyl-2-(1-
adamantyl acetate) with a faster NADH oxidation activity of 1120 min-1 and product formation 
rate of 704 min-1 compared to 1-adamantylmethyl ketone (Table 4. 2). The coupling efficiency 
was 63%. It was oxidised to form two products with a ratio of 84:16 (Figure 4. 4).  
 
These metabolites were generated on a larger scale by a whole-cell turnover system and 
isolated by silica column chromatography. After isolation, the major product (~25 mg) was 
identified via NMR analysis as methyl-2-(trans-4-hydroxy-1-adamantyl) acetate, and the 
minor metabolite (~5 mg) was characterised as methyl-2-(3-hydroxy-1-adamantyl) acetate 













1-adamantylmethyl ketone 70% 32 ± 1.0 923 ± 31 473 ± 22 51 6690 
methyl-2-(1-adamantyl acetate) 95% 0.2 ± 0.03 1120 ± 4 704 ± 28 63 16500 
1-adamantyl acetate 90% 3.9 ± 0.1 1300 ± 16 821 ± 27 63 6050 
2-adamantyl acetate 90% 1.9 ± 0.1 1170 ± 11 877 ± 18 75 11500 
1-adamantyl isobutyrate 95% 1.6 ± 0.1 1360 ± 7 1350 ± 22 99 4130 
2-adamantyl isobutyrate 90% 0.6 ± 0.04 1060 ± 6 722 ± 10 68 7090 




(Figure 4. 4, Figure 4. 6, Figure 4. 7 and Figure C. 14-C. 23) 182. The MS spectra supported 
these metabolite assignments (both m+/z = 224.05, Figure C. 1). The methyl-2-(trans-4-
hydroxy-1-adamantyl) acetate was assigned as the trans isomer due to the characteristic 
interactions of H4 (δ 3.88-3.83) with H5 (δ 1.96-1.88) and H2, H10 (δ 1.72-1.66) in the 1H-1H 
ROESY NMR (Figure 4. 4 and Figure 4. 6).  
  
           (a) 
 
           (b) 
 
Figure 4. 4 (a) GC-MS analysis of the in vitro turnover of 1-adamantylmethyl ketone by 
CYP101B1. 1-Adamantylmethyl ketone (RT 6.9 min) and the products: 3-hydroxy-1-
adamantylmethyl ketone (product 1; RT 9.2 min) and trans-4-hydroxy-1-adamantylmethyl 
ketone (product 2; RT 10.2 min). (b) GC analysis of the in vitro turnover of methyl-2-(1-
adamantyl acetate) by CYP101B1. Methyl-2-(1-adamantyl acetate) (RT 13.0 min) and the 
products: methyl-2-(3-hydroxy-1-adamantyl) acetate (product 1; RT 14.8 min) and methyl 2-
(trans-4-hydroxy-1-adamantyl) acetate (product 2; RT 15.6 min). Impurities are marked (*). 
 






                     
(b) 
      
(c) 
 
Figure 4. 5 (a) 1H NMR spectrum of trans-4-hydroxy-1-adamantylmethyl ketone. (b) ROESY 
NMR spectrum of trans-4-hydroxy-1-adamantylmethyl ketone highlighting the interactions of 
H4 with H2, H5 and H10. (c) 1H NMR spectrum of 3-hydroxy-1-adamantylmethyl ketone. Full 
data are presented in Appendix C (Figure C. 2-C. 13). 











Figure 4. 6 (a) 1H NMR spectrum of methyl-2-(trans-4-hydroxy-1-adamantyl) acetate. (b) 
ROESY NMR spectrum of methyl-2-(trans-4-hydroxy-1-adamantyl) acetate which 
highlighted the interactions of H4 with H2, H5 and H10. (c) 1H NMR spectrum of methyl-2-
(3-hydroxy-1-adamantyl) acetate. Full data are provided in Appendix C (Figure C. 14-C. 23).  






Figure 4. 7 The products generated from CYP101B1 turnovers of 1-adamantylmethyl ketone 
and methyl-2-(1-adamantyl) acetate 182. The product distributions are given as percentages. 
 
The acetate and isobutyrate esters of 1-and 2-adamantanol were synthesised using standard 
methodologies. These were tested as substrates with the intention of observing the activity of 
CYP101B1 for 1- and 2-adamantyl derivatives containing ester protecting groups (Chapter 2 
and Figure A. 1-A. 14) 182.  
 
The addition of 1-adamantyl acetate and 1-adamantyl isobutyrate induced an almost complete 
heme spin shift of CYP101B1 to the high spin form (90% versus 95%; Figure 4. 8). The 
substrate binding was found to be tighter with both 1-adamantyl acetate and 1-adamantyl 
isobutyrate than for the majority of the adamantane derivatives assessed with CYP101B1 
above. The binding affinity of CYP101B1 with the isobutyrate ester, 1.6 µM (Kd) exceeded 
that of the acetate, 3.9 µM (Kd). 
 
 





        (a)                                                                  (b) 
 
          (c)                                                                   (d) 
 Figure 4. 8 Spin-state shifts (red) of CYP101B1 after addition of (a) 1-adamantyl acetate and 
(c) 1-adamantyl isobutyrate. Dissociation constants analysis with (b) 1-adamantyl acetate, (2.0 
µM CYP101B1/Kd 3.9 µM) and (d) 1-adamantyl isobutyrate (1.9 µM CYP101B1/Kd 1.6 µM). 
The concentration of enzyme used in binding studies and the dissociation constants are 
provided in brackets. 
 
The NADH oxidation and product formation rates of CYP101B1 with 1-adamantyl acetate and 
isobutyrate were faster than those of 1-adamantylmethyl ketone and methyl-2-(1-adamantyl 
acetate) (Table 4. 2). The NADH oxidation rates of both were comparable, 1300 and 1360 min–
1, but the coupling efficiency of 1-adamantyl isobutyrate was greater than 1-adamantyl acetate, 
99% versus 63%. Due to a higher efficiency of NADH utilisation, the oxidation of 1-adamantyl 
isobutyrate by CYP101B1 proceeded with a faster product formation rate than 1-adamantyl 
acetate (1350 versus 821 min-1; Table 4. 2). The turnover of 1-adamantyl acetate generated two 
hydroxylated products (MS, m+/z = 210.10 and m+/z = 210.0) in an approximate 4:1 ratio 
(Figure 4. 9 and Figure C. 1). The primary product was isolated (~26 mg) by silica column 
chromatography after generation using a whole-cell biotransformation system. This metabolite 
was characterised by NMR (Figure 4. 10, Figure 4. 13 and Figure C. 24-C. 30) 182. The H2, 
H3, H5, H7, H9 and H10 protons were determined via the correlations with C1 (81.76 ppm) in 




1H-13C HMBC NMR spectrum (Figure 4. 10). The product was identified as 4-hydroxy-1-
adamantyl acetate due to the strong interactions of the carbon peak at 75.74 ppm (C4) with the 
proton peaks of H2, H3, H5, H6, H8 and H10 in the HMBC NMR spectrum (Figure C. 28). 
The orientation of the hydroxy group at C4 position was confirmed through 1H-1H ROESY 
spectrum analysis, and the metabolite was assigned as a trans isomer due to the distinctive 
interactions of H4 (δ 3.96-3.92) with H5 (δ 2.09-2.01), H2 and H10 (δ 2.16-2.09) (Figure 4. 10 
and Figure C. 29-C. 30) 182. The minor product was not isolated as a pure compound, but the 
1H NMR and mass spectrum indicated it was a 3-hydroxy metabolite (m+/z = 210.0; Figure 4. 
10, Figure 4. 13, Figure C. 1 and Figure C. 31). 
     
             (a) 
      
                (b) 
Figure 4. 9 GC-MS analysis of the (a) in vitro and (b) whole-cell turnovers of 1-adamantyl 
acetate by CYP101B1. 1-Adamantyl acetate (RT 6.8 min) and the products; 3-hydroxy-1-
adamantyl acetate (Product 1; RT 8.9 min) and trans-4-hydroxy-1-adamantyl acetate, (Product 
2; RT 9.9 min). Impurities are marked (*). 










Figure 4. 10 (a) 1H NMR spectrum of trans-4-hydroxy-1-adamantyl acetate. (b) ROESY NMR 
of trans-4-hydroxy-1-adamantyl acetate which highlighted the interactions of the H4 with H5 
and H10. (c) The HMBC NMR spectrum of trans-4-hydroxy-1-adamantyl acetate. Full data 
are  given in Appendix C (Figure C. 24-C. 30). 




CYP101B1 catalysed the oxidation of 1-adamantyl isobutyrate regioselectively and generated 
one monooxygenase metabolite, 97% (GC-MS; m+/z = 238.05; Figure 4. 11 and Figure C .1). 
This was purified (~35 mg) via silica column chromatography and characterised by NMR 
analysis (Figure 4. 12 and Figure 4. 13). The distinct multiplet peak at 3.96-3.92 ppm in 1H 
NMR spectrum confirmed a hydroxylated metabolite. The correlations of C1 (81.76 ppm) with 
protons in HMBC NMR spectrum were used to assign H3, H5, H9 and H10 (Figure C. 36) 182. 
H6 and H8 were identified via the characteristic interactions with H5, H3 and H7 in 1H-1H 
gCOSY NMR spectrum (Figure C. 34). The product was confirmed as 4-hydroxy-1-adamantyl 
isobutyrate due to the correlations of C4 (75.82 ppm) with H3, H5, H6 and H8 in HMBC NMR 
spectrum (Figure C. 36). The stereochemistry of this metabolite was determined by the strong 
interactions of H4 (δ 3.96-3.92) with H5 (δ 2.08-2.01) and H10 (δ 2.17-2.09) in 1H-1H ROESY 
NMR spectrum, and therefore the product was confirmed as a trans isomer (Figure 4. 12 (b), 
Figure C. 37-C. 38). A small peak was also detected in the GC-MS analysis of the turnover, 
which had a mass spectrum and retention time consistent with that of 3-hydroxy-1-adamantyl 
isobutyrate (m+/z = 238.05) but was not isolated in sufficient yield from the whole-cell turnover 
to be fully characterised (Figure 4. 11, Figure 4. 13 and Figure C. 1). 
 
 
        (a)                                                                    (b) 
 
Figure 4. 11 GC-MS analyses of the (a) in vitro and (b) whole-cell turnovers of 1-adamantyl 
isobutyrate by CYP101B1. 1-Adamantyl isobutyrate (Product 1; RT 8.6 min) and the product; 
trans-4-hydroxy-1-adamantyl isobutyrate (Product 2; RT 11.5 min). The minor peak (3%) at 
10.6 min has a MS and retention time consistent with it being 3-hydroxy-1-adamantyl 
isobutyrate. Impurities are labelled (*). 
 








Figure 4. 12 (a) 1H NMR spectrum of trans-4-hydroxy-1-adamantyl isobutyrate. (b) ROESY 
NMR spectrum of trans-4-hydroxy-1-adamantyl isobutyrate acetate which highlighted the 
interactions of the H4 with H2, H5 and H10. Full data are presented in Appendix C (Figure C. 
32-C. 38). 
 






Figure 4. 13 The metabolites generated from CYP101B1 turnovers of 1-adamantyl acetate and 
1-adamantyl isobutyrate. The product distributions are given as percentages. 
 
To further evaluate the enzyme binding affinity and activity, 2-adamantyl acetate and 
isobutyrate were investigated as potential substrates. The addition of 2-adamantyl acetate and 
2-adamantyl isobutyrate to CYP101B1 both induced a spin-state shift of ~90% high-spin 
(Figure 4. 14). In line with the substantial spin-state changes, the enzyme also bound tightly 
with both substrates. The binding affinities were tighter than their 1-adamantyl ester 
counterparts (Kd: 1.9 µM and 0.6 µM; Table 4. 2 and Figure 4. 14).  
 
CYP101B1 catalysed the oxidation of these substrates efficiently. The NADH oxidation rates 
with 2-adamantyl acetate and 2-adamantyl isobutyrate were comparable, 1170 min-1 and 1060 
min-1 (Table 4. 2) The coupling efficiency of the turnover of 2-adamantyl acetate was greater 
resulting in a product formation rate of 877 min–1 (Table 4. 2). The oxidation of 2-adamantyl 
isobutyrate by CYP101B1 proceeded with a slower product formation rate than that of 1-
adamantyl isobutyrate predominantly due to a reduced coupling efficiency (68% versus 99%; 
Table 4. 2). 





       (a)                                                              (b) 
 
  (c)                                                                  (d) 
Figure 4. 14 Spin-state shifts (red) of CYP101B1 after addition of (a) 2-adamantyl acetate and 
(c) 2-adamantyl isobutyrate. Dissociation constant analysis with (b) 2-adamantyl acetate (1.8 
µM CYP101B1/Kd 1.9 µM) and (d) 2-adamantyl isobutyrate (2.1 µM CYP101B1/Kd 0.6 µM). 
The concentration of the enzyme used in binding studies, and the dissociation constant are 
provided in brackets. 
 
CYP101B1 oxidised 2-adamantyl acetate into a single hydroxylated metabolite (GC-MS; m+/z 
= 210.10, Figure 4. 15 and Figure C. 1). A CYP101B1 whole-cell oxidation system was used 
to generate this metabolite in sufficient yield for NMR characterisation (Figure 4. 15). The 
product was extracted and isolated (~25 mg) using silica column chromatography and 
identified via NMR analysis (Figure 4. 16, Figure 4. 18 and Figure C. 39-C. 43). The H1 and 
H3 were determined via the interactions with H2 in gCOSY NMR spectrum (Figure C. 44). 
gCOSY was also used to confirm the H4 and H9 peaks through the correlations with H3 and 
H1, respectively (Figure C. 41). The peaks of H1, H3, H4, H8 and H9 were further confirmed 
using the interactions with C2 (78.25 ppm) in the HMBC NMR spectrum (Figure 4. 16 and 
Figure C. 43). The product was identified as 5-hydroxy-2-adamantyl acetate using the 




correlations of C5 (70.12 ppm) with the protons at δ 1.86-1.80 (H4 and H9) and δ 1.78-1.70 
(H4, 2xH6 and H9) in HMBC NMR spectrum (Figure 4. 16 and Figure C. 39-C. 43) 182. A 
minor metabolite was also observed in the turnover, <3%, (RT 10.3 min; Figure 4. 15) which 
had a mass spectrum (m+/z = 210.20) consistent with a hydroxylation product but this was not 
isolated in high enough yield to be characterised in more detail (Figure 4. 15, Figure 4. 18 and 
Figure C. 1) 182.  
 
           (a) 
                            
          (b) 
Figure 4. 15 GC-MS analysis of the (a) in vitro and (b) whole-cell turnovers of 2-adamantyl 
acetate by CYP101B1. 2-Adamantyl acetate (RT 7.1 min) and the product; 5-hydroxy-2-
adamantyl acetate (product 1; RT 9.4 min), and a minor metabolite (product 2; RT 10.1 min) 
whose MS was consistent with a hydroxylation product. Impurities are labelled (*). 








Figure 4. 16 (a) 1H NMR spectrum of 5-hydroxy-2-adamantyl acetate. (b) The HMBC NMR 
spectrum of 5-hydroxy-2-adamantyl acetate which highlighted the correlations of C5 with the 
protons H4, H6 and H9. Full data are in Appendix C (Figure C. 39-C. 43). 
 
GC and GC-MS analysis of the in vitro turnovers of 2-adamantyl isobutyrate showed the 
presence of a single monooxygenase product, ≥97% (m+/z = 238.10; Figure 4. 17 and Figure 
C. 1). A larger scale whole-cell turnover of CYP101B1 was carried out to generate the sole 




metabolite for NMR characterisation. The product was isolated (~40 mg) using silica column 
chromatography and identified as 5-hydroxy-2-adamantyl isobutyrate by NMR analysis via the 
same process as that used to assign the 2-adamantyl acetate metabolite (Figure 4. 18, Figure 4. 
19 and Figure C. 44-C. 48) 182. There was a minor product (≤3%) observed at a higher retention 
time which had mass spectrum (m+/z = 238.25) consistent with a hydroxylation product but 
was not isolated in large enough yield to be characterised further (Figure 4. 17 and Figure C 
.1). 
  
                                   (a)                                                                   (b) 
Figure 4. 17 GC-MS analysis of the (a) in vitro and (b) whole-cell turnovers of 2-adamantyl 
isobutyrate by CYP101B1. 2-Adamantyl isobutyrate (RT 8.9 min) and the products; 5-
hydroxy-2-adamantyl isobutyrate (product 1; RT 11.1 min) and minor (product 2; RT 11.4 
min), whose MS was consistent with a hydroxylation product. Impurities are labelled (*). 
 
 
Figure 4. 18 The products formed from CYP101B1 turnovers of 2-adamantyl acetate and 2-
adamantyl isobutyrate. *There is a small, ≤3%, amount of an uncharacterised minor metabolite 
with a MS consistent of a hydroxylation product detected in these turnovers. The product 
distributions are given as percentages. 










Figure 4. 19 (a) 1H NMR spectrum of 5-hydroxy-2-adamantyl isobutyrate. (b) Zoomed in 
version of HMBC NMR spectrum of 5-hydroxy-2-adamantyl isobutyrate to highlight the 
correlations of C2 and C5 with the protons (H4, H8, H9, H10) and (H1, H3, H4, H6, H7, H9), 
respectively. Full data are provided in Appendix C (Figure C. 44-C. 48). 




Addition of 1-adamantylamine to CYP101B1 induced a spin-state shift of <5% (Figure 4. 20). 
The rate of NADH oxidation was slow (35 ± 0.3 min-1; Table 4. 3). No product could be 
detected for in vitro turnovers of 1-adamantylamine in GC-MS analysis (Figure 4. 21 and 
Figure 4. 22).  
Converting 1-adamantylamine to the acetamide resulted in a substantial increase in the spin-
state of CYP101B1 upon substrate addition. N-(1-adamantyl)acetamide induced a spin-state 
shift to 50% high spin form in CYP101B1 (Figure 4. 20). However, the binding affinity, as 
measured by the dissociation constant (Kd = 55 µM), was lower than those of the adamantyl 
ester derivatives and 1-adamantylmethyl ketone (Figure 4. 20, Table 4. 2 and Table 4. 3). The 
rate of NADH oxidation (955 min-1) was fast, but the product formation activity was lower 166 
min-1 when compared to other adamantyl ester derivatives. This is likely due to the minimal 
productive utilisation of reducing equivalents to metabolite formation (17%; Table 4. 3). 
 
     (a)                                                              (b) 
 
(c) 
Figure 4. 20 Spin-state shifts (red) of CYP101B1 after addition of (a) 1-adamantylamine and 
(b) N-(1-adamantyl)acetamide. (c) Dissociation constant analysis with N-(1-
adamantyl)acetamide (1.7 µM CYP101B1/Kd 55 µM). The concentration of the enzyme used 
in the binding assay and the dissociation constant are given in brackets. 




Table 4. 3 Substrate binding, turnover and coupling efficiency data for the CYP101B1 with 1-
adamantylamine and N-(1-adamantyl)acetamide. The in vitro turnover activities were 
measured as described in Table 4. 1. The Data and rates are provided as described in Table 4. 
1 and Table 4. 2. n.p: no product. - Not calculated due to low detector response to the addition 
of substrate or low substrate solubility interfered with the titration. 
 
 
CYP101B1 oxidised N-(1-adamantyl)acetamide into two hydroxylated products (GC-MS; both 
m+/z = 209.1) in an approximate 3:1 ratio (Figure 4. 21 and Figure C. 1). These were generated 
in more significant quantities via the whole-cell oxidation system, and both were extracted and 
isolated using silica gel chromatography (note; as the products are highly soluble in aqueous 
solution, dichloromethane and petroleum benzine were used instead of ethyl acetate during 
liquid-liquid extraction) 241. The major metabolite was identified as 4-hydroxy-N-(1-
adamantyl)acetamide (isolated ~15 mg) due to distinct peak at δ 3.98-3.84 in 1H NMR 
spectrum, and the correlations of C4 (75.98) with H6 and H8 in HMBC NMR spectrum (Figure 
4. 22 and Figure C. 49-C. 55) 182. The minor metabolite was assigned as the 3-hydroxy product 
(~3 mg) using its NMR spectra (Figure 4. 21, Figure 4. 23 and Figure C. 56-C. 57) 182. Due to 
overlapping proton peaks in ROESY NMR spectrum, the stereochemistry could not be 



















1-adamantylamine <5% - 35 ± 0.3 n.p n.p n.p 
N-(1-adamantyl)acetamide 50% 55 ± 5 955 ± 25 166 ± 9 17 780 






              (a) 
 
                                
            (b) 
 
Figure 4. 21 (a) GC-MS analysis of the in vitro turnover of 1-adamantylamine by CYP101B1. 
1-Adamantylamine (RT 4.05 min). (b) GC-MS analysis of the whole-cell turnover of N-(1-
adamantyl)acetamide by CYP101B1. N-(1-adamantyl)acetamide (RT 9.75 min) and the minor 
product; 3-hydroxy-N-(1-adamantyl)acetamide (product 1; RT 11.8 min) and major product; 
4-hydroxy-N-(1-adamantyl)acetamide (product 2; RT 12.8 min). Impurities are labelled (*). 
 
 









Figure 4. 22 (a) 1H NMR spectrum of 4-hydroxy-N-(1-adamantyl)acetamide. (b) The HMBC 
NMR spectrum of 4-hydroxy-N-(1-adamantyl)acetamide which highlighted the correlations of 
C4 with the protons including H6 and H8. Full data are given in Appendix C (Figure C. 49-C. 
57). 






Figure 4. 23 The products generated from CYP101B1 turnovers of N-(1 adamantyl)acetamide. 
No product was detected in the turnovers with 1-adamantylamine. The product distributions 
are given as percentages. 
4.3. Discussion  
 
CYP101B1 has been reported to oxidise a broad range of substrates, and optimal catalytic 
efficiency was achieved for norisoprenoids and monoterpenoid acetates. All of these substrates 
contain a carbonyl group on a side chain attached to substituted ring systems. These substrates 
are hydroxylated with high activity, total turnover numbers and regioselectivity. The oxidation 
of adamantane derivatives are of interest as they are used as building blocks for many complex 
drug molecules and polymers 234, 236, 237. Microbial oxidative bio-transformations of 
adamantane, 2-adamantanone, adamantanols and related substrates including the acetate esters 
are possible using different bacteria, including Streptomyces, and fungi including 
Basidiomycota, Absidia cylindrospora and Beauveria (Sporotrichum) sulfurescens 234-236, 239, 
241, 242. Certain P450 enzymes such as CYP101A1 and CYP101D2 including their mutants have 
also been reported to oxidise adamantane based substrates, however at lower activities than the 
turnovers of the esters reported here with CYP101B1 143, 238, 240. 
CYP101B1 showed poor affinity and activity for adamantane, 2-adamantanone and 
adamantanols. The importance of the ketone-containing side chain for efficient biocatalysis 
with CYP101B1 can be clearly seen by comparing the binding properties and activities of 
adamantyl acetates and isobutyrates with adamantane, 2-adamantanone, and both 




adamantanols. The oxidation of the esters proceeded more efficiently and was more selective 
with improved binding and catalytic properties.  
1-adamantylmethyl ketone bound tightly to CYP101B1 and gave a faster product formation 
rate compared to 1-adamantanol. Methyl-2-(1-adamantyl acetate) bound to CYP101B1 with 
the highest affinity. This substrate has the highest total turnover number (16500). CYP101B1 
had a higher affinity for the adamantyl isobutyrates than the equivalent acetates. The turnovers 
of 1-adamantyl isobutyrate were selective for the formation of the trans-4-hydroxy product 
(97%). Other substituents at the equivalent position led to the production of the 3-hydroxy 
metabolite as a significant minor product (16-28%) in addition to the 4-hydroxy metabolite. 
The selectivity of ester oxidation was different to 1-adamantanol oxidation which favoured 
oxidation to 1,3-adamantanediol. In the case of 1-adamantyl acetate and isobutyrate, 
hydroxylation was preferred at C4 over the more reactive tertiary position, and the lack of 
product corresponding to a cis-4-hydroxy species must be due to the orientation of the substrate 
in the enzyme active site. Overall, the ketone-containing side chain appeared to hold the 
adamantyl tricyclic ring in such a position that allows only certain C-H bonds to be attacked 
compared to the parent adamantanols which presumably bind in multiple orientations in the 
active site or are highly mobile. 
2-Adamantyl isobutyrate bound more strongly to CYP101B1 than the equivalent acetate but 
was oxidised with low activity. For 2-adamantyl acetate and isobutyrate, hydroxylation occurs 
predominantly at the more reactive bridgehead position to produce the 5-hydroxy metabolite 
whereas for 2-adamantanone and 2-adamantanol a significant level of oxidation was also 
observed at the methylene group at C6. The lower total turnover numbers of the isobutyrate 
esters despite the higher product formation activity may be due to lower solubility and requires 
further optimisation. 
The 1-adamantylamine and N-(1-adamantyl)acetamide frameworks are found in many drugs 
molecules, e.g. rimantadine, adapromine and tromantadine 243-245. The selective 
functionalisation of the acetamide derivative could be used to generate drug metabolites for 
activity studies or to add functional groups for the development of new drugs with improved 
properties. The reduced product formation activity and total turnover number due to a poor 
coupling efficiency of the acetamide versus the ester, require further investigation but could be 
due to an alternative binding mode as reflected in the lower spin-state shift induced by the 




acetamide. Despite the lower turnover activity, the substrate was efficiently metabolised, and 
a large amount of product was generated using the whole-cell biotransformation system. 
The selective oxidation of the adamantyl esters with high activity by CYP101B1 could be 
useful for synthetic chemistry 182, 234-236, 238-240. Acetate, acetamide, isobutyrate and other ester 
or amide groups could be used as directing groups to improve catalytic performance and tune 
the selectivity without protein engineering. The in vitro activity and total turnovers achieved 
with CYP101B1 are significantly higher than those reported for the majority of other P450 
systems (Table 4. 4). Large quantities of the products were generated (up to 3 mM conversion 
of all of the added substrate, ~680 mg L-1) using the whole-cell E. coli oxidation system at low 
cell densities in shake flasks without optimisation. This is encouraging for the scale-up of 
enzyme activity in the future. 




Adamantane substrates Products and Yield (mg)    PFR  
    (min–1) 
1-adamantylmethyl ketone 
3-hydroxy-1-adamantylmethyl ketone (~20) 
trans-4-hydroxy-1-adamantylmethyl ketone (~31) 




704 ± 28 
1-adamantyl acetate 
3-hydroxy-1-adamantyl acetate 
trans-4-hydroxy-1-adamantyl acetate (~26) 
821 ± 27 
1-adamantyl isobutyrate 
3-hydroxy-1-adamantyl isobutyrate 
trans-4-hydroxy-1-adamantyl isobutyrate (~35) 
1350 ± 22 
2-adamantyl acetate 5-hydroxy-2-adamantyl acetate (~25) 877 ± 18 
2-adamantyl isobutyrate 5-hydroxy-2-adamantyl isobutyrate (~40) 722 ± 10 




166 ± 9 




5. The Efficient Oxidation of Hydrophobic Aromatic Substrates   




The CYP101B1 enzyme can bind and oxidise a broad range of substrates including 
monoterpenoids and adamantyl esters as well as hydrophobic aromatic compounds such as 
indole, phenylcyclohexane and p-cymene 175, 182, 233. As CYP101B1 is able to oxidise certain 
aromatic hydrocarbons, it could, therefore, have applications as a biocatalyst for their oxidation 
175, 233. Compared to the norisoprenoids and ester substrates, most of the hydrophobic substrates 
induce a smaller heme spin-state shift when added to CYP101B1 and bind with a lower affinity. 
They are also oxidised at slower product formation rates. Protein engineering of CYP101B1 
could improve the activity and selectivity of this enzyme for the hydrophobic aromatic 
substrates.  
 
5.2.  Protein Engineering  
 
The crystal structure of CYP101B1 has not been solved, but structures of the related P450s 
CYP101C1, CYP101D1 and CYP101D2 from the same bacterium have been reported 47, 143, 
175, 246, 247. One of the best-characterised cytochrome P450 enzymes CYP101A1 (P450cam) 
oxidised (R)-camphor to 5-exo-hydroxycamphor with 100% stereoselectivity 248, 249. 
CYP101D1 and CYP101D2, which belong to the same family as CYP101A1, also selectively 
oxidise camphor to 5-exo-hydroxycamphor 49, 143, 250. The tyrosine residue (Y96) of CYP101A1 
has been shown to be important in determining the substrate specificity 144, 251-253. This residue 
is also conserved in CYP101D1 and CYP101D2 143. These CYP101 family members were used 
as model systems to facilitate the residue to target for mutagenesis 72, 144, 254-258. The analysis of 
the camphor bound crystal structures of CYP101A1 (PDB: 2CPP) and CYP101D1 (PDB: 
3LXI) demonstrated that in both a tyrosine residue forms a hydrogen bond with the carbonyl 
group of the camphor molecule (Figure 5. 1) 248, 250. This helps to hold the substrate in a suitable 
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position for selective hydroxylation 248, 250. Modification of the active site, by replacing the 
tyrosine residue with phenylalanine and alanine enhanced the affinity of CYP101A1 and 
CYP101D2 for hydrophobic substrates such as naphthalene, pyrene, styrene, 
phenylcyclohexane, cyclooctane, adamantane and 2-methylpentane 143, 144, 255, 259-261. This 
residue, therefore, plays a role in determining the substrate range of these P450 enzymes 143, 
255. 
The active site of CYP101B1 was modelled by Swiss-Model using the camphor-bound 
CYP101D1 (PDB ID: 3LXI) crystal structure (Figure 5. 1) 50, 262, 263, 264, 265. Aligning the amino 
acid sequences of the CYP101B1, CYP101D1, CYP101D2, CYP101A1 enzymes show that 
the tyrosine (Y) 96 residue of CYP101A1, is conserved in CYP101D1 and CYP101D2 but not 
in CYP101B1 47, 49, 175, 250. In CYP101B1 a histidine residue aligns sequentially with Y96 of 
CYP101A1. It was hypothesised that H85 of CYP101B1 might play a similar role interacting 
with norisoprenoid and ester substrates potentially through the substrate carbonyl group 175, 176. 
Replacing H85 with a hydrophobic residue, such as phenylalanine, could, therefore, improve 
the affinity of CYP101B1 towards hydrophobic substrates.  
 
Figure 5. 1 (Left) The crystal structure of camphor-bound CYP101D1 (PDB 3LXI) 
highlighting the hydrogen bond interaction between the camphor carbonyl and the conserved 
tyrosine residue (Y98). This is the equivalent residue to Y96 in CYP101A1. CYP101D1 was 
the closest homologue of CYP101B1 in the Protein Data Bank PDB. (Right) The modelled 
structure of CYP101B1 created by Swiss-Model highlighting the potential location of histidine 
85 (H85) 50, 264, 265. The modelled structure of CYP101B1 was designed by Joel Lee 264.
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5.3.  Results 
5.3.1 The oxidation of alkylbenzenes by CYP101B1 and the H85F variant 
 
CYP101B1 has a high affinity for β-ionone (Kd = 0.23 ± 0.1 µM, ≥95% spin state shift), which 
it oxidises into two products 3-hydroxy-β-ionone and 4-hydroxy-β-ionone with a ratio 90:10 
(Table 5. 1, Figure 5. 2 and  Figure 5. 3) 175. The NADH consumption rate, product formation 
activity and coupling efficiency were high, indicating that β-ionone might be closely related to 
the natural substrate for wild-type CYP101B1 48, 49, 250. When β-ionone was tested with the 
H85F variant of CYP101B1 it induced a 50% high spin (HS) state shift and bound less tightly, 
Kd = 5.8 ± 2 µM compared to WT CYP101B1 (Table 5. 1, Figure 5. 2 and  Figure 5. 3) 
233.  
 
   (a)                                                                  (b) 
 
(c) 
Figure 5. 2 Spin-state shifts (red) of (a) H85F CYP101B1 and (b) WT CYP101B1 after 
addition of β-ionone 233. (c) Dissociation constant analysis with β-ionone (1.27 µM H85F 
CYP101B1/Kd 5.8 µM). The difference between A420 and A600 nm was used due to the 
interference of absorbance of the substrate with the analysis below 400 nm. The concentration 
of enzyme used in the binding assay and the dissociation constant (Kd) are provided in brackets. 
Chapter 5                                                   Site Directed Mutagenesis             Alkylbenzenes                                                                                      
 
148 
The weaker binding and lower spin-state shift suggest that the interactions of this substrate in 
the binding pocket of H85F CYP101B1 are less favourable. The oxidation activity was also 
reduced, with a slower NADH oxidation activity (412 versus 1600 nmol.nmol-CYP–1.min–1; 
henceforth abbreviated to min-1), product formation rate (140 min-1 versus 1010 min-1) and 
lower coupling efficiency (34% versus 63%; Table 5. 1).  
 
Table 5. 1. Substrate binding, turnover and coupling efficiency data for CYP101B1 (WT and 
the H85F variant) with β-ionone and p-cymene. The in vitro turnover activities were measured 
using a ArR:Arx:CYP101B1 concentration ratio of 1:10:1 (0.5 μM CYP enzyme, 50 mM Tris, 
pH 7.4). N is the NADH oxidation rate, PFR the product formation rate and C is the coupling 
efficiency, which is the percentage of NADH utilised for the formation of products. The data 
are reported as mean ± S.D. (n = 3) and rates are given in nmol.nmol-CYP–1.min–1. - not 
measured or not able to be determined accurately. 
 
 
The in vitro oxidation of β-ionone by the H85F mutant was found to generate the same two 
metabolites as WT CYP101B1. These were identified using GC-MS coelution experiment with 
the turnover products of WT CYP101B1. However, the selectivity of oxidation was altered. 
While the WT enzyme favoured the generation of the 3-hydroxy metabolite, the H85F mutant 
enzyme catalysed hydroxylation mainly at the more reactive allylic C-H bond to form 4-
hydroxy-β-ionone (Figure 5. 3). The ratio of the two products 3-hydroxy to 4-hydroxy-β-
ionone was observed 9:1 with WT CYP101B1, but in the case of  H85F variant of CYP101B1, 













WT 175 ≥95% 0.23 ± 0.1 1600 ± 100 1010 ± 60 63 
H85F 50% 5.8 ± 2 412 ± 36 140 ± 11 34 
p-cymene 
WT 175 5% - 197 ± 27 25 ± 6 13 
H85F  10% - 272 ± 11 95 ± 7 35 




       (a) 
        
 
           (b) 
Figure 5. 3 (a) GC-MS analysis of the turnover of β-ionone by H85F CYP101B1 (red) and 
CYP101B1 (black). β-Ionone (RT 8.5 min), products were identified as 4-hydroxy-β-ionone 
(10.2 min, product 1) and 3-hydroxy-β-ionone (RT 10.3 min, product 2) by co-elution with the 
WT CYP101B1 turnovers 233. The chromatogram (H85F) was offset along the x and y-axes for 
clarity. (b) The products generated from the CYP101B1 and H85F CYP101B1 turnovers with 
β-ionone. The product distributions are given as percentages (H85F variant in bold) 175, 265, 266. 
 
WT CYP101B1 can oxidise small aromatic compounds like p-cymene and indole 175. p-
Cymene induced only 5% heme spin-state shift in WT CYP101B1. The NADH oxidation rate, 
197 min–1, and the product formation rate, 25 min-1 were low (Table 5. 1). p-Cymene only 
induced a 10% spin-state shift with H85F CYP101B1. The NADH turnover frequency 
increased to 272 min-1, and the product formation rate (95 ± 7 min-1) was nearly 4-fold faster 
than that of wild-type enzyme (Table 5. 1). The coupling efficiency of the p-cymene turnover 
was more significant for the H85F CYP101B1 variant than the WT enzyme (35% versus 13%). 
In vitro oxidation of this substrate by the mutant enzyme generated two products in a similar 
ratio to the WT enzyme (Figure 5. 4 and Figure 5. 3). The minor metabolite was p-α,α-
trimethylbenzyl alcohol alongside with 4-isopropylbenzyl alcohol as the primary metabolite. 
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These metabolites were confirmed by coeluting the turnover products of CYP101B1 which 
were previously identified via coelution experiments in GC-MS with authentic standards 
(Figure 5. 3 and Figure 5. 4) 175. 
 
 
     (a) 
                      
        (b) 
 
Figure 5. 4 (a) GC-MS analysis of the turnover of p-cymene by H85F CYP101B1 (red) and 
CYP101B1 (black). p-Cymene (RT 4.4 min) and the products; p-α,α-trimethylbenzyl alcohol 
(8.2 min) and 4-isopropylbenzyl alcohol (RT 11.1 min). The chromatogram (CYP101B1) was 
offset along the x and y-axes for clarity. Impurities are labelled (*). (b) The products generated 
from the CYP101B1 and H85F CYP101B1 turnovers with p-cymene. The product distributions 
are given as percentages (H85F variant in bold) 175, 265, 266. 
 
 
A range of similarly sized alkylbenzene substrates such as toluene, o-, m- and p-xylene were 
then screened with H85F and WT variants (Figure 5. 5). The effect of size of substrates and 
position of the alkyl substituent on binding and activity parameters of enzymes were 
investigated using isobutylbenzene, n-propylbenzene, isopropylbenzene, indane and 2- and 3-
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ethyltoluene. Styrene, 2-methylstyrene and β-methylstyrene were used to examine the effect of 




         Figure 5. 5 The substrates screened with WT CYP101B1 and H85F CYP101B1 265. 
 
 
Compared to p-cymene, a smaller heme spin-state shift (5%) to both the wild-type and mutant 
enzyme was observed with toluene (Figure 5. 6). The NADH oxidation (69 ± 7 min-1 versus 40 
± 6 min-1) and product formation (3 min-1 versus 1 min-1) rates were slower with the WT and 
mutant enzyme (Table 5. 2). The smaller shift and lower oxidation activity observed with 
toluene, which can be related to p-cymene, by removal of the isopropyl group from the latter, 
suggest that binding of the smaller substrate is suboptimal. The coupling efficiency was also 
minimal, 4% for the mutant enzyme and 2% for WT CYP101B1. In vitro oxidation of toluene 
by WT and H85F mutant variants generated a single metabolite. The mass spectrum analysis 
revealed that it was a hydroxylation product (m+/z = 108.10; Figure 5. 7 and Figure D. 1). The 
metabolite was identified as benzyl alcohol by coelution experiment in GC-MS with an 
authentic standard (Figure 5. 7 and Figure 5. 9). 




   (a)                                                       (b) 
 
Figure 5. 6 Spin-state shifts (red) of (a) H85F CYP101B1 and (b) WT CYP101B1 after 




Figure 5. 7 GC-MS analyses of the turnovers of toluene by H85F CYP101B1 (red) and 
CYP101B1 (black). Toluene (RT 1.8 min, not shown) and the product; benzyl alcohol (4.5 
min).  
 
To assess the effect of altering the position of the methyl group on binding and activity, the 
isomers of xylene were investigated. Addition of o-, m- and p-xylene to CYP101B1 induced 
spin-state shifts of ≤5% which are similar to p-cymene and toluene (Figure 5. 8). These 
substrates effected 10 to 15% heme spin-state shifts in H85F CYP101B1 (Table 5. 2 and Figure 
5. 8). The rates of NADH oxidation of H85F and WT enzymes with o-xylene were 286 ± 4 
min-1 and 55 ± 14 min-1, respectively (Table 5. 2). These values were significantly higher than 
that observed with m- and p-xylene (Table 5. 2). In all instances, H85F showed improved 
activity compared to the WT enzyme.  




    (a)                                                  (b) 
 
   (c)                                      (d) 
 
  (e)                          (f) 
 
Figure 5. 8 Spin-state shifts (red) of H85F CYP101B1 after addition of (a) p-xylene, (c) m-
xylene (e) o-xylene, and spin-state shifts (red) of WT CYP101B1 after addition of (b) p-xylene, 
(d) m-xylene and (f) o-xylene. 
 
The product formation rates observed with H85F mutant for o-xylene (70 ± 3 min-1), m-xylene 
(21 ± 7 min-1) and p-xylene (13 ± 5 min-1) were greater than the WT (Table 5. 2). Poor coupling 
of the redox equivalents to product formation (≤4%) resulted in low levels of metabolites in 
the turnovers of all the xylenes with WT CYP101B1 (Table 5. 2). H85F mutant system 
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displayed higher coupling efficiencies with o-xylene (25% versus 4%), m-xylene (20% versus 
4%) and p-xylene (12% versus 3%) than the WT (Table 5. 2).  
Table 5. 2. Substrate binding, turnover and coupling efficiency data for CYP101B1 (WT and 
the H85F variant) with toluene, o-, m- and p-xylene. The turnover activities were measured as 




Both the WT enzyme and the H85F variant selectively oxidised these substrates into a single 
metabolite with the hydroxylation occurring at a benzylic C-H bond in all cases (Figure 5. 9 
and Figure 5. 10). The products were identified as 2-methylbenzyl alcohol, 3-methylbenzyl 
alcohol and 4-methylbenzyl alcohol after coeluting with authentic standards in GC-MS (Figure 
5. 9 and Figure 5. 10). Mass spectra analyses also supported to these assignments (all mass; 
m+/z= 122.1; Figure D. 1). 
 
Figure 5. 9 The products identified from the WT CYP101B1 and H85F CYP101B1 turnovers 











WT 5% 40 ± 6 1 ± 1 2 
H85F 5% 69 ± 7 3 ± 1 4 
o-xylene 
WT 5%  55 ± 14 3 ± 1 4 
H85F 15% 286 ± 4 70 ± 3 25 
m- xylene 
WT 5% 5 ± 3 2 ± 3 4 
H85F 10% 109 ± 8 21 ± 7 20 
p- xylene 
WT 5% 42 ± 5 1.2 ± 3 3 
H85F 10% 109 ± 10 13 ± 5 12 






                                        (a)                                                                         (b) 
 
 
     (c) 
 
Figure 5. 10 (a) GC-MS analysis of the turnover of o-xylene by H85F CYP101B1 (red) and 
CYP101B1 (black). o-Xylene (RT 4.05 min, not shown) and the product; 2-methylbenzyl 
alcohol (8.7 min). (b) GC-MS analysis of the turnover of m-xylene by H85F CYP101B1 (red) 
and CYP101B1 (black). m-Xylene (RT 3.65 min) and the product; 3-methylbenzyl alcohol (8.6 
min). (c) GC-MS analysis of the turnover of p-xylene by H85F CYP101B1 (red) and 
CYP101B1 (black). p-Xylene (RT 3.75 min) and the product; 4-methylbenzyl alcohol (8.8 
min). The chromatograms (CYP101B1, a, b, c) were offset along the x and y-axes for clarity 
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The spin-state shift of the H85F mutant upon addition of the ethylbenzene was 30% versus 
≤5% with the WT enzyme (Figure 5. 11). Ethylbenzene also bound more tightly to the H85F 
variant (Kd = 2.5 µM versus 520 µM; Figure 5. 11). The rate of NADH oxidation by H85F 
CYP101B1 upon the addition of ethylbenzene was 4-fold faster than that of WT CYP101B1 
(201 ± 22 min-1 versus 47 ± 2 min-1; Table 5. 3). The product formation rate was also greater 
for the mutant (43 ± 4 min-1) due to a higher coupling efficiency than the WT system (21% 
versus 13%; Table 5. 3).  Both variants oxidised ethylbenzene into a major single metabolite 
(Figure 5. 12). This was confirmed as 1-phenylethanol by coelution experiment in GC-MS with 
an authentic standard and mass spectrum analysis (m+/z = 122.05; Figure 5. 12, Figure 5. 16, 
and Figure D. 1). Chiral GC analysis of the in vitro turnovers displayed a mixture of 
enantiomers; (S)-(-)-1-phenylethanol and (R)-(+)-1-phenylethanol in both turnovers (Figure 5. 
12 and Figure 5. 16). The distribution of the enantiomers with the WT enzyme was 55 to 45 % 
(excess (S)-(-)-1-phenylethanol), and the H85F variant also generated more (S)-(-)-1-
phenylethanol (77%; Figure 5. 12 and Figure 5. 16). 
 
     (a)                                                     (b) 
 
    (c)                                                     (d) 
Figure 5. 11 Spin-state shifts (red) of (a) H85F CYP101B1 and (c) WT CYP101B1 after 
addition of ethylbenzene. The dissociation constant analysis of (b) H85F 1.56 µM/Kd 2.5 µM 
and (d) WT CYP101B1 1.31 µM/Kd 520 µM with ethylbenzene. The concentration of the 
enzyme used in the binding studies and the dissociation constants (Kd) are provided. 







          (a)                                                                        (b) 
        
        (c)                                                                     (d) 
 
Figure 5. 12 (a) GC-MS analysis of the turnover of ethylbenzene by H85F CYP101B1 (red) 
and CYP101B1 (black). Ethylbenzene (RT 2.1 min) and the product; 1-phenylethanol (RT 5.05 
min). (b) GC-MS control 1-phenylethanol (RT 5.05 min). (c) Chiral GC analysis of the 
turnover of ethylbenzene H85F CYP101B1 (red) and CYP101B1 (black); (R)-(+)-1-
phenylethanol (RT 11.85 min) and (S)-(-)-1-phenylethanol (RT 12.0 min). (d) Chiral GC 
control of enantiomers (R)-(+)-1-phenylethanol (RT 11.85 min) and (S)-(-)-1-phenylethanol 
(RT 12.0 min). Impurities are labelled (*).
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2-Ethytoluene altered the low heme spin-state to 30% high spin form upon addition to H85F 
CYP101B1. In comparison, it changed only 10% in the WT enzyme (Figure 5. 13). The NADH 
oxidation rate (496 min-1) and product formation activity (262 min-1) were also significantly 
faster for the mutant and the coupling efficiency was greater (53% versus 35%; Table 5. 3). 
Both the WT and H85F variants oxidised 2-ethyltoluene into one major metabolite (70% and 
90%, respectively; m+/z = 135.95) alongside two minor products (Figure 5. 14 and Figure D. 
1). The major metabolite was generated using a whole-cell biotransformation system and 
identified after isolation as (2-ethylphenyl)methanol via NMR analysis (Figure 5. 15, Figure 5. 
16, Figure D. 2-D. 3) 265. The product was assigned as all the aromatic hydrogens and those of 
the ethyl group remained intact (Figure 5. 15). The peak at 4.74 ppm in the 1H NMR (CDCl3), 
indicated the hydroxylation occurred at the methyl group (Figure 5. 15 and Figure D. 2-D. 3). 
One of the minor metabolites 1-(2-methylphenyl)ethanol (m+/z = 136.05), was identified by 
coelution with a standard in GC-MS (RT 7.9 min; Figure 5. 14). The other minor metabolite 
was assigned as 2-ethylbenzaldehyde (m+/z = 136.10), based on its MS fragmentation pattern 
(RT 7.1 min; Figure 5. 14, Figure 5. 16 and Figure D. 1). Chiral GC analysis revealed a roughly 
equal mixture of (S)-1-(2-methylphenyl)ethanol and (R)-1-(2-methylphenyl)ethanol was 
generated by WT CYP101B1 (Figure 5.14 and  Figure 5.16). The H85F mutant was more 
selective and gave a 70% of (S)-1-(2-methylphenyl)ethanol (Figure 5. 14 and Figure 5. 16) 265. 
 
Table 5. 3 Substrate binding, turnover and coupling efficiency data for the turnovers of 
CYP101B1 (WT and the H85F variant) with ethylbenzene, 2- and 3-ethyltoluene. The turnover 
activities were measured as described in Table 5. 1. -not measured. The data are reported as 














WT ≤5% 520 ± 70 47 ± 2 6 ± 6 13 
H85F 30% 2.5 ± 1 201 ± 22 43 ± 4 21 
2-ethyltoluene 
WT 10% -    156 ± 7 55 ± 1 35 
H85F 30% - 496 ± 16 262 ± 15 53 
3-ethyltoluene 
WT 5% - 90 ± 13 15 ± 1 16 
H85F 5% - 228 ± 5 100 ± 3 44 




   (a)                                                   (b) 
Figure 5. 13 Spin-state shifts (red) of (a) H85F CYP101B1 and (b) WT CYP101B1 upon 
addition of 2-ethyltoluene.  
   
        (a)                                                                   (b) 
 
        (c)                                                                (d) 
Figure 5. 14 (a) GC-MS analyses of the turnovers of 2-ethyltoluene by H85F CYP101B1 (red) 
and CYP101B1 (black). The products 2-ethylbenzaldehyde (RT 7.1 min, product 1), 1-(2-
methylphenyl)ethanol (RT 7.9 min, product 2) and (2-ethylphenyl)methanol (RT 9.1 min, 
product 3). (b) GC-MS analysis of whole-cell turnover of 2-ethyltoluene with WT CYP101B1. 
2-Ethyltoluene (RT 3.5 min) and the only product detected was (2-ethylphenyl)methanol (RT 
9.1 min). (c) GC-MS control 1-(2-methylphenyl)ethanol (RT 7.9 min). (d) Chiral GC analyses 
of the in vitro turnovers of WT and mutant CYP101B1. A mixture of enantiomers was 
observed; (R)-(+)-1-(2-methylphenyl)ethanol (RT 19.1 min) and (S)-(-)-1-(2-
methylphenyl)ethanol (RT 19.6 min) 265. Impurities are labelled (*). 




Figure 5. 15 1H NMR of (2-ethylphenyl)methanol (CDCl3) 
265. Full data are in Appendix D 




Figure 5. 16 The products identified from the CYP101B1 and H85F CYP101B1 turnovers of 
ethylbenzene, 2-ethyltoluene and 3-ethyltoluene 265, 272. The product distributions are given as 
percentages (H85F variant in bold). 
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The addition of 3-ethyltoluene induced a ≤5% spin-state to the high spin form in H85F and WT 
enzyme (Figure 5. 17). The NADH oxidation (228 ± 5 min-1) and product formation rates (100 
± 3 min-1) for the H85F variant with 3-ethyltoluene were slower when compared with 2-




    (a)                                                         (b) 
 
Figure 5. 17 Spin-state shifts (red) of (a) H85F CYP101B1 and (b) WT CYP101B1 upon 
addition of 3-ethyltoluene. 
 
The coupling efficiency was nearly 3-fold higher for the H85F variant (44%) than the WT 
enzyme (16%) with 3-ethyltoluene. Three metabolites were detected from the oxidation of 3-
ethyltoluene by WT CYP101B1, and two products arose from the H85F mutant oxidation 
reactions (Figure 5. 18). These metabolites were generated by whole-cell oxidation and purified 
by silica column chromatography. These were characterised via analysis of their MS, NMR or 
coelution experiments (Figure 5. 18 and Figure 5. 16). The two products were common in both 
turnovers and characterised as 1-(3-methylphenyl)ethanol and (3-ethylphenyl)methanol (Based 
on their NMR and mass spectrum analysis; Figure 5. 16, Figure 5. 19, Figure D. 1 and Figure 
D. 4) 267. The latter was formed in excess (more than 60%) in both cases (Figure 5. 16 and 
Figure 5. 18). The additional product found in the WT turnover (around 14% of total product) 
was assigned as 2-ethyl-4-methylphenol using its NMR and mass spectrum (m+/z = 136.05; 
Figure 5. 16, Figure 5. 19, Figure D. 1 and Figure D. 5) 267. Chiral GC analysis could not 
separate the enantiomers of 1-(3-methylphenyl)ethanol. 
 





      (a) 
 
         (b) 
 
Figure 5. 18 (a) GC-MS analyses of the turnovers of 3-ethyltoluene by H85F CYP101B1 (red) 
and CYP101B1 (black). 3-Ethyltoluene (RT 3.48 min) and the product 1-(3-
methylphenyl)ethanol (RT 7.45 min, product 1), (3-ethylphenyl)methanol (RT 9.25 min, 
product 2) and 2-ethyl-4-methylphenol (RT 9.45 min, product 3). (b) GC-MS control of 1-(3-
methylphenyl)ethanol (RT 7.45 min). The chromatogram (CYP101B1) was offset along the x 
and y-axes for clarity. Impurities are labelled (*). 
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(a) 
     
(b) 
Figure 5. 19 (a) 1H NMR of 1-(3-methylphenyl)ethanol. The product was assigned due to the 
characteristic quartet peak at 4.87 ppm, and all the benzylic and methyl protons are intact 267. 
(b) 1H NMR of 2-ethyl-4-methylphenol. The metabolite was characterised as all the proton 
peaks of the methyl and ethyl groups were present. The product was confirmed as 2-ethyl-4-
methylphenol by comparing the NMR spectrum with the 1H NMR reported in the literature 267. 
There is a small amount of impurity present in the NMR sample of 2-ethyl-4-methylphenol. 
Full data are provided in Appendix D (Figure D. 4-D. 5). 
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n-Propylbenzene induced a moderate spin-state shift (30%) but showed tight binding (Kd = 0.6 
± 0.1 µM) to the H85F mutant enzyme (Figure 5. 20 and Table 5. 4). This substrate induced 
only a 5% spin-state shift in WT enzyme and the high dissociation constant of WT CYP101B1 
(Kd = 410 ± 70 µM) indicated significantly weaker binding.  
 
  
  (a)                                                    (b) 
 
  (c)                                                     (d) 
 
Figure 5. 20 Spin-state shifts (red) of (a) H85F CYP101B1 and (c) WT CYP101B1 after 
addition of n-propylbenzene. The dissociation constant analysis of (b) H85F CYP101B1 1.40 
µM/Kd 0.6 µM and (d) WT CYP101B1 1.31 µM/Kd 410 µM. The concentration of the enzyme 
used in the binding assays and the dissociation constant (Kd) are provided. 
 
The H85F mutant oxidised the n-propylbenzene with a NADH oxidation rate of 510 ± 13 min-
1, which was more than 4-fold faster compared to the WT enzyme (Table 5.4). The product 
formation rates were low, 44 min-1 and 9 min-1 for both the H85F mutant and WT enzyme 
respectively, as a result of the reduced coupling efficiencies (9% for H85F and 4% for WT 
CYP101B1; Table 5. 4).  
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Despite low product formation activity and coupling efficiency, n-propylbenzene was oxidised 
to three metabolites by both variant enzymes. Two of these were identified as 1-phenyl-1-
propanol (m+/z = 136.15) and propiophenone (m+/z = 134.1) by GC-MS coelution with 
authentic standards (Figure 5. 21 and Figure D. 1). The further oxidation product 
propiophenone (around 70%) was formed in excess in both turnovers (Figure 5. 21). The third 
metabolite was identified as 1-phenylpropan-2-ol by GC-MS coelution with the product 
generated from the reduction of phenylacetone by LiAlH4 
214. Analysis of the mass spectrum 
(m+/z = 136.10) was also in agreement with this assignment (Figure D. 1). Chiral GC and HPLC 
analysis of 1-phenyl-1-propanol metabolite could not separate the enantiomers. Turnover of 
the WT enzyme generated a 40 (R):60 (S) mixture of 1-phenylpropan-2-ol enantiomers, 
whereas the H85F mutant generated a 26 (R):74 (S) ratio (Figure 5. 21 and Figure 5. 19 (c)) 265. 
 
Table 5. 4. Substrate binding, turnover and coupling efficiency data for CYP101B1 (WT and 
the H85F variant) with n-propylbenzene, isopropylbenzene, isobutylbenzene and indane. The 
turnover activities were measured as described in Table 5. 1. - not measured or not able to be 















WT ≤5% 410 ± 70 121 ± 6 9 ± 5 4 
H85F 30% 0.6 ± 0.1 510 ± 13 44 ± 4 9 
isopropyl-
benzene 
WT 5% - 98 ± 12 14 ± 1 12 
H85F 20% - 381 ± 8 46 ± 2 15 
isobutylbenzene 
WT ≤5% 70 ± 20 156 ± 2 65 ± 4 42 
H85F 20% 0.9 ± 0.1 254 ± 4 108 ± 3 43 
indane 
WT 20% 99 ± 11 118 ± 21 28 ± 3 24 
H85F 65% 9.5 ± 7 363 ± 8 174 ± 9 48 




  (a)                                                                  (b) 
 
      (c) 
 
                                                                            (d) 
Figure 5. 21 (a) GC analyses of the turnovers of n-propylbenzene by H85F CYP101B1 (red) 
and CYP101B1 (black). n-Propylbenzene (RT 3.1 min) and the products; 1-phenylpropan-2-ol 
(RT 6.75 min, product 1), 1-phenyl-1-propanol (RT 7.25 min, product 2), propiophenone (RT 
7.6 min, product 3) 272. The chromatogram (CYP101B1) was offset along the x and y-axes for 
clarity. (b) GC-MS analysis of whole-cell turnover of WT CYP101B1 and products control. 
(c) Chiral GC analyses of 1-phenyl-1-propanol product region to highlight the separation of 
the two enantiomers (RT 13.7 min and 13.8 min). Impurities are labelled (*). (d) The products 
identified from the CYP101B1 and H85F CYP101B1 turnovers of n-propylbenzene. The 
product distributions are given as percentages (H85F variant in bold). 
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Addition of isopropylbenzene and isobutylbenzene shifted the heme to the high spin-state to 
similar levels; 20% and 5% in H85F and WT CYP101B1, respectively (Figure 5. 22 and Figure 
5. 23). The H85F CYP101B1 variant exhibited higher affinity with isobutylbenzene (Kd = 0.9 
± 0.1 µM) than the WT enzyme (Kd = 70 ± 20 µM). This was consistent with the tight binding 
observed for n-propylbenzene (Table 5. 4).  
 
The NADH oxidation and product formation rates of isobutylbenzene oxidation by the H85F 
CYP101B1 were 254 min-1 and 108 min-1, respectively. Both were significantly faster than 
those determined with the WT system (Table 5. 4). The coupling efficiency was similar for 
both variants (43% versus 42%; Table 5. 4). Higher NADH oxidation (381 min-1) and product 
formation (46 min-1) rates were also observed for H85F CYP101B1 with isopropylbenzene 
than for the WT enzyme. The coupling efficiencies of both variants were reduced when 
compared with isobutylbenzene (Table 5. 4). Both enzymes catalysed the selective 
hydroxylation of isobutylbenzene and isopropylbenzene to a single hydroxylated metabolite 
which was detected in the GC-MS analysis (Figure 5. 24). The metabolites were identified as 
arising from hydroxylation of the alkyl substituent tertiary C-H bonds; 2-methyl-1-phenyl-2-
propanol (m+/z = 150.05) and 2-phenyl-2-propanol (m+/z = 136.10). Both were confirmed by 
GC-MS coelution experiments with authentic standards (Figure 5. 24, Figure 5. 25 and Figure 
D. 1). 
 
             
(a)                                                              (b) 
 
Figure 5. 22 Spin-state shifts (red) of (a) H85F CYP101B1 and (b) WT CYP101B1 upon 
addition of isopropylbenzene.  
 







   (a)                                                               (b) 
    
 (c)                                                                 (d) 
 
Figure 5. 23 Spin-state shifts (red) of (a) H85F CYP101B1 and (b) WT CYP101B1 upon 
addition of isobutylbenzene. The dissociation constant analysis of (c) H85F CYP101B1 1.32 
µM/Kd 0.9 µM and (d) WT CYP101B1 1.25 µM/Kd 70 µM with isobutylbenzene. The 











        (a)                                                                   (b) 
 
Figure 5. 24 (a) GC-MS analyses of the turnovers of isobutylbenzene by H85F CYP101B1 
(red) and WT CYP101B1 (black). Isobutylbenzene (RT 4.0 min) and the product; 2-methyl-1-
phenyl-2-propanol (RT 7.45 min; Product control (blue)). (b) GC-MS analyses of the turnover 
of isopropylbenzene by H85F CYP101B1 (red) and CYP101B1 (black). Isopropylbenzene (RT 
2.8 min) and the product; 2-phenyl-2-propanol (RT 5.6 min; Product control (blue)). The 





Figure 5. 25 The products identified from the CYP101B1 and H85F CYP101B1 turnovers of 
isopropylbenzene and isobutylbenzene 265. 
 
The cyclic alkylbenzene indane induced a more substantial spin-state shift (65%) in the H85F 
variant than the WT enzyme. It also bound to the H85F variant with high affinity (Kd = 9.5 ± 7 
µM; Figure 5. 26 and Table 5. 4). Indane induced only a 20% spin-state shift in WT CYP101B1 
and the binding affinity to this enzyme was lower (Kd = 99 ± 11 µM; Figure 5. 26 and Table 5. 
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4). The NADH oxidation and product formation rates of indane oxidation by the H85F variant 
were 363 ± 8 min-1 and 174 ± 9 min-1, respectively (Table 5. 4). These were significantly 
decreased with WT CYP101B1 (118 ± 21 min-1 and 28 ± 3 min-1; Table 5. 4). The coupling 
efficiency of this oxidation reaction for the mutant enzyme was almost 2-fold superior to WT 
(48% versus 24%; Table 5. 4). Both variants oxidised indane into one significant product 
(≤95%) with another minor metabolite (Figure 5. 27). The major metabolite was identified as 
1-indanol (m+/z = 134.10) and minor product as 1-indanone (m+/z = 132.10) by GC-MS 
coelution experiments with authentic standards (Figure 5. 26, Figure 5. 27 and Figure D. 1). 
The chiral HPLC analyses of in vitro turnovers of indane by both enzymes revealed that the 
hydroxylation proceeded with little enantioselectivity (Figure D. 21). 
 
 
   (a)                                                                (b) 
     
   (c)                                                                (d) 
Figure 5. 26 Spin-state shifts of (a) H85F CYP101B1 and (b) WT CYP101B1 after addition 
of indane (red). Dissociation constant analysis of (c) H85F CYP101B1 1.93 µM/ Kd 9.5 µM 
and (d) WT CYP101B1 1.48 µM/Kd 99 µM. The concentration of the enzyme used in the 
binding assays and the dissociation constants (Kd) are provided. 
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(a)                                                                    (b) 
 
(c) 
Figure 5. 27 (a) GC analysis of the in vitro turnover of indane by H85F CYP101B1 (red) and 
CYP101B1 (black). Indane (RT 8.2 min) and the products; 1-indanol (RT 11.6 min, product 1, 
control; green) and 1-indanone (RT 12.7 min, product 2). (b) GC-MS analysis of the in vitro 
turnover of indane by H85F CYP101B1 (red) and CYP101B1 (black). Indane (RT 4.8 min) 
and the products; 1-indanol (product 1; RT 9.2 min) and 1-indanone (RT 10.6 min, product 2 
control; blue). The chromatograms (CYP101B1) were offset along the x and y-axes for clarity. 
Impurities are labelled (*). (c) The products identified from the CYP101B1 and H85F 
CYP101B1 turnovers of indane 265. The product distributions are given as percentages (H85F 
variant in bold). 
 
 
The oxidation of styrene, 2-methylstyrene and β-methylstyrene were examined to see the effect 
of presence of an unsaturated side chain on the binding and activity of both variants. Styrene 
induced 5% and 10% high heme spin-state shifts of WT and H85F CYP101B1, respectively 
(Figure 5. 28 and Table 5. 5). Despite these low shifts, the NADH oxidation rates of both were 
moderately high (153 min-1 for H85F variant and 105 min-1 for WT enzyme; Table 5. 5). The 
H85F variant oxidised this substrate with greater product formation rate (55 min-1) than the 
WT CYP101B1 system (Table 5. 5). The productive use of reducing equivalent to product 
formation was also better for H85F variant (36% versus 13%; Table 5. 5). 




   (a)                                                 (b) 
 
   (c)                                                    (d) 
 
  (e)                                     (f) 
 
Figure 5. 28 Spin-state shifts of (left) H85F CYP101B1 and (right) WT CYP101B1. Heme 




The in vitro turnovers of styrene with both enzymes generated a single metabolite which was 
identified as phenyloxirane by GC-MS coelution (m+/z = 120.15; Figure 5. 29, Figure 5. 33 
and Figure D. 1) 272. A minor product (less than 1%) was detected in the H85F mutant turnover, 
which was assigned as phenylacetaldehyde from its MS fragmentation pattern (m+/z = 120.10; 
Figure 5. 29, Figure 5. 33 and Figure D. 1). Chiral GC analyses of both sets of turnovers showed 
the formation of a roughly equal mixture of (S)-(–)-phenyloxirane and (R)-(+)-phenyloxirane 
(Figure 5. 29 and Figure 5. 33). 
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Table 5. 5 Substrate binding, turnover and coupling efficiency data for CYP101B1 (WT and 
the H85F variant) with styrene, β-methylstyrene and 2-methylstyrene. The in vitro turnover 
activities were measured as described in Table 5. 1. -not measured or not able to be determined 





                                     (a)                                                                    (b) 
 
Figure 5. 29 (a) GC-MS analysis of the turnover of styrene by H85F CYP101B1 (red) and 
CYP101B1 (black). Styrene (RT 2.4 min) and the products; #phenylacetaldehyde (RT 4.75 
min) and phenyloxirane (styrene oxide; RT 5.15 min; control blue). The chromatogram 
(CYP101B; black) was offset along the x and y-axes for clarity. (b) GC chiral column analyses; 
styrene (RT 3.6 min) and the products control; (S)-(-)-phenyloxirane (blue; RT 9.2 min) and 














WT ≤5% - 105 ± 2 14 ± 10 13 
H85F 10% - 153 ± 7 55 ± 7 36 
2-methylstyrene 
WT 5% 450 ± 70 161 ± 9 42 ± 3 26 
H85F 20% 13 ± 4 405 ± 16 219 ± 17 54 
β-methylstyrene 
WT 10% 395 ± 25 76 ± 6 54 ± 17 71 
H85F 35% 1.8 ± 3 90 ± 1 33 ± 3 37 
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The addition of 2-methylstyrene and β-methylstyrene in H85F CYP101B1 induced spin-state 
shifts to 20% and 35% high spin form, respectively. These were greater than these of WT 
CYP101B1 (Figure 5. 30). The H85F variant bound both these substrates with high affinity, 
especially in case of β-methylstyrene, where it exhibited very tight binding (Kd = 1.8 µM versus 
Kd = 13 µM; Figure 5. 30). WT CYP101B1 had a weak binding affinity with both of these 
substrates, as indicated by the measured dissociation constants (Figure 5. 30). 
 
   
(a)                                                                (b) 
 
(c)*                                                                (d)* 
 
Figure 5. 30 Dissociation constant analyses of (a) 2-methylstyrene H85F variant 1.65 µM/Kd 
13 µM, (b) WT 1.32 µM/Kd 450 µM and (c) β-methylstyrene H85F variant 1.83 µM/Kd 1.8 
µM, (d) WT 1.31 µM/Kd 395 µM for the WT enzyme. 
*The difference between A420 and A600 
nm was used due to the interference of substrate with the analysis below 400 nm. The 
concentration of the enzyme used in the binding investigation and the dissociation constant 
(Kd) are provided. 
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The H85F mutant exhibited significant oxidation activity with 2-methylstyrene (NADH 
oxidation rate 405 ± 16 min-1 and product formation rate 219 ± 17 min-1; Table 5. 5). WT 
CYP101B1 had a lower coupling efficiency (26%) which resulted in a reduced product 
formation rate (42 ± 3 min-1; Table 5. 5). A single major metabolite (95%) was detected in GC-
MS analysis of the in vitro turnovers of 2-methylstyrene with both enzymes. This was assigned 
2-(2-methylphenyl)oxirane from the mass spectrum (m+/z = 134.05) and coelution experiment 
in GC-MS with the product of the reaction of 2-methylstyrene with m-chloroperbenzoic acid 
(mCPBA; Figure 5. 31, Figure 5. 33 and Figure D. 1) 268, 272.  
 
  
     (a)                                                              (b) 
 
Figure 5. 31 (a) GC-MS analyses of the turnover of 2-methylstyrene by H85F CYP101B1 
(red), CYP101B1 (black) and 2-(2-methylphenyl)oxirane synthesised by adding mCPBA to 2-
methylstyrene (blue). 2-Methylstyrene (RT 3.75 min) and the minor product (2-
methylphenyl)acetaldehyde (RT 7.2 min, product 1) and the significant product 2-(2-
methylphenyl)oxirane (RT 7.58 min, product 2). The chromatogram (CYP101B; black) was 
offset along the x and y-axes for clarity. (b) Chiral GC analyses of the in vitro turnovers 
overlaid with the racemic mixture of 2-(2-methylphenyl)oxirane (RT 11.6 min and 12.1 min). 
Impurities are labelled (*). The chromatograms were offset along the x and y-axes for clarity. 
 
 
Chiral GC analysis confirmed that 2-(2-methylphenyl)oxirane was generated as a mixture of 
enantiomers (WT (60:40) and H85F (55:45); Figure 5. 31 and Figure 5. 33). The minor product 
was assigned as (2-methylphenyl)acetaldehyde (m+/z = 134.05) based on its MS fragmentation 
pattern (Figure 5. 31, Figure 5. 33 and Figure D. 1). 
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β-Methylstyrene was oxidised by H85F and wild-type CYP101B1 with NADH oxidation rates 
of 90 min-1 and 76 min-1, respectively. These were lower than those of 2-methylstyrene and 
styrene. Unusually the product formation rate was reduced for the mutant enzyme compared to 
the WT (33 min-1 versus 54 min-1; Table 5. 5). The coupling efficiency for the oxidation of β-
methylstyrene by the WT enzyme was greater (71%) than the H85F variant, 37% (Table 5. 5). 
β-Methylstyrene oxidation by both variants generated two metabolites (Figure 5. 32 and Figure 
5. 33). The major product was identified as 3-phenyl-2-propen-1-ol (m+/z = 134.0) by coeluting 
with an authentic standard in both GC and GC-MS (Figure 5. 32, Figure 5. 33 and Figure D. 
1) 272. The second metabolite was confirmed as the epoxide, 2-methyl-3-phenyloxirane (m+/z 
= 134.0) by analysing the mass spectrum and a coelution experiment with the epoxide of β-
methylstyrene synthesised using mCPBA (Figure 5. 32, Figure 5. 33 and Figure D.1) 268. Chiral 
GC analyses showed that an almost equal mixture of the two stereoisomers, (R, R)- and (S, S)-
2-methyl-3-phenyloxirane, were formed in the turnovers of H85F variant but for WT the ratio 
was 58:42 (Figure 5. 32 and Figure 5. 33). 
 
 
       (a)                                                                (b) 
 
Figure 5. 32 (a) GC-MS analyses of the turnovers of β-methylstyrene by H85F CYP101B1 
(red), CYP101B1 (black), and the product 2-methyl-3-phenyloxirane formed by the reaction 
of the substrate with mCPBA (blue). β-Methylstyrene (RT 4.3 min) and the products; 2-methyl-
3-phenyloxirane (RT 6.3 min, product 1) and 3-phenyl-2-propen-1-ol (11.45 min, product 2 
control; green). The chromatogram (CYP101B; black) was offset along the x and y-axes for 
clarity. (b) Chiral GC analyses of both in vitro turnovers and highlighted the region of the 
metabolites and product control (2R, 3R)-(+)-2-methyl-3-phenyloxirane (blue). Impurities are 
labelled (*).  







Figure 5. 33 The products identified from the CYP101B1 and H85F CYP101B1 turnovers of 
the styrene, 2-methylstyrene and β-methylstyrene. The product distributions are given as 
percentages (H85F variant in bold). a WT and the H85F variant generated a 60:40 and 55:45 
mixture of each enantiomer, respectively. b Both the WT and H85F variants generated a 
58(R):42 and 50:50 mixture of each enantiomer, respectively. 
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5.3.2 The oxidation of naphthalene derivatives and related molecules by WT and H85F 
CYP101B1 
The H85F variant of CYP101B1 showed an improved oxidation activity with alkylbenzene 
substrates over the WT enzyme. The cyclic alkylbenzene indane resulted in the greatest spin-
state shift to the high spin form in H85F variant, indicative of a suitable substrate fit in the 
active site of the enzyme. To expand the substrate range towards larger aromatic substrates, 
both variants were investigated with naphthalene derivatives and related molecules (Figure 5. 
34). A series of substituted naphthalenes, bicyclic and tricyclic compounds were selected for 




Figure 5. 34 The naphthalene derivatives and related substrates screened with WT CYP101B1 
and H85F CYP101B1. 
 
 
The addition of 1-methylnaphthalene in H85F and WT CYP101B1, induced the spin-state shift 
to the high spin form of 60% versus 50%, respectively (Figure 5. 35) 265, 266. The substrate 
binding assays showed that H85F variant bound with this substrate more tightly than the WT 
(Kd = 3.3 ± 0.4 µM versus Kd = 63 ± 9 µM; Figure 5. 36) 
265, 266. As with the alkylbenzenes, 1-
methylnaphthalene oxidation occurred with higher NADH oxidation (453 min-1) and product 
formation (161 min-1) rates with the H85F system compared to the WT (Table 5. 6). The 
coupling efficiency was also better (36% versus 16%; Table 5. 6). Both variants selectively 
oxidised 1-methylnaphthalene to a single metabolite (Table 5. 6). This was identified as 1-
naphthylmethanol (m+/z = 158.05) by coeluting with an authentic standard in GC-MS (Figure 
5. 37 and Figure D. 1) 265, 266. 




   (a)                                                   (b) 
 
    (c)                                                
Figure 5. 35 Spin-state shifts (red) of H85F variant after addition of (a) 1-methylnaphthalene, 
(c) 2-methylnaphthalene and spin-state shifts of WT CYP101B1 after addition of (b) 1-
methylnaphthalene. 
 
Table 5. 6 Substrate binding, turnover and coupling efficiency data for CYP101B1 (WT and 
the H85F variant) with 1- and 2-methylnaphthalene. The in vitro turnover activities were 
measured as described in Table 5. 1. The data are reported as mean ± S.D. (n = 3) and rates are 













WT 266 50% 63 ± 9 240 ± 17 38 ± 10 16 
H85F 60% 3.3 ± 0.4 453 ± 25 161 ± 13 36 
2-methylnaphthalene 
WT 266 30% 140 ± 10 212 ± 24 57 ± 18 26 
H85F 50% 16 ± 6 158 ± 13 32 ± 3 20 
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(a)                                                   (b) 
 
(c)                                                    (d) 
Figure 5. 36 Dissociation constant analysis of (a) H85F 1.49 µM/Kd 3.3 µM, (b) WT 
CYP101B1 1.76 µM/Kd 63 µM with 1-methylnaphthalene, and (c) H85F 1.84 µM/Kd 16 µM, 
(d) WT CYP101B1 1.84 µM/Kd 140 µM with 2-methylnaphthalene. The concentration of the 





Figure 5. 37 (a) GC-MS analyses of the turnovers of 1-methylnaphthalene by H85F 
CYP101B1 (red) and CYP101B1 (black). 1-Methylnaphthalene (RT 4.9 min) and the product; 
1-naphthylmethanol (blue; RT 8.7 min) 265, 266. Impurities are labelled (*). The chromatogram 
(CYP101B1) was offset along the x and y-axes for clarity. (b) The product identified from the 
CYP101B1 and H85F CYP101B1 turnovers of the 1-methylnaphthalene 265, 266. 
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2-Methylnaphthalene induced a spin-state shift of 50% in H85F variant and 30% in WT 
enzyme (Figure 5. 35). The H85F mutant bound the substrate nearly 9-fold more tightly (Kd = 
16 ± 6 µM) than the WT (Kd = 140 ± 10 µM; Figure 5. 36). However, there was no clear 
relationship between binding affinity and oxidation activity in the case of 2-methylnaphthalene 
as the NADH oxidation (212 min-1) and product formation (57 min-1) rates of the WT system 
with this substrate were faster than those of the mutant (Table 5. 6). The coupling efficiency 
was also found to be higher with WT CYP101B1 (26% versus 20%; Table 5. 6). The GC-MS 
analyses of the in vitro turnovers of 2-methylnaphthalene showed that a single monooxygenase 
metabolite was formed by both variants (Figure 5. 38). The product was confirmed as 2-
naphthylmethanol (m+/z = 158.15) by GC-MS coelution experiment with an authentic standard 
(Figure 5. 38 and Figure D. 1) 265, 266. 
 
 
        (a) 
 
 
         (b) 
Figure 5. 38 (a) GC-MS analyses of the turnovers of 2-methylnaphthalene by H85F 
CYP101B1 (red) and CYP101B1 (black). 2-Methylnaphthalene (RT 4.8 min) and the product; 
2-naphthylmethanol (RT 8.9 min; standard blue) 265, 266. Impurities are labelled (*). (b) The 
product identified from the CYP101B1 and H85F CYP101B1 turnovers of the 2-
methylnaphthalene 265, 266. 
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The disubstituted naphthalene derivative 1,2-dimethylnaphthalene induced a 40% spin-state 
shift in H85F variant (Figure 5. 39). This was lower than 1-and 2-methylnaphthalene induced 
spin-state alterations with this variant (Figure 5. 39). The WT CYP101B1 had a slightly higher 
spin-state shift, but the binding affinity of the H85F variant was nearly 8-fold tighter (Figure 
5. 39).  
 
 
       (a)                                                              (b) 
       
        (c)                                                                (d) 
Figure 5. 39 Spin-state shifts (red) after addition of 1,2-dimethylnaphthalene to (a) H85F 
CYP101B1 and (c) WT CYP101B1. Dissociation constant analysis of (b) H85F 1.93 µM/Kd 
2.4 µM and (d) WT CYP101B1 1.57 µM/Kd 20 µM with 1,2-dimethylnaphthalene. The 
concentration of the enzyme used in the binding assays and the dissociation constants (Kd) are 
provided. 
 
The NADH oxidation rate (242 min-1 versus 136 min-1) and coupling efficiency (24% versus 
19%) were also higher for the H85F mutant than these of the WT with 1,2-
dimethylnaphthalene, resulting in an increased rate of product formation (84 min-1 versus 17 
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min-1; Table 5. 7). A single metabolite was detected in the in vitro turnovers of both variants. 
GC-MS analyses indicated it was a monooxygenase metabolite (m+/z = 172.05; Figure 5. 40 
and Figure D. 1). This metabolite was generated on a larger scale using whole-cell 
biotransformation system, and it was separated in a pure form (~8 mg) by silica column 
chromatography. The metabolite was confirmed as (1-methyl-2-naphthyl)methanol by 
comparing the NMR spectrum to that published previously (Figure 5. 40, Figure 5. 43 and 
Figure D. 6-D. 8) 265, 315. The 1H NMR spectrum showed a distinct 2H peak at 4.91 ppm, which 
indicated that hydroxylation occurs at one of the methyl groups (Figure 5. 40). The correlation 
of H8 (7.72 ppm) with the H11 (2.71 ppm) in gCOSY NMR spectrum enabled identification 
of 1-methyl-2-naphthyl)methanol not (2-methyl-1-naphthyl)methanol (Figure 5. 40 and Figure 
D. 6-D. 8). 
 
Table 5. 7. Substrate binding, turnover and coupling efficiency data for the CYP101B1 (WT 
and the H85F variant) with alkyl substituted naphthalenes 265, 266. The turnover activities were 
measured as described in Table 5. 1. - not measured or not able to be determined accurately. 















WT 55% 20 ± 4 136 ± 13 25 ± 2 19 
H85F 40% 2.4 ± 0.1 242 ± 8 57 ± 2 24 
1,5-dimethyl 
naphthalene 
WT 55% 28 ± 3 135 ± 5 17 ± 1 13 
H85F 80% 2.6 ± 0.2 355 ± 30 84 ± 12 24 
2,6-dimethyl 
naphthalene 
WT 266 10% - 113 ± 5 23 ± 1 21 
H85F 20% - 76 ± 13 3 ±1 4 
2,7-dimethyl 
naphthalene 
WT 266 30% - 448 ± 44 79 ± 10 18 
H85F 25% - 87 ± 25 6 ±1 7 
acenaphthene 
WT 30% 20 ± 4 165 ± 24 42 ± 7 25 
H85F 60% 5.9 ± 0.6 513 ± 16 245 ± 12 48 









Figure 5. 40 (a) GC-MS analyses of the turnovers of 1,2-dimethylnaphthalene by H85F (red) 
and WT (black) CYP101B1. 1,2-Dimethylnaphthalene (RT 7.0 min) and the product (1-
methyl-2-naphthyl)methanol (RT 10.5 min) 265. Impurities are labelled (*). The chromatogram 
(CYP101B1; black) was offset along the x and y-axes for clarity. (b) 1H NMR spectrum of (1-
methyl-2-naphthyl)methanol. (c) Zoomed in gCOSY NMR spectrum to highlight the 
interaction of H11 and H12. Full data in Appendix D (Figure D. 6-D. 8). 
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The addition of 1,5-dimethylnaphthalene induced a substantial spin-state shift of 80% to the 
high spin form in the H85F mutant (Figure 5. 41). The H85F mutant exhibited a strong binding 
affinity with this substrate (Kd = 2.6 ± 0.2 µM; Figure 5. 41 and Table 5. 7). The WT enzyme 
showed a lower affinity than that of the H85F variant (Kd = 28 ± 3 µM; Figure 5. 41 and Table 
5. 7). The H85F variant catalysed the oxidation of 1,5-dimethylnaphthalene at a faster NADH 
oxidation activity (355 min-1) and product formation rate (84 min-1) than the WT and the 
reaction was more tightly coupled to the use of the reducing equivalent (24% versus 13%; 
Table 5. 7). 
 
 
   (a)                                                   (b) 
   
    (c)                                                    (d) 
Figure 5. 41 Spin-state shifts (red) of (a) H85F variant and (c) WT CYP101B1 after addition 
of 1,5-dimethylnaphthalene. Dissociation constant analysis of (b) H85F CYP101B1 1.70 
µM/Kd 2.6 µM and (d) WT CYP101B1 1.31 µM/Kd 28 µM. The concentration of the enzyme 
used in the binding studies and the dissociation constants (Kd) are provided. 
 
Turnovers of 1,5-dimethylnaphthalene with both H85F and WT CYP101B1 formed a sole 
metabolite (m+/z = 172.1; Figure 5. 42 and Figure D. 1). Whole-cell biotransformation of 1,5-
dimethylnaphthalene was used to generate this in sufficient yield and it was purified (~10 mg) 
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and identified as (5-methyl-1-naphthyl)methanol by NMR analysis (Figure 5. 42, Figure 5. 43 
and Figure D. 8-D. 9). The 1H NMR spectrum had a characteristic multiplet peak at 5.15-5.11 
ppm (m, 2H, 2xH11) enabling characterisation of (5-methyl-1-naphthyl)methanol (Figure 5. 





Figure 5. 42 (a) GC-MS analyses of the turnovers of 1,5-dimethylnaphthalene by both variants. 
1,5-Dimethylnaphthalene (RT 6.8 min) and the product (5-methyl-1-naphthyl)methanol (RT 
10.4 min). Impurities are labelled (*). (b) 1H NMR spectrum of (5-methyl-1-
naphthyl)methanol. Full data are in Appendix D (Figure D. 8-D. 9). 
 
Compared to 1,2 and 1,5-dimethylnaphthalene, 2,6-dimethylnaphthalene induced a lower spin-
state shift in both variants (20% and 10%; Figure 5. 44 and Table 5. 7). The dissociation 
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constant for 2,6-dimethylnaphthalene could not be determined due to low solubility and 
response of the spin-state shift to the addition of the substrate, suggesting weak binding.  
 
 
Figure 5. 43 The products identified from the WT and H85F CYP101B1 turnovers with 
alkylnaphthalenes 265, 266. 
 
 
     (a)                                                    (b) 
Figure 5. 44 Spin-state shifts (red) of (a) H85F and (b) WT variant after addition of 2,6-
dimethylnaphthalene.  
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The product formation activity and coupling efficiency of the H85F variant with this substrate 
were low (3 min-1 and 4%; Table 5. 7). Better activity was observed with the WT CYP101B1 
due to greater coupling efficiency (21% versus 4%). The oxidation of 2,6-dimethylnaphthalene 
by both variants formed one monooxygenase metabolite (m+/z = 172.2; Figure 5. 45, Figure D. 
1). A larger scale in vivo turnover of WT CYP101B1 was used to generate the metabolite in 
enough yield for characterisation. The product was extracted and purified (~21 mg) using silica 
column chromatography and analysed by NMR (Figure 5. 45 and Figure D. 10-D. 13). The 
presence of a single 3H benzylic peak and a characteristic 2H peak at 4.85 ppm in the 1H NMR 
spectrum indicated a methyl hydrogen was abstracted and this was the site of hydroxylation 
(Figure 5. 45, Figure 5. 43, and Figure D. 10-D. 13). The product was assigned as (6-methyl-





Figure 5. 45 (a) GC-MS analyses of the turnovers of 2,6-dimethylnaphthalene by H85F 
CYP101B1 (red) and CYP101B1 (black). 2,6-Dimethylnaphthalene (RT 6.4 min) and the 
product (6-methyl-2-naphthyl)methanol (RT 10.3 min). Impurities are labelled (*). (b) 1H 
NMR spectrum of (6-methyl-2-naphthyl)methanol. Full data in Appendix D (Figure D. 10-D. 
13). 
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2,7-Dimethylnaphthalene has been shown to induce a 30% high spin-state shift upon addition 
to WT CYP101B1 266. This was slightly reduced in the H85F variant (25%; Figure 5. 46). The 
NADH oxidation activity (87 ± 25 min-1) and product formation rate (6 min-1) of the H85F 
mutant enzyme were also slower than the WT enzyme which were in agreement with the lower 
spin-state shift observed (Table 5. 7) 266.   
 
     (a)                                                               (b) 
Figure 5. 46 Spin-state shifts (red) of (a) H85F and (b) WT CYP101B1 after addition of 2,7-
dimethylnaphthalene. 
 
The in vitro turnover of 2,7-dimethylnaphthalene with H85F variant generated a single 
metabolite (Figure 5. 47). That was confirmed as 2-(7-methylnaphthyl)methanol via GC-MS 
coelution with the in vitro turnover metabolite of WT CYP101B1, which was previously 
characterised by Emma A. Hall using NMR spectrum analysis (m+/z = 172.15; Figure 5. 43 
and Figure 5. 47, Figure D. 1, Figure D. 14) 233, 266. 
 
Figure 5. 47 GC-MS analysis of the turnover of 2,7-dimethylnaphthalene by H85F CYP101B1 
(red) and CYP101B1 (black). 2,7-Dimethylnaphthalene (RT 6.3 min) and the product 2-(7-
methylnaphthyl)methanol (RT 10.2 min). Impurities are labelled (*). 
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Acenaphthene is found in tobacco smoke and broiled food 269, 270. This substrate induced the 
heme spin to 60% high spin-state in the H85F variant but only 30% in the WT (Figure 5. 48). 
H85F variant bound acenaphthene with a higher affinity compared to the WT (Kd = 5.9 ± 0.6 
µM versus Kd = 20 ± 4 µM; Figure 5. 48). The NADH oxidation rate (531 min
-1 versus 165 
min-1) and product formation activity (245 min-1 versus 42 min-1) were also significantly greater 
for the H85F variant as was the coupling efficiency (48% versus 25%; Table 5. 7).  
 
 
(a)                                                   (b) 
 
(c)                                                  (d) 
Figure 5. 48 Spin-state shifts (left) and dissociation constants (right) of H85F and WT 
CYP101B1 with acenaphthene. Spin-state shifts (red) of (a) H85F CYP101B1 and (c) WT 
CYP101B1. The dissociation constants of (b) H85F 1.44 µM/Kd 5.9 µM and (d) WT 
CYP101B1 1.32 µM/Kd 20 µM. The concentration of the enzyme used in the binding assays 
and the dissociation constant (Kd) are provided. 
 
 
WT and H85F CYP101B1 mediated oxidation of acenaphthene resulted in a single metabolite. 
The H85F variant catalysed the oxidation with significantly higher yield, and the mass 
spectrum was indicative of a monooxygenase metabolite (m+/z = 170.0, Figure 5. 49 and Figure 
D. 1). The metabolite was generated in a sufficient amount by whole-cell oxidation system. 
This was purified (~16 mg) and characterised by NMR spectrum analysis (Figure 5. 43, Figure 
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5. 49 and Figure D. 16-D. 19). The 1H NMR spectrum displayed a distinct doublet peak at 5.75 
ppm, suggested hydroxylation occurred in the ethylene bridge connecting positions 1 and 8 of 
the naphthalene. Therefore, the product was identified as 1-acenaphthol (Figure 5. 43, Figure 
5. 49 and Figure D. 16-D. 19) 271. The enantioselectivity of the metabolite was investigated by 
chiral HPLC (Figure 5. 49). The WT and the H85F CYP101B1 generated a 70:30 and 60:40 
ratios of the enantiomers, respectively (Figure 5. 49). 
 
 




Figure 5. 49 (a) GC-MS analyses of the in vitro turnovers of acenaphthene by H85F (red) and 
WT (black) CYP101B1. Acenaphthene (RT 16.2 min) and the product; 1-acenaphthol (RT 18.8 
min). The chromatogram (CYP101B1; black) was offset along the x and y-axes for clarity (b) 
Chiral HPLC analysis of the in vitro turnover of acenaphthene by H85F CYP101B1 (red) and 
CYP101B1 (black), and a mixture of enantiomer of 1-acenaphthol was detected. Impurities are 
labelled (*). (c) 1H NMR spectrum of 1-acenaphthol. Full data are in Appendix D (Figure D. 
16-D. 19).
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WT CYP101B1 has been shown to have moderate activity for the oxidation of methyl biphenyl 
compounds and phenylcyclohexane 266. Phenylcyclohexane induced a similar spin-state shift 
in both variants of CYP101B1, but the oxidation activity for H85F variant was slower than the 
WT (Figure 5. 50 and Table 5. 8). The NADH oxidation (106 min-1 versus 293 min-1) and 
product formation rates (22 min-1 versus 141 min-1) were significantly reduced (Table 5. 8). 
The mutant also generated a lower level of oxidised metabolite (Figure 5. 51). A single product 
was observed in the turnover of phenylcyclohexane with both variants (Figure 5. 51). The 
metabolite has been identified as trans-4-phenylcyclohexanol, which was confirmed by GC-
MS coelution experiment with the turnover of WT CYP101B1 (m+/z = 176.15; Figure 5. 51, 
Figure 5. 55 and Figure D. 1) 175, 266. 
 
(a)                                                     (b) 




Figure 5. 51 GC-MS analyses of the turnovers of phenylcyclohexane by H85F (red) and WT 
(black) CYP101B1. Phenylcyclohexane (RT 6.9 min) and the product trans-4-
phenylcyclohexanol (RT 9.2 min) 175, 266. Impurities are labelled (*). The chromatogram 
(CYP101B1; black) was offset along the x and y-axes for clarity. 
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A higher spin-state shift (20%) and comparably slower NADH oxidation rate were measured 
for H85F mutant enzyme upon addition of biphenyl than the WT (Figure 5. 52 and Table 5. 8). 
However, this variant oxidised biphenyl with a higher product formation rate (23 min-1) and 
coupling efficiency (16%) than these of the WT enzyme (Table 5. 8). Both variants oxidised 
biphenyl into single monooxygenase metabolite that was identified as 4-phenylphenol by 
coeluting with an authentic standard in GC-MS (m+/z = 170.15; Figure 5. 52, Figure 5. 55 and 
Figure D. 1) 266. 
 
 
     (a)                                                     (b) 
 
    (c) 
Figure 5. 52 Spin-state shifts (red) of (a) H85F CYP101B1 and (b) WT CYP101B1 after 
addition of biphenyl. (c) GC-MS analyses of the turnovers of biphenyl by H85F CYP101B1 
(red) and CYP101B1 (black). Biphenyl (RT 5.9 min) and the product 4-phenylphenol (RT 
10.25 min; authentic standard: blue). Impurities are labelled (*).  
 
Methylbiphenyls with the substituent at the 2-, 3- and 4-positions were also investigated with 
the H85F mutant enzyme. All these substituted biphenyls induced a small type I spin-state shift 
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(≤30%) upon addition in the H85F mutant (Figure 5. 53). However, in all instances, the NADH 
oxidation and product formation rates were reduced for the H85F mutant versus the WT 
enzyme. The coupling efficiencies with the mutant were also lower (Table 5. 8).   
 
Both variants selectively oxidised 2- and 3-methylbiphenyl into a single metabolite arising 
from the benzylic C-H bond hydroxylation (Figure 5. 54). 2-Biphenylmethanol was confirmed 
by HPLC and GC-MS coelution experiments with an authentic standard (m+/z = 184.05; Figure 
5. 54, Figure 5. 55 and Figure D. 1). 
 
  (a)                                                    (b) 
 
  (c)                                                     (d) 
 
  (e)                                                      (f) 
 
Figure 5. 53 (left) Spin-state shifts (red) of H85F CYP101B1 after addition of (a) 2-
methylbiphenyl, (c) 2-methylbiphenyl, (e) 4-methylbiphenyl, and (right) spin-state shifts (red) 
of WT CYP101B1 with (b) 2-methylbiphenyl, (d) 2-methylbiphenyl and (f) 4-methylbiphenyl. 
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Table 5. 8 Substrate binding, turnover and coupling efficiency data for CYP101B1 (WT and 
the H85F variant) with phenylcyclohexane, biphenyl and substituted biphenyls 266. The in vitro 
turnover activities were measured as described in Table 5. 1. The data are reported as mean ± 
S.D. (n = 3) and rates are given in nmol.nmol-CYP–1.min–1. 
 
 
The oxidised metabolite of 3-methylbiphenyl was generated in a larger amount via the whole-
cell oxidation system, purified using silica column chromatography and identified by NMR 
analysis (Figure D. 15) 266. The characteristic 2H signal at 4.77 ppm (CH2OH) and the presence 
of nine hydrogens signals of the aromatic region in 1H NMR spectrum, allowed characterisation 
of the product as 3-biphenylmethanol (Figure D. 15) 266. The mass spectrum analysis was also 
in agreement with this assignment (m+/z = 184.10; Figure 5. 54, Figure 5. 55, and Figure D. 1) 
233, 266.  
 
GC-MS analysis showed that two metabolites were formed in the turnovers of 4-
methylbiphenyl by H85F CYP101B1. The products were identified by coelution experiment in 
GC-MS and HPLC with the in vitro turnover metabolites of WT CYP101B1 which were 
previously reported (Figure 5. 54 and Figure 5. 55) 233, 266. The H85F variant favoured the 
generation of 4-biphenylmethanol (95%), whereas WT generated 4′-(4-methylphenyl)phenol 












WT 175, 266 20 293 ± 9 141 ± 17 48 
H85F 20 106 ± 5 22 ± 1 21 
biphenyl 
WT 266 15 200 ± 10 8 ± 2 7 
H85F 20 154 ± 5 23 ± 1 16 
2-methylbiphenyl 
WT 266 20 257 ± 9 35 ± 8 14 
H85F 30 102 ± 9 17 ± 1 17 
3-methylbiphenyl 
WT 266 20 127 ± 10 30 ± 12 23 
H85F 20 81 ± 3 7 ± 0.5 8 
4-methylbiphenyl 
WT 266 20 176 ± 10 39 ± 7 22 
H85F 30 72 ± 8 5 ± 1 6 




       (a)                                                                         (b) 
     
                                        (c)                                                                     (d) 
 
Figure 5. 54 (a) GC-MS analyses of the turnovers of 2-methylbiphenyl by H85F (red) and WT 
(black) CYP101B1. 2-Methylbiphenyl (RT 7.6 min) and the product; 2-biphenylmethanol (RT 
10.0 min). (b) GC-MS analyses of the turnovers of 3-methylbiphenyl by H85F (red) and WT 
(black) CYP101B1. 3-Methylbiphenyl (RT 8.3 min) and the products; #3-phenylbenzaldehyde 
(RT 10.1 min) and 3-biphenylmethanol (RT 11.0 min). (c) GC-MS analyses of the turnovers 
of biphenyl by H85F (red) and WT (black) CYP101B1. Biphenyl (RT 5.9 min) and the product; 
4-phenylphenol (RT 10.25 min). (d) HPLC analysis of the turnover of 4-methylbiphenyl by 
H85F (red) and WT (black) CYP101B1. 4-Methylbiphenyl (RT 23.0 min) and the products; 4-
biphenylmethanol (RT 16.1 min, product 1) and 4´-(4-methylphenyl)phenol (RT 18.2 min, 
product 2) 233, 266. The chromatograms (products control and CYP101B1) were offset along the 
x and y-axes for clarity. Impurities are labelled (*).
 






Figure 5. 55 The products generated from the CYP101B1 and H85F CYP101B1 turnovers 





The results indicated that alkylbenzenes and certain methylnaphthalenes were better 
accommodated in the active site of the H85F mutant of CYP101B1. Many of these compounds 
induced a greater spin-state shift in the H85F mutant indicative of a better active site/substrate 
fit. In most instances, the H85F variant displayed a higher binding affinity with these substrates 
than the WT. Many of the hydroxylation reactions of these substrates were selective. Products 
were generated with higher catalytic activity with the H85F variant than they were with the 
WT enzyme. However, longer substrates including biphenyls and phenylcyclohexane 
displayed poor binding and lower activities with the H85F variant.  
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The coupling efficiencies and product formation rates for most of the tested alkyl substituted 
benzenes were higher with the H85F variant. In some occasions, this was despite a lower spin-
state shift. This suggests that the gating mechanism in CYP101B1 may be less stringent than 
is observed in other systems such as CYP101A1, which is in agreement with results obtained 
for other CYP101 family enzymes 47, 250, 273. Changes in the regio- and stereoselectivity of 
product formation were observed in certain substrate oxidations with the H85F mutant enzyme. 
In the oxidation of β-ionone, H85F variant was 90% selective for hydroxylation at the allylic 
C-H bond, generating 4-hydroxy-β-ionone in contrast to the WT enzyme which formed 3-
hydroxy-β-ionone in excess (90%). These selectivity changes indicate that the histidine 85 
residue of CYP101B1 must be in the active site or the access channel of CYP101B1, and that 
it interacts with the norisoprenoid substrate to control its binding orientation 175. The oxidation 
of ethylbenzene, alkylnaphthalenes, acenaphthene and indane were selective, and 
hydroxylation occurred at a benzylic C-H bond. The presence of substituents on the benzene 
ring altered the selectivity with the observation of competition between two alkyl substituents. 
The enzymatic oxidation of 2- and 3-ethyltoluene generated metabolites from oxidation at the 
less reactive methyl substituent which was consistent with the reactivity observed with p-
cymene, suggesting a preference for oxidation at benzylic methyl groups over longer and more 
branched chain alkyl groups. The oxidation of styrene resulted in epoxidation which was also 
consistent in other substituted styrenes. However, oxidation of β-methylstyrene to generate 3-
phenyl-2-propen-1-ol (cinnamyl alcohol) suggests that the allylic methyl group of β-
methylstyrene must be located significantly closer to the heme iron than the more reactive 
alkene. The increased flexibility and longer chain substrates such as n-propylbenzene resulted 
in preferential hydroxylation at the benzylic position though the major metabolite was the 
ketone further oxidation product. Isobutylbenzene hydroxylation was shifted to the tertiary β-
carbon, and the branching in the alkyl chain must alter the binding orientation of substrate in 
the vicinity of the heme iron. When incorporated into whole-cell biotransformation system, 
with the physiological electron transfer partners, ArR/Arx and the CYP101B1 H85F variant 
was capable of synthesising the oxidised metabolites of alkylbenzenes and naphthalenes in 
good yields for characterisation (18-33 mg of purified naphthalene metabolites were generated 
from 200 ml of culture after a 16 h reaction performed as described in the experimental section) 
265. 
The oxidation of o-, m- and p-xylene occurred without any observation of products arising from 
a 1,2-shift, and the oxidation of the longer alkylbenzene substrates displayed minimal 
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desaturation activity (<1%). There was also little or no oxidation at the aromatic ring. All of 
these reactions were observed with CYP102A1 267, 274, 275. The ability of  WT and H85F variant 
of CYP101B1 to favour hydroxylation at less reactive positions in certain substrates may make 
it a useful for future synthetic applications. Longer substrates such as phenylcyclohexane and 
biphenyls were poor substrates for the H85F variant which suggests that this mutation may 
result in less available space for substrate binding or difficult to accommodate into the binding 
pocket. H85A and H85G variants of CYP101B1 have also been investigated with different 
hydrophobic substrates, but they also exhibited lower binding affinity and oxidation activity 
compared to WT CYP101B1 with biphenyls 264. Mutations at other residues in the active site 
of CYP101B1 could be used to generate variants that could bind and oxidise these longer 
aromatic substrates efficiently. The active site of CYP101A1 has been modified, for example, 
glutamine 234 and isoleucine 237 of CYP101B1 align with leucine 244 and valine 247 which 
have been altered to increase the activity of CYP101A1 for unnatural substrates 143. These 
mutagenesis experiments could be expanded to enable the development of biocatalytic routes 
to synthesise fine chemicals arising from the oxidation of aromatic substrates 265. 
 
 




6. The Selective Oxidation of Alkyl Substituted Cubanes Using   
    CYP101B1 Enzyme 
6.1. Introduction 
 
Cubane (C8H8) is comprised of eight methine (CH) units arrayed in a cubic formation, resulting 
in a compact approximately, spherical molecular entity (Figure 6. 1) 276. The unnatural and 
unique geometry of cubane makes it highly strained in nature (SE = 161.5 kcal mol-1) and 
thermodynamically unstable (∆Hf = 144 kcal mol-1) 276-278. However, cubane and its derivatives 
are kinetically stable 276, 278-280.  
 
                                   Figure 6. 1 Three-dimensional views of cubane 281. 
 
Cubane has been hypothesised as a bioisostere for benzene due to its similar size and shape, 
and subsequently, several groups have reported that it can be used to develop new drug 
molecules with improved characteristics over existing candidates 282-284. Some cubane 
analogues have shown improved bioactivity than their benzene counterparts (Figure 6. 2) 277, 
284, 285. For example, different benzene containing drug derivatives and their cubane analogues 
were investigated to compare their activity (Figure 6. 2). Subacube and cubocaine performed 
identically to SAHA (suberoylanilide hydroxamic acid) and benzocaine, respectively (Figure 
6. 2). Diflucuburon also showed better bioactivity over its benzene counterparts (Figure 6. 2) 
277. One advantage of using cubane rather than benzene is that it would be less prone to phase 
I drug metabolism by cytochrome P450 enzymes, due to its strong C-H bond (BDE = 104 kcal 
mol-1; Table 6. 1) 276, 277, 286. The metabolism of cubane by P450 hydroxylation is decreased 
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due to the hindrance of tertiary C-H bonds and its high s orbital character 277, 285, 287. The 
oxidation of a phenyl ring by P450s proceeds via the addition of hydroxyl to the electron-rich 
π-moiety 287. For example, P450cam mediated oxidation of tert-butylcubane and tert-
butylbenzene generated only one metabolite (hydroxylation of the methyl group of tert-
butylcubane) and two metabolites (hydroxylation of the methyl and aromatic ring), respectively 
277. This is one of the proposed explanations for the better activity of diflucuburon over 
diflubenzuron 277. The presence of the eight-membered cubane cage also increases the 
lipophilicity of the drug molecule that allows easier transport across cell membranes 276. 
Furthermore, cubane is considered as a candidate for novel synthesis of fuels, propellants and 
explosives 276, 281. 
 
                            
                
Figure 6. 2 Cubane as a bioisostere for benzene 277, 285. The names for the cubane derivatives 
were based on the hypothetical brand name 277. 
 
The main drawback regarding the use of cubane was the availability of suitable cubane 
precursors to enable synthesis 277. This problem has been overcome by the discovery of large-
scale synthesis of dimethyl cubane-1,4-dicarboxylate, which can be generated on a kilogram 
scale 277. Recently several cubane drug derivatives were synthesised from the dimethyl cubane-
1,4-dicarboxylate precursor, using a wide range of organic chemistry methodologies and 
conditions to which the cubane core proved to be tolerant 277. Another disadvantage of using 
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cubane is functional-group placement and manipulation. New methods for functionalising of 
cubane substrates are required to synthesise potential biologically active pharmacophores and 
agrochemical molecules 277, 283, 288. 
  Table 6. 1 C-H Bond Dissociation Energies (BDE) and s orbital character of different 
substrates 289-293. 
Substrate BDE (kcal mol-1) % of S Character 
Cubane 104 30 
Benzene 111 33.3 
Cyclopropane 106.3 32 
Cyclobutane 99.8 27 
Cyclopentane 95.5 25 
Cyclohexane 100.0 25 
Cyclooctane 95.7 25 
Cyclononane 96.3 25 
Methane 104.3 25 
Ethane 101.2 25 
 
Stability of a bond is linked to the amount of s character as increasing this leads to stronger C-
H bonds 293, 294, 232. Cubane hydrogens (ca. 30% s character) are more readily abstracted by t-
butoxyl radicals than those of cyclopropane (ca. 32% s character) and surprisingly the 
hydrogens of the methyl group in methylcubane 295-297. Several groups have also reported 
oxidation of cubane using methyl(trifluoromethyl)dioxirane, and the selective halogenation of 
cubane by polyhalomethanes as halogen sources under phase-transfer (PT) conditions 298, 299. 
However, there are no reports of efficient and selective oxidation at the primary C-H bonds of 
the methyl group in methylcubane derivatives.  
 
Methylcubanes show interesting reactivity. Mammalian P450-mediated oxidation of 
methylcubanes generated a mixture of cubylmethanol, methylcubanols and other cationic 
rearrangement metabolites 84, 297. In principle, it can be oxidised at two types of C-H bonds 
either the methyl group or a C-H of the cube 84, 296, 297, 300. Radical intermediates would be 
formed during hydroxylation if a hydrogen atom is abstracted. The cubylcarbinyl radical can 
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rearrange rapidly to form different products (Figure 6. 3). If a cationic intermediate (4) is 
formed a distinct rearrangement to 1-homocubanol (5) would be possible (Figure 6. 3) 282. The 
rapid nature of the initial β-scission step (k = 2 x 1010 s-1) of the methylcubane derived radical 
(cubylcarbinyl), is one of the fastest reported radical reactions and enables methylcubane to be 
used as a radical clock 84, 177, 297, 298. The distinct radical and cation rearrangement metabolites, 
enable methylcubane to be used as a mechanistic probe for the identification of radical or 
cationic intermediates formed during the C-H oxidation reaction of P450s (Figure 6. 3) 84, 177, 




Figure 6. 3 Potential radical and cationic rearrangement products which could arise from P450 
oxidation reactions 282. 
 
For example, the methane monooxygenase (MMO) from Methylococcus capsulatus oxidised 
methylcubane to cubylmethanol and MMO from Methylosinus trichosporium OB3b gave rise 
to a mixture of metabolites such as cubylmethanol, methylcubanols and a radical rearrangement 
product (Figure 6. 4) 177, 297. The accurate and detailed analysis of the products was hampered 
due to the low rate, yield and selectivity of the reactions, the fragile nature of methylcubanols 
and the volatile nature of the substrate and products (Figure 6. 4) 301-303. The different 
metabolites observed in methylcubane oxidation by P450 and MMO systems have been 
rationalised via their reactive intermediates (heme versus non-heme) and substrate specificities 
84, 177, 297.  
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There is strong evidence that P450 enzyme hydroxylation occurs via iron(IV)oxo species 
(Compound I) through a radical rebound mechanism (Figure 1. 6) 2, 38, 73, 304. In certain studies 
products arising from cationic intermediates have been rationalised using a two-state model of 
P450 reactivity. Rather than using a second oxidant, such as hydroperoxo complex, Cpd 0 the 
precursor to Cpd I, the two-state model hypothesises that the reactive intermediate (compound 




Figure 6. 4 The reactions of various methane monooxygenase (MMO) and cytochrome P450 
(CYP) enzymes with methylcubane and their product distributions. a Reported as the acetate 
derivatives. The total yield of product in most instances was low (<25 μmoles product or <1% 
yield reported for the CYP reactions and that of MMO M. cap.) 301-303. Higher yields were 
reported with MMO Me. tri. (A yield of 5% was estimated) 301-303. Me. tri. Methylosinus 
trichosporium; M. cap. Methylococcus capsulatus. 
 
 
The selectivity and activity of CYP101B1 can be improved by the addition of carbonyl 
directing groups 176, 182. For example, CYP101B1 can regioselectively oxidise β-ionone, 
isobornyl acetate and 2-adamantyl acetate at a C-H bond on the opposite side of the cyclic ring 
system to the carbonyl-containing substituent 176, 182. In order to assess whether CYP101B1 
could be used to efficiently and selectively introduce a hydroxyl group at the methyl substituent 
of a methylcubane derivative, a series of cubane derivatives were designed and evaluated 
(Figure 6. 5).  





Figure 6. 5 Cubane derivatives used in this study with CYP101B1. All these cubane derivatives 
were synthesised and supplied by Sevan D. Houston (University of Queensland) using standard 
synthetic methods described in Appendix E. 
 
6.2. Results  
 
Addition of 4-methylcubane-1-methoxy carbonyl induced a 50% heme spin-state shift in 
CYP101B1 to the high spin form (Figure 6. 6). The NADH oxidation and product formation 
rates were determined to measure the catalytic activity. The NADH turnover rate was 438 ± 5 
min-1 (Table 6. 2). The amount of product was quantitated by calibrating the GC-MS detector 
response of 4-hydroxymethyl-cubane-1-methoxy carbonyl, and the product formation rate was 
155 min-1 (Table 6. 2). CYP101B1 system displayed a coupling efficiency of 36% for the 
oxidation of the 4-methylcubane-1-methoxy carbonyl (Table 6. 2). 





       Figure 6. 6 Spin-state shift of CYP101B1 with 4-methylcubane-1-methoxy carbonyl (red). 
 
 
GC (BID detector) and GC-MS analysis revealed that a single major product was generated in 
the small-scale in vitro turnovers of CYP101B1 with 4-methylcubane-1-methoxy carbonyl 
(Figure 6. 7 (a)). A larger scale turnover was also carried out with excess NADH (~4 mM) in 
order to generate enough metabolite for NMR analysis (Figure 6. 7 (b)). GC-MS analyses of 
these large-scale turnovers indicated that very little or no substrate remained. The same main 
product was detected in both small and large-scale turnovers by GC-MS. This was identified 
as 4-hydroxymethylcubane-1-methoxy carbonyl by GC-MS coelution experiment with an 
authentic standard (m+/z = 192.35; Figure 6. 7, Figure 6. 8 and Figure E. 7).  
 
The 1H NMR spectrum of turnover product (4-hydroxymethylcubane-1-methoxy carbonyl 
without purification) has two distinctive signals for the six hydrogens of the para-substituted 
cubane (in the range 3.70-4.16 ppm). In addition, there is also a 2H signal peak for the 
hydroxymethyl substituent at 3.76-3.78 (m, 2H, 2xH11), confirming the product identified by 
GC-MS coelution experiment (Figure 6. 8, Figure 6. 9 and Figure E. 8-E. 9). In the larger-scale 
turnovers, several minor metabolites were observed which could be assigned by MS analysis 
and/or coelution experiments. The small peak in GC-MS analysis at RT 5.4 min was confirmed 
as a 4-methylcubane-1-carboxylic acid via MS and coelution experiment with an authentic 
standard, which arises from ester hydrolysis of the substrate (m+/z = 162.0; Figure 6. 7 (b) and 
Figure 6. 7 (c)). Another minor peak at RT 8.16 min was labelled as the further oxidation 
product of 4-hydroxymethylcubane-1-methoxy carbonyl (m+/z = 190.15; Figure 6. 7 (b) and 
Figure 6. 7 (c)). The peak at 9.45 min in the larger-scale turnover has a MS and retention time 
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consistent with hydrolysis of the product ester (4-hydroxymethylcubane-1-carboxylic acid; 
Figure 6. 7 (b) and Figure 6. 7 (c)). Importantly the 1H NMR spectrum of the turnover product 
indicated no radical or cation rearrangement product or hydroxylation on the cubane C-H bonds 
(Figure 6. 7 and Figure E. 8-E. 9). 
 
 
 Table 6. 2 Substrate binding, turnover and coupling efficiency data for the CYP101B1 with 
4-methylcubane-1-methoxy carbonyl, 4-methylcubane-1-acetic acid methyl ester, 4-
ethylcubane-1-methoxy carbonyl, 4-methylcuban-1-yl acetate, 4-methylcubane-1-methyl 
ketone and 4-methylcubane-1-carboxylic acid. The in vitro turnover activities were measured 
using a ArR:Arx:CYP101B1 concentration ratio of 1:10:1 (0.5 μM CYP enzyme, 50 mM Tris, 
pH 7.4). N is the NADH oxidation rate, PFR the product formation rate and C is the coupling 
efficiency, which is the percentage of NADH utilised for the formation of products. The data 
are reported as mean ± S.D. (n = 3). Rates are given in nmol.nmol-CYP–1.min–1. a Measured by 
















4-methylcubane-1-methoxy carbonyl 50 438 ± 5 
 
155 ± 39 36 
 
 
4-ethylcubane-1-methoxy carbonyl 70 690 ± 28 298 ± 32 43 
4-methylcubane-1-acetic acid methyl ester 85 468 ± 7 189 ± 35 41 
4-methylcuban-1-yl acetate 60 374 ± 10 <10 <2.5 
4-methylcubane-1-methyl ketone 30 251 ± 10 <10 <5 
4-methylcubane-1-carboxylic acid <5 39a n.d. n.d 
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 (a)                                                                     (b) 
 
       (c) 
Figure 6. 7 (a) GC-MS analysis of the in vitro turnover of 4-methylcubane-1-methoxy 
carbonyl by CYP101B1. The turnover is shown in black, the product control (4-
hydroxymethylcubane-1-methoxy carbonyl) in blue and a control turnover where no NADH 
was added in red. Impurities have been labelled (*), as have #4-methylcubane-1-carboxylic acid 
(RT 5.4 min), and an additional impurity$ in the no NADH turnover. (b) GC-MS analysis of 
the in vitro larger scale turnover of 4-methylcubane-1-methoxy carbonyl by CYP101B1 using 
excess NADH. The large-scale turnover is overlaid with the product (4-hydroxymethyl-
cubane-1-methoxy carbonyl, blue) control. (c) The same larger scale turnover overlaid with a 
CYP101B1 turnover (blue) of the product control (4-hydroxymethylcubane-1-methoxy 
carbonyl), highlighting the formation of the further oxidation product labelled # (RT 8.16 min). 
4-Methylcubane-1-carboxylic acid (RT 5.4 min, #) was identified by MS and a coelution 
experiment with an authentic standard. It arises from ester hydrolysis of the substrate. The peak 
at 9.45 minutes# in the larger-scale turnover appears after all the substrate has been oxidised 
and has a MS and retention time consistent with hydrolysis of the product ester (4-hydroxy-
methylcubane-1-carboxylic acid). The chromatograms (b and c) have been offset along the x 
and y-axes for clarity. 





Figure 6. 8 1H NMR spectrum of 4-hydroxymethylcubane-1-methoxy carbonyl (4-
methylcubane-1-methoxy carbonyl turnover). The NMR experiment was performed without 
purification due to the low quantity of metabolite and available substrate. Full data are 





Figure 6. 9 Products identified after the oxidation of the substrates 4-methylcubane-1-methoxy 
carbonyl, 4-ethylcubane-1-methoxy carbonyl and 4-methylcubane-1-acetic acid methyl ester 
by CYP101B1. 
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The replacement of the methyl group with an ethyl substituent in 4-ethylcubane-1-methoxy 
carbonyl, induced slightly higher heme spin-state shift upon addition in CYP101B1 (% HS ~ 
70%; Figure 6. 10). The oxidation activity of CYP101B1 was also increased for this substrate 
with a faster NADH oxidation activity (690 min-1 versus 438 min-1), product formation rate 




  Figure 6. 10 Spin-state shift of CYP101B1 with the 4-ethylcubane-1-methoxy carbonyl (red). 
 
 
The in vitro oxidation of 4-ethylcubane-1-methoxy carbonyl by CYP101B1 was found to give 
a single product (Figure 6. 11). The metabolite was identified as 4-(1-hydroxyethyl)-cubane-
1-methoxy carbonyl by GC/GC-MS coelution experiment with an authentic standard (m+/z = 
206.45; Figure 6. 9, Figure 6. 11 and Figure E. 7). The MS fragmentation pattern of this 
turnover product indicated that the cubane structure remained intact (some important 
fragmentations 206.45, 191 (-CH3), 175 (-OH); Figure E. 7).  
 
There was no 2-hydroxyethyl product detected in these turnovers. The chiral GC analysis of 
the in vitro turnover of CYP101B1 and the standard 4-(1-hydroxyethyl)-cubane-1-methoxy 
carbonyl displayed a broad single peak at RT 23.8 min, hindering determination of the 
enantioselectivity of the reaction (Figure 6. 11 (b)). 
 
 




   (a)                                                                   (b) 
 
Figure 6. 11 (a) GC-MS analysis of the in vitro turnover of 4-ethylcubane-1-methoxy carbonyl 
by CYP101B1 in black and a control turnover where no NADH was added in red. The 
substrate: 4-ethylcubane-1-methoxy carbonyl (RT 6.05 min); the product: 4-(1-hydroxyethyl)-
cubane-1-methoxy carbonyl (RT 8.95 min). A peak with an MS consistent with $4-
ethylcubane-1-carboxylic acid was observed in the turnovers with or without NADH (RT 6.95 
min; m+/z = 175.2). Other impurities have been labelled (*). (b) Chiral GC analysis of the 
turnover of 4-ethylcubane-1-methoxy carbonyl by CYP101B1. 4-Ethylcubane-1-methoxy 
carbonyl (RT 16.3 min); a peak consistent with that of the hydrolysed substrate has been 
tagged, # 4-ethylcubane-1-carboxylic acid (RT 17.6 min), and the product: 4-(1-hydroxyethyl)-
cubane-1-methoxy carbonyl (RT 23.8 min). Impurities have been marked *. 
 
 
The addition of the 4-methylcubane-1-acetic acid methyl ester to CYP101B1 resulted in a more 
extensive shift than the 4-methylcubane-1-methoxy carbonyl, indicating a good 
substrate/active site fit (85% versus 50%; Figure 6. 13 and Table 6. 2). CYP101B1 catalysed 
the turnover of this substrate with a faster NADH turnover (468 ± 7 min-1) and product 
formation (189 ± 35 min-1) rates than those of 4-methylcubane-1-methoxy carbonyl and 4-
ethylcubane-1-methoxy carbonyl (Table 6. 2). The coupling efficiency was also improved 













A single major product was detected by GC-MS and GC analysis of the in vitro turnovers of 
CYP101B1 with the 4-methylcubane-1-acetic acid methyl ester (m+/z = 206.35; Figure 6. 13 
(a) and Figure E. 7). A larger scale in vitro turnover was carried out with an excess NADH to 
generate the metabolite in a sufficient yield for NMR characterisation (Figure 6. 13 (b) and 
Figure 6. 9). GC-MS analysis of this large-scale turnover displayed that very little or no 
substrate remained and that the same significant product observed in the smaller-scale turnover 
was present. Some minor metabolite peaks were detected which were assigned as the ester 
hydrolysis of the substrate, product and further oxidation of the initial product (Figure 6. 13 
(b)). Mass fragmentation patterns of the main product (m+/z = 206.35, 190.95 (-OH), 175.0 (-
CH3), 131.05 (-COO)) and minor products indicated that the cubane structure remained intact 
(Figure E. 7). The NMR spectrum of the extracted large-scale turnovers showed that the main 
product had two distinctive signals for six para-substituted hydrogens of cubane (in the range 
3.83-3.88 ppm and 3.71-3.76 ppm; Figure 6. 14 and Figure E. 10-E. 13). In addition, a 2H peak 
was present as expected for the hydroxymethyl substituent, δ 3.79-3.76 (m, 2H, 2xH12; Figure 
6. 14 and Figure E. 10-E. 13). The NMR spectrum for 4-methylcubane-1-acetic acid methyl 
ester turnover displayed no signals in the vinyl region or other signals that would indicate 
radical or cation rearrangement product(s) (cyclobutenes have distinctive peaks above 6 ppm) 
or hydroxylation on the cubane C-H bonds (Figure 6. 14 and Figure E. 10-E. 13). 
 
 




                                 
    (a) 
 
  (b) 
 
Figure 6. 13 (a) The GC-MS analysis of the small-scale turnover of 4-methylcubane-1-acetic 
acid methyl ester by CYP101B1. The turnover is shown in black, the control (the turnover 
without NADH) in red. The substrate 4-methylcubane-1-acetic acid methyl ester (RT 5.1 min); 
and the product 4-hydroxymethylcubane-1-acetic acid methyl ester (RT 9.0 min). A minor 
metabolite (RT 6.2 min; m+/z = 176.15; labelled, $) arising from the possible hydrolysis of the 
ester (4-methylcubane-1-acetic acid). (b) The GC-MS analysis of a large-scale in vitro turnover 
of 4-methylcubane-1-acetic acid methyl ester. All the substrate has been transformed into 
product. The minor product (RT 8.95 min #; m+/z = 204.0) has an MS consistent with an 
aldehyde further oxidation product and is only detected when all the substrate has been 
converted. Other possible minor peaks arising from hydrolysis of the ester (substrate and 
product) have been labelled, 6.0 min $ and 9.8 min #. Impurities are marked (*). 
 





Figure 6. 14 1H NMR spectrum of 4-hydroxymethylcubane-1-acetic acid methyl ester (4-
methylcubane-1-acetic acid methyl ester). The NMR experiment was performed without 
purification due to the low quantity of metabolite and available substrate. Some impurities were 
present in the NMR sample including the starting material, the aldehyde, further oxidation 
product, and hydrolysed product/starting material. Full data are provided in Appendix E 
(Figure E. 10-E. 13). 
 
 
4-Methylcuban-1-yl acetate induced a 60% shift of CYP101B1 to the high spin form (Figure 
6. 15 and Table 6. 2). 4-Methylcubane-1-methyl ketone effected a lower spin-state change 
(30%), while 4-methylcubane-1-carboxylic acid did not alter the spin-state (≤5%) significantly 
(Figure 6. 15 and Table 6. 2). The NADH turnovers with 4-methylcuban-1-yl acetate (374 min-
1) and 4-methylcubane-1-methyl ketone (251 min-1) were found to be slower than the substrates 
described previously, and the rate was lowest for 4-methylcubane-1-carboxylic acid (39 min-
1). Little or no product could be detected by GC-MS analysis after CYP101B1 mediated 
oxidation of 4-methylcubane-1-methyl ketone and 4-methylcubane-1-carboxylic acid and more 











                                  (a)                                                                      (b) 
 
 
                                                                        (c) 
 
Figure 6. 15 Spin-state shifts (red) of CYP101B1 with (a) 4-methylcuban-1-yl acetate, (b) 4-











  (a)                                                                  (b) 
 
       (c) 
 
Figure 6. 16 (a) GC-MS analysis of the turnover of 4-methylcuban-1-yl-acetate by CYP101B1. 
4-Methylcuban-1-yl-acetate (RT 3.9 min). There was a small amount of a possible hydroxy 
metabolite at RT 7.7 min (m+/z = 191.00). (b) GC-MS analysis of the turnover of 4-
methylcubane-1-methyl ketone by CYP101B1. 4-Methylcubane-1-methyl ketone (RT 4.2 
min). There is a small peak of a potential product at RT 8.35 min (m+/z = 175.25), and an 
unidentified metabolite at RT 5.3 min has been labelled as (#). (c) GC-MS analysis of the 
turnover of 4-methylcubane-1-carboxylic acid by CYP101B1. 4-Methylcubane-1-carboxylic 









CYP101B1 efficiently oxidised the methyl C-H bonds of certain cubane derivatives. 
Unexpectedly that no rearrangement products were detected. This may be due to significantly 
faster radical rebound than radical rearrangement. The rearrangement may be slower in these 
substituted cubane systems, or the substituted cubanes are not able to rearrange in the 
environment of the CYP101B1 active site. To address the question of the radical rearrangement 
rate, derivatives of the methoxycarbonyl substrate have been synthesised which could undergo 
Barton decarboxylation reactions (thiohydroxamate ester) and Barton-McCombie 
deoxygenation (imidazole thiocarbamate ester) (Figure 6. 17 and full data in Appendix E). 
 
imidazole carbamate ester                            4-hydroxymethylcubane-1-methoxy carbonyl 
                                                                                     and imidazole carbamate ester   
                                                                                            (3:2 inseparable mixture)                                       
 
 
                            thiohydroxamate ester                                thiophenol ester 
 
 
                              thiohydroxamate ester                               thiopyridine ether 
 
 
Figure 6. 17 Barton-McCombie deoxygenations and Barton decarboxylation to monitor radical 
rearrangement. No evidence of homocubane, and no significant alkene signals from a radical 
rearrangement product. All this synthetic work was performed by Sevan D. Houston 
(University of Queensland) using standard methods described completely in Appendix E. 
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The synthesised imidazole thiocarbamate ester was treated with the radical initiator 
azobisisobutyronitrile (AIBN) and Bu3SnH to yield 4-hydroxymethylcubane-1-methoxy 
carbonyl (34%) and an imidazole carbamate ester, 23% with a mixture of other unidentified 
products (Figure 6. 17 and Full data in Appendix E) 305. Irradiation of the thioxhydroxamate 
ester in the presence of thiophenol in anhydrous DCM, generated thiophenol ester (28%) and 
other impurities 306. Irradiation in deuterated benzene yielded a thiopryidine ether 12% (Full 
data in Appendix E) 306. All of the starting material was converted in this turnover and the other 
products formed could not be identified. Importantly, there was no evidence of homocubane, 
no significant alkene signals from a radical rearrangement product (potentially less than 5%) 
and no generation of the 4-methylcubane-1-methoxy carbonyl. Barton decarboxylation was 
used to synthesise 4-ethylcubane-1-methoxy carbonyl from the reaction of 4-
methoxycarbonylcuban-1-yl propanoic acid with oxalyl chloride, in which a radical at the β-
carbon would be generated 307. The reaction proceeded smoothly, yielding the product in 91% 
yield (Figure 6. 18 and Full data in Appendix E). 
 
                          
 
Figure 6. 18. Barton decarboxylation approach to synthesise 4-ethylcubane-1-methoxy 
carbonyl (described fully in Appendix E) 307. 
 
Minimal radical rearrangement products from these chemical reactions were observed. The 
cubylcarbinyl radical from the substituted cubane derivatives in these reactions may 
decompose to undetectable products. Alternatively, this could be because of the slower rate of 
radical rearrangement or greater instability of the radical or the radical rearrangement products 
of the tested cubane derivative. These chemical reactions indicated the substituted cubane 
framework is stable to radical conditions and the cubylcarbinyl radical is difficult to form 
compared to a typical alkyl radical.  
However, the P450 enzyme CYP101B1 is able to efficiently and selectively hydroxylate the 
substrates at the α-carbon C-H bonds in high yield with little or no rearrangement product 
arising from a radical or cationic intermediate.  
 4-methoxycarbonylcuban-1-yl 
         propanoic acid         
 4-ethylcubane-1-methoxy carbonyl 
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The mechanism of action of this enzyme is best explained by hydrogen abstraction to generate 
a radical intermediate (Figure 6. 19) 85. It is hypothesised the lifetime of this intermediate will 
vary depending on the spin-state of the Cpd I reactive intermediate 98, 308-310. Longer radical 
lifetimes (intermediates) are expected on pathways proceeding via the quartet state, on the other 
hand, the trajectory of doublet state is calculated to proceed in a barrier-less fashion via a short-
lived transition state 311. This could explain why radical rearrangement products after the 
enzymatic turnover are not observed. An alternative explanation could be that the enzyme 
active site sterically prevents the rearrangement pathway. However, CYP101B1 is capable of 
tightly binding and efficiently oxidising larger substrates than those tested here, e.g. 2-




Figure 6. 19 The proposed mechanism of the hydroxylation reactions of CYP101B1 with the 
4-methylcubane-1-methoxy carbonyl and 4-ethylcubane-1-methoxy carbonyl. 
 
 
Another alternative explanation is that of the cage effect proposed by Groves and coworkers. 
This involves the proximity of the substrate radical and metal centre in the confined space of 
P450 active site, which is hypothesised to affect the rates of rearrangement of monooxygenases 
38. After the initial hydrogen abstraction, a caged radical pair (FeIV-OH .R) can form containing 
the substrate radical (.R) and a reduced iron hydroxide (FeIV-OH; Figure 6. 20)  38, 312. If a water 
molecule or any protein functional group can insert or interfere with close proximity of the 
substrate radical and metal-centre (Fe-OH…H2O .R), a rearranged product could arise (Figure 
6. 20) 38, 312. Overall, the radical formed during P450 catalysed hydroxylation seems to possess 
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the characteristics of both an intermediate (cage escape) and a transition state (oxygen rebound 
without rearrangement) depending on the system. 
 
      
 
Figure 6. 20 An overview of the in-cage radical recombination and diffusive case escape 38, 
312. 
 
In summary, CYP101B1 was shown to be an efficient catalyst for the hydroxylation of cubane 
derivatives which have been designed to fit into the substrate binding pocket of the enzyme. 
The presence of an ester or ketone substituent on the cube promoted selective oxidation at the 
position opposite to the functional group. The directing group could place the methyl group 
close to the reactive iron-oxo species, resulting in hydroxylation solely at the methylcubyl 
group. This is notoriously difficult to achieve using chemical methodologies. Little or no 
methylcubanol or rearrangement metabolites were observed in these turnovers. These results 
support the kinetics of a putative radical rebound mechanism and argue against the involvement 
of any carbocation based mechanism in these oxidations. Further work is required to fully 
assess the nature of radical intermediates formed during the monooxygenase catalysed C-H 
hydroxylations of these and other cubane derivatives.




7. Futile Redox Cycling in Cytochrome P450 Electron Transfer   
    Systems Induced by Oxygenated Aromatics 
 
7.1.  Introduction 
 
P450 enzyme-mediated oxidation depends on several successive steps including electron 
transport and oxygen activation 313. P450s accept two electrons sequentially from NAD(P)H 
via redox partner(s) (Figure 1. 3). Instead of the productive utilisation of these reducing 
equivalents, they can be diverted to unproductive (futile) reactions which can generate 
cytotoxic reactive oxygen species (ROS). This phenomenon is called uncoupling which mainly 
arises from events at the P450 active site during oxygen activation by the heme centre (Figure 
1. 3) 71. Unproductive loss of the reducing equivalent can also occur between the electron 
transfer proteins. For example, the slow leaking of electrons in mitochondrial electron transfer 
system in the absence of substrate and the P450 enzyme has been reported 77, 78.  
 
Cytochrome P450s are one of the major classes of enzyme involved in the metabolism of 
different toxic chemicals 80. Many compounds including polycyclic aromatic hydrocarbons, 
arylamines, quinones, nitrofurantoin and naphthoquinones have been described to show 
enzyme-catalysed redox cycles in biological systems 81, 83, 314. Most of these substrates convert 
to reactive intermediates by accepting one electron and are able to transfer the electron to 
molecular oxygen to form a toxic superoxide anion radical 81, 83, 314. This superoxide anion 
radical can dismutate to form hydrogen peroxide and singlet oxygen 81. Most of these 
compounds induce oxidative stress and DNA damage which are the leading cause of 
cytotoxicity, mutagenicity, and carcinogenicity 81, 316-318. However, many anticancer drugs and 
antitumor therapies are effective through a redox cycling mechanism 319, 320. Studies have 
demonstrated that many of these substrates can inhibit and inactivate the function of 
mammalian P450s 80, 81-83. For example, they impede the enzyme activity by facilitating the 
uncoupling process through redox cycling in microsomal cytochrome P450 reductase and 
cytochrome b5 reductase 81-83. NADPH cytochrome P450 reductase is the enzyme that transfers 
electrons to the microsomal P450 enzymes. It can initiate a futile redox cycle by donating an 
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electron to a quinone, a process that interferes with the electron flow to the P450s and inhibits 
monooxygenase activity 83, 321. NADH cytochrome b5 reductase, an electron transfer protein 
of cytochrome b5, also displayed a similar type of activity in the presence of redox-active 
chemicals 83.  
Most bacterial P450s get the reducing equivalents for catalysis from NAD(P)H through a 
flavin-containing reductase (ferredoxin reductase) and iron-sulfur protein (ferredoxin) 46, 47.  
The mitochondrial P450s use a similar system consisting of an adrenodoxin reductase and 
adrenodoxin in which only adrenodoxin is soluble, and the reductase and P450 enzyme are 
bound with the membrane (Figure 1. 5) 44, 46, 47. Ferredoxin/adrenodoxin reductase first receives 
two electrons from NAD(P)H and transfer the electrons one at a time from the flavin cofactor 
to the iron-sulfur clusters of ferredoxin/adrenodoxin. This then acts as a carrier and delivers 
the electrons one at a time to the active site of the P450.  
  
Exogenous substrates which can mediate uncoupling during the transfer of electrons from 
nicotinamide cofactors to the P450, have not been described in detail with bacterial or 
mitochondrial electron transfer systems 71, 322-324. In the present study, the ability of bacterial 
P450 electron transfers system containing ferredoxin [2Fe–2S] to catalyse the redox cycling 
with different oxygenated aromatics including naphthalene and naphthoquinone derivatives, 
were investigated (Figure 7. 1). The investigation of these aromatic compounds with bacterial 
and mitochondrial P450 systems and their electron transfer partners could enable to determine 
if this process interferes with electron flow from NAD(P)H to P450s. This is likely to have an 
important implication for understanding how this class of compounds inhibit the activity of 
bacterial and mitochondrial P450 systems. 
 
                            Figure 7. 1 Oxygenated aromatics used in the current study. 
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7.2.  Results  
 
The reaction of CYP101B1 system with naphthalene has previously been described 233. 
Naphthalene did not induce a significant spin-state shift (20%) on binding to CYP101B1. 
However, the NADH turnover rate was reasonably fast (90 min-1) and increased over the course 
of the reaction (Figure 7. 2) 233, 266. Minimal levels of naphthol metabolites or any others were 
detected in GC/GC-MS analysis (Figure 7. 2) 266. CYP101B1, therefore, oxidised naphthalene 
with a low product formation rate and coupling efficiency. Even when an excess of NADH (~4 
to 6 mM) was added, only low levels of 1-naphthol were detected 233, 266. 
 
To investigate the cause of the increasing NADH oxidation rate over time in the presence of 
naphthalene, both naphthols were screened as substrates. Addition of 1-naphthol and 2-
naphthol shifted the spin-state of CYP101B1 to the high spin form: 60% and 40%, respectively 
266. The binding affinities were also determined and reported by Emma A. Hall (Dissociation 
constants; 165 μM and 195 μM, respectively) 266. The NADH oxidation rate of a fully 
constituted CYP101B1/ArR/Arx system with 1-naphthol was four-fold higher than 2-naphthol 
(2090 versus 560 nmol. nmol. P450-1 min-1; Figure 7. 3).  
 
 
  (a)                                                                 (b) 
 
Figure 7. 2 (a) UV-Vis NADH oxidation assay of CYP101B1 with naphthalene.  (b) GC-MS 
analysis of turnover of naphthalene by CYP101B1 using excess NADH (black) overlaid with 
the turnover of 1-naphthol (red) and 2-naphthol (blue) 233, 266. The inset shows a more detailed 
view of the region where 1- and 2-naphthol elute (RT 11.0 min and RT 11.15 min). 
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No metabolites were detected in the GC-MS analysis of these in vitro turnovers of 1-naphthol 
and 2-naphthol. However, with excess NADH (~ 4 mM) low levels of metabolites were 
detected in GC-MS analyses of both substrates (Figure 7. 4) 266. The oxidation of 1-naphthol 
by CYP101B1 generated one metabolite which was assigned as 1,4-naphthoquinone via mass 
spectrometry and GC-MS coelution with an authentic commercial standard 233, 266. CYP101B1 
oxidised 2-naphthol into 2,6-dihydroxynaphthalene which was identified by a GC-MS 
coelution experiment and analysis of the mass spectrum (Figure 7. 4). No evidence of 2-
naphthol or 2,6-dihydroxynaphthalene was detected in the turnovers of naphthalene by 
CYP101B1. The quantities of unreacted naphthalene and naphthol substrates remained high in 
turnovers with excess NADH (~4 mM). Therefore, other oxidation products, such as those 
arising from oxidative aryl coupling also do not seem to appear in a significant amount 325-327.  
 
Control turnovers without the CYP101B1 enzyme were also carried out. The NADH oxidation 
rate in the presence of just the electron transfer proteins ArR and Arx with 1-naphthol (1 mM) 
was 1560 min-1, and 2-naphthol (1 mM) was 871 min-1 (Table 7. 1 and Figure 7. 3). The NADH 
oxidation activity was dramatically reduced in the absence of both Arx and CYP101B1 (Figure 
7. 3). The assays indicated that the NADH rate acceleration observed in the naphthalene 
turnovers might arise from transfer of electrons from ferredoxin, Arx, to the oxygenated 
substrates (or an impurity present in these substrates). 
 
 
Figure 7. 3 NADH oxidation assays of CYP101B1 with 1-naphthol (red), 1-naphthol no P450 
control (blue) and 1-naphthol, no Arx and P450 control (black) 233, 266. 
 
 




(a)                                                                          (b) 
 
 
Figure 7. 4 (a) GC analysis of the turnover of 1-naphthol (black) and a control of 1,4-
naphthoquinone (red) 233, 266. (b) GC analysis of the turnover of 2-naphthol (black) and controls 
of 1,7-dihydroxynaphthalene (red), 2,6-dihydroxynaphthalene (blue) and 2,7-
dihydroxynaphthalene (magenta) 233, 266. Emma A. Hall did these analyses. Repeating these 
experiments showed similar activity and product formation. The inset shows the region where 
the products elute in more detail. Impurities are labelled (*). 
 
Table 7. 1 The NADH oxidation rates of CYP101B1/Arx/ArR system and only Arx/ArR with 
naphthalene, 1-naphthol and 2-naphthol. The in vitro turnovers were measured using a 
ArR:Arx:CYP101B1 concentration ratio of 1:10:1 (0.5 μM CYP enzyme, 50 mM Tris, pH 7.4). 
a The P450 enzyme was omitted in the turnover. Rates are given in nmol. nmol. P450-1 min-1 
in the presence of P450 enzyme (Note for ease of comparison the NADH oxidation rates 
provided in the main text in the absence of the P450 enzyme are given in the same units as 
if the P450 enzyme was present) 233, 266. b The initial rate of NADH oxidation as the rate 
increased over time. 
 
Substrate NADH oxidation rate 266  NADH oxidation rate a 
naphthalene  90 b - 
1-naphthol 2090  1560 
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1,4-Naphthoquinone was screened as a substrate, which induced a rapid NADH oxidation rate 
in CYP101B1 system at 0.5 mM concentration (2334 min-1; Table 7. 2). The addition of 1,4-
naphthoquinone also resulted in very fast NADH oxidation rate in the absence of CYP101B1. 
This occurred even when this substrate was present in very low concentration (~4 µM of 
substrate; 1305 min-1, 50 nM; 321 min-1; Table 7. 2). Analysis of these turnovers by GC-MS 
showed no product arising from the monooxygenase activity of CYP101B1. The majority of 
the reducing equivalents in both systems containing the P450 and/or electron transfer proteins 
ended up as hydrogen peroxide (as measured by the standard procedure described in the 
experimental chapter; Table 7. 2) 181. 
 
The high NADH oxidation rate upon addition of 1,4-naphthoquinone suggested that the 
acceleration of the NADH oxidation rate in the case of naphthalene in CYP101B1/ArR/Arx 
turnover could be due to the presence or generation of a small amount of 1,4-naphthoquinone. 
CYP101B1 first oxidised the naphthalene to 1-naphthol followed by further oxidation to the 
1,4-naphthoquinone. The presence of 1,4-naphthoquinone either as an impurity or oxidation 
product of 1-naphthol turnovers may be the reason for the acceleration of the NADH oxidation 
rate. Instead of acting as a substrate or promoting established P450 uncoupling pathways, 1,4-
naphthoquinone receives electrons from ferredoxin (Arx) and converts to the semiquinone 
form. This can then donate an electron to molecular oxygen to form superoxide with the 
semiquinone reverting to the parent quinone 328. The cytotoxic superoxide could spontaneously 
dismutate to hydrogen peroxide and singlet dioxygen. These steps would inhibit the productive 
activity of P450 by removing the reducing equivalents from the monooxygenase enzyme 
(Figure 7. 5) 81, 83, 328. This activity was similar to that reported for NADPH cytochrome P450 
reductase (FAD/FMN cofactors) discussed above (Figure 7. 5) 77, 81. Overall, this resulted in 
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Table 7. 2 The NADH oxidation rates of CYP101B1/Arx/ArR system and only Arx/ArR with 
1,4-naphthoquinone. The rates were measured and reported same as described in Table 7. 1. 
The added NADH concentration (μM), NADH oxidation rate and hydrogen peroxide 
concentration (μM) are given. [a] The turnovers containing CYP101B1 are provided in the 
brackets. The P450 enzyme was omitted in all other turnovers. In certain instances, the detected 
levels of hydrogen peroxide were higher than the theoretical maximum value. This is most 





 conc. (µM) 
NADH oxidation  
rate  
H2O2 
conc. (µM)  
500 
344 3180 462 
(328) a (2334) a (413) a 
50 
336 2572 486 
(323) a (2186) a (517) a 
8 326 2755 486 
4 303 1305 407 
0.5 314 321 279 
0.2 317 128 187 
0.1 309 125 231 
0.05 306 122 182 
    
    
 
                             
                       Figure 7. 5 Enzymes mediated futile redox cycling 83, 329, 330. 
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In order to investigate how this futile redox cycle inhibits the product formation activity of 
CYP101B1, 2-adamantyl acetate and 1-naphthol were used together in fully reconstituted 
CYP101B1 turnovers. Addition of 1-naphthol and 2-adamantyl acetate induced the spin-state 
shift to 60% and 90% high spin form in CYP101B1, respectively. 2-Adamantyl acetate bound 
very tightly with CYP101B1, and 1-naphthol displayed a weaker binding affinity (Kd = 1.9 µM 
versus Kd = 165 µM) 
182, 266. CYP101B1 oxidised 2-adamantyl acetate with a NADH oxidation 
rate of 1170 min-1, product formation rate of 877 min-1 and a high coupling efficiency of 75% 
(Table 7. 3) 182. However, in the presence of 1-naphthol (1000 µM) the product formation 
diminished to 264 min-1 and a coupling efficiency reduced to 15% despite rapid NADH 
oxidation rate (1723 min-1). A minimal amount of 1,4-naphthoquinone was observed either as 
an oxidation product of 1-naphthol or impurity. CYP101B1 turnovers with 2-adamantyl acetate 
showed progressively higher product formation activities and coupling efficiencies as the 
concentration of 1-naphthol was decreased (Table 7. 3 and Figure 7. 6).  
 
Table 7. 3 The NADH oxidation rates of CYP101B1 with 2-adamantyl acetate in the presence 
of 1-naphthol. The rates were measured using a ArR:Arx:CYP101B1 concentration ratio of 
1:10:1 (0.5 μM CYP enzyme, 50 mM Tris, pH 7.4). 2-Adamantyl acetate concentration was 








Coupling         
   efficiency (%) 
1000 1723 264 15 
500 1550 281 18 
125 1061 490 46 
62.5 814 456 56 
31 813 448 55 
15 798 547 67 
0 1170 877 75 
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(a)                                                                      (b) 
 
Figure 7. 6 (a) GC-MS analyses of the in vitro turnovers of 2-adamantyl acetate with 
CYP101B1/ArR/Arx system in the presence of different concentrations of 1-naphthol. The 
internal standard; p-cresol, RT 2.10 min (not shown); 1,4-naphthoquinone#, RT 6.2 min; 2-
adamantyl acetate, RT 6.8 min, 1-naphthol, RT 7.3 min and the product; 5-hydroxy-2-
adamantyl acetate, RT 8.9 min 182. The internal standard was added to 0.2 mM in all cases, and 
the product concentration was determined via the procedure described in the experimental 
chapter. (b) Zoom of the 8.5 to 10 min region to highlight the product peaks. For clarity, the 
chromatograms (a and b) were offset along the x and y-axes. 
 
 
To assess the effect of 1,4-naphthoquinone on the inhibition of CYP101B1/Arx/ArR 
monooxygenase activity, this substrate was investigated with 2-adamantyl acetate. When 1,4-
naphthoquinone (0.1 mM) and 1-adamantyl acetate (1.0 mM) were added together to the 
CYP101B1/Arx/ARr system, the product formation activity diminished to ~4 min-1 (Table 7. 
4). This was despite a fast NADH oxidation activity of 2032 min-1 (Table 7. 4 and Figure 7. 7). 
Overall the productive utilisation of the NADH reducing equivalents decreased from 75% to 
0.17%. The product formation rates and use of reducing equivalents (coupling efficiency) of 
CYP101B1 were low even when minimal amounts (~1 µM) of 1,4-naphthoquinone were used. 
The concentration of 1,4-naphthoquinone and the product formation activity of CYP101B1 
system with 2-adamantyl acetate exhibited a linear relationship. Increasing the 1,4-
naphthoquinone level in the system decreased the product formation activity (Table 7. 4 and 
Figure 7. 7). In all cases the NADH consumption rates were rapid, and these suggested that the 
naphthoquinone interferes with the transfer of reducing equivalents from Arx to CYP101B1. 
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Table 7. 4 The NADH oxidation rates of CYP101B1 with 2-adamantyl acetate in the presence 
of 1,4-naphthoquinone. The rates were determined using a ArR:Arx:CYP101B1 concentration 
ratio of 1:10:1 (0.5 μM CYP enzyme, 50 mM Tris, pH 7.4). The 2-adamantyl acetate 
concentration was used 1000 μM in all the turnovers. Rates are given in nmol. nmol. P450-1 




NADH oxidation rate 
(CYP101B1) 
Product 
formation rate  
Coupling   
efficiency (%) 
100 2032 4 0.17 
20 1807 37 2 
5 916 222 24 
2 704 269 38 
1 633 279 44 
    
 
  (a)                                                                         (b) 
Figure 7. 7 (a) GC-MS analyses of in vitro turnovers of 2-adamantyl acetate with the 
CYP101B1/ArR/Arx system in the presence of different concentrations of 1,4-
naphthoquinone. The internal standard; p-cresol, RT 2.15 min; 1,4-naphthoquinone#, RT 6.3 
min; 2-adamantyl acetate, RT 6.9 min, and the product; 5-hydroxy-2-adamantyl acetate, RT 
9.1 min 182. The chromatograms were slightly shifted due to GC-MS method change. The 
internal standard was added to 0.2 mM in all cases, and the product concentration was 
determined via the procedure described in the experimental chapter. (b) Zoomed in version of 
the 9 to 9.75 min region to highlight the product peaks. For clarity, the chromatograms (a and 
b) were offset along the x and y-axes. 
Chapter 7                                                                                                    Futile Redox Cycling 
 
231 
2-Methyl-1,4-naphthoquinone, also known menadione or vitamin K3, is a toxic quinone 
usually used to investigate the mechanisms underlying oxidative injury 83, 329, 331-333. Menadione 
acts as a potent inhibitor of different P450 mediated metabolism 329, 334. For example, in the 
presence of menadione, quinone redox cycling inhibited the reduction of cytochrome b5 by 
cytochrome b5 reductase and this activity together with generating the cytotoxic reactive 
oxygen species might be the leading cause of tissue injury in the presence of this substrate 83. 
Addition of menadione (500 µM) to CYP101B1 in vitro turnover system induced a fast NADH 
oxidation rate (2350 min-1) similar to that observed with 1,4-naphthoquinone. The control 
turnover without P450 showed a similarly high NADH oxidation rate (2360 min-1). The rapid 
oxidation of NADH occurred at concentrations as low as 5 μM (296 min-1; Table 7. 5). No 
menadione metabolite was detected in GC-MS analyses of any of the turnovers containing the 
P450. Large amounts of reducing equivalents ended up as hydrogen peroxide due to futile 
redox cycling in the absence and presence of CYP101B1 (Table 7. 5).  
 
Table 7. 5 The NADH oxidation rates of CYP101B1/Arx/ArR system and only Arx/ArR with 
menadione. The rates were measured and reported same as described in Table 7. 1. [a] The 
NADH oxidation concentration, NADH oxidation rate and hydrogen peroxide concentration in 
the presence of CYP101B1 are provided in the brackets. The P450 enzyme was omitted in all 




 conc. (µM) 
NADH oxidation rate  H2O2 
conc. (µM)  
500 
314 2360 298 
(305) a (2350) a (268) a 
200 306 2357 274 
50 314 2000 311 
20 307 2026 328 
5 307 1113 273 
2 331 1119 233 
0.5 320 296 103 
0.2 344 97 10 
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Menadione was also screened in the presence of the substrate 2-adamantyl acetate to investigate 
how this quinone inhibits the monooxygenase activity of the CYP101B1/Arx/ArR system. 
Addition of 100 µM of menadione significantly diminished the productive activity of this 
system with the product formation rate (2-adamantyl acetate) decreasing from 877 min-1 to ~ 5 
min-1 (Table 7. 6). Product formation activity of this P450 system remained low in the presence 
of menadione even at a concentration of 5 µM despite the relative fast NADH oxidation rates 
observed in each turnover (Table 7. 6 and Figure 7. 8). Results of the current study indicate 
that menadione can also act as an electron acceptor from Arx (Figure 7. 8) 335. Thus the 
metabolism of 2-adamantyl acetate by CYP101B1 is decreased due to the interruption of 
electron transfer from NAD(P)H to CYP101B1 via Arx/ArR system 335. A similar type of 
inhibition by menadione has also been reported for P450s including CYP1A2, CYP2B6 and 
CYP3A4 mediated metabolism of parathion and aniline hydroxylase that catalysed the 
hydroxylation of p-aniline 329, 335, 336. Menadione inhibits the activity of these mammalian 
enzymes through the NADPH-Cytochrome P450 reductase-mediated futile redox cycling, 
which preferentially uses the electrons from NADPH instead of delivering to the active site of 
the enzymes 329, 335, 336. In this process, the reduction of oxygen also leads to the formation of 
reactive oxygen species (ROS) 328, 337. 
 
Table 7. 6 The NADH oxidation rates of CYP101B1 with 2-adamantyl acetate in the presence 
of menadione. The oxidation rates were determined using a ArR:Arx:CYP101B1 concentration 
ratio of 1:10:1 (0.5 μM CYP enzyme, 50 mM Tris, pH 7.4). The concentration of 2-adamantyl 
acetate was used 1000 μM in all turnovers. Rates are given in nmol. nmol. P450-1 min-1. No 










Coupling   
efficiency 
(%) 
100 2064 4.5 0.22 
20 1860 0.3 0.016 
10 1476 10.4 0.71 
5 1254 77.4 6.2 
0.1 839 357 42.5 
 





                               
 (b) 
 
Figure 7. 8 (a) GC-MS analyses of the in vitro turnovers of 2-adamantyl acetate with 
CYP101B1/ArR/Arx system in the presence of different concentrations of menadione. The 
internal standard; p-cresol, RT 2.15 min; 2-adamantyl acetate, RT 6.9 min, menadione, RT 7.8 
min; and the product; 5-hydroxy-2-adamantyl acetate, RT 9.1 min 182. The internal standard 
was added to 0.2 mM in all cases. (b) Zoomed in 7.5 to 10.0 min region to highlight the product 
peaks. For clarity, the chromatograms (a and b) were offset along the x and y-axes. 
 
 
Vitamin K1 (Phytonadione) shares the quinone backbone of menadione and  1,4-
naphthoquinone. Addition of vitamin K1 (250 µM) to the CYP101B1 system induced a lower 
NADH oxidation rate (103 min-1) than either menadione or 1,4-naphthoquinone (Table 7. 7). 
This could potentially be due to lower solubility of vitamin K1 in aqueous solution. GC-MS 
analysis of the in vitro turnovers showed that CYP101B1 generated no metabolite. Most of the 
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reducing equivalents were again converted to H2O2 as a result of futile redox cycling.  Assays 
were performed without the P450, and the NADH oxidation rate was similar to that described 
above. Most of the reducing equivalents were diverted to hydrogen peroxide. When the 
concentration of vitamin K1 was decreased to 100 µM, the NADH oxidation rate was reduced, 
but high levels of hydrogen peroxide were still detected. Overall, these results show that 
vitamin K1 is also capable of accepting electrons from NAD(P)H via Arx and involved in the 
futile redox cycling 335. 
 
Table 7. 7 The NADH oxidation rates of CYP101B1/Arx/ArR system and only Arx/ArR with 
vitamin K1. The rates were measured and reported same as described in Table 7. 1. a The 
NADH oxidation concentration, NADH oxidation rate and hydrogen peroxide concentration in 
the presence of CYP101B1 are provided in the brackets. The P450 enzyme was omitted in all 
the other turnovers.  
 
Vitamin K1  
conc. (µM) 
NADH 
 conc. (µM) 
NADH oxidation  
rate  
H2O2 
conc. (µM)  
250 
314 84 298 
(306) a (103) a (268) a 
100 306 52 294 
 
 
CYP101B1 oxidised 2-naphthol to generate 2,6-dihydroxynaphthalene (Figure 7. 4 (b)) 266. 
Therefore, this diol was also examined as a substrate of CYP101B1 and to asses if this 
metabolite also could inhibit the catalytic activity of this enzyme system. 2,6-
Dihydroxynaphthalene induced a NADH oxidation rate of 1045 min-1 in the turnover of 
CYP101B1 system (Table 7. 8). GC-MS analysis showed no detectable product arose from this 
turnover. The NADH oxidation rate was greater when 2,6-dihydroxynaphthalene was added to 
a turnover where P450 was omitted (Table 7. 8). Hydrogen peroxide assays showed that most 
of the reducing equivalents ended up as hydrogen peroxide. However, it should be noted that 
in certain instances the detected levels of hydrogen peroxide were higher than expected. This 
is most likely due to the phenolic substrate interfering with the H2O2 assays which also use 
phenol as a substrate.  
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Table 7. 8 The NADH oxidation rates of CYP101B1/Arx/ArR system and only Arx/ArR with 
2,6-dihydroxynaphthalene. The rates were measured and reported same as described in Table 
7. 1. a The turnover with the presence of CYP101B1 was shaded. The P450 was omitted in all 
the other turnovers. Rates are given in nmol. nmol. P450-1 min-1. -not determined. - detected 






NADH oxidation  
rate  
H2O2 
conc. (µM)  
500 a 301 a 1045 a 243 a 
250 302 1704 255 
100 - 1611 - 
50 - 1518 - 
10 - 1405 - 
5 - 1138 - 
0.5 - 360 - 
 
 
To determine whether 2,6-dihydroxynaphthalene is also an inhibitor of CYP101B1-mediated 
metabolism of 2-adamantyl acetate, this diol (1000 µM) and 2-adamantyl acetate (1000 µM) 
was added together in the CYP101B1/Arx/ArR system, the amount of product formation 
decreased 44-fold. Only 1% substrate was converted to product whereas in the normal turnover 
the conversion was 44% (Figure 7. 9). When the concentration of the diol reduced to 100 µM 
in the CYP101B1 turnover assay, the product formation activity was diminished to 198 min-1 
from 877 min-1, despite a fast NADH oxidation rate (855 min-1). The product formation activity 
was nearly 3-fold lower when the concentration of 2,6-dihydroxynaphthalene was reduced to 
20 µM than the normal 2-adamantyl acetate turnover without 2,6-dihydroxynaphthalene 
(Figure 7. 9). 2,6-Dihydroxynaphthalene induced fast NADH oxidation rates in the absence of 
CYP101B1 and generated excessive amounts of hydrogen peroxide in each turnover. Addition 
of this substrate facilitates futile redox cycling in the turnovers, and this may be due to the 
presence of small amounts of 2,6-naphthoquinone. Further study with 2,6-naphthoquinone 
could be attempted to fully understand the futile redox cycle and intermediates formed in the 
2,6-dihydroxynaphthalene turnovers. 




                                   (a)                                                                      (b) 
 
Figure 7. 9 (a) GC-MS analyses of the in vitro turnovers of 2-adamantyl acetate with the 
complete CYP101B1 system in the presence of different concentrations of 2,6-
dihydroxynaphthalene. The internal standard; p-cresol, RT 2.15 min; 2-adamantyl acetate, RT 
6.9 min, the product; 5-hydroxy-2-adamantyl acetate, RT 9.1 min, and 2,6-
dihydroxynaphthalene, RT 11.8 min 182. The internal standard was added to 0.2 mM in all 
cases. (b) Zoomed in 7.5 to 10.0 min region to highlight the product peaks. The percentage of 
total amount of substrate (2-adamantyl acetate) converted to product in the presence or absence 
of 2,6-dihydroxynaphthalene were also given. For clarity, the chromatograms (a and b) were 
offset along the x- and y-axes. 
 
 
Phenolic compounds such as alkylmethoxy phenols, flavonoids and catechin have been shown 
to inhibit the activity of P450 by forming cytotoxic quinoid and/or quinone methides species 
through redox cycling 330, 338-341. In the current study, 3-methoxyphenol was investigated. 
Addition of 3-methoxyphenol (2000 µM) in the turnover mixture without CYP101B1 induced 
a high NADH oxidation rate (1814 min-1; Table 7. 9). The NADH oxidation rates were fast at 
different concentrations without P450, and a high amount of hydrogen peroxide was detected 
in all cases (Table 7. 9). These NADH oxidation rates and a large amount of hydrogen peroxide 
without the presence of CYP101B1 indicated 3-methoxyphenol or an impurity in the sample 
could also act as a redox active chemical. 
 
6-Methoxy-1-tetralone is a bicyclic aromatic hydrocarbon. The NADH oxidation rates were 
lower with 6-methoxy-1-tetralone in Arx/ArR system with no CYP101B1 than the 3-
methoxyphenol. However, again, high levels of hydrogen peroxide were generated in these 
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turnovers (Table 7. 9). The findings suggest that these substrates may accept electrons from 
redox proteins and convert to a radical anion. This unstable intermediate donates electron to 
the molecular oxygen to generate superoxide which then dismutates to hydrogen peroxide. 
However, further study is required to fully determine the reason of futile redox cycling in the 
presence of these substrates. Other substrates including phenylphenols, biphenylmethanols or 
naphthylmethanols have been screened with this system previously, but a minimal activity of 
this type was detected 266. 
 
Table 7. 9 The NADH oxidation rates of Arx/ArR with 3-methoxyphenol and 6-methoxy-1-
tetralone. The rates were measured and reported same as described in Table 7. 1. n.d. Not 
determined. In certain instances, the detected levels of hydrogen peroxide were higher than the 













2000 314 1814 541 
1500 314 1704 534 
1000 306 1158 438 
500 306 373 195 
250 317 232 213 
100 331 119 n.d. 
50 338 80 n.d. 
25 305 74 n.d. 
6-methoxy-1-
tetralone  
1000 338 547 213 
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Oxygenated aromatics redox cycling by mitochondrial P450s electron transfer partners 
 
Adrenodoxin (Adx) is an iron-sulfur protein of the broad family of [2Fe-2S]- 
ferredoxins 342. It supplies reducing equivalents from NADPH dependent adrenodoxin 
reductase (AdR) to the active site of mitochondrial P450s 52, 342. This system was also tested 
with the oxygenated aromatics to investigate if adrenodoxin is a mediator of futile redox 
cycling of these substrates as observed for the bacterial ferredoxin system. 
 
Different concentrations of 1-naphthol (2500 to 10 µM) were added in Adx/AdR system, and 
NADPH oxidation rates were monitored (Table 7. 10). The rates were lower when compared 
to Arx/ArR system (Table 7. 10). The hydrogen peroxide assays displayed that a significant 
amount of reducing equivalents was converted to hydrogen peroxide.  
 
Table 7. 10 The NADPH oxidation rates of Adx/AdR system with 1-naphthol. The oxidation 
rates were measured using a AdR:Adx system (0.1 μM AdR and 1 μM Adx). The original 
concentration of both enzymes were Adx; 374 µM and AdR; 34 µM. Rates are given same as 










2500 320 145 - 
2000 354 209 - 
1500 320 177 225 
1000 352  200  255 
500 324  189  219 
200 318  193 - 
100 313  150  231 
50 325 143 - 
20 320 121 316 
10 312 113 - 
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The turnovers assays of Adx and AdR (without any P450 enzyme) with 1,4-naphthoquinone 
(250 µM) and menadione (250 µM), showed a NADPH consumption rate of 165 min-1 and 151 
min-1, respectively (Table 7. 11). For phenolic compounds, 2,6-dihydroxynaphthalene and 3-
methoxyphenol also induced similar NADPH oxidation rates with this system (Table 7. 11). A 
large amount of hydrogen peroxide was detected in each turnover assay (Table 7. 11). 
 
Table 7. 11 The NADPH oxidation rates of Adx/AdR system with different oxygenated 
aromatics. The rates were measured using a AdR:Adx concentration ratio of (0.1 μM AdR and 












250 1,4- naphthoquinone 294 165 264 
100 1,4-naphthoquinone 318 169 261 
250 menadione 267 151 267 
100 menadione 261 137 261 
250 2,6-dihydroxynaphthalene 312 140 292 
250 3-methoxy phenol 301 148 298 
100 3-methoxy phenol 310 138 304 
 
 
Cytochrome P450 reductase (CPR) is an enzyme which transfers reducing equivalents from 
NADPH to human P450s 343, 344. The enzyme (FAD/FMN cofactors) have been reported to 
reduce many quinone derivatives and under the suitable condition and capable of initiate redox 
cycling 333, 345, 346. The enzyme was screened with 1-naphthol. Upon addition of 2000 µM of 1-
naphthol, the enzyme showed a NADPH turnover rate 418 min-1. The rate of NADPH oxidation 
decreased as the concentration of the substrate was lowered (Table 7. 12). A high level of H2O2 
was noticed in these turnovers. A similar type of activity has also been described for this 
enzyme with various redox active substrates such as menadione and parathion 314, 329, 334, 347. 
CPR has been reported to reduce the substrate to the radical anion, and this anion reduced the 
molecular oxygen to superoxide anion that rapidly dismutates to hydrogen peroxide 314, 329, 334, 
347. In the current study, CPR catalysed the futile redox cycling with the 1-naphthol (1,4-
naphthoquinone) and generated a significant amount of hydrogen peroxide in the turnover 
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assays presumably via a similar mechanism. It is assumed that this is the same process which 
occurs with the other redox partners assessed here. 
 
Table 7. 12 The NADPH oxidation rates of CPR system with 1-naphthol. The oxidation rates 
were measured using a human P450 reductase system (0.2 μM CPR). The original 
concentration of enzyme was 11.5 µM. Rates are given same as CYP101B1/Arx/ArR system 






NADPH oxidation  
rate  
H2O2 
conc. (µM)  
2000 315 ± 15 418 ± 28 277 
1500              314 ± 3 366 ± 39 300 
1000 326 ± 16 322 ± 34 274 
500 -          248 ± 1 n.d 
200 - 169 ± 11 n.d 
100 -          100 ± 6 n.d 
50 - 39 ± 6 n.d 
 
 
7.3. Discussion  
 
The oxidation of naphthalene by CYP101B1/Arx/ArR system proceeds with a NADH 
oxidation rate that increased over time. Minimal amounts of naphthols or other metabolites 
were observed despite a moderately high NADH oxidation rate. We hypothesised that the 
metabolite(s) which form in the turnovers of naphthalene could be the reason for the increase 
in the NADH oxidation rate over time. To test the hypothesis, 1-naphthol and 2-naphthol were 
screened as substrates in the CYP101B1 system, which generated a minimal amount of 
metabolite 1,4-naphthoquinone and 2,6-dihydroxynaphthalene, respectively, despite very fast 
NADH oxidation rates. Both 1- and 2-naphthol were tested with only Arx/ArR system, and no 
P450 was added in the turnovers. The turnovers of ArR/Arx system with naphthols without the 
CYP101B1 enzyme, even exceeds the rate of NADH oxidation than the fully reconstituted 
CYP101B1 system, indicated a small amount 1,4-naphthoquinone might be already present as 
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an impurity with 1-naphthol. A large amount of hydrogen peroxide was detected in each 
turnover with or without P450 enzyme. To check 1,4-naphthoquinone is most likely the 
primary cause of rapid NADH oxidation, different concentrations of this substrate were added 
in the turnover assays with or without the P450 enzyme. In spite of very high NADH oxidation 
rates, no detectable product was observed in the turnovers of CYP101B1. Hydrogen peroxide 
assays of all turnovers containing either the complete P450 system or only the redox partners 
revealed that the majority of the reducing equivalents were converted to H2O2. This indicated 
that the bacterial ferredoxin (Arx) could reduce 1,4-naphthoquinone to semiquinone and 
catalyse redox cycling (Figure 7. 10). Hence a large quantity of hydrogen peroxide was 
detected in the turnovers without P450. This type of exogenous oxygenated aromatic mediated 
uncoupling pathway in bacterial electron transfer systems containing ferredoxin would be an 
additional form uncoupling. The presence of menadione and vitamin K1 in the 
CYP101B1/Arx/ArR or only Arx/ArR system displayed similar effect to 1,4-naphthoquinone. 
The dihydroxylated naphthalene, 3-methoxyphenol and 6-methoxy-1-tetralone also induced 
high NADH oxidation with the ArR/Arx system and formed a large quantity of hydrogen 
peroxide suggesting this ArR/Arx system was capable of catalysing futile redox cycle to these 




Figure 7. 10 An overview of how 1,4-naphthoquinone could interrupt the electron transfer to 
P450 during naphthalene or 1-naphthol metabolism.  
 
The effect of 1,4-naphthoquinone, menadione and 2,6-dihydroxynaphthalene in the CYP101B1 
catalysed oxidation of 2-adamantyl acetate were examined combining both substrates in the 
assays. This demonstrated that these substrates were each potent inhibitors of CYP101B1 
metabolism. In the presence of these redox active substrates the yield of 5-hydroxy-2-
adamantyl acetate was dramatically reduced, and in certain instances, no product was formed. 
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These redox active chemicals were seen to inhibit the activity of CYP101B1 by interfering 
with the electron transfer.  
The investigation of mitochondrial P450s redox partners Adx/Adr and cytochrome P450 
reductase (CPR) with 1-naphthol and 1,4-naphthoquinone indicated that they also catalysed the 
futile redox cycling with these substrates. This type of activity was in agreement with the 
previously reported activities of CPR enzyme 314, 329, 334, 347. However, further study is required 
with other oxygenated substrates to fully assess these systems. 
 
This form of uncoupling in electron transfer partners would make these P450 systems 
unsuitable biocatalysts for the oxidation of substrates which can accept electrons from the 
redox partners or that generate metabolite(s) which can do this. Electron transport proteins 
mediated futile redox cycling interferes with the function of the P450, and in mitochondrial 
P450 system which can lead to inhibit the biosynthesis of steroid and drug metabolism 323. This 
is most likely the primary cause of toxicity of these substrates. In these instances using an 
alternate system such as peroxygenases may be more effective 266. 
 
Further investigation is required to find out the exact mechanism of the transfer of 
the electrons from the ferredoxin (Adx and Arx) to the naphthoquinones, and 
other related substrates like dihydroxybenzene, alkylpolyphenols, menaquinone and aromatic 
nitro compounds which results in the subsequent generation of hydrogen peroxide 81, 266. It 
would also be essential to determine if this uncoupling behaviour is generic 
across all class I electron transfer systems including Fdx having iron–sulfur-cluster of  [3Fe–
4S] and [4Fe–4S] type 44, 56, 348. To understand the thermodynamics of the electron transfer 
process and structural features of the substrates which can inhibit with the electron transfer 
process in this way further studies could be attempted, e.g. redox potential determination 324, 
342, 349. The quantification and detection of any superoxide and the ROS such as hydroxyl 
radical formation in this process will be valuable. The superoxide can be quantified using 
several standard methods and chemicals, e.g. nitroblue tetrazolium, epinephrine, superoxide 
dismutase (assayed after superoxide dismutation to H2O2) and spin-traps with ESR 
spectroscopic equipment 323, 350, 351. These results are essential when considering the toxicity of 
polyaromatic substrates and their oxygenated metabolites 266, 319, 352. 








The investigations detailed herein describe efforts towards developing novel C-H 
functionalisation reactions using biocatalysts. This study concentrates on the application of the 
cytochrome P450 enzymes in the biocatalytic oxidation of a wide range of substrates including 
alicyclic compounds, adamantanes, aromatic substrates and cubanes. The oxidation activity of 
CYP101B1 and CYP101C1 enzymes was investigated with different sized cyclic alkanes and 
ketones as well as the esters of cyclic alcohol and cyclohexylacetic acid in order to fully explore 
the substrate range of these enzymes. A comparative study between CYP101B1 and 
CYP101C1 with these cyclic and linear compounds provided insight into their catalytic 
activity, regio and stereoselectivity patterns. 
 
Adamantane derivatives are used as building blocks for many complex drug molecules and 
polymers. CYP101B1 oxidised adamantane based substrates but at low product formation 
activity and selectivity. We envisioned that introduction of an ester directing group to 
adamantanols, which would mimic the butenone side chain of β-ionone, could improve the 
enzyme monooxygenase activity. This substrate engineering approach was effective, and the 
oxidation of these engineered adamantyl esters proceeded more efficiently and was highly 
regioselective. 
 
The oxidation of hydrophobic aromatic compounds including alkylbenzenes, styrenes, 
substituted naphthalenes were investigated with CYP101B1. The binding affinity and 
oxidation activity of CYP101B1 with these hydrophobic substrates were low. Protein 
engineering of the active-site of CYP101B1 was undertaken. The H85F variant exhibited 
higher binding affinities and resulted in greater metabolite yields with certain aromatic 
substrates. 
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Methylcubane was used to investigate the mechanistic pathways of P450 hydroxylation. To 
probe the product-determining step a series of cubane derivatives were designed and screened. 
These are capable of distinguishing between radical or carbocation intermediates formed 
during the oxidation.  
 
Several electron transfer proteins including bacterial (Arx/ArR) and mitochondrial (Adx/AdR) 
were investigated to assess futile redox cycling with oxygenated aromatics. The high NADH 
oxidation rates in the absence of P450 enzyme and the significant quantity of hydrogen 
peroxide observed in these turnovers indicated that these enzymes facilitate the uncoupling in 
the presence of certain oxygenated aromatics.  
 
Chapter 3: The binding and kinetic properties of CYP101B1 and CYP101C1 were determined 
with a range of cycloalkanes.  However, most of the reactions proceed at low product formation 
activity. The addition of a ketone group to these cyclic compounds improved the binding 
affinity and activity. CYP101C1 showed different regioselectivity for cycloalkanones, and it 
hydroxylated these substrates at the C-2 position. CYP101B1 catalysed the oxidation of these 
cyclic ketones with higher product formation rates than the CYP101C1 system. However, the 
selectivity was often reduced for CYP101B1, e.g. in the case of cycloundecanone 
hydroxylation occurred at the 2-, 5- and 6-positions. CYP101B1 also generated cyclisation 
metabolites with cyclononanone and cyclodecanone. The regioselectivity enhanced for larger 
cycloalkanones like cyclododecanone and cyclopentadecanone, where the hydroxylation 
occurs predominantly on the remote site of the ring to the ketone moiety to form C-7 (96%) 
and C-8 (90%) hydroxy products, respectively. The majority of the cycloalkanols 
(cyclohexanol and cyclooctanol) investigated with both enzymes did not show any activity. 
The exception was cyclododecanol which was metabolised by both enzymes. The esters 
derivatives of the cycloalkanols did bind tightly with CYP101B1. The productive oxidation 
rates of the CYP101B1 enzyme were 2 to 25-fold faster than these of the CYP101C1. The 
coupling efficiencies of the CYP101B1 with these substrates were also significantly improved. 
Both enzymes catalysed the selective oxidation of these cyclic esters, and the hydroxylation 
occurs solely on the other side of the ring to the ester directing group.  
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CYP101C1 oxidised α-terpinyl acetate with a high product formation rate and coupling 
efficiency, whereas, CYP101B1 did not show any activity with this substrate. CYP101B1 and 
CYP101C1 catalysed the oxidation of linear substrates including 2-nonanone, 2-undecanone, 
linalyl acetate and citronellyl acetate. CYP101C1 exhibited higher biocatalytic activities with 
linalyl acetate and citronellyl acetate. The ability to catalyse the oxidation of a range of cyclic 
and linear compounds highlighted the potential of these two enzymes to functionalise inert C-
H bonds. 
 
Overall, cyclic ketones and esters were good substrates for CYP101B1 and CYP101C1. The 
presence of a ketone or an ester carbonyl group significantly improved the activity. The work 
on CYP101B1 clearly shows that the enzyme must hold the substrate in a way that selective 
C-H bond abstraction occurs on the opposite side of the ring to the carbonyl functionality. 
There is also a good correlation with the substrate binding parameters and the activity. This 
trend can be observed when comparing for example cyclodecanone versus cyclooctanone and 
cycloctyl acetate versus cyclooctanol. It is however important to note that better binding does 
not always result in improved activity or total turnover number and we hypothesis that this is 
related to the solubility of the substrate for example cyclododecyl acetate versus cyclooctyl 
acetate. There is currently no structural data for the CYP101B1 enzyme to help explain why 
the substrates are bound in this manner. The use of a homology model to direct mutagenesis 
was found not to be as successful as related studies with P450cam (Chapter 5). Crystal structure 
data are available for the related enzymes CYP101A1 (P450cam), CYP101D1, CYP101D2 and 
CYP101C1 47, 49, 248, 250, 264, 265. While the first three share some similarities as well as important 
differences are observed 47, 175, 248, 250. Of relevance here is that the CYP101C1 structure is 
significantly different to the others 47. It contains additional loops and short helices and has a 
distinctive active site 47. This is in line with the altered substrate range of this enzyme. 
CYP101B1 is functionally different from all of the above-mentioned enzymes (dissimilar 
substrate range) which suggests that its structure (especially around the active site) will not 
closely resemble the others. However based on the CYP101C1 structure, we would predict that 
the butenone side chain of the norisoprenoids (and the carbonyl moiety of the ketones or esters) 
will interact with residues near the entrance of the substrate binding pocket and hold the 
opposite side of the ring system close to the heme iron to allow selective C-H bond abstraction. 
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Further investigation of larger (>C15) and smaller (<C6) cyclic and linear compounds with 
ketone and ester moieties would be valuable to expand their substrate range. Lactones and 
lactams, e.g. ε-caprolactone, ε-caprolactam, pentadecanolide and 16-hexadecanolide, which 
have received attention because of their chemical versatility, could be investigated with these 
monooxygenase enzymes. Crystal structures of substrate-bound CYP101B1 would enable to 
determine the amino acids of the active site of CYP101B1 which interact with the ketone 
oxygen. Protein engineering of both enzymes could be a useful approach to improve the 
binding affinity and selectivity further.  
 
Chapter 4: Tricyclic adamantane derivatives were studied with CYP101B1, and the enzyme 
showed low affinity for adamantane and adamantanols. Low product formation activity and 
selectivity were also observed in these turnovers. Substrate engineering was used to enhance 
the binding affinity and activity of CYP101B1 for this class of substrates. The introduction of 
ester protecting groups (acetate and isobutyrate) to the adamantanols, significantly improved 
the binding affinity of CYP101B1 when compared to parent alcohols. The enzyme oxidised 
these compounds with fast product formation activities and high regio- and stereoselectivity. 
The enzyme predominantly oxidised 1-adamantyl acetate/isobutyrate and 2-adamantyl 
acetate/isobutyrate at the C-4 and C-5 position, respectively. All the 4-hydroxy metabolites are 
confirmed as having a trans arrangement of the alcohol and ester. The same approach was also 
applied where an acetamide moiety was used to replace the amine moiety of 1-
adamantylamine. The acetamide was metabolised by CYP101B1 whereas the amine was not. 
Significant quantities of metabolites were generated using a whole-cell system which indicated 
that CYP101B1 could be used to synthesise these products on a larger scale. These observations 
demonstrate that the substrate engineering strategy using ester and amide protecting groups 
could be useful for this class of substrates and other. 
 
The yield of hydroxylated metabolites could be significantly improved using higher density 
cell cultures in a fermentor with more control of the pH and nutrients, when combined with a 
substrate feeding/product removal regime. Further investigation could be undertaken with 
other adamantane derivatives found in pharmaceutical compositions such as adamantane-1-
carboxamide, adamantyl-alkylamines, n-[1-(adamantan-1-yl)ethyl]acetamide and 
tromantadine 237.  
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Chapter 5: CYP101B1 was shown to catalyse the oxidation of aromatic substrates including 
alkylbenzenes, styrenes, alkyl substituted naphthalenes and the tricyclic acenaphthene. 
However, the binding affinity and activity were low. Replacement of histidine (H85) residue, 
from the active site by a hydrophobic phenylalanine residue altered the functional properties 
of the enzyme. Variations in the binding affinity and selectivity were observed when β-ionone 
was screened with each variant. The H85F variant of CYP101B1 exhibited tighter binding 
affinities and gave higher metabolite yields with the majority of the hydrophobic aromatic 
substrates tested including naphthalene derivatives. Studies were also carried out with biphenyl 
and substituted biphenyls. However, the activity of H85F variant with these longer 
hydrophobic compounds was not significantly improved over the WT enzyme. Other variants 
of CYP101B1 such as H85A and H85G have also been investigated with different hydrophobic 
substrates, but they also showed lower binding affinity and oxidation activity compared to WT 
CYP101B1 with biphenyls 264. The productivity may be enhanced towards larger aromatic 
compounds by altering other active site residues, for example, I237 and Q234. Solving the 
crystal structure would be valuable for this enzyme to facilitate further mutagenesis studies and 
makes the enzyme truly efficient and practical towards a wide range of aromatic substrates 
particularly biphenyls.  
 
Chapter 6: CYP101B1 was studied with substituted methylcubanes, and these reactions were 
used to probe the mechanism of hydroxylation in P450. Most of the methylcubane derivates 
were oxidised with high activity and selectively. The cubane skeleton remained intact after all 
the turnovers. The enzyme abstracted one of the protons from the methyl group and little or no 
rearrangement product was detected. This is most likely due to the faster radical rebound 
compared to radical rearrangement. The metabolites which arise from the oxidation of 
CYP101B1 supported the absence of any involvement of a carbocation-based intermediate 
during the oxidation of methyl C-H bond. This could be further investigated to determine the 
nature of radical intermediates formed. Additional studies with other related mechanistic 
probes are required in order to verify the current findings and more precisely define the 
hydroxylation mechanism of this enzyme.  
 
Chapter 7: The NAD(P)H oxidation activities of both bacterial and mitochondrial P450 
electron transfer proteins were found to be fast in the presence of different oxygenated 
aromatics but in the absence of the monooxygenase enzyme. Assays showed that most of the 
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reducing equivalents in these turnovers were converted into H2O2. The likely mechanism for 
this H2O2 formation in the turnovers is that the redox partner proteins catalyse the reduction of 
naphthoquinones to the corresponding semiquinones. These unstable semiquinones donate an 
electron to molecular oxygen, generating superoxide anions which then dismutate to hydrogen 
peroxide and O2. This type of uncoupling of reducing equivalents without the presence of P450 
enzyme highlighted the ability of ferredoxin or adrenodoxin iron-sulfur proteins to catalyse 
this futile redox cycling which should be considered an additional form of uncoupling in these 
systems.  
 
Overall, this futile redox cycling significantly reduces the catalytic performance of CYP101B1 
by impairing the electron transfer from physiological redox partners to the heme of the enzyme. 
For illustration, the presence of any of these naphthoquinones in the fully reconstituted 
CYP101B1 system, significantly reduced the P450 mediated metabolism of 2-adamantyl 
acetate. The cytochrome P450 reductase (CPR) was also studied with oxygenated aromatics 
and shown to catalyse this futile redox cycle. 
 
More work is necessary to elucidate the exact mechanism of electron transfer during redox 
cycling reactions, and how these redox active chemicals interact with the electron transfer 
proteins. The investigation of redox cycle in cell would be useful to find out the physiological 
significances of a small quantity of quinone on P450 activity in vivo, e.g. ESR detection and in 
vivo spin traps would be used to determine the mechanism of futile redox cycling. 
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NMR of 1-adamantyl acetate 182: 
1H NMR (500 MHz, CDCl3) δ 2.18-2.13 (m, 3H, H3, H5 & H7), 2.11-2.08 (m, 6H, 2xH2, 
2xH9 & 2xH10), 1.96 (s, 3H, 3xH12), 1.70-1.61 (m, 6H, 2xH4, 2xH6 & 2xH8). 
13C NMR (126 MHz, CDCl3) δ 172.92 (C11), 82.65 (C1), 43.68 (C2, C9 & C10), 38.65 (C4, 
C6 & C8), 33.31 (C3, C5 & C7), 25.47 (C12).  
 
Figure A. 1 1H NMR spectrum of 1-adamantyl acetate. 
 
Figure A. 2 13C NMR spectrum of 1-adamantyl acetate. 




Figure A. 3 gCOSY NMR spectrum of 1-adamantyl acetate. 
 
Figure A. 4 HSQC NMR spectrum of 1-adamantyl acetate. 
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NMR data for 2-adamantyl acetate 182: 
1H NMR (500 MHz, CDCl3) δ 4.96-4.83 (m, 1H, H2), 2.07 (s, 3H, 3xH12), 2.05-1.97 (m, 4H, 
H1, H3, H8 & H10), 1.88-1.82 (m, 4H, H4, H5, H7 & H9), 1.80-1.73 (m, 4H, H4, 2xH6 & 
H9), 1.56 (d, J = 10.6 Hz, 2H, H8 & H10). 
13C NMR (126 MHz, CDCl3) δ 173.50 (C11), 79.54 (C2), 40.04 (C6), 39.01 (C4 & C9), 34.65 
(C1 & C3), 34.37 (C8 & C10), 29.88/29.69 (C5/C7), 24.23 (C12). 
 
Figure A. 5 1H NMR spectrum of 2-adamantyl acetate.  




Figure A. 6 13C NMR spectrum of 2-adamantyl acetate. 
 
Figure A. 7 gCOSY NMR spectrum of 2-adamantyl acetate. 




Figure A. 8 HSQC NMR spectrum of 2-adamantyl acetate. 
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NMR data for 1-adamantyl isobutyrate 182: 
1H NMR (500 MHz, CDCl3) δ 2.43 (sept, J = 7.0 Hz, 1H, H12), 2.19-2.14 (m, 3H, H3, H5 & 
H7), 2.13-2.05 (m, 6H, 2xH2, 2xH9 & 2xH10), 1.72-1.63 (m, 6H, 2xH4, 2xH6 & 2xH8), 1.11 
(d, J = 7.0 Hz, 6H, 3xH13 & 3xH14). 
 
 
Figure A. 9 1H NMR spectrum of 1-adamantyl isobutyrate.  
 




Figure A. 10 gCOSY spectrum NMR of 1-adamantyl isobutyrate. 
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NMR for 2-adamantyl isobutyrate 182: 
1H NMR (500 MHz, CDCl3) δ 4.93-4.87 (m, 1H, H2), 2.57 (sept, J = 7.0 Hz, 1H, H12), 2.05-
1.96 (m, 4H, H1, H3, H8 & H10), 1.87-1.81 (m, 4H, H4, H5, H7 & H9), 1.79-1.41 (m, 4H, H4,  
2xH6 & H9), 1.56 (d, J = 11.9 Hz, 2H, H8 & H10), 1.19 (d, J = 7.0 Hz, 6H, 3xH13 & 3xH14). 
13C NMR (126 MHz, CDCl3) δ 179.0 (C11), 79.04 (C2), 40.04 (C6), 38.98 (C4 & C9), 37.06 
(C12), 34.49 (C1 & C3), 34.44 (C8 & C10), 29.91/29.66 (C5/C7), 21.70 (C13 & C14). 
 
Figure A. 11 1H NMR spectrum of 2-adamantyl isobutyrate. 




Figure A. 12 13C NMR spectrum of 2-adamantyl isobutyrate. 
 
Figure A. 13 gCOSY NMR spectrum of 2-adamantyl isobutyrate. 




Figure A. 14 HSQC NMR spectrum of 2-adamantyl isobutyrate. 
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NMR data for cyclohexyl isobutyrate: 
1H NMR (500 MHz, CDCl3) δ 4.82-4.66 (m, 1H, H1), 2.52 (septet, J = 7.0 Hz, 1H, H8), 1.88-
1.66 (m, 10H), 1.16 (d, J = 7.0 Hz, 6H, 3xH9 & 3xH10). 
 
 
Figure A. 15 1H NMR spectrum of cyclohexyl isobutyrate.  
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NMR data for cyclooctyl Acetate  
1H NMR (500 MHz, CDCl3) δ 4.95-4.85 (m, 1H, H1), 1.99 (s, 3H, 3xH10), 1.83-1.42 (m, 14H). 
 
 
Figure A. 16 1H NMR spectrum of cyclooctyl acetate 
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NMR data for cyclooctyl isobutyrate 
1H NMR (500 MHz, CDCl3) δ 4.99-4.84 (m, 1H, H1), 2.49 (septet, J = 7.0 Hz, 1H, H10), 1.85-
1.43 (m, 14H), 1.15 (d, J = 7.0 Hz, 6H, 3xH11 & 3xH12). 
 
 
Figure A. 17 1H NMR spectrum of cyclooctyl isobutyrate. 
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NMR data for cyclododecyl acetate 
1H NMR (500 MHz, CDCl3) δ 5.05-4.95 (m, 1H, H1), 2.03 (s, 3H, 3xH14), 1.76-1.63 and 1.53-
1.26 (m, 22H). 
 
 
Figure A. 18 1H NMR spectrum of cyclododecyl acetate. 
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Figure B. 1 Mass Spectra Analysis 
 
 
MS analysis of cyclooctane products 
 
MS analysis of cyclooctanone RT 6.6 min (m+/z = 126.05)  
     
MS analysis of cyclooctanol RT 6.9 min (m+/z = 128.05)  
    
         
zoomed in version 
 
 
MS analysis of cyclodecane and its products 
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MS analysis of cyclodecanol RT 10.45 min (m+/z = 156.20) 
  
       
zoomed in version 
 
MS analysis of cyclododecane, cyclododecanol and their products 
 
MS analysis of cyclododecane RT 6.8 min (m+/z = 168.20) 
 
MS analysis of 1,7-cyclododecanediol RT 12.9 min (m+/z = 200.10)  
    
         
zoomed in version 
MS analysis of cyclododecanone RT 7.6 min (m+/z = 182.15) 
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MS analysis of cyclododecanol RT 7.9 min (m+/z = 184.2) 
 
 
zoomed in version 
 
MS analysis of cyclononanone and its products 
MS analysis of cyclononanone RT 9.1 min (m+/z = 140.15; CYP101B1) 
 
MS analysis of 1-hydroxy-10-oxabicyclo[4.3.1]decane RT 11.2 min (m+/z = 156.15) 217. 
Experimental m+/z = 156.15, 138.15, 120.15, 113.10, 97.15, 94.10, 81.10, 71.10, 69.15, 68.15, 
67.15, 55.10, 43.10. 
Reported 217 m+/z = 156 (17), 113 (64), 110 (66), 97 (81), 71 (63), 69 (84), 68 (97), 55 (100). 
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MS analysis of 2-hydroxycyclononanone RT 12.2 min (m+/z = 156.15; CYP101C1) 221. 
Experimental m+/z = 156.15, 138.15, 120.15, 110.15, 95.15, 94.10, 82.10, 67.15, 57.10, 41.10. 
Reported m+/z = 156, 138, 120, 110, 95, 95, 82, 67, 57, and 41 (WSS: Spectral data were 
obtained from Wiley Subscription Services, Inc. (US)). 
 
       
zoomed in version 
 
MS analysis of cyclodecanone and its products 
MS analysis of cyclodecanone RT 7.5 min (m+/z = 154.20; GC-FID RT 2.9 min). 
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MS analysis of 2-hydroxycyclodecanone RT 10.6 min (m+/z = 170.2; CYP101C1; GC-FID RT 
7.2 min). 
Experimental m+/z = 170.2, 152.20, 134.2, 111.1, 108.15, 98.1, 96.10, 95.15, 82.15, 81.10, 
67.15, 57.10 and 41.10. 
Reported 219 m+/z = 170, 152, 134, 111, 98, 81, 57 and 41.  
 
     
zoomed in version 
MS analysis of 1-oxabicyclo[5.3.1]undecan-1-ol and 5-hydroxycyclodecanone RT 13.4 min 
(m+/z = 170.20; CYP101B1; GC-FID RT 10.0 min) 218. 
 
       
zoomed in version 
MS analysis of 1-oxabicyclo[6.3.1]undecan-1-ol and 6-hydroxycyclodecanone RT 13.7 min 
(m+/z = 170.1; CYP101B1; GC-FID RT 10.9 min). 
 
 
zoomed in version 
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MS analysis of cycloundecanone and its products 
MS analysis of cycloundecanone RT 6.4 min (m+/z = 168.20). 
   
MS analysis of 2-hydroxycycloundecanone RT 8.4 min (m+/z = 184.40; CYP101C1). 
Experimental m+/z = 184.40, 166.20, 148.20, 138.15, 133.15, 122.20, 119.15, 111.15, 98.15, 
95.15, 82.10, 81.15, 68.10, 67.15, 57.10, 55.15 and 41.10. 
Reported 220 m+/z = 184, 119, 111, 98, 85, 81, 68 and 55. 
               
      
zoomed in version 
MS analysis of further oxidation product of CYP101B1 turnover at RT 8.8 min (m+/z = 
182.30).  
Experimental m+/z = 182.30, 166.10, 155.55, 148.10, 137.35, 133.50, 109.20, 98.10, 95.10, 
83.10, 67.10, 58.10, 55.0 and 43.10. 
 
        
zoomed in version 
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MS analysis of product 5-hydroxycycloundecanone RT 9.3 min (m+/z = 184.3; CYP101B1).  
Experimental m+/z = 184.3, 166.20, 148.15, 137.15, 128.15, 127.15, 123.15, 113.15, 109.10, 
81.10, 71.10, 67.15, 55.10 and 41.10. 
 
      
zoomed in version 
MS analysis of product 6-hydroxycycloundecanone RT 9.45 min (m+/z = 184.2; CYP101B1). 
Experimental m+/z = 184.2, 166.20, 148.20, 137.15, 127.15, 123.15, 113.15, 109.10, 98.15, 
95.15, 85.10, 81.15, 67.15, 58.10, 55.10 and 41.10. 
    
      
zoomed in version    






                         































113.15 127.15 166.20137.15 148.20 184.20
196.65






55.10 67.15 85.10 95.15
113.15
127.15 166.2059.15 137.15115.15 148.20141.15
184.20155.25
Appendix B (Chapter 3) 
 
296 
MS analysis of cyclododecanone and its products 
MS analysis of cyclododecanone RT 12.1 min (m+/z = 182.2). 
 
 
MS analysis of 2-hydroxycyclododecanone RT 15.5 min (m+/z = 198.25; CYP101C1) 219, 220.  
Experimental m+/z = 198.25, 180.25, 170.15, 162.20, 149.25, 136.10, 133.20, 124.10, 123.10, 
133.20, 121.20, 111.10, 109.15, 98.15, 95.15, 82.15, 81.10, 68.10, 67.15, 57.10, 55.10 and 
41.10. 
Reported 2 m+/z = 198, 180, 136, 124, 111, 98, 96, 95, 82, 81, 68, 67 and 57. 
             
        
zoomed in version 
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MS analysis of minor unidentified product at RT 16.9 min (m+/z = 198.35; CYP101B1).  
Experimental m+/z = 198.35, 180.35, 162.30, 155.35, 151.25, 137.25, 127.55, 111.20, 98.20, 
81.20, 71.05, 67.15. 55.15 and 43.15  
 
        
zoomed in version 
MS analysis of 7-hydroxycyclododecanone RT 17.7 min (m+/z = 198.50; CYP101B1) 208. 
Experimental m+/z = 198.05, 180.05, 162.10, 151.05, 137.1, 123.05, 113.1, 95.05, 84.05, 84.05, 
81.10, 67.05. 55.00 and 41.10  
Reported 208 m+/z = 198, 180, 109, 81 and 55. 
 
       
zoomed in version 
 
MS analysis of cyclopentadecanone and its products  
MS analysis of cyclopentadecanone RT 13.1 min (m+/z = 224.25).  
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MS analysis of 2-hydroxycyclopentadecanone RT 14.6 min (m+/z = 240.25; CYP101C1) 219, 
222.  
Experimental m+/z = 240.25, 222.25, 166.25, 152.10, 149.15, 135.15, 124.10, 123.20, 110.10, 
109.15, 96.15, 82.10, 67.10, 55.10 and 41.10. 
Reported 219, 222 m+/z = 240, 222, 166, 152, 138, 124, 110, 96, 82 and 55. 
    
        
zoomed in version 
MS analysis of 8-hydroxycyclopentadecanone  RT 15.6 min (m+/z = 240.25; CYP101B1) 208. 
 
 
MS analysis of cyclopentadecanone minor product (cyclopentadecane-1,8-dione) CYP101B1 
RT 15.1 min (m+/z = 238.20; CYP101B1) 208. 
Experimental m+/z = 238.20, 220.20, 181.20, 125.15, 112.10, 111.15, 98.15, 84.15, 83.10, 
69.10, 55.10 and 43.10. 
Reported 208 m+/z = 238, 181, 126, 112, 111, 98 and 84. 
 
       
zoomed in version 
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MS analysis of cyclohexyl acetate product 
MS analysis of trans-4-hydroxycyclohexyl acetate RT 10.6 min (m+/z = 158.00)  
 
 
MS analysis of cyclohexyl butyrate product 
MS analysis of trans-4-hydroxy cyclohexyl butyrate RT 8.5 min (m+/z = 186.20)  
 
       
zoomed in version 
 
MS analysis of cyclohexyl isobutyrate product 
MS analysis of trans-4-hydroxycyclohexyl isobutyrate RT 7.9 min (m+/z =186.0)  
 
       
























61.05 98.10 114.10 125.00 132.15107.00 140.10 168.00150.10 191.00178.00
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MS analysis of cis/trans-4-tert-butylcyclohexyl acetate substrate and its product 
 
MS analysis of cis/trans 4-tert-butylcyclohexyl acetate RT 10.45 min (m+/z = 198.30). 
 
 
MS analysis of cis/trans 4-tert-butylcyclohexyl acetate RT 10.9 min (m+/z = 198.10). 
 
 
MS analysis of proposed cis-4-(1-hydroxy-2-methylpropan-2-yl) cyclohexyl acetate RT 13.2 
min (m+/z = 214.10; CYP101B1). 
 
     
 
MS analysis of trans-4-(1-hydroxy-2-methylpropan-2-yl) cyclohexyl acetate RT 14.1 min 
(m+/z = 214.20; trans). 
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MS analysis of methyl cyclohexylacetate product 
MS analysis of methyl-2-(trans-4-hydroxycyclohexyl)acetate RT 9.9 min (m+/z = 172.0; RT 
18.5 min in GC-FID).  
 
       
zoomed in version 
 
MS analysis of ethylcyclohexyl acetate products 
MS analysis of ethyl-trans-2-(4-hydroxycyclohexyl)acetate RT 7.0 min (m+/z = 186.15; RT 
20.1 min in GC-FID).  
 
         
zoomed in version 
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MS analysis of cyclooctyl acetate and its products 
MS analysis of cyclooctyl acetate RT 6.5 min (m+/z = 170.10).  
 
MS analysis of further oxidation product cyclooctyl acetate RT 8.8 min (m+/z = 184.10; 
CYP101C1)  
 
         
zoomed in version 
MS analysis of 5-hydroxycyclooctyl acetate RT 8.95 min (m+/z = 186.20). 
 
        
zoomed in version 
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MS analysis of cyclooctyl isobutyrate and its products 
MS analysis of cyclooctyl isobutyrate RT 8.0 min (m+/z = 198.05). 
 
MS analysis of 5-hydroxycyclooctyl isobutyrate RT 10.2 min (m+/z = 214.9). 
 
MS analysis of further oxidation product of cyclooctyl isobutyrate RT 10.1 min (m+/z = 
212.15).  
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MS analysis of cyclododecyl acetate and its products 
MS analysis of cyclododecyl acetate RT 9.6 min GC-MS (m+/z = 226.15; RT 5.6 min in GC). 
    
MS analysis of 7-hydroxycyclododecyl acetate (cis) RT 12.8 min GC-MS (m+/z = 242.0; 
CYP101C1; RT 16.5 min in GC). 
 
      
zoomed in version 
MS analysis of 7-hydroxycyclododecyl acetate (trans) RT 13.6 min (m+/z = 242.10; 
CYP101B1; RT 17.3 min in GC). 
 
      
zoomed in version 
MS analysis of 5-hydroxycyclododecyl acetate RT 12.4 min (RT 16.2 min GC).  
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MS analysis of α-terpinyl acetate and its products 
MS analysis of α-terpinyl acetate RT 12.6 min (m+/z = 196.25).  
 
       
zoomed in version 
MS analysis of 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-trimethyl-,α-acetate at RT 17.4 
min (m+/z = 212.10; CYP101C1). 
 
       
zoomed in version 
MS analysis of 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-trimethyl-,α-acetate (other 
diastereomer) at RT 17.0 min (m+/z = 212.10; CYP101C1). 
     
          
zoomed in version 
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MS analysis of 2-nonanone and its products 
 
MS analysis of 2-nonanone RT 5.8 min (m+/z = 142.05).  
 
MS analysis of 3-hydroxy-2-nonanone RT 8.5 min (m+/z = 158.65; CYP101C1).  
Experimental m+/z = 158.65, 115.15, 97.15, 85.10, 74.05, 71.15, 69.15, 55.10, 43.10. 
 
      
zoomed in version 
 
MS analysis of 8-hydroxy-2-nonanone RT 11.25 min (m+/z = 158.20; CYP101B1). 
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MS analysis of 2-undecanone and its products 
MS analysis of 2-undecanone RT 6.2 min (m+/z = 170.25). 
 
MS analysis of 3-hydroxy-2-undecanone RT 11.5 min (m+/z = 186.25; CYP101C1) 219. 
Experimental m+/z = 186.25, 143.20, 125.25, 111.50, 97.15, 83.10, 69.15, 55.10, 43.05. 
Reported 219 m+/z = 186, 143, 125, 111, 97, 83, 69, 55 and 43. 
   
MS analysis of 8-hydroxy-2-undecanone RT 14.95 min (m+/z = 186.20; CYP101B1).  
    
         
zoomed in version                         
MS analysis of a mixture of unidentified metabolites of CYP101B1 turnovers at RT 15.2 min 
and 15.9 min. 
          
               
zoomed in version 
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MS analysis of citronellyl acetate and its product 
MS analysis of citronellyl acetate RT 12.7 min (m+/z = 198.40).  
 
        
zoomed in version 
MS analysis of citronellyl acetate epoxide RT 15.5 min (m+/z = 214.60).  
      
    
zoomed in version 
MS analysis of citronellyl acetate epoxide synthesised using mCPBA RT 15.5 min (m+/z = 
214.35).  
 
     
zoomed in version 
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MS analysis of linalyl acetate and its products 
MS analysis of linalyl acetate RT 9.9 min (m+/z = 196.0)  
 
MS analysis of 6,7-epoxy-3,7-dimethyl-1-octen-3-yl acetate at RT 12.5 min (CYP101C1) 232. 
Experimental m+/z = 152.10, 147.10, 137.15, 121.15, 119.10, 109.10, 95.10, 94.10, 93.15, 
81.10, 79.10, 69.15, 68.10, 67.10, 59.10, 55.10, 53.15 and 43.05. 
Reported 232 m+/z = 152.1(22), 137.1(17), 119.1(20), 109.1(45), 96.05(19), 95.1(23), 93.1(21), 
91.1(28), 82.1(28), 81.1(100), 79.1(79), 77.1(24), 71.1(36), 69.1(22), 68.1(71), 67.1(83), 
55.1(49), 53.1(32). 
    
        
zoomed in version 
MS analysis of 6,7-epoxy-3,7-dimethyl-1-octen-3-yl acetate synthesised using mCPBA (RT 
12.5 min) 232. 
  
      
zoomed in version 
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MS analysis of 1,2-epoxy-3,7-dimethyl-6-octen-3-yl acetate at RT 12.6 min (CYP101C1).  
  
MS analysis of 1,2-Epoxy-3,7-dimethyl-6-octen-3-yl acetate synthesised using mCPBA (RT 
12.6 min).  
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   NMR analysis of the generated products by the CYP101B1 and CYP101C1 
 
NMR of mixture of 1,7-cyclododecanediol, 1,6-cyclododecanediol and 1,4-




Figure B. 2 1H NMR spectrum of mixture of 1,7-cyclododecanediol, 1,6-cyclododecanediol 
and 1,4-cyclododecanediol or diastereomer of 1,6-cyclododecanediol (CYP101B1). The 
metabolites were assigned using carbon signal intensities.  




Figure B. 3 13C NMR spectrum of mixture of 1,7-cyclododecanediol, 1,6-cyclododecanediol 
and 1,4-cyclododecanediol or diastereomer of 1,6-cyclododecanediol (CYP101B1). The 
metabolites were assigned using the carbon signal intensities given Table 3. 2.  
 
Figure B. 4 gCOSY NMR spectrum of a mixture of cyclododecanediol products (CYP101B1). 




Figure B. 5 HSQC NMR spectrum of a mixture of cyclododecanediol products (CYP101B1). 
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Data for 2-hydroxycyclononanone 221: 
1H NMR (500 MHz, CDCl3) δ 4.28-4.21 (m, 1H, H2), 3.7-3.72 (m, 1H, OH (C2)), 2.83-2.73 
(m, 1H, H9), 2.37-2.22 (m, 2H, H3 & H9), 2.12-2.01 (m, 1H, H3), 1.89-1.81 (m, 2H, H6 & 
H8), 1.68-1.57 (m, 3H, H4, H7 & H8), 1.49-1.42 (m, 3H, H4, H6 & H7), 1.39-1.32 (m, 1H, 
H5), 1.31-1.25 (m, 1H, H5). 
13C NMR (126 MHz, CDCl3) δ 219.16 (C1), 79.86 (C2), 39.81 (C9), 31.16 (C3), 27.91 (C4), 
27.42 (C6), 27.33 (C8), 26.64 (C5), 23.14 (C7). 
 
 
Figure B. 7 1H NMR spectrum of 2-hydroxycyclononanone (CYP101C1) 221. 
  










Figure B. 8 (a) 13C NMR spectrum of 2-hydroxycyclononanone. (b) Zoomed in version of the 
20 to 80 ppm region to highlight the carbon peaks. 




Figure B. 9 gCOSY NMR spectrum of 2-hydroxycyclononanone. 
 
 
Figure B. 10 HSQC NMR spectrum of 2-hydroxycyclononanone. 
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NMR for 1-hydroxy-10-oxabicyclo[4.3.1]decane 217, 218: 
1H NMR (600 MHz, CDCl3) δ 4.15-4.02 (m, 1H, H5), 2.42 (br s, 1H, OH1 (C1)), 2.13-2.03 
(m, 1H, H9), 1.95-1.85 (m, 3H, H2, H3 & H8), 1.82-1.70 (m, 4H, H3, H4, H6 & H7), 1.70-
1.61 (m, 3H, H6, H7 & H9), 1.55-1.46 (m, 2H, H2 & H8), 1.40-1.34 (m, 1H, H4).  
13C NMR (151 MHz, CDCl3) δ 100.36 (C1), 75.11 (C5), 39.22 (C2), 38.48 (C9), 32.85 (C6), 
30.26 (C4), 23.92 (C7), 22.60 (C8), 20.21 (C3). 
 
 
Figure B. 11 1H NMR spectrum of 1-hydroxy-10-oxabicyclo[4.3.1]decane (cyclononanone; 
CYP101B1) 217, 218. 




Figure B. 12 13C NMR spectrum of 1-hydroxy-10-oxabicyclo[4.3.1]decane (cyclononanone; 
CYP101B1) 217, 218. 
 
Figure B. 13 gCOSY NMR spectrum of 1-hydroxy-10-oxabicyclo[4.3.1]decane 
(cyclononanone; CYP101B1). 
 









Figure B. 15 Zoomed in HMBC NMR spectrum of 1-hydroxy-10-oxabicyclo[4.3.1]decane to 
highlight the C-H interactions in 18 to 108 ppm region (cyclononanone; CYP101B1). 




Figure B. 16 HMBC NMR spectrum of 1-hydroxy-10-oxabicyclo[4.3.1]decane 
(cyclononanone; CYP101B1). 
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Data for 2-hydroxycyclodecanone 219: 
1H NMR (500 MHz, CDCl3) δ 4.29-4.17 (m, 1H, H2), 3.88-3.76 (m, 1H, OH2 (C2)), 3.24-3.11 
(m, 1H, H10), 2.32-2.06 (m, 4H, 2xH3, H9, H10), 1.74-1.59 (m, 3H, H5, H6 & H9), 1.55-1.47 
(m, 1H, H4), 1.46-1.31 (m, 6H, H4, H5, H6, 2xH7 & H8), 1.12-0.99 (m, 1H, H8).  
13C NMR (126 MHz, CDCl3) δ 216.62 (C1), 79.11 (C2), 37.67 (C10), 31.73 (C3), 28.84 (C4), 
27.55 (C8), 25.73 (C7), 25.45 (C5), 25.37 (C9), 23.12 (C6).  
 
      
Figure B. 17 1H NMR spectrum of 2-hydroxycyclodecanone (CYP101C1). 
 








Figure B. 19 gCOSY NMR spectrum of 2-hydroxycyclodecanone (CYP101C1). 





Figure B. 20 HSQC NMR spectrum of 2-hydroxycyclodecanone (CYP101C1). 
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NMR for 1-oxabicyclo[5.3.1]undecan-1-ol 218 : 
1H NMR (500 MHz, CDCl3) δ 4.07-4.97 (m, 1H, H5), 2.50-2.43 (m, 1H, OH1(C1)), 1.92-1.72 
(m, 8H, H2, H3, H6, H7, H8, H9 & 2xH10), 1.71-1.61 (m, 4H, H2, H4, H7 & H8), 1.60-1.47 
(m, 3H, H2, H4 & H9), 1.40-1.33 (m, 1H, H3), 1.2-1.15 (m, 1H, H6). 
13C NMR (126 MHz, CDCl3) δ 98.85 (C1), 76.33 (C5), 40.33 (C2), 39.95 (C10), 35.24 (C6), 




Figure B. 21 1H NMR spectrum of 1-oxabicyclo[5.3.1]undecan-1-ol (72%; B; CYP101B1). 
The other minor product 5-hydroxycyclodecanone (A) was also present (28%) in the NMR. 
The H5 (A) peak of 5-hydroxycyclodecanone at 3.79 ppm was observed (Table 3. 4) 218. 








Figure B. 23 gCOSY NMR spectrum of 1-oxabicyclo[5.3.1]undecan-1-ol (CYP101B1). 














Figure B. 25 Zoomed in (18 ppm to 104 ppm region) version of HMBC NMR spectrum of 1-
oxabicyclo[5.3.1]undecan-1-ol to highlight the C-H interactions in this region (CYP101B1). 
The product was confirmed oxabicycloalkanols as 13C and HMBC NMR had no C=O peak. 
Instead of C=O peak, a characteristic signal of C1 was observed at 98.85 ppm which displayed 
a correlation with H5 (3.97-4.07 ppm) in HMBC NMR. The product was further confirmed by 
comparing the NMR spectrum with the reported NMR in the literature 218. 
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NMR for 1-oxabicyclo[6.3.1]undecan-1-ol and and 6-hydroxycyclodecanone mixture 218:   
1H NMR (600 MHz, CDCl3) δ 4.13-4.01 (m, 1H, H6; B), 3.9-3.79 (m, 1H, H6; A), 2.70-1.59 
(m, 2H, 2xH2; A), 2.41-2.33 (m, 2H, 2xH10; A), 2.01-1.87 (m, 4H, 2xH2; B & 2xH3; A), 1.80-
1.72 (m, 8H, 2xH5; B, 2xH7; B, 2xH10; B & 2xH9; A), 1.7-1.61 (m, 4H, 2xH4; B & 2xH8; 
B), 1.63-1.46 (m, 12H, 2xH3; B, 2xH9; B, 2xH4; A, 2xH5; A, 2xH7; A & 2xH8; A) 
13C NMR (151 MHz, CDCl3) δ 217.20 (C1; A), 105.08 (C1; B), 78.08 (C6; B), 72.20 (C6; A), 
44.54 (C2 & C10; A), 43.18 (C2 & C10; B ), 36.47 (C5 & C7; A&B), 27.57 (C4 & C8; B), 
25.93 (C3 & C9; A), 25.36 (C4 & C8; A, C3 & C9; B). 
 
 
Figure B. 27 1H NMR spectrum of 1-oxabicyclo[6.3.1]undecan-1-ol and 6-
hydroxycyclodecanone mixture (CYP101B1). The H6; B and H6; A was confirmed by 
comparing the reported 1H NMR in literature (Table 3. 4) 218. 







Figure B. 28 (a) 13C NMR spectrum of 1-oxabicyclo[6.3.1]undecan-1-ol and 6-
hydroxycyclodecanone mixture (CYP101B1) 218. (b) Zoomed in version of 13C NMR spectrum 
(70 ppm to 220 ppm region) to highlight the minor metabolite signals that was assigned as 4-
hydroxy via the HMBC NMR below. 
 




Figure B. 29 gCOSY NMR spectrum of 1-oxabicyclo[6.3.1]undecan-1-ol and 6-
hydroxycyclodecanone mixture (CYP101B1). 
 
Figure B. 30 HSQC NMR spectrum of 1-oxabicyclo[6.3.1]undecan-1-ol and 6-
hydroxycyclodecanone mixture (CYP101B1). 




          (a) 
 
       (b) 
Figure B. 31 (a) Zoomed in (20 ppm to 80 ppm region) version of HMBC NMR spectrum of 
1-oxabicyclo[6.3.1]undecan-1-ol and 6-hydroxycyclodecanone mixture to highlight the 
interactions of C-H in this region (CYP101B1). (b) Zoomed in (100 ppm to 220 ppm region) 
version of the HMBC NMR of 1-oxabicyclo[6.3.1]undecan-1-ol and 6-hydroxycyclodecanone 
(CYP101B1) which highlighted the correlations of C1,A and C1,B with the protons. 




           (a) 
 
      (b) 
 
Figure B. 32 (a) Zoomed in gCOSY NMR spectrum to highlight the interaction of H4 with 
H3. (b) Zoomed in version of HMBC NMR to highlight the peak of 4-hydroxy metabolite that 
confirmed by the correlations of C4 (72.83) with the protons of 2.41-2.33 ppm and 2.01-1.87 
ppm. The product was not fully characterised due to noise and low yield. 
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NMR for 2-hydroxycycloundecanone 216, 220, 221 : 
1H NMR (500 MHz, CDCl3) δ 4.30-4.24 (m, 1H, H2), 3.6-3.44 (m, 1H, OH2 (C2)), 2.96-2.75 
(m, 1H, H11), 2.37-2.25 (m, 1H, H11), 2.13-1.95 (m, 2H, H3 & H10), 1.79-1.5 (m, 4H, H4, 
H8, H9 & H10), 1.42-1.10 (m, 10H, H3, H4, 2xH5, 2xH6, 2xH7, H8 & H9). 
13C NMR (126 MHz, CDCl3) δ 216.74 (C1), 79.19 (C2), 39.90 (C11), 32.22 (C3), 29.45 (C7), 




Figure B. 33 1H NMR spectrum of 2-hydroxycycloundecanone (CYP101C1). 




Figure B. 34 13C NMR spectrum of 2-hydroxycycloundecanone (CYP101C1). 
 
 
Figure B. 35 gCOSY NMR spectrum of 2-hydroxycycloundecanone (CYP101C1). 









Figure B. 37 Zoomed in HSQC NMR spectrum to highlight the C-H correlations in 20-40 ppm 
region. 




Zoomed in 20-80 ppm region (HMBC NMR) 
 
Zoomed in C=O region of HMBC NMR spectrum. The product was confirmed as 2-hydroxy 
metabolite as C1 showed strong connections with H2, OH2, H3, H10 and H11. 
 
 Figure B. 38 Zoomed in HMBC NMR spectrum of 2-hydroxycycloundecanone. 
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NMR for 5-hydroxycycloundecanone: 
1H NMR (600 MHz, CDCl3) δ 3.76-3.70 (m, 1H, H5), 2.55-2.42 (m, 4H, 2xH2 & 2xH11), 
1.89-1.82 (m, 2H, 2xH3), 1.81-1.74 (m, 1H, H10), 1.73-1.63 (m, 2H, H4 & H10), 1.61-1.55 
(m, 1H, H4), 1.54-1.50 (m, 2H, H6 & H9), 1.48-1.42 (m, 1H, H6), 1.40-1.33 (m, 3H, H7, H8 
& H9), 1.31-1.26 (m, 2H, H7 & H8). 
13C NMR (151 MHz, CDCl3) δ 216.69 (C1), 72.36 (C5), 45.02 (C11), 44.97 (C2), 37.77 (C4), 
36.57 (C6), 28.68 (C9), 27.71 (C8), 25.0 (C10), 24.85 (C7), 22.33 (C3). 
 
 
Figure B. 40 1H NMR spectrum of 5-hydroxycycloundecanone (CYP101B1; GC-MS RT 9.25 
min). 
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Figure B. 41 13C NMR spectrum of 5-hydroxycycloundecanone. 
 
 
Figure B. 42 gCOSY NMR spectrum of 5-hydroxycycloundecanone. 















Zoomed in C=O region of HMBC NMR spectrum to highlight the C1 correlations with the H2, 
H3, H10 and H11. 
 
Zoomed in HMBC NMR to highlight the C-H interactions in 25 to 90 ppm region. The product 
was assigned as 5-hydroxycycloundecanone  as C5 have strong correlations with H3, H4 and 
H6. H4 was confirmed by the interaction between C4 with H2 peak in the HMBC NMR. 
Figure B. 44 HMBC NMR spectrum of 5-hydroxycycloundecanone (CYP101B1). 
Appendix B (Chapter 3) 
 
343 
NMR for 6-hydroxycycloundecanone: 
1H NMR (600 MHz, CDCl3) δ 3.72-3.66 (m, 1H, H6), 2.60-2.36 (m, 4H, 2xH2 & 2xH11), 
1.84-1.72 (m, 4H, 2xH3, 2xH10), 1.63-1.56 (m, 2H, 2xH5), 1.54-1.48 (m, 1H, H9), 1.47-1.42 
(m, 3H, H4 & 2xH7), 1.41-1.33 (m, 4H, H4, 2xH8 & H9). 
13C NMR (151 MHz, CDCl3) δ 216.91 (C1), 72.73 (C6), 44.71 (C2), 44.17 (C11), 35.81 (C7), 
34.79 (C5), 29.23 (C9), 25.18 (C10), 25.0 (C3), 24.42 (C4), 23.89 (C8). 
 
Figure B. 45 1H NMR spectrum of 6-hydroxycycloundecanone (CYP101B1). 
   
Figure B. 46 13C NMR spectrum of 6-hydroxycycloundecanone. 




Figure B. 47 gCOSY NMR spectrum of 6-hydroxycycloundecanone. 
 
 
Figure B. 48 HSQC NMR spectrum of 6-hydroxycycloundecanone. 
  




Zoomed in C=O region, which highlights the correlations of C1 with the H2, H11, H3 and 
H10. 
 
Zoomed in HMBC NMR to highlight the C-H interactions in 20 to 80 ppm region. The product 
was confirmed 6-hydroxycycloundecanone as C6 showed correlations with H4, H5, H7 and 
H8. C4 and C5 were assigned due to the interactions with H2 and H3, respectively. The H4 
and H5 proton peaks in 1H NMR were identified using the HSQC NMR. 
Figure B. 49 HMBC NMR spectrum of 6-hydroxycycloundecanone. 
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NMR for 2-hydroxycyclododecanone 208, 216, 219, 220: 
1H NMR (500 MHz, CDCl3) δ 4.44-4.34 (m, 1H, H2), 3.58-3.50 (m, 1H, OH2 (C2)), 3.01-2.96 
(m, 1H, H12), 2.26-2.18 (m, 1H, H10), 2.17-2.1 (m, 1H, H12), 1.99-1.87 (m, 2H, 2xH3), 1.60-
1.50 (m, 1H, H4), 1.21-1.46 (m, 13H, 2xH5, 2xH6, 2xH7, 2xH8, 2xH9, H10 & 2xH11), 0.77-
0.93 (m, 1H, H4).  
13C NMR (126 MHz, CDCl3) δ 215.55 (C1), 79.18 (C2), 36.93 (C12), 33.39 (C3), 28.76 (C5), 
28.72 (C11), 26.60, 25.34 (C8 & C9), 25.11 (C6), 24.73 (C7), 24.05 (C10), 21.35 (C4). 
 
Figure B. 50 1H NMR spectrum of 2-hydroxycyclododecanone (CYP101C1). 
 
Figure B. 51 1H NMR spectrum of 2-hydroxycyclododecanone (standard). 




Figure B. 52 13C NMR spectrum of 2-hydroxycyclododecanone (CYP101C1). 
 
 
Figure B. 53 gCOSY NMR spectrum of 2-hydroxycyclododecanone (CYP101C1). 




Figure B. 54 HSQC NMR spectrum of 2-hydroxycyclododecanone (CYP101C1). 
  




Zoomed in HMBC NMR spectrum to highlight the interactions of the C=O region. The product 
was confirmed 2-hydroxy due to the correlations of C1 (215.55 ppm) with OH2 (3.58-3.50 
ppm), H12 (3.01-2.96 ppm), H12 (2.17-2.1 ppm) and H3 (1.99-1.87 ppm). 
 
Zoomed in the region 15-80 ppm to highlight the interactions of C4 and C3 with H2 (4.44-4.34 
ppm). 
Figure B. 55 HMBC NMR spectrum of 2-hydroxycyclododecanone (CYP101C1). 
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Data for 7-hydroxycyclododecanone 208:  
1H NMR (500 MHz, CDCl3) δ 3.75-3.65 (m,1H, H7), 2.81-2.68 (m, 2H, H2 & H12), 2.25-2.11 
(m, 2H, H2 & H12), 1.92-1.8 (m, 2H, H3 & H11), 1.68-1.51 (m, 4H, H3, H6, H8 & H11), 1.49-
1.39 (m, 6H, H4, H5, H6, H8, H9 & H10), 1.37-1.29 (m, 2H, H5 & H9), 1.27-1.17 (m, 2H, H4 
& H10).  
13C NMR (126 MHz, CDCl3) δ 215.27 (C1), 71.43 (C7), 42.96 (C2 & C12), 36.62 (C6 & C8), 




Figure B. 56 1H NMR spectrum of 7-hydroxycyclododecanone (CYP101B1). 








Figure B. 58 gCOSY spectrum NMR of 7-hydroxycyclododecanone. 



















Zoomed in the 20 to 76 ppm region, which highlighted the C-H correlations 
 
 
Zoomed in the HMBC NMR C=O region to highlight the interactions of C1 (215.27 ppm) with 
H2 and H12 (2.81-2.68 ppm & 2.25-2.11 ppm) and with H3 and H11 (1.92-1.8 ppm & 1.68-
1.51 ppm). 
         
Figure B. 60 HMBC NMR spectrum of 7-hydroxycyclododecanone (CYP101B1). 
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NMR for 8-hydroxycylopentadecanone 208: 
1H NMR (600 MHz, CDCl3) δ 3.71-3.64 (m, 1H, H8), 2.47-2.33 (m, 4H, 2xH2 & 2xH15), 
1.74-1.60 (m, 4H, 2xH3 & 2xH14), 1.58-1.43 (m, 4H, 2xH7 & 2xH9), 1.40-1.25 (m, 14H, 
2xH4, 2xH5, 2xH6, 2xH10, 2xH11, 2xH12 & 2xH13).  
13C NMR (151 MHz, CDCl3) δ 215.30 (C1), 72.70 (C8), 44.86 (C2), 44.56 (C15), 37.35 (C7), 
37.30 (C9), 30.18 (C5), 30.16 (C13), 29.64 (C4), 29.63 (C11), 29.51 (C12), 26.26 (C3), 25.90 
(C6), 25.70 (C14), 25.45 (C10). 
 
Figure B. 61 1H NMR spectrum of 8-hydroxycyclopentadecanone (CYP101B1). 
 







Figure B. 62 (a) 13C NMR spectrum of 8-hydroxycyclopentadecanone and some minor peaks 
were also observed indicating one or two minor metabolites (5%) might present. (b) Zoomed 
in 13C NMR spectrum of 8-hydroxycyclopentadecanone from the 25 to 73 ppm region. 




Figure B. 63 gCOSY NMR spectrum of 8-hydroxycyclopentadecanone (CYP101B1). 
 
 
Figure B. 64 Zoomed in (20 to 50 ppm region) HSQC NMR spectrum of 8-
hydroxycyclopentadecanone (CYP101B1). 




Figure B. 65 HSQC NMR spectrum of 8-hydroxycyclopentadecanone (CYP101B1). 
 
 
Figure B. 66 Zoomed in (20 to 30 ppm region) HMBC NMR spectrum of 8-
hydroxycyclopenta- decanone which highlighted the correlations of carbons with the protons. 
 




Figure B. 67 Zoomed in C=O (215.30 ppm) region of HMBC NMR spectrum of 8-
hydroxycyclopenta- decanone which highlighted the correlations of C1 (215.30 ppm) with H2, 
H3, H14 and H15. 
 
Figure B. 68 HMBC NMR spectrum of 8-hydroxycyclopentadecanone. 
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NMR data for trans-4-hydroxycyclohexyl acetate:  
1H NMR (500 MHz, CDCl3) δ 4.77-4.70 (m, 1H, H1), 3.76-3.68 (m, 1H, H4), 2.04 (s, 3H, 
3xH8), 2.02-1.93 (m, 4H, H2eq, H3eq, H5eq & H6eq), 1.54-1.36 (m, 4H, H2ax, H3ax, H5ax & 
H6ax). 
13C NMR (126 MHz, CDCl3) δ 173.27 (C7), 74.38 (C1), 71.66 (C4), 34.94 (C3 & C5), 31.27 




Figure B. 69 1H NMR spectrum of trans-4-hydroxycyclohexyl acetate (cyclohexyl acetate).  
 




Figure B. 70 13C NMR spectrum of trans-4-hydroxycyclohexyl acetate (cyclohexyl acetate). 
 
 
Figure B. 71 gCOSY NMR spectrum of trans-4-hydroxycyclohexyl acetate (cyclohexyl 
acetate). 




Figure B. 72 HSQC NMR spectrum of trans-4-hydroxycyclohexyl acetate (cyclohexyl 
acetate). 
 
Figure B. 73 HMBC NMR spectrum of trans-4-hydroxycyclohexyl acetate (cyclohexyl 
acetate). 




                 (a) 
 
                 (b) 
 
Figure B. 74 (a) ROESY NMR spectrum of trans-4-hydroxycyclohexyl acetate. (b) Zoomed 
in ROESY NMR highlighted the interactions of H1 (4.77-4.70 ppm) and H4 (3.76-3.72 ppm) 
with the protons of 2.02-1.93 ppm and 1.54-1.36 ppm region. 
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Data for trans-4-hydroxycyclohexyl butyrate:  
1H NMR (500 MHz, CDCl3) δ 4.78-4.66 (m, 1H, H1), 3.71-3.60 (m, 1H, H4), 2.22 (t, J = 7.4 
Hz, 2H, 2xH8), 1.99-1.88 (m, 4H, H2eq, H3eq, H5eq & H6eq), 1.61 (sextet, J = 7.4 Hz, 2H, 
2xH9), 1.47-1.33 (4H, H2ax, H3ax, H5ax & H6ax), 0.91 (t, J = 7.4 Hz, 3H, 3xH10) 
13C NMR (126 MHz, CDCl3) δ 175.93 (C7), 74.11 (C1), 71.47 (C4), 39.17 (C8), 34.80 (C3 & 




Figure B. 75 1H NMR spectrum of trans-4-hydroxycyclohexyl butyrate (cyclohexyl butyrate). 
 




Figure B. 76 13C NMR spectrum of trans-4-hydroxycyclohexyl butyrate (cyclohexyl butyrate). 
 
 
Figure B. 77 gCOSY NMR spectrum of trans-4-hydroxycyclohexyl butyrate (cyclohexyl 
butyrate). 


















                              (a) 
 
 
                              (b) 
Figure B. 79 (a) ROESY NMR spectrum of trans-4-hydroxycyclohexyl butyrate. (b) Zoomed 
in ROESY NMR which highlighted the interactions of H1 (4.78-4.66 ppm) and H4 (3.71-3.60 
ppm) with the protons of 1.99-1.88 ppm and 1.47-1.33 ppm region. 
 
Appendix B (Chapter 3) 
 
367 
NMR for trans-4-hydroxycyclohexyl isobutyrate: 
1H NMR (500 MHz, CDCl3) δ 4.78-4.69 (m, 1H, H1), 3.78-3.7 (m, 1H, H4), 2.51 (septet, J = 
7 Hz, 1H, H8), 2.04-1.89 (m, 4H, H2eq, H3eq, H5eq & H6eq), 1.51-1.43 (m, 4H, H2ax, H3ax, H5ax 
& H6ax), 1.16 (d, J = 7.0 Hz, 6H, 3xH9 & 3xH10) 
13C NMR (126 MHz, CDCl3) δ 179.33(C7), 73.82(C1),71.6 (C3), 36.83 (C8), 34.75 (C3 & 












Figure B. 81 13C NMR spectrum of trans-4-hydroxycyclohexyl isobutyrate (cyclohexyl 
isobutyrate). 
 
Figure B. 82 gCOSY NMR spectrum of trans-4-hydroxycyclohexyl isobutyrate (cyclohexyl 
isobutyrate). 





Figure B. 83 HSQC NMR spectrum of trans-4-hydroxycyclohexyl isobutyrate (cyclohexyl 
isobutyrate). 
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NMR for 4-(1-hydroxy-2-methylpropan-2-yl)cyclohexyl acetate: 
1H NMR (500 MHz, CDCl3) δ 4.66-4.56 (m, 1H, H1), 3.39 (s, 2H, 2xH8), 2.06-1.95 (m, 5H, 
H2, H6, 3xH12), 1.81-1.72 (m, 2H, H3, H5), 1.35-1.27 (m, 3H, H2, H4, H6), 1.2-1.13 (m, 2H, 
H3, H5), 0.84 (s, 6H, 3xH9, 3xH10). 
13C NMR (126 MHz, CDCl3) δ 173.39 (C11), 76.18 (C1), 73.38 (C8), 44.57 (C4), 34.68 (C2 
& C6), 27.73 (C3 & C5), 24.39 (C12), 24.11 (C7). 
 
 
Figure B. 84 1H NMR spectrum of 4-(1-hydroxy-2-methylpropan-2-yl)cyclohexyl acetate (4-
tert-butylcyclohexyl acetate). The coupling constants of H1 peak J = 4.2, 11.3 Hz indicated it’s 
a trans isomer of 4-tert-butylcyclohexyl acetate (Figure B. 85). 







Figure B. 85 (a) The 1H NMR spectrum of a mixture of cis and trans 4-tert-butylcyclohexyl 
acetate (substrate). (b) Zoomed in 1H NMR spectrum of the substrate to highlight the H1 peaks 
and from the coupling constants of both peak cis and trans isomers were assigned. 




Figure B. 86 13C NMR spectrum of 4-(1-hydroxy-2-methylpropan-2-yl)cyclohexyl acetate (4-
tert-butylcyclohexyl acetate). 
 
Figure B. 87 gCOSY NMR spectrum of 4-(1-hydroxy-2-methylpropan-2-yl)cyclohexyl 
acetate (4-tert-butylcyclohexyl acetate). 




Figure B. 88 HSQC NMR spectrum of 4-(1-hydroxy-2-methylpropan-2-yl)cyclohexyl acetate 
(4-tert-butylcyclohexyl acetate). 
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NMR data for methyl-2-(trans-4-hydroxycyclohexyl)acetate:  
1H NMR (500 MHz, CDCl3) δ 3.68 (s, 3H, 3xH9), 3.59-3.52 (m, 1H, H4), 2.21 (d, J = 6.8 Hz, 
2H, 2xH7), 2.02-1.94 (m, 2H, H3eq & H5eq), 1.84-1.74 (m, 3H, H1, H2eq & H6eq), 1.36-1.28 
(m, 2H, H3ax & H5ax), 1.12-1.00 (m, 2H, H2ax & H6ax). 
13C NMR (126 MHz, CDCl3) δ 175.94 (C8), 73.25 (C4), 54.10 (C9), 43.71 (C7), 37.86 (C3 & 




Figure B. 89 1H NMR spectrum of methyl-2-(trans-4-hydroxycyclohexyl)acetate 
(methylcyclohexyl acetate). The coupling constants of H4 and H1 indicated their axial 
orientation and therefore the metabolite was assigned as a trans isomer. 








Figure B. 91 gCOSY NMR spectrum of methyl-2-(trans-4-hydroxycyclohexyl)acetate. 




Figure B. 92 HSQC NMR spectrum of methyl-2-(trans-4-hydroxycyclohexyl)acetate. 
 
 
Figure B. 93 HMBC NMR spectrum of methyl-2-(trans-4-hydroxycyclohexyl)acetate. 
 
 




Figure B. 94 Zoomed in ROESY NMR of methyl-2-(trans-4-hydroxycyclohexyl)acetate 
which highlighted the interactions of H7 (equatorial side chain) with the H6ax/eq protons. 
 
 
Figure B. 95 Zoomed in ROESY NMR spectrum of methyl-2-(trans-4-
hydroxycyclohexyl)acetate which highlighted the interactions of H4 (axial) with the protons 
H2/6ax at 1.12-1.00 ppm. 
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 NMR data for ethyl-trans-2-(4-hydroxycyclohexyl)acetate: 
1H NMR (500 MHz, CDCl3) δ 4.13 (q, J = 7.1 Hz, 2H, 2xH9), 3.59-3.50 (m, 1H, H4), 2.19 (d, 
J = 6.7 Hz, 2H, 2xH7), 2.02-1.91 (m, 2H, H3eq & H5eq), 1.84-1.71 (m, 3H, H1, H2eq & H6eq), 
1.3-1.23 (m, 5H, H3ax, H5ax & 3xH10), 1.11-1.01 (m, 2H, H2ax & H6ax). 
13C NMR (126 MHz, CDCl3) δ 175.52 (C8), 73.26 (C4), 62.86 (C9), 43.98 (C7), 37.87 (C3 & 




Figure B. 96 1H NMR spectrum of ethyl-trans-2-(4-hydroxycyclohexyl)acetate 
(ethylcyclohexyl acetate). The coupling constants of H1 and H4 indicated their axial orientation 
and therefore the metabolite was assigned as a trans isomer. 
 




Figure B. 97 13C NMR spectrum of ethyl-trans-2-(4-hydroxycyclohexyl)acetate. 
 
 
Figure B. 98 gCOSY NMR spectrum of ethyl-trans-2-(4-hydroxycyclohexyl)acetate. 




Figure B. 99 HSQC NMR spectrum of ethyl-trans-2-(4-hydroxycyclohexyl)acetate.  
 
 
Figure B. 100 HMBC NMR spectrum of ethyl-trans-2-(4-hydroxycyclohexyl)acetate. 




Figure B. 101 Zoomed in ROESY NMR spectrum of ethyl-trans-2-(4-
hydroxycyclohexyl)acetate which highlighted the interactions of H4 (3.59-3.50 ppm; axial) 
with the protons H2/6ax at 1.11-1.01 ppm.  
 
 
Figure B. 102 Zoomed in ROESY NMR spectrum of ethyl-trans-2-(4-
hydroxycyclohexyl)acetate which displayed the interactions of H7 (equatorial side chain) with 
the H6ax/eq protons. 
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NMR for 5-hydroxycyclooctyl acetate: 
1H NMR (500 MHz, CDCl3) δ 4.93-4.85 (m, 1H, H1), 3.87-3.78 (m, 1H, H5), 2.01 (s, 3H, 
3xH10), 1.90-1.77 (m, 4H, H2, H4, H6 & H8), 1.75-1.59 (m, 8H, H2, 2xH3, H4, H6, 2xH7 & 
H8). 
13C NMR (126 MHz, CDCl3) δ 173.0 (C9), 76.61 (C1), 73.88 (C5), 37.87 (C4 & C6), 34.93 





Figure B. 103 (a) 1H NMR spectrum of 5-hydroxycyclooctyl acetate. (b) Zoomed in 1H NMR 
to highlight the H1 and H5 peaks splitting patterns. The coupling constants of H1 (3.6 and 8.6 
Hz) and H5 (3.7 and 8.3) nearly similar indicated their similar orientation (both axial). Hence, 
the metabolite is presumed to be a trans isomer.  




Figure B. 104 13C NMR of 5-hydroxycyclooctyl acetate. Minor signals indicated the presence 
of other diastereomer of 5-hydroxycyclooctyl acetate (77.19, 74.25, 38.53, 35.58, 24.68, 22.79 
ppm). But full characterisation of this minor metabolite was not possible due to low yield. 
 
 
Figure B. 105 gCOSY NMR spectrum of 5-hydroxycyclooctyl acetate. 




Figure B. 106 HSQC NMR spectrum of 5-hydroxycyclooctyl acetate. 
 
Figure B. 107 HMBC NMR spectrum of 5-hydroxycyclooctyl acetate. 








Figure B. 108 (a) ROESY NMR spectrum of 5-hydroxycyclooctyl acetate. (b) Zoomed in 
ROESY NMR to highlight the strong interactions of H1 and H5 with the other protons. 
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NMR for 5-hydroxycyclooctyl isobutyrate:  
1H NMR (500 MHz, CDCl3) δ 4.95-4.89 (m, 1H, H1), 3.88-3.74 (m, 1H, H5), 2.48 (septet, J = 
7.0 Hz, 1H, H10), 1.94-1.88 (m, 2H, H4, H6), 1.82-1.76 (m, 2H, 2H, H2 & H8), 1.76-1.56 (m, 
8H, H2, 2xH3, H4, H6, 2xH7 & H8), 1.13 (d, J = 7.0 Hz, 6H, 3xH11 & 3xH12). 
13C NMR (126 MHz, CDCl3) δ 179.06 (C9), 76.10 (C1), 73.92 (C5), 37.85 (C4 & C6), 36.81 
(C10), 34.92 (C2 & C8), 21.59 (C3, C7), 21.53 (C11 & C12). 
 
                                                                       (a) 
   
(b) 
Figure B. 109 (a) 1H NMR of 5-hydroxycyclooctyl isobutyrate. (b) The coupling constants of 
H1 and H5 were similar to each other suggested their similar orientation (both axial), therefore 
the metabolite is presumed to be a trans isomer of 5-hydroxycyclooctyl isobutyrate. 




Figure B. 110 13C NMR spectrum of 5-hydroxycyclooctyl isobutyrate. The minor carbon 
signals: 76.78, 76.40, 74.22, 74.07, 38.53, 36.86, 36.30, 35.50, 33.32, 32.78, 32.33, 29.81, 
25.36, 25.07 and 22.77. Minor signals indicated the presence of other diastereomer of 5-
hydroxycyclooctyl isobutyrate and a minor unidentified metabolite. But fully characterisation 
of these metabolites were not possible due to low yield. 
 
Figure B. 111 gCOSY NMR spectrum of 5-hydroxycyclooctyl isobutyrate. 




Figure B. 112 HSQC NMR spectrum of 5-hydroxycyclooctyl isobutyrate. 
 
 
Figure B. 113 HMBC NMR spectrum of 5-hydroxycyclooctyl isobutyrate. 




                                                                                  (a) 
 
 
                                                                                 (b) 
Figure B. 114 (a) ROESY NMR spectrum of 5-hydroxycyclooctyl isobutyrate. (b) Zoomed in 
ROSEY NMR to highlight the strong interactions of H1 and H5 with adjacent protons. 
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NMR for 7-hydroxycyclododecyl acetate 150 (CYP101B1): 
1H NMR (500 MHz, CDCl3) δ 4.91 (t, J = 8.1 Hz, 1H, H1), 3.89-3.80 (m, 1H, H7), 2.02 (s, 3H, 
3xH14), 1.73-1.61 (m, 4H, H2, H6, H8 & H12), 1.57-1.50 (m, 4H, H2, H6, H8 & H12), 1.48-
1.32 (m, 12H, 2xH3, 2xH4, 2xH5, 2xH9, 2xH10 & 2xH11). 
13C NMR (126 MHz, CDCl3) δ 170.57 (C13), 73.61 (C1), 70.83 (C7), 30.83 (C2 & C12), 27.53 







Figure B. 115 (a) 1H NMR spectrum of 7-hydroxycyclododecyl acetate 150. (b) Zoomed in 
proton NMR to highlight the H1 and H7 peaks. The H1 and H7 peaks and their coupling 
constants JH1 = 5.5, 8.1 Hz and JH7 = 5.0, 8.0 Hz are almost similar, suggested both protons are 
in the same orientation (both axial). The product therefore assigned as a trans isomer.  
 








Figure B. 116 (a) 13C NMR spectrum of 7-hydroxycyclododecyl acetate (trans; RT 17.3 min 
in GC) 150. The product was assigned as 7-hydroxy as in 13C showed symmetrical carbon peaks 
of the cyclic ring. (b) The NMR highlighted the minor carbon signals of 7-
hydroxycyclododecyl acetate (cis; RT 16.5 min) 150. The 13C NMR also had additional minor 
product signals, that product was presumed to be another alcohol or the other diastereomer of 
5-hydroxycyclododecyl acetate (RT 16.4 min; see below Table B. 1). 




Figure B. 117 gCOSY NMR spectrum of 7-hydroxycyclododecyl acetate. 







Figure B. 118 (a) HSQC NMR of 7-hydroxycyclododecyl acetate (trans). (b) Zoomed in the 
HSQC NMR in 65 to 80 ppm region to highlight the interactions of minor product C1 and C7 
signals with the proton of 5.04-4.99 ppm and 3.9-3.81 ppm regions, which was assigned as 
other diastereomer of 7-hydroxy cyclododecyl acetate (cis; RT 16.5 min in GC; Table B. 1) 150. 
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Figure B. 119 1H NMR spectrum of 5-hydroxycyclododecyl acetate (RT 16.2 min in GC). 
 
Figure B. 120 13C NMR highlighted the carbon signals of 5-hydroxycyclododecyl acetate. 
 
Table B. 1 The carbon signals detected in the 13C NMR of different metabolites of 
cyclododecyl acetate (in CDCl3). 
Products 13C NMR signals 
5-hydroxycyclododecyl acetate (RT 16.2 min 
in GC) 
170.86, 71.31, 68.39, 33.19, 32.92, 30.88, 
29.69, 29.56, 23.82, 23.63, 23.54, 21.36, 
20.70, 20.32 
Unidentified metabolite: another alcohol or 
other diastereomer of 5-hydroxycyclododecyl 
acetate, Signals observed in 13C NMR of 5-
hydroxycyclododecyl acetate (RT 16.4 min) 
71.54, 68.55, 32.88, 32.71, 29.44, 23.51, 
23.46, 22.22, 21.87, 21.36, 20.99, 20.96, 
20.87, C=O peak not detected 
trans-7-hydroxycyclododecyl acetate 150 170.57, 73.61, 70.83, 30.83, 27.53, 25.88, 
21.36, 19.14, 18.97 
cis-7-hydroxycyclododecyl acetate 150 71.73, 68.75, 32.43, 29.14, 24.07, 21.36, 
20.97, 20.94, 18.97, C=O peak not detected 




    (a) 
 
 
    (b) 
 
Figure B. 121 (a) gCOSY NMR spectrum of 5-hydroxycyclododecyl acetate. (b) HSQC NMR 
spectrum of 5-hydroxycyclododecyl acetate. 




Figure B. 122 HMBC NMR spectrum of 5-hydroxycyclododecyl acetate. The metabolite was 
confirmed 5-hydroxy metabolite as both H1 and H5 showed strong interactions with C3.  
 
 
Figure B. 123 1H NMR spectrum of 7-hydroxycyclododecyl acetate (cis; CYP101C1). But this 
product was not generated in enough yield for characterisation by NMR. The peak of H1 (5.04-
4.99 ppm) and GC coelution experiment with the metabolite of CYP101B1, enabled 
confirmation as 7-hydroxycyclododecyl acetate (cis) 150. 
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NMR for 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-trimethyl-,α-acetate: 
1H NMR (500 MHz, CDCl3) δ 5.52-5.41 (m, 1H, H3), 4.20 (brd s, 1H, H5), 2.28-2.19 (m, 1H, 
H1), 2.19-2.13 (m, 1H, H6), 2.02-1.97 (m, 4H, H2 & 3xH12), 1.92-1.85 (m, 1H, H2), 1.76 (s, 
3H, 3xH7), 1.48-1.41 (2s, 6H, 3xH9 & 3xH10), 1.35-1.20 (m, 1H, H6).  
13C NMR (126 MHz, CDCl3) δ C11 (173.12), C4 (139.06), C3 (126.18), C8 (86.64), C5 





Figure B. 124 1H NMR spectrum of 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-trimethyl-
,α-acetate (CYP101C1). The minor peaks at 5.56 ppm and 4.01 ppm indicated the presence of 
other diastereomer of 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-trimethyl-,α-acetate 
(Figure B. 131). 
  




Figure B. 125 gCOSY NMR spectrum of 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-
trimethyl-,α-acetate (CYP101C1). 
 
Figure B. 126 Zoomed in gCOSY NMR spectrum region of 4.1 ppm to 5.55 ppm to highlight 
the interactions. The product was confirmed due to strong coupling of H5 (4.21 ppm) with H6 
(2.19-2.13 ppm) and H6 (1.35-1.20). H3 showed strong coupling with H2 and a weak coupling 
with the H7. 




                                                                      (a) 
 
 
                                                         (b) 
Figure B. 127 (a) 13C NMR of 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-trimethyl-,α-
acetate (CYP101C1). (b) Highlighted the signals of minor product which was assigned as the 
other diastereomer of 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-trimethyl-, α-acetate. 




Figure B. 128 HSQC NMR spectrum of 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-
trimethyl-,α-acetate (CYP101C1), highlighted the C-H interactions. 
 
Figure B. 129 HMBC NMR spectrum of 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-
trimethyl-,α-acetate (CYP101C1). 





Figure B. 130 HMBC NMR spectrum of 3-cyclohexene-1-methanol, 5-hydroxy-α,α,4-
trimethyl-,α-acetate (CYP101C1), highlighted the correlations of C5 with H3, H6 and H7. 
  






Figure B. 131 Zoomed in HMBC NMR spectrum of major product (3-cyclohexene-1-
methanol, 5-hydroxy-α,α,4-trimethyl-,α-acetate) to highlight the minor product signals. The 
minor product was presumed to be diastereomer of the main product as C5 signal showed a 
correlation with H7 as well as the presence of two alkene carbons peaks at 120 to 140 ppm 
region in the 13C NMR.  
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NMR for 8-hydroxy-2-nonanone: 
1H NMR (500 MHz, CDCl3) δ 3.86-3.73 (m, 1H, H8), 2.44 (t, J = 7.4 Hz, 2H, 2xH3), 2.14 (s, 
3H, 3xH1), 1.69-1.59 (m, 2H, 2xH4), 1.48-1.39 (m, 3H, H6 & 2xH7), 1.37-1.29 (m, 3H, 2xH5 
& H6), 1.19 (d, J = 6.2 Hz, 3H, 3xH9). 
13C NMR (126 MHz, CDCl3) δ 211.86 (C2), 70.71 (C8), 46.30 (C3), 41.73 (C7), 32.54 (C1), 




Figure B. 132 1H NMR spectrum of 8-hydroxy-2-nonanone (CYP101B1). 
 




Figure B. 133 13C NMR spectrum of 8-hydroxy-2-nonanone (CYP101B1). 
 
 
Figure B. 134 gCOSY NMR spectrum of 8-hydroxy-2-nonanone (CYP101B1). 








Figure B. 136 HMBC NMR spectrum of 8-hydroxy-2-nonanone (CYP101B1). 
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NMR for 8-hydroxy-2-undecanone: 
1H NMR (500 MHz, CDCl3) δ 3.63-3.53 (quintet, 1H, H8), 2.44 (dd, J = 15.5, 7.8 Hz, 2H, 
2xH3), 2.14 (s, 3H, 3xH1), 1.65-1.53 (m, 2H, 2xH4), 1.52-1.37 (m, 6H, H6, 2xH7, 2xH9 & 
H10), 1.36-1.28 (m, 4H, 2xH5, H6 & H10), 0.96-0.88 (m, 3H, 3xH11).  
13C NMR (126 MHz, CDCl3) δ C2 (211.83), C8 (74.26), C3 (46.32), C9 (42.38), C7 (39.90), 
C1 (32.50), C5 (31.84), C6 (28.06), C4 (26.42), C10 (21.53), C11 (16.78). 
 
 












Figure B. 138 (a) 13C NMR spectrum of 8-hydroxy-2-undecanone. (b) The zoomed in 13C 
NMR of the region 70-76 ppm to highlight the carbon peaks of minor metabolites. 








Figure B. 140 HSQC NMR spectrum of 8-hydroxy-2-undecanone (CYP101B1). 









Figure B. 141 (a and b) HMBC NMR spectrum of 8-hydroxy-2-undecanone (CYP101B1). (b) 
The product was confirmed 8-hydroxy-2-undecanone as carbon signal (74.26 ppm) showed 
correlations with the protons H6, H7, H9 and H10 (1.52-1.37 ppm).  







Figure B. 142 (a) Zoomed in the HMBC NMR spectrum of 8-hydroxy-2-undecanone to 
highlight the C-H interactions of minor metabolites. The peak at 75.94 ppm showed a strong 
correlation with H11 protons and this product was assigned as a 9-hydroxy metabolite. The 
minor signal at 74.34 ppm displayed the interaction with the protons at 1.52-1.28 ppm. Other 
carbon signals C1, C4, C5, C6, C8, C9, C10, C11 of this metabolite were identified using the 
C-H correlations in the HMBC NMR (b). Hydroxylation did not occur at C3 as 74.34 ppm 
carbon signal has no correlation with H4 peak. Therefore the product was presumed to be a 7-
hydroxy metabolite. However, full characterisation of these metabolites were not possible due 
to noise and low yield. 
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Figure C. 1 Mass Spectra Analysis 
 
MS analysis of 1-adamantylmethyl ketone products 
MS analysis of 3-hydroxy-1-adamantylmethyl ketone (m+/z = 194.05) RT 9.2 min. 
 
MS analysis of trans-4-hydroxy-1-adamantylmethyl ketone (m+/z = 194.05) RT 10.2 min. 
 
MS analysis of methyl-2-(1-adamantyl acetate) 
MS analysis of methyl-2-(trans-4-hydroxy-1-adamantyl) acetate (m+/z = 224.05) RT 15.6 min. 
 
MS analysis of methyl-2-(3-hydroxy-1-adamantyl) acetate (m+/z = 224.05) RT 14.8 min. 
 
 
MS analysis of 1-adamantyl acetate 















107.0555.05 81.0567.05 194.05133.05123.05117.05 147.05 176.10161.15 167.25







79.05 105.0555.05 194.0567.05 95.05 123.15117.05 179.10 192.05147.35 161.35 167.10









55.10 67.05 164.10107.05 117.05 193.05146.10 174.05 224.05 238.00










55.10 193.05 206.05121.05 149.05 181.10 227.20
247.20







111.0555.10 82.1069.10 132.00 207.00121.15 168.20 192.15140.30
216.25
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MS analysis of trans-4-hydroxyl-1-adamantyl acetate (m+/z = 210.10) RT 9.9 min 
 




MS analysis of 1-adamantyl isobutyrate 
MS analysis of trans-4-hydroxy-1-adamantyl isobutyrate (m+/z = 238.05) RT 11.5 min 
  





MS analysis of 2-adamantyl acetate 















67.10 132.1081.10 121.10 149.10 208.10195.05165.50 180.55







149.10 208.10129.10 195.05 210.20165.50155.55 180.55
218.35
141.60









149.15 206.90 238.05163.15 220.25177.20








55.10 107.0571.00 81.10 133.10 207.00117.05 149.10 235.00220.20163.50
249.40








79.1058.10 107.1067.10 132.15121.10 149.15 210.10167.20 182.15 193.40
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MS analysis of a minor product from 2-adamantyl acetate turnover RT 10.1 min (m+/z = 
210.20)  
 
         
Zoomed in version 
 
 
MS analysis of 2-adamantyl isobutyrate 
MS analysis of 5-hydroxy-2-adamantyl isobutyrate (m+/z = 238.10) RT 11.1 min. 
 
MS analysis of minor product from 2-adamantyl isobutyrate (m+/z = 238.25) RT 11.4 min 
 















79.05 117.1057.10 132.10104.0567.05 81.05 122.10 207.05148.10 167.25 194.45







141.15 155.10 167.25 210.20194.45







58.05 79.05 107.10 132.10117.10 163.10 238.10220.05202.15180.45







150.1079.05 132.10117.10104.1058.10 81.10 134.15 167.10 235.95207.10195.45
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MS analysis of N-(1-adamantyl)acetamide 
MS analysis of 3-hydroxy-N-(1-adamantyl)acetamide (m+/z = 209.1) RT 11.8 min. 
 
MS analysis of 4-hydroxy-N-(1-adamantyl)acetamide (m+/z = 209.1) RT 12.8 min. 
  







110.05 209.1057.10 93.10 136.05108.0579.05 149.20 166.15 191.10 210.05124.05 176.10






94.05 209.1057.10 110.1079.10 100.10 191.10149.1081.10 166.15 210.05124.10 179.10




Data for trans-4-hydroxy-1-adamantylmethyl ketone (~31 mg) 182:  
1H NMR (500 MHz, CDCl3) δ 3.88-3.84 (m, 1H, H4), 2.14-2.06 (m, 5H, H6, H8 & 3xH12), 
2.02-1.95 (m, 3H, H3, H5 & H7), 1.90-1.83 (m, 2H, H2 & H10), 1.82-1.75 (m, 4H, H2, 2xH9 
& H10), 1.45 (d, J = 12.6 Hz, 2H, H6 & H8). 
13C NMR (126 MHz, CDCl3) δ 216.17 (C11), 76.15 (C4), 48.34 (C1), 40.94 (C9), 39.93 (C2 
& C10), 36.68 (C3 & C5), 32.62 (C6 & C8), 29.86 (C7), 27.18 (C12). 
 
 
Figure C. 2 1H NMR spectrum of trans-4-hydroxy-1-adamantylmethyl ketone. 
 




Figure C. 3 13C NMR spectrum of trans-4-hydroxy-1-adamantylmethyl ketone. 
 
 
Figure C. 4 gCOSY NMR spectrum of trans-4-hydroxy-1-adamantylmethyl ketone. 





Figure C. 5 HSQC NMR spectrum of trans-4-hydroxy-1-adamantylmethyl ketone. 
 
        
         









Figure C. 6 (a) HMBC NMR spectrum of trans-4-hydroxy-1-adamantylmethyl ketone. (b) 
Zoomed in C=O region to highlight the interactions of C11 with H2, H9 and H10. 
 




Figure C. 7 Zoomed in ROESY NMR spectrum of trans-4-hydroxy-1-adamantylmethyl 
ketone to highlight the interactions of H4 with H2, H5 and H10. 
 
 
Figure C. 8 ROESY NMR spectrum of trans-4-hydroxy-1-adamantylmethyl ketone. 
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Data for 3-hydroxy-1-adamantylmethyl ketone (~20 mg) 182:  
1H NMR (500 MHz, CDCl3) δ 2.34-2.27 (m, 2H, H5 & H7), 2.12 (s, 3H, 3xH12), 1.78-1.74 
(m, 2H, 2xH2), 1.73-1.67 (m, 8H, 2xH4, 2xH8, 2xH9 & 2xH10), 1.63-1.59 (m, 2H, 2xH6). 
13C NMR (126 MHz, CDCl3) δ 214.87 (C11), 71.21 (C3), 52.65 (C1), 48.42 (C2), 47.03 (C4 




Figure C. 9 1H NMR spectrum of 3-hydroxy-1-adamantylmethyl ketone. 
 
 




Figure C. 10 13CNMR spectrum of 3-hydroxy-1-adamantylmethyl ketone. 
 
 
Figure C. 11 gCOSY NMR spectrum of 3-hydroxy-1-adamantylmethyl ketone. 




Figure C. 12 HSQC NMR spectrum of 3-hydroxy-1-adamantylmethyl ketone. 
  







Figure C. 13 Zoomed in HMBC NMR spectrum of 3-hydroxy-1-adamantylmethyl ketone to 
highlight the interactions of carbons (35-80 ppm, 70-73 ppm, 213-217 ppm) with protons. 
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Data for methyl-2-(trans-4-hydroxy-1-adamantyl) acetate (~25 mg):  
1H NMR (500 MHz, CDCl3) δ 3.88-3.83 (m,1H, H4), 3.65 (s, 3H, 3xH13), 2.10 (s, 2H, 2xH11), 
2.08-2.04 (m, 2H, H6 & H8), 1.96-1.88 (m, 3H, H3, H5 & H7), 1.72-1.66 (m, 2H, H2 & H10), 
1.65-1.59 (m, 4H, H2, 2xH9 & H10), 1.43 (d, J = 11.9 Hz, 2H, H6 & H8);  
13C NMR (126 MHz, CDCl3) δ 174.75 (C12), 76.63 (C4), 53.80 (C13), 50.35 (C11), 44.91 




Figure C. 14 1H NMR spectrum of methyl-2-(trans-4-hydroxy-1-adamantyl) acetate. 
 
 








Figure C. 16 gCOSY NMR spectrum of methyl-2-(trans-4-hydroxy-1-adamantyl) acetate. 








Figure C. 18 Zoomed in ROESY NMR spectrum of methyl-2-(trans-4-hydroxy-1-adamantyl) 
acetate highlighting the interactions of H4 with H2, H5 and H10. 
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Data for methyl-2-(3-hydroxy-1-adamantyl) acetate (~5 mg):  
1H NMR (500 MHz, CDCl3) δ 3.65 (s, 3H, 3xH13), 2.24-2.19 (m, 2H, H5, H7), 2.17 (s, 2H, 
2xH11), 1.71-1.61 (m, 4H, 2xH4 & 2xH8), 1.56-1.50 (m, 8H, 2xH2, 2xH6, 2xH9 & 2xH10). 
13C NMR (126 MHz, CDCl3) δ 174.90 (C12), 71.34 (C3), 53.85 (C13), 52.53 (C2), 50.29 
(C11), 47.09 (C4 & C8), 43.60 (C9 & C10), 38.60 (C1), 37.82 (C6), 33.24 (C5 & C7). 
 
 










Figure C. 21 13C NMR spectrum of methyl-2-(3-hydroxy-1-adamantyl) acetate. The product 
was confirmed 3-hydroxy as the carbon signals at 47.09 (C4 & C8), 43.60 (C9 & C10), 33.24 
(C5 & C7) displayed double the intensity than other peaks, suggesting the hydroxylation at 
symmetrical C3.  
 
Figure C. 22 gCOSY NMR spectrum of methyl-2-(3-hydroxy-1-adamantyl) acetate. 




Figure C. 23 HSQC NMR spectrum of methyl-2-(3-hydroxy-1-adamantyl) acetate. 
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Data for trans-4-hydroxy-1-adamantyl acetate (~26 mg) 182:  
1H NMR (500 MHz, CDCl3) δ 3.96-3.92 (m, 1H, H4), 2.16-2.09 (m, 7H, 2xH2, H7, 2xH9 & 
2xH10), 2.09-2.01 (m, 4H, H3, H5, H6 & H8), 1.96 (s, 3H, 3xH12),1.45 (d, J = 12.1 Hz, 2H, 
H6 & H8).  
13C NMR (126 MHz, CDCl3) δ 173.0 (C11), 81.76 (C1), 75.74 (C4), 43.93 (C9), 42.21 (C2 & 
C10), 38.93 (C3 & C5), 32.60 (C7), 32.34 (C6 & C8), 25.25 (C12). 
 
 
Figure C. 24 1H NMR spectrum of trans-4-hydroxy-1-adamantyl acetate. 
 
 




Figure C. 25 13C NMR spectrum of trans-4-hydroxy-1-adamantyl acetate. 
 
.  
Figure C. 26 gCOSY spectrum NMR of trans-4-hydroxy-1-adamantyl acetate. 




Figure C. 27 HSQC of NMR spectrum of trans-4-hydroxy-1-adamantyl acetate. 
 
 
Figure C. 28 HMBC NMR spectrum of trans-4-hydroxy-1-adamantyl acetate. 
 




Figure C. 29 Zoomed in ROESY NMR spectrum of trans-4-hydroxy-1-adamantyl acetate 
highlighting the interactions of the H4 with H5 and H10. 
 
 
Figure C. 30 ROESY NMR spectrum of trans-4-hydroxy-1-adamantyl acetate. 
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Data for 3-hydroxy-1-adamantyl acetate (~2 mg) 182: 
1H NMR (500 MHz, CDCl3) δ 2.36-2.29 (m, 2H), 2.14-2.04 (m, 6H), 1.99 (s, 3H, 3xH12), 
1.74-1.65 (m, 6H). 
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Data for trans-4-hydroxy-1-adamantyl isobutyrate (~35 mg) 182:  
1H NMR (500 MHz, CDCl3) δ 3.96-3.92 (m, 1H, H4), 2.42 (sept, J = 7.0 Hz, 1H, H12), 2.17-
2.09 (m, 7H, 2xH2, H7, 2xH9 & 2xH10), 2.08-2.01 (m, 4H, H3, H5, H6 & H8), 1.44 (d, J = 
14.7 Hz, 2H, H6 & H8), 1.11 (d, J = 7.0 Hz, 6H, 3xH13 & 3xH14).  
13C NMR (126 MHz, CDCl3) δ 179.19 (C11), 81.20 (C1), 75.82 (C4), 43.94 (C9), 42.21 (C2 
& C10), 38.94 (C3 & C5), 37.57 (C12), 32.60 (C7), 32.38 (C6 & C8), 21.69 (C13 & C14). 
 
 
Figure C. 32 1H NMR spectrum of trans-4-hydroxy-1-adamantyl isobutyrate. 
  




Figure C. 33 13C NMR spectrum of trans-4-hydroxy-1-adamantyl isobutyrate 
 
 
Figure C. 34 gCOSY NMR spectrum of trans-4-hydroxy-1-adamantyl isobutyrate. 




Figure C. 35 HSQC NMR spectrum of trans-4-hydroxy-1-adamantyl isobutyrate. 
 
   
Figure C. 36 HMBC NMR spectrum of trans-4-hydroxy-1-adamantyl isobutyrate. 
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Figure C. 37 Zoomed in ROESY NMR spectrum of trans-4-hydroxy-1-adamantyl isobutyrate 
highlighting the interactions of the H4 hydrogen with H2, H5 and H10. 
 
 
Figure C. 38 ROESY NMR spectrum of trans-4-hydroxy-1-adamantyl isobutyrate. 
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Data for 5-hydroxy-2-adamantyl acetate (~25 mg) 182: 
1H NMR (500 MHz, CDCl3) δ 4.89-4.86 (m, 1H, H2), 2.21-2.10 (m, 3H, H1, H3 & H7), 2.08 
(s, 3H, 3xH12), 1.95 (d, J = 12.8 Hz, 2H, H8 & H10), 1.86-1.80 (m, 2H, H4 & H9), 1.78-1.70 
(m, 4H, H4, 2xH6 & H9), 1.43 (d, J = 12.3 Hz, 2H, H8 & H10). 
13C NMR (126 MHz, CDCl3) δ 173.21 (C11), 78.25 (C2), 70.12 (C5), 47.81 (C6), 46.03 (C4 
& C9), 36.20 (C1 & C3), 32.99 (C8 & C10), 32.26 (C7), 24.06 (C12). 
 
 
Figure C. 39 1H NMR spectrum of 5-hydroxy-2-adamantyl acetate. 
 




Figure C. 40 13C NMR spectrum of 5-hydroxy-2-adamantyl acetate. 
 
 
Figure C. 41 gCOSY NMR spectrum of 5-hydroxy-2-adamantyl acetate. 
  




Figure C. 42 HSQC NMR spectrum of 5-hydroxy-2-adamantyl acetate. 
 
 
Figure C. 43 HMBC NMR spectrum of 5-hydroxy-2-adamantyl acetate. 
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Data for 5-hydroxy-2-adamantyl isobutyrate (40 mg) 182: 
1H NMR (500 MHz, CDCl3) δ 4.90-4.84 (m, 1H, H2), 2.62-2.52 (sept, J = 7.0 Hz, 1H, H12), 
2.20-2.10 (m, 3H, H1, H3 & H7), 1.94 (d, J = 12.7 Hz, 2H, H8 & H10), 1.84 (d, J = 11.9 Hz, 
2H, H4 & H9), 1.79-1.69 (m, 4H, H4, 2xH6 & H9), 1.43 (d, J = 12.5 Hz, 2H, H8, H10), 1.19 
(d, J = 7.0 Hz, 6H, 3xH13 & 3xH14). 
13C NMR (126 MHz, CDCl3) δ 179.11 (C11), 77.76 (C2), 70.15 (C5), 47.74 (C6), 45.96 (C4 
& C9), 37.02 (C12), 36.20 (C1 & C3), 33.04 (C8 & C10), 32.27 (C7), 21.69 (C13 & C14). 
 
 
Figure C. 44 1H NMR spectrum of 5-hydroxy-2-adamantyl isobutyrate. 




Figure C. 45 13C NMR spectrum of 5-hydroxy-2-adamantyl isobutyrate. 
 
 
Figure C. 46 gCOSY NMR spectrum of 5-hydroxy-2-adamantyl isobutyrate. 
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                                                                       (a) 
 
    
                                                                    (b) 
 
Figure C. 48 (a) Zoomed in HMBC NMR spectrum (40 to 180 ppm region) of 5-hydroxy-2-
adamantyl isobutyrate. (b) HMBC NMR spectrum of 5-hydroxy-2-adamantyl isobutyrate. 
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Data for 4-hydroxy-N-(1-adamantyl)acetamide (~15 mg) 182:  
1H NMR (500 MHz, CDCl3) δ 5.15 (s, 1H, NH11), 3.98-3.84 (m, 1H, H4), 2.10-1.94 (m, 11H, 
2.10-1.96, 2xH2 & 2xH10; 2.07-1.96, H3 & H5; 2.01-1.97, H7; 2.01-1.96, H6 & H8; 1.98-
1.93, 2xH9), 1.91 (s, 3H, 3xH13), 1.47 (d, J = 12.2 Hz, 2H, H6 & H8).  
13C NMR (126 MHz, CDCl3) δ 172.09 (C12), 75.98 (C4), 53.76 (C1), 44.42 (C9), 42.68 (C2 
& C10), 37.89 (C3 &C5), 32.47 (C6 & C8), 31.30 (C7), 27.29 (C13). 
 
 
Figure C. 49 1H NMR spectrum of 4-hydroxy-N-(1-adamantyl)acetamide. 








Figure C. 51 gCOSY NMR spectrum of 4-hydroxy-N-(1-adamantyl)acetamide. 
  




Figure C. 52 HSQC NMR spectrum of 4-hydroxy-N-(1-adamantyl)acetamide. 
 
 
Figure C. 53 HMBC NMR spectrum of 4-hydroxy-N-(1-adamantyl)acetamide. 




Figure C. 54 Zoomed in ROESY NMR spectrum of 4-hydroxy-N-(1-adamantyl)acetamide. 
This highlights the potential interactions between the H4 hydrogen and those on C2 and C10, 
which would indicate the trans-isomer consistent with the previous studies though we can not 




Figure C. 55 ROESY NMR spectrum of 4-hydroxy-N-(1-adamantyl)acetamide. 
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Data for 3-hydroxy-N-(1-adamantyl)acetamide (~2 mg) 182: 
1H NMR (500 MHz, CDCl3) δ 5.19 (s, 1H, NH11), 2.33-2.22 (m, 2H, H5, H7), 1.99 (s, 2H, 
2xH2), 1.94-1.89 (m, 5H, 3xH13 & 2xH6), 1.74-1.65 (m, 4H, 2xH9 & 2xH10 or 2xH4 & 
2xH8), 1.58-1.56 (m, 4H, 2xH9 & 2xH10 or 2xH4 & 2xH8). 
 
 
Figure C. 56 1H NMR spectrum of 3-hydroxy-N-(1-adamantyl)acetamide. 
 
Figure C. 57 gCOSY NMR spectrum of 3-hydroxy-N-(1-adamantyl)acetamide.
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Figure D. 1 MS analysis of products 
 
MS analysis of β-ionone products  
MS analysis of 4-hydroxy-β-ionone (m+/z = 208.10) RT 10.2 min 
 
MS analysis of 3-hydroxy-β-ionone (m+/z = 208.30) RT 10.3 min 
 
      
Zoomed in 
 
MS analysis of p-cymene products  
MS analysis of p-α,α-trimethylbenzyl alcohol (m+/z = 150.2) RT 8.2 min 
 














77.05 115.10105.20 129.2055.10 65.10 131.10 157.20142.1570.15 95.00 163.15 190.15 208.10176.20 194.15
218.90







123.0561.10 193.1070.05 131.25 157.05148.0595.05
207.25158.20 194.20176.30
219.40



















91.1065.10 117.15 150.2051.05 77.10 105.1559.15 127.85







43.10 51.10 115.1565.1060.15 102.1074.10 87.05 128.15 152.20141.30
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MS analysis of toluene product  
MS analysis of benzyl alcohol (m+/z = 108.10) RT 4.5 min 
 
 
MS analysis of o-xylene product  
MS analysis of 2-methylbenzyl alcohol (m+/z = 122.1) RT 8.7 min  
   
 
MS analysis of p-xylene product  
MS analysis of 4-methylbenzyl alcohol (m+/z = 122.1) RT 8.8 min 
   
 
MS analysis of m-xylene product  
MS analysis of 3-methylbenzyl alcohol (m+/z = 122.1) RT 8.6 min 
   
 
MS analysis of ethylbenzene product 













105.1579.10 150.1591.10 119.1543.10 51.10 115.1565.1060.15 102.1074.10 87.05 128.15 152.20141.30
















122.1065.0551.10 63.10 104.0570.2052.05 94.2086.15 117.20 132.70124.25
139.20









104.1070.1052.05 86.10 133.45117.0096.10 124.00








51.05 122.0553.40 105.0563.05 74.05 91.0587.05 98.10 124.10 138.15112.40
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MS analysis of 2-ethyltoluene products  
MS analysis of 2-ethylbenzaldehyde (m+/z = 134.10) RT 7.10 min 
 
MS analysis of 1-(2-methylphenyl)ethanol (m+/z = 136.05) RT 7.90 min 
 
MS analysis of (2-ethylphenyl)methanol (m+/z = 136.15) RT 9.1 min 
 
 
MS analysis of 3-ethyltoluene products  
MS analysis of 1-(3-methylphenyl)ethanol (m+/z = 136.05) RT 7.45 min 
 
MS analysis of (3-ethylphenyl)methanol (m+/z = 136.05) RT 9.25 min 
 
MS analysis of 2-ethyl-4-methylphenol (m+/z = 136.05) RT 9.45 min 
  












51.05 107.0065.05 122.00115.0561.0055.05 75.00 86.10 94.00 136.10







136.0594.0557.50 70.10 103.0085.95 107.40 134.15







51.05 65.05 107.0057.7043.05 135.9574.00 87.05 94.05







77.05 136.0565.0560.3051.05 117.0594.05 105.0557.40 134.0570.00 87.00 125.20







91.05 105.05 121.0551.0544.00 65.05 117.05 135.0574.00 86.00 94.05






121.0579.05 107.0061.05 136.0591.0569.95 105.1551.05 73.0557.10 117.15 134.3596.20
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MS analysis of n-propylbenzene products  
MS analysis of 1-phenylpropan-2-ol (m+/z = 136.10) RT 6.75 min 
 
MS analysis of 1-phenyl-1-propanol (m+/z = 136.15) RT 7.25 min 
 
MS analysis of propiophenone (m+/z = 134.1) RT 7.6 min 
 
 
MS analysis of isopropylbenzene product  
MS analysis of 2-phenyl-2-propanol (m+/z = 136.10) RT 5.6 min 
 
 
MS analysis of isobutylbenzene product  
MS analysis of 2-methyl-1-phenyl-2-propanol (m+/z = 150.05) RT 7.45 min 
 
MS analysis of indane products  
MS analysis of 1-indanol (m+/z = 134.10) RT 9.2 min 
 
MS analysis of 1-indanone (m+/z = 132.10) RT 10.6 min 
  








51.10 60.80 77.05 103.10 107.05 121.10115.1070.05 136.1094.1587.10
148.70







43.05 51.10 136.15105.1091.10 119.1557.15 61.10 65.10 70.10 82.05
148.25
95.40 128.25







106.1043.05 74.0552.10 63.10 91.10 115.15 119.1084.90 136.10
148.60
98.25








91.1063.0552.05 74.05 107.0087.05 136.2096.30 147.20125.30







65.05 135.05117.0551.05 77.05 105.05 150.05128.0587.05






115.05105.1091.1077.0551.10 55.05 63.1043.05 74.05 106.10 118.1087.05 129.10 136.1598.05 147.40







43.05 63.10 74.0052.05 89.0585.05 98.00 115.15106.05 147.40129.40
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MS analysis of styrene products  
MS analysis of phenylacetaldehyde (m+/z = 120.10) RT 4.75 min 
 
MS analysis of phenyloxirane (m+/z = 120.15) RT 5.15 min 
 
 MS analysis of β-methylstyrene products  
 
MS analysis of 2-methyl-3-phenyloxirane (m+/z = 134.0) RT 6.3 min 
 
MS analysis of 3-phenyl-2-propen-1-ol (m+/z = 134.0) RT 11.45 min 
 
 
MS analysis of 2-methylstyrene products  
MS analysis of minor product (2-methylphenyl)acetaldehyde (m+/z = 134.0) RT 7.2 min 
 
 















70.10 119.15104.1051.10 65.20 77.0557.25 85.30







44.10 51.10 63.10 107.1077.0552.10 74.10 86.05 98.45









106.0552.05 70.05 86.95 96.55






78.05 134.00105.05 115.0051.0543.05 55.05 63.05 74.00 106.05 118.0587.00 98.05







77.05 134.0591.05 107.0551.05 122.0561.05 65.05 116.0573.05 95.1087.40







51.05 63.05 117.0543.05 106.0552.05 74.00 87.05 98.05 136.10126.35
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MS analysis of 1-methylnaphthalene product  
MS analysis of 1-naphthylmethanol (m+/z = 158.05) RT 8.7 min 
 
 
MS analysis of 2-methylnaphthalene product  
MS analysis of 2-naphthylmethanol (m+/z = 158.15) RT 8.9 min 
 
 
MS analysis of 1,2-dimethylnaphathlene product  
MS analysis of (1-methyl-2-naphthyl)methanol (m+/z = 172.05) RT 10.5 min 
 
 
MS analysis of 1,5-dimethylnaphathlene product  


















141.05130.05115.0563.0551.05 77.05 102.05 156.0543.10 89.00 191.40177.40166.45







44.05 141.05130.05115.0563.1051.05 77.10 155.0570.10 102.0589.05 196.10177.35







115.05 141.1076.05 157.1063.0551.05 75.10 89.05 130.1044.05 102.05 197.15175.20 191.40






141.10115.10 128.10 172.10155.1062.90 70.1051.15 89.0076.05 102.15 130.30 191.30 197.10182.20
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MS analysis of 2,6-dimethylnaphathlene product  
MS analysis of (6-methyl-2-naphthyl)methanol (m+/z = 172.2) RT 10.3 min 
 
 
MS analysis of 2,7-dimethylnaphathlene product 
MS analysis of 2-(7-methylnaphthyl)methanol (m+/z = 172.15) RT 10.2 min 
 
 
MS analysis of acenaphthene product 
MS analysis of 1-acenaphthol RT 18.8 min (m+/z = 170.0) 
 
 
MS analysis of phenylcyclohexane product 
MS analysis of trans-4-phenylcyclohexanol (m+/z = 176.15) RT 9.2 min 
 
 
MS analysis of biphenyl product 













115.10 157.1585.1563.1043.10 51.10 76.05 130.1569.65 102.05 183.20
198.45







63.0551.10 69.60 155.1589.0576.00 102.10 130.00111.10 183.90 191.10








84.50 115.0575.7563.0557.30 127.0589.0543.05 98.05 138.05111.05 157.10 197.10181.15 190.75







91.10 158.15143.10115.05 129.1078.0551.05 65.10 102.05 174.25154.15 193.30185.20






141.1544.05 115.1085.1063.10 69.9055.10 76.05 152.10102.10 128.10 197.30
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MS analysis of 2-methylbiphenyl product 
MS analysis of 2-biphenylmethanol (m+/z = 184.05) RT 10.0 min 
 
 
MS analysis of 3-methylbiphenyl products 
MS analysis of 3-phenylbenzaldehyde (m+/z = 182.05) RT 10.1 min 
 
MS analysis of 3-biphenylmethanol (m+/z = 184.10) RT 11.1 min 
 
 
MS analysis of 4-methylbiphenyl product 
MS analysis of 4-biphenylmethanol RT 11.25 min (m+/z = 184.10; RT 16.1 in HPLC) 
 















44.00 63.05 82.20 155.15115.05
128.10 139.10105.0591.1069.50
137.15 170.05 186.10 196.15







61.15 99.10 182.05152.75113.1083.10 127.50 169.55141.15133.40 191.25








77.05 165.05 183.1051.10 107.10 115.0563.05 128.0591.0575.00 141.05








63.05 75.10 165.10115.10 127.10107.1089.05 139.05130.10 193.20







183.1061.10 70.00 165.1051.10 152.15115.0577.00 91.00 128.15 141.10102.10
198.20
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                                                             NMR Analysis 
Data for (2-ethylphenyl)methanol: 
1H NMR (500 MHz, DMSO-d6) δ 7.35 (d, J = 6.6 Hz, 1H, H6), 7.24 (d, J = 7.6 Hz, 1H, H3) 
7.18-7.12 (m, 2H, H4 & H5), 4.52 (s, 2H, 2xH9), 2.60 (q, J = 7.9 Hz, 2H, 2xH7), 1.14 (t, J = 
7.9 Hz, 3H, 3xH8).  
 
Figure D. 2 1H NMR of (2-ethylphenyl)methanol (DMSO-d6). The characteristic singlet peak 
at 4.52 ppm indicated the hydroxylation took place at methyl group. There is a small amount 




Figure D. 3 1H NMR spectrum of (2-ethylphenyl)methanol (500 MHz, CDCl3). The peak at 
4.74 ppm indicated hydroxylation occurred at methyl group (C9). There is a small amount of 
impurity present in the NMR sample. 
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Data for 1-(3-methylphenyl)ethanol: 
1H NMR (500 MHz, CDCl3) δ 7.23 (d, J = 7.5 Hz, 1H, H6) 7.20 (s, 1H, H2), 7.17 (d, J = 7.5 
Hz, 1H, H5), 7.09 (d, J = 7.4 Hz, 1H, H4), 4.87 (q, J = 6.5 Hz, 1H, H7), 2.36 (s, 3H, 3xH9), 
1.49 (d, J = 6.5 Hz, 3H, 3xH8). 
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Data for 2-ethyl-4-methylphenol: 
1H NMR (500 MHz, CDCl3) δ 6.94 (s, 1H, H3), 6.89 (d, J = 8.1 Hz, 1H, H6), 6.68 (d, J = 8.1 
Hz, 1H, H5), 2.54 (q, J = 7.6 Hz, 2H, 2xH7), 2.22 (s, 3H, 3xH9), 1.18 (t, J = 7.6 Hz, 3H, 3xH8). 
 
 
Figure D. 5 1H NMR spectrum of 2-ethyl-4-methylphenol 267. A small amount of impurity was 
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Data for (1-methyl-2-naphthyl)methanol: 
1H NMR (500 MHz, CDCl3) δ 8.08 (d, J = 8.6 Hz, 1H, H5), 7.83 (d, J = 8.8 Hz, 1H, H4), 7.72 




Figure D. 6 1H NMR spectrum of (1-methyl-2-naphthyl)methanol 315. 
 







Figure D. 7 (a) gCOSY NMR spectrum of (1-methyl-2-naphthyl)methanol. (b) Zoomed in 
gCOSY NMR spectrum to highlight the interaction of H11 with H8. 
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Data for (5-methyl-1-naphthyl)methanol:  
1H NMR (500 MHz, CDCl3) δ 8.02 (d, J = 8.5 Hz, 2H, H4 & H8), 7.56 (d, J = 6.9 Hz, 1H, H2), 





Figure D. 9 1H NMR spectrum of (5-methyl-1-naphthyl)methanol. 
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Data for (6-methyl-2-naphthyl)methanol: 
1H NMR (500 MHz, CDCl3) δ 7.78 (s, 1H, H1), 7.76 (d, J = 3.1 Hz, 1H, H8), 7.75-7.73 (m, 
1H, H4), 7.62 (s, 1H, H1, H5), 7.46 (dd, J = 8.3, 1.6 Hz, 1H, H7), 7.34 (dd, J = 8.3, 1.5 Hz, 
1H, H3), 4.85 (m, 2H, 2xH11), 2.53 (s, 3H, 3xH12).  
13C NMR (126 MHz, CDCl3) δ 140.02 (C9), 138.25 (C10), 135.83 (C2), 134.24 (C6), 131.13 




Figure D. 11 1H NMR spectrum of (6-methyl-2-naphthyl)methanol. 




Figure D. 12 13C NMR spectrum of (6-methyl-2-naphthyl)methanol.   
 
 
Figure D. 13 gCOSY NMR spectrum of (6-methyl-2-naphthyl)methanol.  




Figure D. 14 HSQC NMR spectrum of (6-methyl-2-naphthyl)methanol.   
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Data for 2-(7-methylnaphthyl)methanol 266: 
 
Figure D. 15 1H NMR spectrum of 2-(7-methylnaphthyl)methanol. 
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Data for 1-acenaphthol:  
1H NMR (500 MHz, CDCl3) δ 7.76 -7.74 (m, 1H, H6), 7.66 (d, J = 8.2 Hz, 1H, H8), 7.58-7.53 
(m, 2H, H5 & H10), 7.49 (dd, J = 15.1, 7.0 Hz, 1H, H9), 7.31 (d, J = 6.8 Hz, 1H, H4), 5.75 (d, 
J = 7.5 Hz, 1H, H1), 3.82 (dd, J = 17.9, 7.5 Hz, 1H, H2), 3.26 (d, J = 17.8 Hz, 1H, H2).  
13C NMR (126 MHz, CDCl3) δ 148.34 (C11), 144.19 (C3), 139.81 (C12), 133.86 (C7), 130.88 






Figure D. 16 1H NMR spectrum of 1-acenaphthol. 




Figure D. 17 13C spectrum NMR of 1-acenaphthol. 
 
 
Figure D. 18 gCOSY NMR spectrum of 1-acenaphthol. 
 




Figure D. 19 HSQC NMR spectrum of 1-acenaphthol. 
 
 
Data for 3-biphenylmethanol 233, 266: 
 
Figure D. 20 1H NMR spectrum of 3-biphenylmethanol. 
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Figure D. 21 Chiral HPLC analysis of the in vitro turnovers of CYP101B1 and H85F 
CYP101B1 with indane, and a racemic mixture of enantiomers was detected. 
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 Figure E.1 General Experimental – Synthesis (All this synthetic work was 
performed and written (Page 479-496) by Sevan D. Houston (University of 
Queensland)). 
 
NMR spectra were recorded under standard conditions (unless stated otherwise) using Bruker 
AV 500, 400 and 300 MHz or Bruker AS 500 spectrometers and were referenced using residual 
monoprotic solvent peaks (e.g. CDCl3, C6D6 etc.) 
353. Coupling constants (J) are quoted to the 
nearest 0.1 Hz. The following abbreviations are used to report multiplicities: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, quin = quintet, sext = sextet, sep = septet, br = 
broad. High-resolution ESI mass spectra were recorded using a Bruker MicroTOF-Q 
(quadrupole-Time of Flight) with a Bruker ESI source. IR spectra were recorded using a 
Perkin-Elmer 400 FTIR spectrometer. Samples were run either as neat oils or solids. Melting 
points were determined using a Digimelt MPA 160 melting point apparatus and are reported 
uncorrected. Crystallographic data were collected at 190 K on an Oxford Diffraction Gemini 
Ultra S CCD diffractometer employing graphite monochromated Mo-Kα radiation (0.71073 Å) 
in the range 2 < 2θ < 50°. Flash column chromatography was run using Merck silica gel 60 
(230–400 mesh). Fractions were initially visualised using UV irradiation and subsequently by 
heating TLC plates exposed to either ceric ammonium molybdate (Goofy’s stain) or 10% 
aqueous potassium permanganate. TLC was performed with Merck silica gel plates, precoated 
with silica gel 60 F254 (0.2 mm). Unless specified otherwise, all reactions were magnetically 
stirred and performed in oven-dried glassware under a positive pressure of argon (4 Å mol. 
Sieve/silica drying tube) at ambient room temperature. Solvents were distilled to dryness prior 
to use based on the methods described by Amarego 354. Unless stated otherwise commercially 
available chemicals were used without further purification. 2-Mercaptopyridine N-oxide 
sodium salt was concentrated to dryness, washed with ethyl acetate then dried under high 
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E. 2 Summary Schemes 
2.1 CYP450 Substrates 
 
                          Scheme E.2. 1 Synthesis of 4-methylcubane CYP450 probes. 
 
                       Scheme E.2. 2 Synthesis of 4-ethylcubane-1-methoxy carbonyl. 
2.2 CYP450 Alcohol Standards 
 
                    Scheme E.2. 3 Synthesis of alcohol product standards 
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2.3 Barton-McCombie Deoxygenation 
 
      Scheme E.2. 4 Barton-McCombie deoxygenation of imidazole thiocarbamate ester. 
 
 
           Scheme E.2. 5 Barton-McCombie deoxygenation of xanthate ester 
 
 
                     Scheme E.2. 6 Barton Decarboxylation of thiohydroxamate ester. 
 
E. 3 Experimental Procedures - Synthesis 
3.1 4-Methylcubane CYP450 Substrates  
                                                                   1,4-Diiodocubane 
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The procedure reported by Tsanaktsidis et al 355 was followed. Cubane-1,4-dicarboxylic acid 
356 (1.000 g, 5.20 mM) was dissolved in thionyl chloride (10 mL) and heated to reflux for 1h. 
On cooling to r.t. the mixture was concentrated in vacuo and further dried under high vacuum 
(1 h). Separately, freshly ground 2-mercaptopyridine N-oxide sodium salt (2.373 g, 15.91 mM), 
DMAP (74 mg, 0.14 mM) and 2,2,2-trifluoroiodoethane (2.56 mL, 26.07 mM) were suspended 
in anhydrous DCM (25 mL) and heated to reflux whilst under irradiation from a 500-W 
tungsten lamp. The newly formed acid chloride was suspended in anhydrous DCM (25 mL) 
and added slowly to the refluxing mixture. After refluxing for 2.5 h the cooled suspension was 
washed with water (50 mL), hydrochloric acid (1 M, 50 mL) and brine (50 mL). The organic 
phase was then dried over magnesium sulphate and concentrated by distillation at atmospheric 
pressure. Purification of the crude material was performed by trituration with cold diethyl ether 
(0 C, 5 mL), which gave the title compound (1.372 g, 74%) as an off-white solid. Data reported 
are consistent with Tsanaktsidis et al.356. 





The procedure reported by Eaton et al 357 was followed. 1,4-Diiodocubane (1.107 g, 3.11 mM) 
was suspended in anhydrous diethyl ether (40 mL) together with iodomethane (3.87 mL, 62.2 
mM) in a 22 °C water bath. Ethereal methyllithium (1.6 M, 38.9 mL, 62.2 mM) was slowly 
added dropwise and the suspension stirred for 16 h. The now homogeneous solution was cooled 
to -78 °C before the addition of methanol (1 mL). The solution was warmed to room 
temperature, and water (5 mL) was added. The organic phase was separated and washed with 
hydrochloric acid (1 M, 40 mL). The organic phase was then dried over magnesium sulphate 
and concentrated by distillation at atmospheric pressure. The crude residue was subjected to 
column chromatography (pentane) affording the title compound (535 mg, 70%) as a white 
solid. 
1H-NMR (300 MHz, CDCl3) δH = 4.19-4.15 (m, 3H), 3.83-3.80 (m, 3H), 1.29 (s, 3H) ppm. 
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                                               4-Methylcubane-1-carboxylic acid 
 
Adapted from the procedure of Eaton et al.358 4-methylcubane-1-iodide (535 mg, 2.19 mM) 
was suspended in anhydrous THF (50 mL) at -78 °C under an argon atmosphere. tert-Butyl 
lithium (1.2 M in pentane, 4.93 mL, 5.91 mM) was slowly added dropwise and the solution 
allowed to stir for 15 min. Separately, carbon dioxide (ca 1 L) was bubbled into anhydrous 
THF (100 mL) at -78 °C under an argon atmosphere. The cubyl lithium solution at -78 °C was 
transferred dropwise via cannula to the cooled carbon dioxide solution over a period of 20 min. 
[Note: a rapid rate of addition can result in the formation of dicubyl ketone whilst a slow rate 
of addition can result in decomposition of the cubyllithium]. The reaction mixture was stirred 
for a further 30 min before warming to room temperature over 30 min. Saturated ammonium 
chloride (20 mL) was added, and the THF was removed in vacuo on a rotary evaporator with 
the water bath temperature maintained at 25 °C. The remaining aqueous phase was washed 
with diethyl ether (2 x 20 mL), acidified to pH 1 with aqueous hydrochloric acid (10 M, 1 mL) 
and then extracted with diethyl ether (6 x 20 mL). The combined organic phases were dried 
over magnesium sulphate and concentrated in vacuo. The crude residue was subjected to 
column chromatography (50% ethyl acetate/petroleum ether v/v) to give the title compound 
(136 mg, 38%) as a white solid.  
1H-NMR (400 MHz, CDCl3) δH = 4.14-4.11 (m, 3H), 3.68-3.65 (m, 3H), 1.28 (s, 3H) ppm. 
13C-NMR (100 MHz, CDCl3) δC = 178.3, 56.3, 47.6, 46.0, 19.5 ppm. 
1H-NMR (500 MHz, C6D6) δH = 4.03-4.00 (m, 3H), 3.35-3.33 (m, 3H), 0.96 (s, 3H) ppm. 
13C-NMR (125 MHz, C6D6) δC = 179.9, 57.3, 56.6, 48.2, 46.7, 19.8 ppm. 
 
HRMS (ESI): m/z calcd for C10H10O2Na ([M+Na]
+): 185.0573, found 185.0570. 
FT–IR υmax = 2979, 1675, 1419, 1310, 1226, 939, 734 cm
-1. 
MP 139.7-140.4 C. 
 
                                        4-Methylcubane-1-methoxy carbonyl 
 
The procedure reported by Klunder et al 359 was followed. 4-Methylcubane-1-carboxylic acid 
(13 mg, 0.080 mM) was stirred in ethereal diazomethane (ca 1.2 mL) at r.t. for 30 min. Excess 
diazomethane was blown off with a stream of argon, and the remaining diethyl ether was 
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removed by distillation at atmospheric pressure. The crude residue was subjected to column 
chromatography (20% diethyl ether/pentane v/v), and the pooled fractions containing product 
were concentrated by distillation at atmospheric pressure to give the title compound (12 mg, 
85%) as a white, sweet smelling solid. 
1H-NMR (400 MHz, CDCl3) δH = 4.10-4.07 (m, 3H), 3.70 (s, 3H), 3.65-3.63 (m, 3H), 
1.28 (s, 3H) ppm. 
13C-NMR (100 MHz, CDCl3) δC = 173.3, 56.6, 56.2, 51.6, 47.5, 46.0, 19.5 ppm. 
HRMS (ESI): m/z calcd for C11H12O2Na ([M+Na]
+): 199.0730, found 199.0726. 
MP 63.1–64.2 C. 
 
 
                                             4-Methylcubane-1-methyl ketone 
 
The procedure reported by Choi et al. 301 was followed. Methyllithium (1.6 M in diethyl ether, 
0.29 mL, 0.462 mM) was added to a solution of 4-methylcubane-1-carboxylic acid (15 mg, 
0.092 mM) in anhydrous diethyl ether (2 mL) at -78 °C under an argon atmosphere. The flask 
was from removed from the cold bath and the white suspension stirred at r.t. After 1.5 h the 
reaction mixture was re-cooled to -78 °C and then quenched with dry ice (ca 1 g). On warming 
to r.t. over 30 min saturated ammonium chloride (2 mL) was added. The phases were separated, 
and the aqueous phase washed with diethyl ether (2 x 2 mL). The combined organic phases 
were dried over magnesium sulphate and concentrated by distillation at atmospheric pressure. 
The residual oil was used for subsequent reactions without further purification. In a separate 
experiment, 4-methylcubane-1-carboxylic acid (13 mg, 0.80 mM) was treated in the manner 
described, but purified by column chromatography (10% diethyl ether/DCM v/v). The pooled 
fractions containing product were concentrated by distillation at atmospheric pressure to give 
the title compound (12 mg, 94%) as a colourless, sweet-smelling oil. 
1H-NMR (400 MHz, CDCl3) δH = 4.12-4.10 (m, 3H), 3.63-3.61 (m, 3H), 2.12 (s, 3H), 
1.30 (s, 3H) ppm. 
13C-NMR Lit:301 (CDCl3) δC = 207.0, 64.5, 56.4, 46.9, 54.9, 24.6, 19.4 ppm. 
  HRMS (ESI): m/z calcd for C11H13O ([M+H]
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                                                  4-Methylcuban-1-yl acetate 
 
The procedure reported by Choi et al.301 was followed. 4-Methylcubane-1-methyl ketone above 
was dissolved in DCM (1 mL) at r.t. and m-CPBA (77%, 45 mg, 0.18 mM) added in one 
portion. After 16 h the reaction mixture was diluted with DCM (4 mL) and then washed with 
saturated sodium carbonate (2 x 5 mL), water (5 mL) and brine (5 mL). The organic phase was 
dried over magnesium sulphate and concentrated by distillation at atmospheric pressure. The 
crude residue was subjected to column chromatography (20% diethyl ether/pentane v/v), and 
the pooled fractions containing product were concentrated by distillation at atmospheric 
pressure to give the title compound (15 mg, 93% over 2 steps) as a colourless, sweet-smelling 
oil. 
1H-NMR (400 MHz, CDCl3) δH 4.12-4.09 (m, 3H), 3.55-3.52 (m, 3H), 2.08 (s, 3H), 1.27 
(s, 3H) ppm. 
13C-NMR Lit:301 (CDCl3) δC = 169.3, 89.0, 55.7, 50.9, 44.1, 21.0, 19.4 ppm. 
HRMS (ESI): m/z calcd for C11H12O2Na ([M+Na]
+): 199.0730, found 199.0727. 
 
                                               4-Methylcubane-1-acetic acid methyl ester 
 
The procedure reported by Klunder et al. 359 was followed. 4-Methylcubane-1-carboxylic acid 
(23 mg, 0.14 mM) was dissolved in thionyl chloride (10 mL) and heated to reflux for 1h under 
an argon atmosphere. The thionyl chloride was removed in vacuo (70 °C, 200 torr) to leave a 
brown coloured oil. The remainder of this sequence should be performed behind a blast shield. 
To the resulting acid chloride was cautiously added ethereal diazomethane (ca 10 mL) 
dropwise. The reaction was monitored by TLC (20% diethyl ether/DCM v/v) until complete 
consumption of the acid chloride (Rf = 0.27) had taken place, and formation of the diazo 
intermediate (Rf = 0.82) was observed. The resulting solution was sealed with a rubber septum 
then allowed to stand at r.t. for 4 days before concentration by distillation at atmospheric 
pressure. The resulting yellow coloured oil was, without mechanical agitation, taken up in 
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degassed methanol (15 mL) and added to a Pyrex test tube with cold finger and side outlet (for 
pressure equalisation and inert gas) under an argon atmosphere and irradiated with a 400-W 
medium pressure Hanovia mercury arc lamp filtered through quartz. [Note: the Pyrex test tube 
had a diameter of 3.0 cm. The light source was housed in the centre of a quartz water jacket 
which had a diameter of 5.0 cm. The distance between the outer walls of the Pyrex test tube 
and the quartz water jacket was 2.0 cm. The pyrex cold finger and quartz water jacket were 
cooled with circulating water chilled with ice. Magnetic stirring was not required as the solution 
was homogenised by the resulting convection current]. After 4.5 h the methanol was removed 
in vacuo (70 °C, 325 torr) and the residue was purified by column chromatography (2.5% 
diethyl ether/pentane v/v). The pooled fractions containing product were concentrated by 
distillation at atmospheric pressure to give the title compound (2 mg, 9%) as a colourless, 
sweet-smelling oil. 
1H-NMR (400 MHz, CDCl3) δH = 3.67-3.65 (m, 3H), 3.53–3.51 (m, 3H), 2.65 (s, 2H), 
1.27 (s, 3H) ppm. 
13C-NMR (100 MHz, CDCl3) δC = 172.2, 56.5, 55.5, 51.5, 46.7, 45.4, 38.5, 20.0 ppm. 
HRMS (ESI): m/z calcd for C12H15O2 ([M+H]
+): 191.1067, found 191.1063. 
 
                                            4-Ethylcubane-1-methoxy carbonyl 
4-Methoxycarbonylcuban-1-yl-acetic acid 
 
Adapted from the procedure of Eaton and Yip.360 To a solution of 4-methoxycarbonylcubane-
1-carboxylic acid (1.042 g, 5.05 mM) in anhydrous DCM (40 mL) was added oxalyl chloride 
(0.52 mL, 6.06 mM) and anhydrous DMF (1 drop) under an argon atmosphere. After 1 h the 
mixture was concentrated in vacuo and further dried under high vacuum (1 h). The remainder 
of this sequence should be performed behind a blast shield. The resulting acid chloride was 
suspended in diethyl ether (10 mL). Ethereal diazomethane (ca 60 mL) was added and the 
reaction monitored by TLC (ethyl acetate) until complete consumption of the acid chloride (Rf 
= 0.24), and formation of the diazo (Rf = 0.54) was observed. Excess diazomethane was blown 
off with argon, and the remaining diethyl ether was removed under reduced pressure. The 
resulting yellow solid was, without mechanical agitation, taken up in a degassed THF (40 mL) 
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and water (15 mL) and added to a Pyrex test tube with cold finger and side outlet (for pressure 
equalisation and inert gas) under an argon atmosphere and irradiated with a 400-W medium 
pressure Hanovia mercury arc lamp filtered through quartz. [Note: the Pyrex test tube had a 
diameter of 3.0 cm. The light source was housed in the centre of a quartz water jacket which 
had a diameter of 5.0 cm. The distance between the outer walls of the Pyrex test tube and the 
quartz water jacket was 2.0 cm. The Pyrex cold finger and quartz water jacket were cooled 
with circulating water chilled with ice. Magnetic stirring was not required as the solution was 
homogenised by the resulting convection current]. After 6 h the THF was removed in vacuo, 
and the remaining water was washed with DCM (3 x 20 mL). The combined organic extracts 
were dried over magnesium sulphate and concentrated. The crude residue was subjected to 
chromatography (50→100% ethyl acetate/petroleum ether v/v) to give the title compound (722 
mg, 65%) as an off-white solid. 
1H-NMR (500 MHz, CDCl3) δH = 4.16–4.14 (m, 3H), 3.87–3.85 (m, 3H), 3.71 (s, 3H), 
2.72 (s, 2H) ppm. 
13C-NMR (125 MHz, CDCl3) δC = 176.8, 172.9, 56.3, 54.6, 51.7, 46.7, 46.5, 37.7 ppm. 
HRMS (ESI): m/z calcd for: C12H11O4 ([M-H]
-): 219.0663; found: 219.0665. 
FT–IR υmax = 2993, 1693, 1431, 1320, 1237, 1207, 1087, 929, 842, 735 cm
-1. 
MP 120.2–122.8 C. 
 
                                       4-Methoxycarbonylcuban-1-yl-propanoic acid  
 
Adapted from the procedure of Eaton and Yip.360 To a solution of 4-methoxycarbonylcuban-
1-yl-acetic acid (490 mg, 2.23 mM) in anhydrous DCM (20 mL) was added oxalyl chloride 
(0.26 mL, 3.03 mM) and anhydrous DMF (1 drop) under an argon atmosphere. After 1 h the 
mixture was concentrated in vacuo and further dried under high vacuum (1 h). The remainder 
of this sequence should be performed behind a blast shield. The resulting acid chloride was 
suspended in diethyl ether (10 mL). Ethereal diazomethane (ca 20 mL) was added and the 
reaction monitored by TLC (ethyl acetate) until complete consumption of the acid chloride (Rf 
= 0.48), and formation of the diazo (Rf = 0.63) was observed. Excess diazomethane was blown 
off with argon, and the remaining diethyl ether was removed under reduced pressure. The 
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resulting yellow solid was, without mechanical agitation, taken up in a degassed THF (20 mL) 
and water (8 mL) and added to a Pyrex test tube with cold finger and side outlet (for pressure 
equalisation and inert gas) under an argon atmosphere and irradiated with a 400-W medium 
pressure Hanovia mercury arc lamp filtered through quartz. [Note: the Pyrex test tube had a 
diameter of 3.0 cm. The light source was housed in the centre of a quartz water jacket which 
had a diameter of 5.0 cm. The distance between the outer walls of the Pyrex test tube and the 
quartz water jacket was 2.0 cm. The Pyrex cold finger and quartz water jacket were cooled 
with circulating water chilled with ice. Magnetic stirring was not required as the solution was 
homogenised by the resulting convection current.] After 6 h the THF was removed in vacuo, 
and the remaining water was washed with DCM (3 x 20 mL). The combined organic extracts 
were dried over magnesium sulphate and concentrated. The crude residue was subjected to 
chromatography (50→100% ethyl acetate/petroleum ether v/v) to give the title compound (386 
mg, 74%) as an off-white solid. 
1H-NMR (500 MHz, CDCl3) δH = 4.10–4.08 (m, 3H), 3.75–3.73 (m, 3H), 3.69 (s, 3H), 
2.33 (t, J = 7.6 Hz, 2H), 1.95 (t, J = 7.6 Hz, 2H) ppm. 
13C-NMR (125 MHz, CDCl3) δC = 179.9, 173.0, 58.8, 56.5, 51.7, 46.2, 45.8, 29.1, 27.9 
ppm. 
HRMS (ESI): m/z calcd for: C13H14O4Na ([M+Na]
+): 257.0784; found: 257.0796. 
FT–IR υmax = 2985, 1704, 1436, 1321, 1204, 1087, 926, 840 cm
-1. 
MP 74.8–77.6 C. 
                     
4-ethylcubane CYP450 Substrate  
 
                                       4-Ethylcubane-1-methoxy carbonyl 
 
The procedure reported by Ko et al. 361 was followed. To a solution of 4-
methoxycarbonylcuban-1-yl-propanoic acid (45 mg, 0.19 mM) in anhydrous DCM (5 mL), 
was added oxalyl chloride (0.03 mL, 0.35 mM) and anhydrous DMF (1 drop) under an argon 
atmosphere. After 1 h the mixture was concentrated in vacuo and further dried under high 
vacuum (1 h). Separately, freshly ground 2-mercaptopyridine N-oxide sodium salt (60 mg, 0.40 
Appendix E (Chapter 6) 
 
490 
mM) and DMAP (1 mg, 0.008 mM) were suspended in anhydrous chloroform (7 mL) and 
heated to reflux whilst under irradiation from a 500-W tungsten lamp. [Note: the chloroform 
was washed with water and distilled from calcium hydride prior to use in order to remove the 
ethanol stabiliser]. The newly formed acid chloride was suspended in chloroform (7 mL) and 
added slowly over 20 min to the refluxing mixture. After reflux (2 h) the suspension was 
washed with water (10 mL) and brine (10 mL) then dried over magnesium sulphate and 
concentrated by distillation at atmospheric pressure. Purification by column chromatography 
(10% diethyl ether/pentane v/v) gave the title compound (33 mg, 91%) as a sweet-smelling oil.  
1H-NMR (500 MHz, CDCl3) δH = 4.08-4.06 (m, 3H), 3.72-3.70 (m, 6H), 1.59 (q, J = 7.4 
Hz, 2H), 0.85 (t, J = 7.4 Hz, 3H) ppm. 
13C-NMR (125 MHz, CDCl3) δC = 173.3, 60.7, 56.6, 51.6, 46.1, 45.6, 25.6, 7.7 ppm. 
HRMS (ESI): m/z calcd for: C12H14O2Na ([M+Na]
+): 213.0886; found: 213.0881. 
FT–IR υmax = 2966, 1727, 1435, 1320, 1290, 1208, 1087, 840 cm
-1. 
 
Cubane Alcohol Standards 
 
                                         4-Hydroxymethylcubane-1-methoxy carbonyl 
 
Following the procedure of McGonagle and Savage:362 to a solution of 4-
methoxycarbonylcubane-1-carboxylic acid (199 mg, 0.97 mM) in anhydrous THF (12 mL) at 
0 C under an argon atmosphere was slowly added borane dimethylsulfide complex (5 M in 
diethyl ether, 0.23 mL, 1.15 mM). The solution was allowed to warm to r.t. over 1 h and then 
water (1 mL) was cautiously added. The THF was removed in vacuo, and the residue was 
diluted with water (10 mL) then extracted with DCM (3 x 10 mL). The combined organic 
phases were dried over magnesium sulphate and concentrated. The crude residue was subjected 
to column chromatography (50% ethyl acetate/petroleum ether v/v) to give the title compound 
(170 mg, 91%) as a white solid.  
1H-NMR (500 MHz, CDCl3) δH = 4.16-4.14 (m, 3H), 3.90-3.88 (m, 3H), 3.78-3.77 (m, 
2H), 3.71 (s, 3H) ppm. 
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                                      4-(1-Hydroxyethyl)-cubane-1-methoxy carbonyl 
 
Adapted from the procedure of Moore et al. 363 N-methylmorpholine N-oxide (116 mg, 0.99 
mM) and oven dried 3Å molecular sieves (ca 30 mg) were weighed into a round bottom flask 
and placed under high vacuum for 1 h before backflushing with argon. 4-
Hydroxymethylcubane-1-methoxy carbonyl (50 mg, 0.26 mM), tetrapropylammonium 
perruthenate (5 mg, 0.013 mM) were added followed by anhydrous acetonitrile (2 mL). The 
reaction was monitored by TLC (50% ethyl acetate/petroleum ether v/v) until complete 
consumption of the alcohol (Rf = 0.22) and formation of the aldehyde (Rf 0.46) was observed 
(10 min). Water (5 mL) was added to the reaction mixture followed by extraction with pentane 
(3 x 5 mL). The combined organic phases were dried over magnesium sulphate (oven dried), 
transferred to a round bottom flask and diluted with anhydrous THF (15 mL) then cooled to -
40 C under an argon atmosphere. Methyl magnesium bromide (3 M in diethyl ether, 0.09 mL, 
0.27 mM) was slowly added dropwise over 10 min. On warming to r.t. over 30 min saturated 
ammonium chloride (5 mL) was cautiously added. The THF was removed in vacuo, and the 
remaining aqueous phase was washed with DCM (3 x 5 mL). The combined organic phases 
were dried over magnesium sulphate and concentrated. The crude residue was subjected to 
column chromatography (20% ethyl acetate/petroleum ether v/v) to give the title compound 
(13 mg, 24%) as a colourless oil. 
1H-NMR (500 MHz, CDCl3) δH = 4.13-4.11 (m, 3H), 3.98 (q, J = 6.4 Hz, 1H), 3.90-3.88 
(m, 3H), 3.71 (s, 3H), 1.14 (d, J = 6.4 Hz, 3H) ppm. 
13C-NMR (125 MHz, CDCl3) δC = 172.8, 67.6, 62.3, 56.6, 51.7, 46.1, 44.0, 17.0 ppm. 
HRMS (ESI): m/z calcd for: C12H14O3Na ([M+Na]
+): 229.0835; found: 229.0841. 
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4-(2-Hydroxyethyl)cubane-1-methoxy carbonyl and 4-(2-hydroxyethyl)cubane-1 
(hydroxymethyl) 
 
To a solution of 4-methoxycarbonylcuban-1-yl-acetic acid (15 mg, 0.068 mM) in anhydrous 
THF (3 mL) at 0 C under an argon atmosphere was slowly added borane dimethylsulfide 
complex (5 M in diethyl ether, 0.02 mL, 0.1 mM). The solution was allowed to warm to r.t. 
over 1 h and then water (1 mL) was cautiously added. The THF was removed in vacuo and the 
residue diluted with water (5 mL) and extracted with DCM (3 x 5 mL). The combined organic 
phases were dried over magnesium sulphate and concentrated. The crude residue was subjected 
to column chromatography (50% ethyl acetate/petroleum ether v/v) to give the title alcohol (3 
mg, 21%) and diol (9 mg, 74%) as colourless oils.  
4-(2-Hydroxyethyl)cubane-1-methoxy carbonyl 
1H-NMR (500 MHz, CDCl3) δH = 4.14–4.12 (m, 3H), 3.80–3.78 (m, 3H), 3.74 (t, J = 
6.7 Hz, 2H), 3.70 (s, 3H), 1.89 (t, J = 6.7 Hz, 2H) ppm. 
13C-NMR (125 MHz, CDCl3) δC = 173.1, 60.0, 57.7, 56.4, 51.6, 46.6, 46.5, 35.7 ppm. 
HRMS (ESI): m/z calcd for: C12H14O3Na ([M+Na]
+): 229.0835; found: 229.0832. 




1H-NMR (500 MHz, CDCl3) δH = 3.78–3.73 (m, 7H), 3.70–3.68 (m, 3H), 1.89 (t, J = 
6.8 Hz, 2H) ppm. 
13C-NMR (125 MHz, CDCl3) δC = 64.1, 60.1, 59.3, 58.2, 45.7, 43.8, 36.2 ppm. 
HRMS (ESI): m/z calcd for: C11H14O2Na ([M+Na]
+): 201.0886; found: 201.0881. 
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E. 4 Barton-McCombie Deoxygenation 
 
                                               Imidazole thiocarbamate ester 
 
Adapted from the procedure of Sauer and Barriault.364 To a solution of 4-
hydroxymethylcubane-1-methoxy carbonyl (56 mg, 0.29 mM) in anhydrous DCM (5 mL) 
under an argon atmosphere was added DMAP (43 mg, 0.35 mM) and thiocarbonyldiimidazole 
(122 mg, 0.62 mM). The mixture was left to stir for 16 h before being concentrated. The crude 
residue was subjected to column chromatography (50% ethyl acetate/petroleum ether v/v) to 
give the title compound (80 mg, 91%) as an off-white solid. 
 
1H-NMR (500 MHz, CDCl3) δH = 8.31 (s, 1H), 7.60 (m, 1H), 7.04 (m, 1H), 4.83 (s, 2H), 
4.24–4.22 (m, 3H), 4.01-3.99 (m, 3H), 3.71 (s, 3H) ppm. 
13C-NMR (125 MHz, CDCl3) δC = 184.6, 172.2, 136.8, 131.0, 118.0, 73.4, 56.6, 55.6, 
51.8, 46.8, 45.3 ppm. 
HRMS (ESI): m/z calcd for: C15H15N2O3S ([M+H]
+): 303.0798; found: 303.0797. 
FT–IR υmax = 2990, 1721, 1383, 1339, 1282, 1227, 1088, 981, 656 cm
-1. 
MP 84.1–85.2 C. 
 
                                             Barton-McCombie deoxygenation 
 
Adapted from the procedure of Sauer and Barriault. 364. Imidazole thiocarbamate ester (14 mg, 
0.046 mM) was suspended in benzene-d6 (0. 8 mL) in an RBF and freeze-pump-thaw degassed 
three times. AIBN (1.6 mg, 0010 mM) and tributyltin hydride (27 µL, 0.10 mM) were added, 
and the mixture was heated to reflux for 11 h and then cooled to r.t. The reaction mixture was 
concentrated under a steam of nitrogen and purified by column chromatography (10% KF / 
silica w/w, 365 5→20% ethyl acetate/petroleum ether v/v) to give a 3:2 inseparable mixture of 
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4-hydroxymethylcubane-1-methoxy carbonyl and imidazole carbamate ester (6 mg, 57%) as a 
colourless oil. 1H and 13C NMR data for the imidazole carbamate ester were obtained by 
subtraction of an authentic spectrum of 4-hydroxymethylcubane-1-methoxy carbonyl. 
4-Hydroxymethylcubane-1-methoxy carbonyl 
1H-NMR (500 MHz, C6D6) δH = 4.05-4.03 (m, 3H), 3.57-3.55 (m, 3H), 3.41 (s, 3H), 
3.29-3.28 (m, 2H) ppm. 
13C-NMR (125 MHz, C6D6) δC = 171.9, 63.0, 59.2, 56.9, 50.9, 46.7, 44.8 ppm. 
 
Imidazole carbamate ester 
1H-NMR (500 MHz, C6D6) δH = 7.98 (s, 1H), 7.08 (m, 1H), 6.95 (m, 1H), 3.96–3.94 (m, 
3H), 3.83 (s, 2H), 3.45-3.53 (m, 3H), 3.40 (s, 3H) ppm. 
13C-NMR (125 MHz, CDCl3) δC = 171.4, 148.9, 137.1, 131.3, 117.1, 67.6, 56.7, 55.5, 
51.1, 46.7, 45.0 ppm. 
HRMS (ESI): m/z calcd for: C15H14N2O4Na ([M+Na]
+): 309.0846; found: 309.0847. 
 
                                                                  Xanthate ester 
Adapted from the procedure of Zhu et al.366 To a solution of 4-hydroxymethylcubane-1-
methoxy carbonyl (50 mg, 0.26 mM) in anhydrous THF (10 mL) under an argon atmosphere 
at 0 C was added sodium hydride (60% dispersion in mineral oil, 31 mg, 0.78 mM). The 
mixture was heated to reflux for 2 h, then cooled to r.t. before addition of carbon disulphide 
(17 µL, 0.31 mM). The mixture was heated to reflux for an additional 1 h, then again cool to 
r.t. before addition of methyl iodide (19 µL, 0.31 mM). After stirring for 1 h the THF was 
blown off with argon. The residue was taken up in saturated ammonium chloride (10 mL) and 
washed with DCM (3 x 10 mL). The combined organic phases were dried over magnesium 
sulphate and concentrated in vacuo. The crude residue was subjected to column 
chromatography (10→40% ethyl acetate/petroleum ether v/v) to give the title xanthate ester (8 
mg, 11%) and transesterified xanthate ester (8 mg, 7%) as white solids. 
 




1H-NMR (500 MHz, CDCl3) δH = 4.77 (s, 2H), 4.21–4.19 (m, 3H), 3.97–3.95 (m, 3H), 
3.71 (s, 3H), 2.56 (s, 3H) ppm. 
13C-NMR (125 MHz, CDCl3) δC = 216.5, 172.5, 73.8, 56.5, 56.0, 51.7, 46.8, 45.4, 19.2 
ppm. 
HRMS (ESI): m/z calcd for: C13H14O3S2Na ([M+Na]
+): 305.0277; found: 305.0269. 
FT–IR υmax = 2991, 1724, 1435, 1328, 1215, 1064, 726 cm
-1. 
MP 78.0–80.2 C 
 
Transesterified xanthate ester 
1H-NMR (500 MHz, C6D6) δH = 4.41 (s, 2H), 4.09 (s, 2H), 4.02–3.97 (m, 6H), 3.62–
3.60 (m, 3H), 3.54–3.52 (m, 3H), 3.38 (s, 3H), 2.11 (s, 2H) ppm. 
13C-NMR (125 MHz, CDCl3) δC = 216.7, 171.6, 171.5, 73.9, 64.1, 56.8, 56.8, 56.7, 55.8, 
51.0, 47.0, 46.8, 45.4, 45.4, 19.0 ppm. 
HRMS (ESI): m/z calcd for: C23H22O5S2Na ([M+Na]
+): 465.0801; found: 465.0794. 
FT–IR υmax = 2989, 1721, 1300, 1212, 1067, 842 cm
-1. 
MP 101.2–102.3 C. 
 
E. 5 Barton Decarboxylation 
Thiohydroxamate ester 
 
Adapted from the procedure of Eaton and Yip.360 To a solution of 4-methoxycarbonylcuban-
1-yl-acetic acid (29 mg, 0.13 mM) in anhydrous DCM (5 mL) was added oxalyl chloride (0.03 
mL, 0.35 mM) and anhydrous DMF (1 drop) under an argon atmosphere. After 1 h the mixture 
was concentrated in vacuo and further dried under high vacuum (1 h). The newly formed acid 
chloride was taken up in anhydrous THF (5 mL) and to this was added DMAP (0.5 mg, 0.0023 
mM), which turned the clear solution turbid. The reaction flask was covered in aluminium foil, 
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placed in a water bath at r.t. and then freshly ground 2-mercaptopyridine N-oxide sodium salt 
(36 mg, 0.24 mM) was added in two portions. The mixture was left to stir for 16 h and then 
filtered through glass wool. The filtrate was purified by column chromatography (dry load, 
silica gel ca 1 g, 50% ethyl acetate/petroleum ether v/v) to give the title compound (35 mg, 
82%) as a yellow solid. 
 
1H-NMR (500 MHz, C6D6) δH = 7.43–7.40 (m, 1H), 6.44–6.42 (m, 1H), 6.03–5.99 (m, 
1H), 5.40–5.36 (m, 1H), 4.11–4.09 (m, 3H), 3.72–3.70 (m, 3H), 3.41 (s, 3H), 
2.51 (s, 2H) ppm. 
13C-NMR (125 MHz, C6D6) δC = 176.7, 171.8, 166.3, 137.6, 137.1, 132.2, 110.8, 56.5, 
54.0, 51.0, 47.0, 46.8, 35.1 ppm. 
HRMS (ESI): m/z calcd for: C17H15NO4SNa ([M+Na]
+): 352.0614; found: 352.0616. 
FT–IR υmax = 3389, 2990, 1802, 1718, 1608, 1527, 1608, 1527, 1448, 1323, 1208, 
1133, 1089, 1067, 841, 755 cm-1. 
MP 152 C (decomp). 
 
Barton decarboxylation–thiophenol ester 
 
Adapted from the procedure of Eaton and Yip.360 To a borosilicate glass microwave vessel was 
added thiohydroxamate ester (17.5 mg, 0.079 mM) and anhydrous DCM (2.5 mL) followed by 
thiophenol (12 µL, 0.12 mM). The vessel was placed in a water bath at r.t. and then irradiated 
with a 500-W tungsten lamp for 10 min. [Note: the borosilicate glass microwave vessel had a 
diameter of 1.3 cm and was placed in the centre of a water bath, which had a diameter of 11.5 
cm. The distance between the outer wall of the microwave vessel and the light source was 10 
cm. Magnetic stirring was not required as the solution was homogenised by the resulting 
convection current]. Concentration by distillation at atmospheric pressure and purification by 
column chromatography (25% ethyl acetate/petroleum ether v/v) gave the title compound (7 
mg, 28%) as a yellow oil. 
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1H-NMR (500 MHz, CDCl3) δH = 7.43–7.39 (m, 5H), 4.18–4.16 (m, 3H), 3.92–3.91 (m, 
3H), 3.70 (s, 3H), 3.02 (s, 2H) ppm. 
13C-NMR (125 MHz, CDCl3) δC = 194.7, 172.8, 134.6, 129.6, 129.4, 127.7, 56.3, 55.2, 
51.7, 47.0, 46.9, 46.7 ppm. 
HRMS (ESI): m/z calcd for: C18H16O3SNa ([M+Na]
+): 335.0712; found: 335.0713. 
FT–IR υmax = 2988, 1705, 1478, 1440, 1320, 1204, 1087, 962, 747 cm
-1. 
                                          
                             Barton decarboxylation – thiopyridine ether 
 
Adapted from the procedure of Eaton and Yip.360 Thiohydroxamate ester (5 mg, 0.015 mM) 
was dissolved in benzene-d6 (0.5 mL) in a round bottom flask. The solution was freeze-pump-
thaw degassed three times with argon and then transferred to a borosilicate glass NMR tube. 
The NMR tube was placed in a water bath at r.t. and irradiated with a 500-W tungsten lamp for 
5 min. [Note: the borosilicate glass NMR tube had a diameter of 5 mm and was placed in the 
centre of a water bath, which had a diameter of 11.5 cm. The distance between the outer wall 
of the NMR tube and the light source was 10 cm. Magnetic stirring was not required as the 
solution was homogenised by the resulting convection current]. Concentration by distillation 
at atmospheric pressure and purification by column chromatography (20% ethyl 
acetate/petroleum ether v/v) gave the title compound (0.5 mg, ca 12%). Further attempts to 
purify the title compound using HPLC were unsuccessful.  
 
1H-NMR (500 MHz, C6D6) δH = 8.21 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 6.87 (dt, J = 8.1, 
1.0 Hz, 1H), 6.74 (ddd, J = 8.1, 7.3, 1.9 Hz, 1H), 6.37 (ddd, J = 7.3, 4.9, 1.1 
Hz, 1H), 4.03-4.01 (m, 3H), 3.63-3.61 (m, 3H), 3.50 (s, 2H), 3.36 (s, 3H) ppm. 
13C-NMR (175 MHz, CDCl3) δC = 171.9, 159.3, 149.4, 135.6, 122.6, 119.2, 58.1, 56.9, 
50.9, 46.4, 46.3, 32.3 ppm. 
HRMS (ESI): m/z calcd for: C16H16NO2S ([M+H]
+): 286.0896; found: 286.0905. 
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Figure E. 6 The GC-MS analysis of the turnover of 4-(2-hydroxyethyl)cubane-1-methoxy 
carbonyl by CYP101B1. 4-(2-hydroxyethyl)cubane-1-methoxy carbonyl, (RT 9.95 min). 
 
 
Figure E. 7 MS analysis of the substrates and products of the cubanes. 
 
4-methylcubane-1-methoxy carbonyl 
4-methylcubane-1-methoxy carbonyl RT 4.75 min (m+/z = 176.00) 
 
4-methylcubane-1-carboxylic acid RT 5.4 min (m+/z = 162.15) – see MS of standard later  
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4-methylcubane-1-methoxy carbonyl product: 4-hydroxymethylcubane-1-methoxy 
carbonyl  
Product RT 8.65 min (m+/z = 192.35) 
 
       
zoomed in version 
MS of synthesised standard of 4-hydroxymethylcubane-1-methoxy carbonyl  
 
Product RT 8.16 min aldehyde further oxidation product (m+/z = 190.15) 
 
Product RT 9.45 min–ester hydrolysis of product (m+/z = 177.5) 
    
        
zoomed in version 
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4-methylcubane-1-acetic acid methyl ester 
 
MS analysis of 4-methylcubane-1-acetic acid methyl ester RT 5.1 min (m+/z = 190.05) 
 
 
MS analysis of 4-methylcubane-1-acetic acid methyl ester RT 6.13 min (m+/z = 176.15) 
possibly hydrolysis to carboxylic acid 
 
       
zoomed in version 
 
Product: 4-hydroxymethylcubane-1-acetic acid methyl ester RT 9.0 min (m+/z = 206.35)  
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Product: RT 8.95 min; m+/z = 204.00 (aldehyde - only found large-scale turnover after all the 
product has been consumed). 
 
              
   zoomed in version 
4-methylcuban-1-yl acetate  
substrate RT 3.9 min (m+/z = 175.35) 
 
       
zoomed in version 
product 7.7 min (m+/z = 191.00) 
  
          
zoomed in version 
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4-methylcubane-1-methyl ketone  
MS analysis of substrate RT 4.2 min (m+/z = 160.05) 
 
         
zoomed in version 
MS analysis of possible 4-methylcubane-1-methyl ketone product RT 8.35 min (m+/z = 175.25) 
 
       
zoomed in version 
4-ethylcubane-1-methoxy carbonyl 
4-ethylcubane-1-methoxycarbonyl RT 6.05 min (m+/z = 190.20) 
 
4-ethylcubane-1-carboxylic acid RT 6.95 min (m+/z = 175.20) 
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4-(1-hydroxyethyl)-cubane-1-methoxy carbonyl, from enzyme turnover, RT 8.95 min (m+/z = 
206.45)  
 
       
zoomed in version 
4-(1-hydroxyethyl)-cubane-1-methoxy carbonyl RT 8.95 min synthesised control GC-MS 
 
4-(2-hydroxyethyl)-cubane-1-methoxy carbonyl RT 9.95 min (m+/z = 206.30) 
 
         
zoomed in version 
4-methylcubane-1-carboxylic acid RT 5.4 min (m+/z = 162.0) 
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Note there is a small amount of impurity in the NMR but nothing in the vinyl region (radical 
rearrangement) or in the region expected for the cation rearrangement product. Possible Minor 
products from ester hydrolysis and potentially starting material (GC-MS and the NMR 
combined seems to rule out oxidation on cube C-Hs) 301-303, 367, 368. 
4-hydroxymethylcubane-1-methoxy carbonyl (500 MHz, CDCl3): δ 4.16-4.13 (m, 3H, H3, H5 
& H8), 3.91-3.87 (m, 3H, H2, H6 & H7), 3.78 (m, 2H, 2xH11), 3.71 (s, 3H, 3xH10). 
 
Figure E. 8 Zoomed in (3.2 to 4.7 ppm region) version of 1H NMR spectrum of 4-
hydroxymethylcubane-1-methoxy carbonyl (4-Methylcubane-1-methoxy carbonyl; 
CYP101B1).  




Figure E. 9 1H NMR spectrum of 4-hydroxymethylcubane-1-methoxy carbonyl (4-
Methylcubane-1-methoxy carbonyl; CYP101B1). The large peak at 2.17 is acetone. 
 
4-hydroxymethylcubane-1-acetic acid methyl ester 
 
 
Overoxidation to the aldehyde is suggested by a peak at 9.76 ppm and peaks from the cubane 
structure at above 4 ppm. Also, there is a small EtOH impurity, and ester hydrolysis of the 
substrate and product interfere with the signals as well. However for all the impurities, the cube 
seems intact, and there is no evidence for other products from GC-MS 301-303, 367. 
 
Impurities –  starting material 
  aldehyde, further oxidation product 
  hydrolysed product or starting material 
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4-hydroxymethylcubane-1-acetic acid methyl ester (600 MHz, CDCl3) δ 3.88-3.83 (m, 3H, 
H3, H5 & H8), 3.79-3.76 (m, 2H, 2xH12), 3.75-3.70 (m, 3H, H2, H6 & H7), 3.69 (s, 3H, 
3xH11), 2.68 (s, 2H, 2xH9). 
13C NMR (151 MHz, CDCl3) δ 174.48 (C10), 66.48 (C12), 54.03 (C11), 48.46 (C2, C6 & C7), 
46.56 (C3, C5 & C8), 40.67 (C9), 25.33 (C4), 16.76 (C1). 
 
Figure E. 10 Zoomed in (2.65 to 3.9 ppm region) 1H NMR of 4-hydroxymethylcubane-1-acetic 
acid methyl ester (4-Methylcubane-1-acetic acid methyl ester; CYP101B1).  
    
Figure E. 11 1H NMR spectrum of 4-hydroxymethylcubane-1-acetic acid methyl ester (4-
Methylcubane-1-acetic acid methyl ester; CYP101B1). 




Figure E. 12 13C NMR spectrum of 4-hydroxymethylcubane-1-acetic acid methyl ester (4-
Methylcubane-1-acetic acid methyl ester; CYP101B1). 
 
Figure E. 13 HSQC NMR spectrum of 4-hydroxymethylcubane-1-acetic acid methyl ester (4-
Methylcubane-1-acetic acid methyl ester; CYP101B1). 
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